Blue Book 2023

FORMULARI UBAT KEMENTERIAN KESIHATAN MALAYSIA BILANGAN 1/2023
Generic Name MDC Category Indications Prescribing Restrictions Dosage

Abacavir Sulphate 300mg tablet J05AF06-183-T10-01-XXX A* Antiretroviral combination therapy of HIV infection in i. Patients unsuitable or failed other HAART treatment ii. Adult: 300mg twice daily or 600mg daily Children: i. Weighing 14
adults and adolescents from 12 years of age. Patients who have renal impairment (CrCl < 50ml/min) to <20kg: one-half of a scored abacavir tablet twice daily ii.
when Abacavir and Lamivudine fixed-dose combination is Weighing ≥20kg to <25kg: one-half of a scored abacavir tablet in
not recommended the morning and one whole tablet in the evening iii. Weighing at
least 25kg: according to adult dose
Abacavir Sulphate 600 mg and Lamivudine 300 J05AR02-964-T10-01-XXX A* Antiretroviral combination therapy of HIV infection in None ADULTS & ADOLESCENT (> 12 years of age): Recommended dose
mg Tablet adults and adolescents from 12 years of age with the is one tablet once daily. Not to be used in adults or adolescents
following criteria: i)Patients unsuitable or failed other weigh less than 40kg. CHILDREN : Not recommended
HAART treatment. ii)Patients who are at high risk of
renal impairment. iii)Patients with osteoporosis or at
high risk of bone loss.
Abiraterone acetate 250mg tablet L02BX03-000-T10-01-XXX A* With prednisone or prednisolone, for the treatment of Prescribing restrictions: i. Those who have progressed on 1,000mg once daily
metastatic castration-resistant prostate cancer (mCRPC) OR failed prior docetaxel chemotherapy ii. Those who are
in adult men. contraindicated or unsuitable for chemotherapy
Acarbose 50mg Tablet A10BF01-000-T10-01-XXX A/KK Only for treatment of: i) Non insulin dependent diabetes i) As second/third line treatment of diabetes type 2, with Initially 50 mg daily, increase to 3 times daily up to 100 mg 3
mellitus (NIDDM) when diet therapy is insufficient ii) HBA1c < 8%. ii) For patient who have postprandial times daily. Maximum dose: 100 mg 3 times daily
Non insulin dependent diabetes mellitus (NIDDM) in hyperglycemia when treated with combination of
combination with existing conventional oral therapy available oral anti-diabetic/insulin. iii) The use of acarbose
where glycaemic control is inadequate should be reviewed 6 months after initiation and stopped
if HBA1c reduction is less than 0.5%.
Acetazolamide 250mg Tablet S01EC01-000-T10-01-XXX B Reduction of intraocular pressure in open-angle None 250mg 1-4 times a day, the dosage being titrated according to
glaucoma, secondary glaucoma and peri-operatively in patient response
angle-closure glaucoma
Acetazolamide 500mg Injection S01EC01-000-P40-01-XXX B Reduction of intra-ocular pressure in open-angle None Adult : 250-1000mg per 24hours, usually in divided doses for
glaucoma, secondary glaucoma and peri-operatively in amounts over 250mg daily
angle-closure glaucoma
Acetylcysteine 200mg/ml Injection V03AB23-520-P30-01-XXX A* Antidote for paracetamol poisoning None Diluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in
200 ml over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours,
followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose:
300mg/kg in 20 hour
Acetylsalicylic Acid 100 mg & Glycine 45 mg B01AC06-259-T10-01-XXX B i) Prevention of myocardial infarct, stroke, vascular None 1 tablet daily
Tablet occlusion and deep vein thrombosis. ii) Transient
ischaemic attacks
Acetylsalicylic Acid 150mg Dispersible Tablet N02BA01-000-T40-03-XXX C Initial treatment of cardiovascular disorders such as None 150mg to be taken daily. Dose to be individualised. Use in
angina pectoris and myocardial infarction and for the children under 16 years old is not recommended
prevention of cardiovascular events in patients at risk.
Other such uses include the treatment and prevention of
cerebrovascular disorders such as stroke
Acetylsalicylic Acid 300 mg Soluble Tablet N02BA01-000-T40-01-XXX C Initial treatment of cardiovascular disorders such as None 150mg to be taken daily. Use in children under 16 years old is not
angina pectoris and myocardial infarction and for the recommended
cerebrovascular disorders such as stroke.
April 2023 1

Acetylsalicylic Acid 75mg Dispersible Tablet N02BA01-000-T40-02-XXX C Initial treatment of cardiovascular disorders such as None Dose to be individualised. 150mg to be taken daily. Use in
angina pectoris and myocardial infarction and for the children under 16 years old is not recommended
cerebrovascular disorders such as stroke
Acitretin 10mg Capsule D05BB02-000-C10-01-XXX A* i) Severe form of psoriasis including erythrodermic None ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted
psoriasis and local or generalized pustular psoriasis. ii) according to response, usually within range 25-50 mg daily for
Severe disorders of keratinization, such as -congenital further 6-8 weeks (max: 75 mg daily). In disorders of
ichthyosis -pityriasis rubra pilaris -Darier's disease -other keratinization, maintenance therapy of less than 20mg/day and
disorders of keratinization which may be resistant to should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally
other therapies up to 1 mg/kg daily to a max. 35 mg daily for limited periods
Acitretin 25 mg Capsule D05BB02-000-C10-02-XXX A* i) Severe form of psoriasis including erythrodermic None ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted
psoriasis and local or generalized pustular psoriasis. ii) according to response, usually within range 25-50 mg daily for
Severe disorders of keratinization, such as -congenital further 6-8 weeks (max: 75 mg daily). In disorders of
ichthyosis -pityriasis rubra pilaris -Darier's disease -other keratinization, maintenance therapy of less than 20mg/day and
disorders of keratinization which may be resistant to should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally
other therapies up to 1 mg/kg daily to a max. 35 mg daily for limited periods
Acriflavine 0.1% Lotion D08AA03-000-L60-01-XXX C+ Infected skin, lesions, cuts, abrasions, wounds and burns. None Apply undiluted three times daily to the affected part .
Actinomycin D (Dactinomycin) 500 mcg/ml L01DA01-110-P40-01-XXX A i) For solid tumours ii) Gestational trophoblastic disease None i) ADULT: 500 mcg IV daily for max of 5 days. CHILD: 1.5 mg/m2
Injection once every 3 weeks (if weight less than 10 kg, 50 mcg/kg) ii) 500
mcg IV on Days 2, 4, 6, 8, 10, repeat every 7 - 10 days or 500 mcg
IV bolus on Days 1 and 2, repeat every 15 days
Acyclovir 200 mg Tablet J05AB01-000-T10-01-XXX A/KK i) Treatment of Herpes simplex & Varicella zoster None Indication (i) Treatment for Herpes Simplex: ADULT - 200mg 5
infections ii) Prophylaxis of Herpes simplex infections in times daily; In severely immune-compromised patients: dose can
immune-compromised patients be doubled to 400 mg. CHILD - two years and above should be
given adult dosages, infants and children below two years old
should be given half the adult dose. Treatment for Varicella
Zoster: ADULT - 800mg 5 times daily; CHILD 6 years and over: 800
mg four times daily, 2 - < 6 years: 400 mg four times daily, Under
2 years: 200 mg four times daily. Indication (ii) ADULT - Immune-
compromised patients: 200 mg four times daily. Severely immune-
compromised patients: dose can be doubled to 400 mg. CHILD -
two years and above should be given adult dosages, infants and
children below two years old should be given half the adult dose.
Dosing is according to Product Information Leaflet.
April 2023 2

Acyclovir 200 mg/5 ml Suspension J05AB01-000-L80-01-XXX A* i) Mucocutaneous Herpes Simplex infection in None i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less
immunocompromised and AIDS patients ii) Primary and than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400
recurrent Varicella Zoster infection in mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily.
immunocompromised and AIDS patients iii) Severe CHILD : less than 2 years, half adult dose; more than 2 years,
Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe adult dose. v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT:
primary HSV infections (eg. Neonatal herpes, 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6
encephalitis, eczema herpeticum, genital herpes, gingival years: 800 mg four times daily. CHILD: less than 2 years; 400mg 4
stomatitis, vaginal delivery with maternal vulva herpes) times daily, more than 2 years; 800 mg 4 times daily
v) Severe and complicated varicella infection (eg.
Encephalitis, purpura fulminans) vi) Severe zoster
infection in paediatrics (eg.Encephalitis, purpura
fulminans, immunocompromised patients and facial,
sacral and motor zoster)
Acyclovir 250 mg Injection J05AB01-000-P4-001-XXX A* i)Treatment of Herpes simplex & Varicella zoster ADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to
infections ii)Prophylaxis of Herpes simplex infections in 10mg/kg every 8 hourly in varicella-zoster in the
immune-compromised patients immunocompromised and in simplex encephalitis (usually given
for at least 10 days in encephalitis; possibly for 14 - 21 days).
NEONATE & INFANT up to 3 months with disseminated herpes
simplex: 20mg/kg every 8 hourly for 14 days (21 days in CNS
involvement), varicella-zoster 10-20mg/kg every 8 hourly usually
for 7 days. CHILD, 3 months - 12 years: Herpes simplex or
Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500
mg/m2 8 hourly for varicella-zoster in the immunocompromised
and in simplex encephalitis (usually given for 10 days in
encephalitis)
Acyclovir 3% Eye Ointment S01AD03-000-G51-01-XXX A* Only for the treatment of herpes simplex keratitis None Apply 1 cm 5 times daily. Continue for at least 3 days after healing
Acyclovir 5% Cream D06BB03-000-G10-01-XXX A* Herpes simplex infections of the skin, including initial None Apply every 4 hours for 5 - 10 days
and recurrent labial and genital herpes simplex infections
Acyclovir 800 mg Tablet J05AB01-000-T10-02-XXX A/KK i)Treatment of Herpes simplex & Varicella zoster - Indication (i) Treatment for Herpes Simplex: ADULT - 200mg 5
infections ii)Prophylaxis of Herpes simplex infections in times daily; In severely immune-compromised patients: dose can
immune-compromised patients be doubled to 400 mg. CHILD - two years and above should be
given adult dosages, infants and children below two years old
should be given half the adult dose. Treatment for Varicella
Zoster: ADULT - 800mg 5 times daily; CHILD - 6 years and over:
800 mg four times daily, 2 - < 6 years: 400 mg four times daily,
Under 2 years: 200 mg four times daily. Indication (ii) ADULT -
Immune-compromised patients: 200 mg four times daily.
Severely immune-compromised patients: dose can be doubled to
400 mg. CHILD - two years and above should be given adult
dosages, infants and children below two years old should be
given half the adult dose. Dosing is according to Product
Information Leaflet.
April 2023 3

Adalimumab 40mg Injection L04AB04-000-P50-01-XXX A* i) Third line treatment of: - Severe rheumatoid arthritis - None i)Severe rheumatoid arthritis, Psoriatic arthritis, Ankylosing
Psoriatic arthritis - Ankylosing spondylitis after failure of spondylitis : Subcutaneous 40 mg every other week ii)Chronic
conventional DMARDs or other biologics ii)Treatment of plaque psoriasis : Initial, 80 mg SC, followed by 40 mg SC every
adults with moderate to severe chronic plaque psoriasis other week starting one week after the initial dose iii) & iv)
who have not responded to, have contraindication or Crohn's disease & Ulcerative colitis: 160mg at week 0 (dose can
are unable to tolerate phototherapy and/or systemic be administered as four injections in one day or as two injections
therapies including acitretin, methotreaxate and per day for two consecutive days) and 80mg at week 2. After
cyclosporine iii) Crohn's Disease a) For treatment of induction treatment, the recommended maintenance dose is
moderately to severely active Crohn's Disease in adult 40mg every other week via subcutaneous injection.
patients who have inadequate response to conventional
therapy b) For treatment of moderately to severely
active Crohn?s Disease in adult patients who have lost
response to or are intolerant to infliximab iv) Ulcerative
Colitis - For treatment of moderately to severely active
ulcerative colitis in adult patients who have had an
inadequate response to conventional therapy including
corticosteroids and 6-mercaptopurine or azathioprine, or
who are intolerant to or have medical contraindications
for such therapies
Adapalene 0.1% Cream D10AD03-000-G10-01-XXX A* Acne vulgaris where comedones, papules and pustules None Apply once daily to the affected areas after washing at bedtime
predominate in those sensitive to benzoyl peroxide or
topical tretinoin [third line treatment]
Adapalene 0.1% Gel D10AD03-000-G30-01-XXX A/KK Treatment for acne vulgaris where comedones, papules None Apply once daily to the affected areas after washing at bedtime
and pustules predominate
Adenosine 3 mg/ml Injection C01EB10-000-P30-01-XXX B Rapid conversion of paroxysmal supraventricular None ADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds).
tachycardia to sinus rhythm Second dose: If the first dose does not result in elimination of the
supraventricular tachycardia with in 1 or 2 minutes, 6 mg should
be given also as a rapid IV bolus. Third dose: If the second dose
does not result in elimination of the supraventicular tachycardia
with in 1-2 minutes, 12 mg should be given also as a rapid IV bolus
Adrenaline Acid Tartrate (Epinephrine) 1 mg/ml C01CA24-123-P30-01-XXX B Cardiopulmonary resuscitation None 1 mg by intravenous injection repeated every 3-5 minutes
Injection according to response
Afatinib Dimaleate 30mg Film-Coated Tablet L01XE13-253-T32-02-XXX A* First-line monotherapy for the treatment of Epidermal i) Adenocarcinoma histology. ii) Patient's ECOG 40mg once daily to be taken without food. Maximum dose is
Growth Factor Receptor (EGFR) TKI-naïve adult patients Performance Status 0-1. **To be prescribed by 50mg once daily.
with locally advanced or metastatic non-small cell lung Consultants/Specialists from disciplines of oncology and
cancer (NSCLC) with activating EGFR mutation(s). oncology-trained respiratory physician)**
Afatinib Dimaleate 40mg Film-Coated Tablet L01XE13-253-T32-03-XXX A* First-line monotherapy for the treatment of Epidermal i) Adenocarcinoma histology. ii) Patient's ECOG 40mg once daily to be taken without food. Maximum dose is
Growth Factor Receptor (EGFR) TKI-naïve adult patients Performance Status 0-1. **To be prescribed by 50mg once daily.
with locally advanced or metastatic non-small cell lung Consultants/Specialists from disciplines of oncology and
cancer (NSCLC) with activating EGFR mutation(s). oncology-trained respiratory physician)**
April 2023 4

Aflibercept 40mg/ml solution for injection (vial) S01LA05-000-P30-01-XXX A* i) Treatment of neovascular (wet) age-related macular For indication (ii): a) Treatment of naive patients with i) The recommended dose is 2mg aflibercept, equivalent to
degeneration (wet AMD) ii) Visual impairment due to visual acuity equal or worse than 20/50; or b) Patients 0.05mL (50 μL) given as intra-vitreal injection. Aflibercept
diabetic macular edema (DME) iii) Macular Oedema with poor response to treatment with ranibizumab. For treatment is initiated with one injection per month for three
secondary to Retinal Vein Occlusion (branch RVO or indication (iii): a) First line for patient not able to comply consecutive doses, followed by one injection every two months.
central RVO) with monthly ranibizumab injection after initial loading ii) 2 mg aflibercept (equivalent to 50 microliters) administered by
doses b) Second line for patient who are refractory to intravitreal injection monthly for the first 5 consecutive doses,
ranibizumab injection c) To be prescribed by followed by one injection every 2 months. There is no
Ophthalmologist only requirement for monitoring between injections. iii) 2 mg
aflibercept (equivalent to 50 microliters) administered by
intravitreal injection monthly. The interval between two doses
should not be shorter than one month.
Agomelatine 25 mg Tablet N06AX22-000-T10-01-XXX A* Major depression - The recommended dose is 25mg once daily at bedtime, maybe
increased to 50mg once daily at bedtime.
Albendazole 200 mg Tablet P02CA03-000-T10-01-XXX C+ i) Single or mixed infestations of intestinal parasites ii) - i)Child 12-24months: 200mg as a single dose ii) Adult & Child
Strongyloides infection above 2 years: 400mg as a single dose for 3 consecutive days;
Child 12 - 24months: 200mg as a single dose for 3 consecutive
days
Albendazole 200 mg/5 ml Suspension P02CA03-000-L80-01-XXX C+ i) Single or mixed infestations of intestinal parasites ii) - i)Child 12-24months: 200mg as a single dose ii) Adult & Child
Strongyloides infection above 2 years: 400mg as a single dose for 3 consecutive days;
Child 12 - 24months: 200mg as a single dose for 3 consecutive
days
Alcohol 70% Solution D08AX08-000-L99-01-XXX C+ Use as antiseptic and disinfectant None Apply to the skin undiluted or when needed
Alendronate Sodium 70 mg and Cholecalciferol M05BB03-972-T10-02-XXX A* i) Osteoporosis in postmenopausal women with a history - 1 tablet once weekly [70mg/5600 IU]. Patient should receive
5600 IU Tablet of vertebral fracture and whom oestrogen replacement supplemental calcium or vitamin D, if dietary vitamin D
therapy is contraindicated ii) Male Osteoporosis inadequate. The tablet should be taken at least half and hour
before the first food, beverage, or medication of the day with
plain water only. To facilitate delivery to stomach and thus
reduce the potential for esophageal irritation, it should only be
swallowed upon arising for the day with a full glass of water and
patient should not lie down for at least 30 minutes and until after
their first food of the day.
Alendronate Sodium 70 mg Tablet M05BA04-520-T10-01-XXX A* i) Osteoporosis in postmenopausal women with a history - 70 mg once weekly. Swallow the tablet whole with a full glass of
of vertebral fracture and whom oestrogen replacement plain water only on an empty stomach at least 30 minutes before
therapy is contraindicated. ii) Osteoporosis (Male) breakfast (and any other oral medication); stand or sit upright for
at least 30 minutes and do not lie down until after eating
breakfast
Alfacalcidol 0.25 mcg Capsule A11CC03-000-C10-01-XXX A/KK i) Chronic kidney disease mineral bone disorder ii) - Initial dose ADULT and CHILD above 20kg body weight : 1 mcg
Osteoporosis iii) Hypoparathyroidism and daily; CHILD under 20kg body weight : 0.05 mcg/kg/day.
pseudohypoparathyroidism iv) Rickets and osteomalacia Maintenance dose : 0.25 mcg to 2 mcg daily Dosing is
individualised based on serum calcium level and according to
product insert/protocol
Alfacalcidol 1 mcg Capsule A11CC03-000-C10-02-XXX A/KK i) Chronic kidney disease mineral bone disorder ii) - Initial dose ADULT and CHILD above 20kg body weight : 1 mcg
April 2023 5

Alfacalcidol 2 mcg/ml Drops A11CC03-000-D50-01-XXX A* i) Neonatal hypocalcemia ii) Osteoporosis iii) - NEONATES : 0.1 mcg/kg/day Dosing is individualised based on
Hypoparathyroidism and pseudohypoparathyroidism iv) serum calcium level and according to product insert/protocol
Rickets and osteomalacia
Alfacalcidol 2 mcg/ml Injection A11CC03-000-P30-01-XXX A* i) Chronic kidney disease mineral bone disorder ii) - Initial dose ADULT and CHILD above 20kg body weight : 1 mcg
Alfentanil HCl 0.5 mg/ml Injection N01AH02-110-P30-01-XXX A* For use as short acting narcotic analgesic in short - Initial dose: 20 - 40 mcg/kg. Supplemental dose: 15 mcg/kg or
procedures and day-care surgical procedures infusion 0.5 - 1.0 mcg/kg/min
Alfuzosin HCl 10mg Tablet G04CA01-110-T10-01-XXX A* Treatment of functional symptoms related with benign None 10 mg once a day pre bed
prostatic hypertrophy (BPH)
Alglucosidase alfa 5 mg/ml Injection A16AB07-000-P40-01-XXX A* Infantile-onset Pompe disease - 20 mg/kg of body weight administered once every 2 weeks as an
intravenous infusion. Monitoring It is suggested that patients be
monitored periodically for IgG antibody formation. Patients who
experience Infusion-associated reactions suggestive of
hypersensitivity may be tested for IgE antibodies to alglucosidase
alfa. Treated patients who experience a decrease in benefit
despite continued treatment with Alglucosidase Alfa, in whom
antibodies are suspected to play a role, may be tested for
neutralization of enzyme uptake or activity.
Alkaline Nasal Douche R01A000-999-L50-01-XXX B To remove nasal plug None To be diluted with an equal volume of warm water before use
Allopurinol 100 mg Tablet M04AA01-000-T10-02-XXX A/KK i) Frequent and disabling attacks of gouty arthritis (2 or - Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily
more attacks/year). ii) Clinical or radiographic signs of (depending on renal function).
erosive gouty arthritis. iii) The presence of tophaceous
deposits. iv) Urate nephropathy. v) Urate nephrolithiasis.
vi) Impending cytotoxic chemotherapy or radiotherapy
for lymphoma or leukaemia
Allopurinol 300 mg Tablet M04AA01-000-T10-01XXX A/KK i) Frequent and disabling attacks of gouty arthritis (2 or - Initial dose: 50-100 mg daily. Maintenance: 300-900mg daily
more attacks/year). ii) Clinical or radiographic signs of (depending on renal function).
erosive gouty arthritis. iii) The presence of tophaceous
deposits. iv) Urate nephropathy. v) Urate nephrolithiasis.
vi) Impending cytotoxic chemotherapy or radiotherapy
for lymphoma or leukaemia
All-Trans Retinoic Acid (Tretinoin) 10 mg L01XX14-000-C10-01-XXX A* Acute promyelocytic leukaemia None Induction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45
Capsule mg/m2 daily for 2 weeks every 3 months. Renal/or hepatic
insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols
Alprazolam 0.25 mg Tablet N05BA12-000-T10-01-XXX A/KK Anxiety disorders - 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3
times daily), increased if necessary to a total dose of 3 mg/day.
Not recommended for children
Alprazolam 0.5 mg Tablet N05BA12-000-T10-02-XXX A Anxiety disorders - 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3
April 2023 6

Alprazolam 1 mg Tablet N05BA12-000-T10-03-XXX A Anxiety disorders - 0.25 - 0.5 mg 3 times daily (elderly or delibitated 0.25 mg 2-3
Alprostadil 500 mcg/ml Injection C01EA01-000-P30-01-XXX A* For treatment of congenital heart diseases which are None 0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased
ductus arteriosus dependent to lowest effective dose
Alteplase 50 mg per vial Injection B01AD02-000-P40-01-XXX A* Thrombolytic treatment of acute ischaemic stroke. - 0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with
10% of the total dose administered as an initial intravenous
bolus. Treatment must be started as early as possible within 4.5
hours after onset of stroke symptoms and after exclusion of
intracranial haemorrhage by appropriate imaging technique.
Amantadine HCl 100 mg Capsule N04BB01-110-C10-01-XXX B Parkinson's disease - Initial dose: 100 mg daily and is increased to 100 mg twice daily
(not later than 4 p.m.) after a week. Elderly over 65 years: less
than 100 mg or 100 mg at intervals of more than 1 day
Amikacin 125 mg/ml Injection J01GB06-183-P30-03-XXX A Infections due to susceptible organisms - ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days.
Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly.
Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg
followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
Amikacin 250mg/ml Injection J01GB06-183-P30-02-XXX A Infections due to susceptible organisms - ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days.
Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly.
Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg
followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
Amiloride HCl 5 mg & Hydrochlorothiazide 50 C03EA01-900-T10-01-XXX B i) Diuretic as an adjunct to the management of None i) Initially 1 - 2 tab daily adjusted according to response. Max : 4
mg Tablet oedematous states ii) Hypertension tabs daily. ii) 1 -2 tabs daily as a single or divided dose
Amino Acids Injection B05BA01-910-P30-01-XXX A Source of amino acids in patients needing IV nutrition - Dose to be individualised. ADULT usually 500-2000 ml by IV.
ADULT usual requirement for amino acid: 1-2 g/kg/day
Amino Acids with Electrolytes Injection B05BA10-910-P30-02-XXX A Source of amino acids and electrolytes in patients - Dose to be individualised. ADULT usual requirement for amino
needing IV nutrition acid 1-2 g/kg/day
Amino Acids with Glucose with Electrolytes B05BA10-910-P30-03-XXX A Source of amino acids, carbohydrate and electrolytes in - Dose to be individualised. ADULT usual requirement for amino
Injection patients needing IV nutrition acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day
Amino Acids, Glucose and Lipid with B05BA10-910-P30-01-XXX A Source of amino acids, carbohydrate, lipid and - Dose to be individualised. ADULT: 500 - 2000 ml daily given by IV.
Electrolytes Injection electrolytes in patients needing IV nutrition ADULT usual requirement for amino acid 1-2 g/kg/ day,
carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day
Amino Acids, Glucose and Lipid without B05BA10-910-P30-04-XXX A Source of amino acids and carbohydrate in patients - ADULT usual requirement for amino acid 1-2 g/kg/ day,
Electrolytes Injection needing IV nutrition. carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day. Dosing is
individualised and according to product insert/protocol.
Aminophylline 25mg/ml Injection R03DA05-000-P30-01-XXX B Reversible airways obstruction, acute severe None Adult: Loading dose: 6 mg/kg (ideal body weight) or 250-500 mg
brochospasm (25 mg/ml) by slow inj or infusion over 20-30 min. Maintenance
infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Children: 6
months and over (if not previously on theophylline): Loading
dose: 6mg/kg. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-
16 yr: 0.8 mg/kg/hr. Dosing is individualised and according to
product insert/protocol.
April 2023 7

Amiodarone 200 mg Tablet C01BD01-110-T10-01-XXX A* Arrhythmias None 200 mg 3 times daily for 1 week, then reduced to 200 mg twice
daily for another week. Maintenance dose, usually 200 mg daily
or the minimum required to control the arrhythmia. Dosing is
according to product insert / protocol.
Amiodarone 50 mg/ml Injection C01BD01-110-P30-01-XXX A* i) Arrhythmias ii) Cardiopulmonary resuscitation of shock- None i) Initial: 5mg/kg over 20-120minutes Maintenance: 10-
resistant ventricular fibrillation in cardiac arrest 20mg/kg/24hr Max. dose: 1.2g/24hr. ii) Initial: 300mg or 5mg/kg
rapid Additional 150mg if condition persists. Dosing is according
to product insert / protocol.
Amisulpride 100mg Tablet N05AL05-000-T10-01-XXX A* Treatment of psychoses, particularly acute or chronic None Predominantly negative episodes: 50-300 mg once daily adjusted
schizophrenia disorders characterized by positive according to the patient's response. Mixed episodes with positive
symptoms(e.g. delusion, hallucinations, thought and negative symptoms: 400-800 mg/day in 2 divided doses
disorders) and/or negative symptoms(e.g. blunted adjusted according to the patient's response. Should be taken on
emotions, emotional and social withdrawal) including an empty stomach (Preferably taken before meals)
when the negative symptoms predominate
Amisulpride 400mg Tablet N05AL05-000-T10-02-XXX A* Treatment of psychoses, particularly acute or chronic None Predominantly negative episodes: 50-300 mg once daily adjusted
schizophrenia disorders characterized by positive according to the patient's response. Mixed episodes with positive
symptoms(e.g. delusion, hallucinations, thought and negative symptoms: 400-800 mg/day in 2 divided doses
disorders) and/or negative symptoms(e.g. blunted adjusted according to the patient's response. Should be taken on
emotions, emotional and social withdrawal) including an empty stomach (Preferably taken before meals)
when the negative symptoms predominate
Amitriptyline HCl 25 mg Tablet N06AA09-110-T10-01-XXX B Depression None Initially 25mg 3 times a day. Maintenance: 25-100mg daily in
divided doses. Hospitalized patient: 100mg/day &gradually
increase to 200-300mg/day. ADOLESCENT and ELDERLY: initially
20-30mg/day in divided doses w/ gradual increments. CHILD
under 16 years are not recommended
Amlodipine 10 mg and Valsartan 160 mg Tablet C09DB01-935-T10-03-XXX A/KK Essential hypertension in patients whose blood pressure None Doses range from amlodipine besylate 5 mg/valsartan 160 mg to
is not adequately controlled by monotherapy amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily,
with dose titration occurring every 1 to 2 weeks if necessary.
MAX amlodipine besylate 10 mg/valsartan 320 mg
Amlodipine 10 mg Tablet C08CA01-000-T10-02-XXX B Hypertension None 5 mg once daily. Max: 10 mg once daily
Amlodipine 5 mg and Valsartan 160 mg Tablet C09DB01-935-T10-02-XXX A/KK Essential hypertension in patients whose blood pressure None Doses range from amlodipine besylate 5 mg/valsartan 160 mg to
is not adequately controlled by monotherapy amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily,
with dose titration occurring every 1 to 2 weeks if necessary.
MAX amlodipine besylate 10 mg/valsartan 320 mg
Amlodipine 5 mg Tablet C08CA01-000-T10-01-XXX B Hypertension None 5 mg once daily. Max: 10 mg once daily
Ammonium Bicarbonate, Tincture Ipecac, etc R05CA04-900-L21-01-XXX C Cough None Adults, the elderly and children over 12 years: 10- 20ml, repeated
Mixture after 4 hours if required. Not more than 4 doses to be taken in
any 24 hours.
Amorolfine 5% Nail Lacquer D01AE16-110-L50-01-XXX A* Fungal nail infections None Apply to affected nail once or sometimes twice a week after
filling and cleansing, allow to dry, treat finger nail for 6 months,
toe nail for 9 - 12 months (review at intervals of 3 months)
Amoxicillin & Clavulanate 228 mg/5 ml Syrup J01CR02-961-F21-02-XXX A/KK Infections caused by susceptible organisms - Mild to Moderate infection: 25mg/kg/day (based on Amoxicillin
dose) in 2 divided dose. Severe infection: 45mg/kg/day (based on
Amoxicillin dose) in 2 divided dose
April 2023 8

Amoxicillin 1 g & Clavulanate 200 mg Injection J01CR02-961-P40-02-XXX A Infections caused by susceptible organisms. Respiratory - CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12
tract, skin, soft tissue, GUT infection, septicaemia, years: 30mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent
peritonitis, post-operative infection & osteomyelitis infusion 6 - 8 hourly
Amoxicillin 250 mg Capsule J01CA04-012-C10-01-XXX B Infections caused by susceptible strains of gram positive - ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in
and gram negative organisms divided doses 8 hourly
Amoxicillin 250mg/5mL Oral Solution J01CA04-012-L80-01-XXX B Infections caused by susceptible strains of gram positive CHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than
and gram negative organisms 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
Amoxicillin 500 mg & Clavulanate 125 mg J01CR02-961-T10-02-XXX A/KK Infections due to beta-lactamase producing strain where - ADULT & CHILD more than 12 years: Mild to moderate infections:
Tablet amoxicillin alone is not appropriate. Respiratory tract, 625 mg twice daily.
skin, soft tissue, GUT infection, septicaemia, peritonitis,
post-operative infection & osteomyelitis
Amoxicillin 500 mg and Clavulanate 100 mg J01CR02-961-P40-01-XXX A Infections caused by susceptible organisms. Respiratory - CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12
Injection tract, skin, soft tissue, GUT infection, septicaemia, years: 30 mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent
peritonitis, post-operative infection and osteomyelitis infusion 6 - 8 hourly
Amoxicillin 500 mg Capsule J01CA04-012-C10-02-XXX B Infections caused by susceptible strains of gram positive - ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in
and gram negative organisms divided doses 8 hourly
Amoxicillin Trihydrate 125 mg/5 ml Syrup J01CA04-012-F10-01-XXX B Infections caused by susceptible strains of gram positive - CHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than
and gram negative organisms 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
Amphotericin B 0.15% Eye Drops S01A000-801-D20-02-XXX A Fungal infection of the cornea None 1 drop hourly or 2 hourly
Amphotericin B 0.25% Eye Drops S01A000-801-D20-03-XXX A Fungal infection of the cornea None 1 drop hourly or 2 hourly
Amphotericin B 50 mg Injection (Conventional) J02AA01-801-P40-01-XXX A Systemic fungal infections - ADULT: 0.25 mg/kg/day by IV infusion, gradually increase if
tolerated to 1 mg/kg/day. Maximum in severe cases: 1.5 mg/kg
daily or on alternate days. For neonates, lower doses are
recommended
Ampicillin Sodium & Sulbactam Sodium 250 J01CR01-961-F21-01-XXX A Treatment of susceptible bacterial infections - ADULT: 375-750mg twice daily. CHILDREN (weight < 30kg): 25-
mg/5 ml Suspension 50mg/kg/day in two divided doses. For children weighing 30kg
and more, follow usual adult dose.
Ampicillin Sodium & Sulbactam Sodium 375 mg J01CR01-961-T10-01-XXX A/KK Treatment of susceptible bacterial infections - ADULT: 375-750mg twice daily CHILDREN AND INFANTS: 25-
Tablet 50mg/kg/day in 2 divided doses, if ≥ 30kg use an adult dose
Ampicillin Sodium 1g & Sulbactam Sodium J01CR01-961-P40-02-XXX A Treatment of susceptible bacterial infections - ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g
500mg Injection Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of
surgical infections: 1.5 - 3 g at induction of anaesthesia. May be
repeated 6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day
in divided doses every 12 hour
Ampicillin Sodium 500 mg & Sulbactam Sodium J01CR01-961-P40-01-XXX A Treatment of susceptible bacterial infections - ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g
250 mg Injection Sulbactam per day. CHILD: 150-300mg/kg/day 6 - 8 hourly.
Prophylaxis: 1.5 -3 g at induction of anaesthesia. May be
repeated 6 - 8 hourly
Ampicillin Sodium 500 mg Injection J01CA01-520-P40-01-XXX B Treatment of susceptible bacterial infections (non beta- - 250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day.
lactamase-producing organisms); meningitis Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided
doses. Usual children dose less than 10 years, half adult dose
Ampicillin Trihydrate 125 mg/5 ml Suspension J01CA01-012-F21-01-XXX B Treatment of susceptible bacterial infections (non beta- - CHILD: 50 - 100 mg/kg/day 4 times daily. Under 1 year: 62.5 - 125
lactamase-producing organisms) mg 4 times daily, 1 - 10 years: 125 - 250 mg 4 times daily
April 2023 9

Anastrozole 1 mg Tablet L02BG03-000-T10-01-XXX A* Hormonal therapy in breast cancer in post-menopausal - 1 mg daily
women if failed /contraindicated with Tamoxifen
Anidulafungin 100mg Injection J02AX06-000-P30-01-XXX A* Treatment of invasive candidiasis, including candidemia - Loading dose of 200 mg on day 1, then 100 mg once daily
in adults when intolerance or resistance to Amphotericin thereafter for at least 14 days after the last positive culture.
B or Fluconazole
Anti Rhd Immunoglobulin Injection J06BB01-000-P30-01-XXX B Prevention of Rh(D) sensitisation to Rh(D)-negative - i) Antenatal prophylaxis: According to general recommendations,
woman: i) Pregnancy/delivery of Rh(D)-positive infant ii) currently administered doses range from 50 – 330 micrograms or
Abortion/threatened abortion, ectopic pregnancy or 250 - 1650 IU. For specific details, please refer to product's
hydatidiform mole iii) Transplacental haemorrhage package insert. ii) Postnatal prophylaxis: According to general
resulting from antepartum haemorrhage, amniocentesis, recommendations, currently administered doses range from 100
chorionic biopsy or obstetric manipulative procedures – 300 micrograms or 500 – 1500 IU. For specific details, please
e.g. external version or abdominal trauma refer to product's package insert.
Antilymphocyte/Antithymocyte L04AA03-000-P30-01-XXX A* i) To be used when conventional anti-rejection therapy is - 10 - 30 mg/kg body weight daily. Slow IV infusion (over at least 4
Immunoglobulin (from Horse) Injection not successful ii) Treatment of aplastic anaemia not hours) diluted in 250 - 500 ml Normal Saline. For Graft versus
responding to oxymethalone after 3 months, in which host disease treatment:40 mg/kg/day
there is persistent pancytopenia with repeated attacks
of septicaemia and bleeding. iii) Severe aplastic anaemia
with the following parameters: a) Granulocyte less than
0.5x109/L b) Platelet less than 20x109/L c) Reticulocyte
less than 20x109/L iv) As a conditioning regime prior to
transplant. v) Graft-versus-host disease treatment
Antirabies Immunoglobulin Injection J06BB05-000-P30-01-XXX B Treatment of rabies, post-exposure None Human rabies immunoglobulin: 20 iu/kg; half by IM and half by
infiltration around the wound. Equine rabies immunoglobulin:
40iu/kg of body weigth in adults and children. Note: Please refer
to package insert for recommendations by the manufacturer.
Antithymocyte Immunoglobulin (from rabbit) L04AA04-000-P30-01-XXX A* i)Prophylaxis of acute graft rejection ii)Treatment of - i)1.0 - 1.5 mg/kg/day for 2 - 9 days after transplantation of a
Injection acute graft rejection iii)Prophylaxis of acute and chronic kidney, pancreas or liver, for 2 - 5 days after heart transplantation
graft versus host disease iv)Treatment of steroid- ii)1.5 mg/kg/day for 3 - 14 days iii)2.5 - 5.0 mg/kg/day for 4 days
resistant, acute graft versus host disease v)Treatment of iv)2.5 - 5.0 mg/kg/day for 5 days v)2.5 - 3.5 mg/kg/day for 5 days
aplastic anemia
Antivenene Cobra Injection J06AA03-000-P30-02-XXX B Treatment of patients who exhibit manifestations of - Initial dose of 100ml of reconstituted antivenene given by slow
systemic envenoming following a bite by Cobra (Naja intravenous infusion (2ml/min). Subsequent dose can be given
kaouthia). every 12 hours according to the clinical symptoms. As product
may differ from batches and manufacturer, it is strongly
recommended to refer to the product insert on dosing
recommendation.
Antivenene Pit Viper Injection J06AA03-000-P30-01-XXX B Treatment of patients who exhibit manifestations of - Initial dose of 30ml of reconstituted antivenene given by slow
systemic envenoming following a bite by Malayan Pit intravenous infusion (2ml/min). Subsequent dose can be given
Viper (Calloselasma rhodostoma). every 6 hours according to the clinical symptoms. As product may
differ from batches and manufacturer, it is strongly
recommended to refer to the product insert on dosing
recommendation.
Antivenene Serum (Sea snake) 1000 units J06AA03-000-P30-03-XXX B Treatment of patients who exhibit manifestations of - 1000 units by IV infusion over 1/2 to 1 hour. In severe cases 3000
Injection systemic envenoming following a bite by sea snake. -10000 units may be required
April 2023 10

Apixaban 2.5mg film coated tablet. B01AF02-000-T32-01-XXX A* Prevention of stroke and systemic embolism in adult None 5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally
patients with non-valvular atrial fibrillation (NVAF), with twice daily in NVAF patients with at least two of the following
one or more risk factors, such as prior stroke or transient characteristics: age ≥80 years old, body weight≤60kg, or serum
ischaemic attack (TIA); age ≥ 75 years; hypertension; creatinine≥1.5mg/dL (133micromole/L).
diabetes mellitus; symptomatic heart failure (NYHA Class
≥ II).
Apixaban 5mg film coated tablet. B01AF02-000-T32-02-XXX A* Prevention of stroke and systemic embolism in adult None 5 mg taken orally twice daily. Dose reduction: 2.5mg taken orally
patients with non-valvular atrial fibrillation (NVAF), with twice daily in NVAF patients with at least two of the following
one or more risk factors, such as prior stroke or transient characteristics: age ≥80 years old, body weight≤60kg, or serum
ischaemic attack (TIA); age ≥ 75 years; hypertension; creatinine≥1.5mg/dL (133micromole/L).
diabetes mellitus; symptomatic heart failure (NYHA Class
≥ II).
Aprepitant 125 mg Capsule A04AD12-000-C10-02-XXX A* In combination with other antiemetic agents for - 125 mg 1 hour prior to chemotherapy on Day 1. To be given as
prevention of delayed nausea and vomiting associated part of a 3-day regimen that includes a corticosteroid and a 5-HT3
with initial and repeat course of highly emetogenic antagonist
chemotherapy
Aprepitant 80 mg Capsule A04AD12-000-C10-01-XXX A* In combination with other antiemetic agents for - 80 mg once daily in the morning on Days 2 and Day 3. To be given
prevention of delayed nausea and vomitting associated as part of a 3-day regimen that includes a corticosteroid & a 5-
with initial and repeat course of highly emetogenic HT3 antagonist
chemotherapy
Aqueous Cream D02AX00-000-G10-01-XXX C+ As an emollient for dry skin. Can be used as soap None As a soap or apply to the skin as an emollient cream
substitute for bathing.
Aripiprazole 10mg Tablet N05AX12-000-T10-01-XXX A* i) Treatment of acute episodes of schizophrenia and for - Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day.
maintenance of clinical improvement during Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment
continuation therapy. ii) Treatment of acute manic should occur at intervals of not less than 24 hour
episodes associated with bipolar I disorder
Aripiprazole 15mg Tablet N05AX12-000-T10-02-XXX A* i) Treatment of acute episodes of schizophrenia and for - Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day.
maintenance of clinical improvement during Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment
continuation therapy. ii) Treatment of acute manic should occur at intervals of not less than 24 hour
episodes associated with bipolar I disorder
Aripiprazole 400 mg powder and solvent for N05AX12-010-P20-01-XXX A* Maintenance treatment of schizophrenia in adult As second-line therapy among patients with poor or Recommended starting and maintenance dose is 400 mg to be
prolonged-release suspension for injection patients stabilized with oral aripiprazole uncertain adherence to oral antipsychotics. administered once monthly as a single injection (no sooner than
26 days after the previous injection). After the first injection,
treatment with 10 mg to 20 mg oral aripiprazole should be
continued for 14 consecutive days to maintain therapeutic
aripiprazole concentrations during initiation of therapy.
Arsenic Trioxide 1 mg/ml Injection L01XX27-550-P30-01-XXX A* Relapsed acute promyelocytic leukaemia (APML). To be prescribed by consultant haematologist only. Induction : 0.15 mg/kg/day IV until bone marrow remission. Total
induction dose ≤ 60 doses. Consolidation : 0.15 mg/kg/day IV for
25 doses in 5 weeks (5 days per week, followed by 2 days
interruption; treatment should begin 3-6 weeks after completion
of induction therapy).
Artemether 20mg + Lumefantrine 120mg Tablet P01BE52-981-T10-01-XXX B Acute uncomplicated falciparum malaria - ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as
a single dose at the time of initial diagnosis, again 4 tablets after
8 hours and then 4 tablets twice daily (morning and evening) on
each of the following two days (total course comprises 24
tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6
dose regimen with 1 to 3 tablets per dose, depending on
bodyweight
April 2023 11

Artesunate 100 mg and Mefloquine HCI 220 P01BF02-000-T10-02-XXX A Treatment of acute uncomplicated Plasmodium - Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x
mg Tablet falciparummalaria, resulting either from P. falciparum 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg
mono-infection or mixed infection with P. vivax. OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet
100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two
tablet 100/220mg OD x 3 days
Artesunate 25 mg and Mefloquine HCI 55 mg P01BF02-000-T10-01-XXX A Treatment of acute uncomplicated Plasmodium - Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x
Tablet falciparummalaria, resulting either from P. falciparum 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg
mono-infection or mixed infection with P. vivax. OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet
100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two
tablet 100/220mg OD x 3 days
Artesunate 60 mg Injection P01BE03-000-P30-01-XXX B Treatment of severe malaria in adults and children. - 2.4mg of artesunate/kg body weight, by intravenous (IV) or
intramuscular (IM) injection, at 0, 12 and 24 hours, then once
daily until oral treatment can be substituted. For adults and
children with severe malaria or who are unable to tolerate oral
medicines, artesunate 2.4 mg/kg body weight IV or IM given on
admission (time = 0), then at 12 hrs and 24 hrs, then once a day
for 5-7 days is the recommended treatment.
Artificial tears/eye lubricant ophthalmic gel S01KA02-000-G32-XX-XXX B Symptomatic relief of severe dry eye conditions and as None Instill 1-2 drops in affected eye(s) as needed. Refer to product
lens lubricant during ophthalmic diagnostic procedures information leaflet.
Artificial tears/eye lubricant ophthalmic S01XA20-900-G51-XX-XXX A Moisturizes the ocular surface and provides soothing None Apply a small amount into the eye. Refer product information
ointment relief from symptoms associated with dry, irritated eyes. leaflet.
Artificial tears/eye lubricant ophthalmic S01XA20-000-D20-XX-XXX B Tear deficiency, ophthalmic lubricant; for relief of dry None 1 - 2 drops several times a day. Refer to product information
solution eyes and eye irritation leaflet.
Ascorbic Acid 100 mg Tablet A11GA01-000-T10-02-XXX C+ Vitamin C deficiency - ADULT: 100-250 mg once or twice daily CHILD: 100 mg three
times daily for one week followed by 100mg daily until symptoms
abate.
Ascorbic Acid 500 mg Tablet A11GA01-000-T10-03-XXX C+ Vitamin C deficiency - ADULT: 100-250 mg once or twice daily CHILD: 100 mg three
times daily for one week followed by 100mg daily until symptoms
abate.
Ascorbic Acid 500 mg/2 ml Injection A11GA01-000-P30-01-XXX B For prevention and treatment of scurvy - Therapeutic: Not less than 250 mg daily in divided doses
Asenapine 10mg Sublingual Tablet N05AH05-253-T70-02-XXX A* For second or third line treatment in adult for: i) - i) Schizophrenia: - Acute treatment in adults: Recommended
Schizophrenia ii) Bipolar Disorder - Monotherapy: Acute starting and target dose of asenapine is 5mg given twice daily. -
treatment of manic or mixed episodes associated with Maintenance dose: 5mg twice daily. ii) Bipolar Disorder: -
Bipolar I disorder. - Adjunctive therapy: As adjunctive Monotherapy: 10mg twice daily. Adjunctive therapy: 5mg twice
therapy with either lithium or valproate for the acute daily with lithium or valproate. Dose can be increased to 10mg
treatment of manic or mixed episodes associated with twice daily based on clinical response.
Bipolar I Disorder.
Asenapine 5mg Sublingual Tablet N05AH05-253-T70-01-XXX A* For second or third line treatment in adult for: i) - i) Schizophrenia: - Acute treatment in adults: Recommended
Schizophrenia ii) Bipolar Disorder - Monotherapy: Acute starting and target dose of asenapine is 5mg given twice daily. -
treatment of manic or mixed episodes associated with Maintenance dose: 5mg twice daily. ii) Bipolar Disorder: -
Bipolar I disorder. - Adjunctive therapy: As adjunctive Monotherapy: 10mg twice daily. Adjunctive therapy: 5mg twice
therapy with either lithium or valproate for the acute daily with lithium or valproate. Dose can be increased to 10mg
treatment of manic or mixed episodes associated with twice daily based on clinical response.
Bipolar I Disorder.
April 2023 12

Atazanavir 300mg capsule J05AE08-183-C11-01-XXX A* Treatment of HIV-1 infected, antiretroviral treatment For Infectious Disease Consultant use, in patients with The recommended dose is 300mg once daily taken with ritonavir
experienced adults, in combination with other treatment failure on NNRTI regime. 100mg once daily and with food. Ritonavir is used as a booster of
antiretroviral medicinal products. atazanavir pharmacokinetics. If atazanavir with ritonavir is co-
administrated with didanosine, it is recommended that
didanosine be taken 2 hours after atazanavir with ritonavir taken
with food.
Atenolol 100 mg Tablet C07AB03-000-T10-02-XXX B i) Hypertension ii) Arrhythmias iii) Angina pectoris iii) None i), ii) & iii) 50 - 100 mg daily iv) Dosing is individualised and
Myocardial infarction according to product insert / protocol.
Atenolol 50 mg Tablet C07AB03-000-T10-01-XXX B i) Hypertension ii) Arrhythmias iii) Angina pectoris iii) None i), ii) & iii) 50 - 100 mg daily iv) Dosing is individualised and
Myocardial infarction according to product insert / protocol.
Atomoxetine HCl 10 mg Capsule N06BA09-110-C10-01-XXX A* Attention deficit hyperactivity disorder (ADHD) in - CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for
children 6 years and older who do not respond to at least 7 days, then increased according to response.
methylphenidate or who have intolerable effects or have Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more
tics. Diagnosis should be made according to DSM IV than 70 kg: Initially 40 mg/day for at least 7 days then increased
criteria or the guidelines in ICD-10 according to response. Maintenance: 80 mg/day. Max 100 mg/
day
day
day
day
Atomoxetine HCl 60mg Capsule N06BA09-110-C10-05-XXX A* Attention deficit hyperactivity disorder (ADHD) in - CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for
day
Atorvastatin 20 mg Tablet C10AA05-000-T10-02-XXX B i) Hypercholesterolaemia ii) Prevention of cardiovascular None i) & ii) 10 mg once daily. Maximum: 80 mg daily
disease
Atorvastatin 40 mg Tablet C10AA05-000-T10-01-XXX B i) Hypercholesterolaemia ii) Prevention of cardiovascular None i) & ii) 10 mg once daily. Maximum: 80 mg daily
disease
Atorvastatin 80 mg Tablet C10AA05-000-T10-04-XXX A/KK i) Hypercholesterolaemia ii) Prevention of cardiovascular None i) & ii) 10 mg once daily. Maximum: 80 mg daily
disease
April 2023 13

Atosiban 7.5mg/ml Injection G02CX01-122-P30-01-XXX A* To delay imminent preterm birth in pregnant women None Initial intravenous bolus dose of 6.75mg (as 7.5 mg/ml solution)
with: i)Regular uterine contractions of at least 30 Immediately followed by a continuous loading intravenous
seconds duration at a rate of ≥ 4 per 30 minutes ii) A infusion at 18mg/hr for 3 hours and then followed by intravenous
cervical dilation of 1 to 3 cm (0 - 3 nulliparas) and infusion at 6mg/hr up to 45 hours. The total duration of
effacement of ≥ 50% iii) Age ≥ 18 years iv) A gestational treatment should not exceed 48 hours and the total dose per
age from 28 until 33 completed weeks v) A normal foetal treatment course should not exceed 330mg of the active
heart rate. substance. The dosing is individualized according to product
insert / protocol.
Atracurium Besylate 10 mg /ml in 2.5 ml M03AC04-197-P30-01-XXX A* Muscle relaxant in general anaesthesia, Endotracheal - Adult & children >2 mth 0.3-0.6 mg/kg IV. Endotracheal
Injection intubation, Aid controlled ventilation. intubation dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2
mg/kg as required. Continuous infusion rates of 0.3-0.6 mg/kg/hr
to maintain neuromuscular block during long surgical procedure.
Atracurium Besylate 10 mg /ml in 5 ml Injection M03AC04-197-P30-02-XXX A* Muscle relaxant in general anaesthesia, Endotracheal - Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation
intubation, Aid controlled ventilation. dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2 mg/kg as
required. Continuous infusion rates of 0.3-0.6 mg/kg/hr to
maintain neuromuscular block during long surgical procedure.
Atropine Sulphate 0.3%, Cocaine HCl 1.7%, S01F000-183-P30-01-XXX A Subconjunctival injection to dilate pupils resistant to None 1 - 2 drops
Adrenaline Acid Tartrate (Epinephrine) 0.03% topical mydriatics
Mydriatic Injection
Atropine Sulphate 1% Eye Drops S01FA01-183-D20-01-XXX B Determination of refraction, strabismus, iritis and None Use in adults - For uveitis: 1 drop in the eye(s), 3 times daily. - For
iridocyclitis, after extra or intracapsular extraction of lens refraction: 1 drop in the eye(s), repeated 1 hour before the
examination
Atropine Sulphate 1mg/ml Injection A03BA01-183-P30-01-XXX B i) Reduce vagal inhibition,salivary and bronchiol None i) Adult: 300-600 mcg IM/SC 30-60 minutes before anaesthesia.
secretion in anaesthesia ii) Reversal of excessive Alternatively, 300-600 mcg IV immediately before induction of
bradycardia iii) Reversal of effect of competitive muscle anaesthesia. Child: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9
relaxants iv) Overdosage with other compounds having kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin
muscarinic action v) Organophosphate poisoning 30-60 minutes before anaesthesia. ii) Adult: 500 mcg every 3-5
minutes. Total: 3 mg. Max Dosage: 0.04 mg/kg body weight. iii)
Adult 0.6-1.2 mg before or with anticholinesterase iv) Adult: 0.6-1
mg IV/IM/SC, repeated every 2 hr. v) Adult: 2 mg IV/IM, every 10-
30 minutes until muscarinic effects disappear or atropine toxicity
appears. In severe cases, dose can be given as often as every 5
minutes. In moderate to severe poisoning, a state of
atropinisation is maintained for at least 2 days and continued for
as long as symptoms are present. Child: 20 mcg/kg given every 5-
10 minutes.
Azacitidine Powder for suspension for injection L01BC07-000-P40-01-XXX A* First line therapy for intermediate-2 and high risk MDS, - Recommended starting dose for the first treatment cycle, for all
100mg/vial CMMOL with 10-29% blasts with no transplant option patients regardless of baseline haematology laboratory values, is
and elderly AML with 20-30% blasts and multilineage 75mg/m2 of body surface area. Injected subcutaneously. Daily for
dysplasia. 7 days, followed by a rest period of 21 days (28 day treatment
cycle).
April 2023 14

Azathioprine 50 mg Tablet L04AX01-000-T10-01-XXX A i) Prophylaxis of rejection in organ and tissue transplant - i) Adult: 1-5 mg/kg/day. Adjust dose according to clinical
ii) Auto-immune diseases iii) Rheumatoid arthritis response and haematological tolerance. Dose may also be given
via IV administration. ii) Adult: 1-3 mg/kg/day. Discontinue
treatment if there is no improvement after 12 week. iii) Adult:
Initially, 1 mg/kg/day given in 1-2 divided doses for 6-8 week,
may increase by 0.5 mg/kg every 4 week until response or up to
2.5 mg/kg/day. Maintenance: Reduce dose gradually to achieve
the lowest effective dose.
Azelaic Acid 20% Cream D10AX03-000-G10-01-XXX A* Acne vulgaris - Apply twice daily (sensitive skin, once daily for 1st week).
Treatment should not exceed 6 months
Azelastine Hydrochloride 137mcg & R01AD58-984-A41-01-XXX A* Symptomatic treatment of moderate to severe allergic As a second line treatment: only for those whose One actuation in each nostril twice daily
Fluticasone Propionate 50mcg Nasal Spray rhinitis and rhino-conjunctivitis in adults and children 12 symptoms remain uncontrolled on oral antihistamine or
years and older where use of a combination (intranasal intranasal corticosteroids (INS) monotherapy, or on a
antihistamine and glucocorticoid) is appropriate combination of oral antihistamine plus INS
Azithromycin 200 mg/5 ml Granules J01FA10-011-F10-01-XXX A*, A/KK PRESCRIBER CATEGORY A*: Treatment of complicated - CHILD 36 - 45 kg: 400 mg, 26 - 35 kg: 300mg, 15 - 25 kg 200 mg,
respiratory tract infections. PRESCRIBER CATEGORY less than 15 kg: 10 mg/kg. To be taken daily for 3 days or to be
A/KK: Treatment of pertussis taken as a single dose on day 1, then half the daily dose on days 2
-5
Azithromycin 250 mg Tablet J01FA10-011-T10-01-XX A*, A/KK Category of prescriber A/KK is only approved for - i) 1 g as a single dose; ii) 500mg in a single dose on day 1 then
indications: (i) Adult treatment of uncomplicated genital 250mg per day on days 2-5 iii) 500 mg daily for 3 days; iv) 1 g
infections due to Chlamydia trichomatis or susceptible weekly
Neisseria gonorrhoea. (ii) Treatment of pertussis The
following indications are still under the category of
prescriber A*: (iii) Treatment of complicated respiratory
tract infections; (iv) Prophylaxis against Mycobacterium
avium complex in patients with advanced HIV.
Azithromycin 500 mg Injection J01FA10-011-P40-01-XXX A* i) Severe atypical pneumonia ii) Treatment of pelvic - i) 500 mg IV as a single daily dose for a minimum of two days
inflammatory diseases (PID) caused by susceptible followed by 500 mg oral dose as a single daily dose to complete a
organisms in patients who require initial IV therapy 7 - 10 days course ii) 500 mg as a single dose by the IV route for 1
or 2 days followed by oral azithromycin at a single daily dose of
250 mg to complete a 7-day course of therapy.
Bacampicillin 400 mg Tablet J01CA06-000-T10-01-XXX B Infections caused by ampicillin-sensitive gram positive& - ADULT: 400 mg twice daily. Severe infection: 800 mg twice daily.
gram negative microorganisms CHILD more than 25 kg: 12.5 - 25 mg/kg 12 hourly
Baclofen 10mg Tablet M03BX01-000-T10-01-XXX B Spasticity of the skeletal muscle None ADULT:5 mg 3 times daily. Max: 80 mg daily (20mg 4 times a day).
CHILD: starting dose: 0.3mg/kg/day in divided dose, titrate up
cautiously in 1 -2 weeks interval. Usual maintenance dose: 0.75 -
2 mg/kg daily (age more than 10 years, maximum: 2.5 mg/kg
daily). The dose should not exceed 40 mg/day in children below 8
years of age, but a maximum dose of 60 mg/day may be given in
children over 8 years of age. Dosing is individualised and
according to product insert/protocol
Balanced Salt Solution B05CB10-907-L50-01-XXX A For irrigation during ocular surgery - Irrigate as directed
Balanced Salt Solution PLUS (fortified with B05CB10-905-L50-01-XXX A For irrigation during intraocular surgery especially in - Irrigate as directed
sodium bicarbonate, glucose & glutathione) patients with poor cornea endothelium and poorly
controlled diabetes
April 2023 15

Baricitinib 2mg film-coated tablets L04AA37-000-T32-01-XXX A* Treatment of moderate to severe active rheumatoid To be prescribed by Rheumatologist only 4mg once daily
arthritis in adult patients who have responded
inadequately to, or who are intolerant to one or more
disease-modifying anti-rheumatic drugs. May be used as
monotherapy or in combination with methotrexate.
Baricitinib 4mg film-coated tablets L04AA37-000-T32-02-XXX A* Treatment of moderate to severe active rheumatoid To be prescribed by Rheumatologist only 4mg once daily
arthritis in adult patients who have responded
inadequately to, or who are intolerant to one or more
disease-modifying anti-rheumatic drugs. May be used as
monotherapy or in combination with methotrexate.
Barium Sulphate Suspension V08BA01-183-L80-01-XXX B For x-ray examination of the alimentary tract: i) - i) Up to 150 ml of a 50% - 200% suspension orally ii) Up to 300 ml
Oesophagus ii) Stomach and duodenum iii) Colon of a 30% - 200% suspension orally iii) Up to 2 litre of a 30% -
200% suspension orally
Basiliximab 20 mg Injection L04AC02-000-P30-01-XXX A* Prophylaxis of acute organ rejection in de novo renal None ADULT & CHILD 2 years and above & 35 kg or more:20 mg /dose.
transplantation. 2 years or more but less than 35kg:10 mg/dose. First dose given
within 2 hours before start of transplantation and second dose
4th day after transplant
BCG (Bacillus Calmette-Guérin) Intravesical L03AX03-000-P30-01-XXX A* Superficial bladder cancer None 80mg intravesically once weekly for 8 weeks. Dosing is
Injection individualised and according to product inserts/protocols.
BCG Vaccine Freeze-Dried Injection J07AN01-000-P40-01-XXX C+ For the prevention of tuberculosis. None 0.05 to 0.1 ml by intradermal. Dosing is according to
Immunisation Schedule under NIP.
Beclomethasone Dipropionate 100 mcg/dose R03BA01-133-A21-01-XXX B Prophylaxis of asthma especially if not fully controlled by None Adults: The usual maintenance dose is one to two inhalations
Inhaler bronchodilators (200-400 mcg) twice daily.If needed,the dose can be increased up
to 1600 mcg/day divided in two to four doses : Children 6-12
years old: One inhalation (200 mcg) two times daily and dose may
be increased up to 800 mcg/day in divided two to four doses if
necessary.
Beclomethasone dipropionate 100mcg and R03AK07-986-A21-01-XXX A/KK i) Regular treatment of asthma where use of a None For asthma, the dosage is based on treatment approach: i)
formoterol fumarate dihydrate 6mcg combination product (inhaled corticosteroid and long- Maintenance therapy (taken as regular maintenance treatment
pressurized inhalation solution acting beta2 agonist) is appropriate in: a) Patients not with a separate as needed rapid-acting bronchodilator): Dose
adequately controlled with inhaled corticosteroids and recommendations for adults 18 years and above: One or two
"as needed" inhaled short-acting beta2 agonist, or b) inhalations twice daily. The maximum daily dose is 4 inhalations.
Patients already adequately controlled on both inhaled ii) Maintenance and reliever therapy (taken as regular
corticosteroids and long-acting beta2-agonists. The maintenance treatment and as needed in response to asthma
following indication (COPD) is categorised as A* - To be symptoms): Dose recommendations for adults 18 years and
initiated by Consultant/ Specialists from disciplines above: The recommended maintenance dose is 1 inhalation twice
related to the listed indication only: ii) Treatment of daily (one inhalation in the morning and one inhalation in the
COPD patients with a blood eosinophil count of 300 evening). Patients should take 1 additional inhalation as needed
cells/microliter and more iii) Treatment of COPD patients in response to symptoms. If symptoms persist after a few
with blood eosinophil count of 100 cells/microliter and minutes, an additional inhalation should be taken. The maximum
more with history of repeated exacerbation despite daily dose is 8 inhalations. For COPD: 2 puffs two times a day.
regular treatment with long-acting bronchodilators.
Beclomethasone Dipropionate 200mcg/dose R03BA01-133-A21-02-XXX A/KK Prophylaxis of asthma especially if not fully controlled by None ADULT : 1 - 2 puff twice daily. May increase to 2 puff 2 - 4 times
Inhaler bronchodilators daily CHILD : 1 puff twice daily. May increase to 1 puff 2 - 4 times
daily
April 2023 16

Bendamustine Hydrochloride 100mg/vial L01AA09110P3302XX A* Bendamustine is indicated for monotherapy in patients Monotherapy for iNHL refractory to rituximab: 120mg/m2 body
powder for concentrate for solution for infusion with indolent B-cell non-Hodgkin's lymphomas (iNHL) surface area bendamustine hydrochloride on days 1 and 2; every
that has progressed during or within six months of 3 weeks.
treatment with rituximab or a rituximab-containing
regimen.
Bendamustine Hydrochloride 25mg/vial L01AA09110P3301XX A* Bendamustine is indicated for monotherapy in patients Monotherapy for iNHL refractory to rituximab: 120mg/m2 body
powder for concentrate for solution for infusion with indolent B-cell non-Hodgkin's lymphomas (iNHL) surface area bendamustine hydrochloride on days 1 and 2; every
that has progressed during or within six months of 3 weeks.
treatment with rituximab or a rituximab-containing
regimen.
Benzalkonium 0.01% - 0.02% Cream D08AJ01000G1001XX B Prevention and treatment of nappy rash Wash and dry baby's bottom. Apply by spreading the cream
evenly paying particular attention to the fold of the skin, after
every nappy change
Benzalkonium Chloride Disinfectant Solution V07AV00100L9908XX C Low level disinfectant suitable for general cleaning and Cleaning purposes: Dilute 1 in 10. Disinfection, use undiluted
disinfection of hard surface
Benzathine Penicillin 2.4 MIU (1.8 g) Injection J01CE08702P4001XX B i) Treatment of mild to moderately severe infections due i) ADULT: 1.2 mega units IM ii) For syphillis: 2.4 mega units
to Penicillin G-sensitive organisms ii) Treatment of weekly for 1 - 3 weeks
syphillis
Benzhexol 2 mg Tablet N04AA01110T1001XX B i) Symptomatic treatment of paralysis agitans and of i) & iii) Initial: 1-2mg daily Maintenance: Gradual increment to 6-
parkinsonism, arteriosclerotic, idiopathic, or post- 10mg daily according to response ii) 5-15mg daily Dosing is
encephalitic origin ii) Alleviate extrapyramidal syndrome individualised and according to product insert / protocol.
induced by phenothiazine derivatives or reserpine iii)
Spasmodic torticollis, facial spasms and other dyskinesia
Benzoic Acid Compound Half Strength (Paed) D01AE12952G5001XX C Tinea infections of the skin Apply sparingly to affected area once or twice daily
Ointment
Benzoic Acid Compound Ointment D01AE12952G5002XX C Tinea infections of thickened skin of palms and soles Apply sparingly to affected area once or twice daily
Benzoin Compound Tincture D08AX00000L5001XX C Infected skin, lesions, cuts, abrasions, wounds and burns Apply undiluted to the skin 1 or 2 times daily. Duration of
therapy, may be weeks to months depending on the infection
being treated
Benzoyl Peroxide 10% Gel D10AE01241G3002XX B Mild to moderate acne vulgaris Apply 1-2 times daily preferably after washing with soap and
water
Benzoyl Peroxide 5% Gel D10AE01241G3001XX B Mild to moderate acne vulgaris Apply 1-2 times daily preferably after washing with soap and
water
Benzydamine HCl 0.15% Solution A01AD02110M2001XX B For relief of painful condition of the oral cavity Used as a 30 seconds gargle or rinse, undiluted. ADULT 15 ml.
CHILD less 12 years 5-15 ml. Uninterrupted treatment should not
be more than 7 days
Benzydamine Hydrochloride 3.0 mg/ml throat A01AD02110A4201XX A* Temporary relief of painful conditions of the mouth and ADULTS and CHILDREN OVER 12 YEARS: 2-4 sprays (1-2mg)
spray throat including tonsillitis, sore throat, radiation directly onto the sore/inflamed area and swallow gently. Repeat
mucositis, aphthous ulcers, pharyngitis, swelling, every 1 1/2 to 3 hours as necessary. CHILDREN 6-12 YEARS: 2
redness, inflammatory conditions, post-orosurgical and sprays (1mg) directly onto sore/ inflamed area and swallow
periodontal procedures. (For pediatric and gently. Repeat every 11/2 to 3 hours as necessary. CHILDREN
otorhinolaringology use. Restrict to patients who are not UNDER 6 YEARS: Not recommended. Uninterrupted treatment
able to gargle) should not exceed seven days, unless under medical supervision
Benzyl Benzoate 12.5 % Emulsion (Child) P03AX01252L2001XX C Scabies - for child 2-12 years old After bath, apply over the whole body, neck down and leave on
for 24 hours then wash off. Reapply for another 24 hours, the
first repeat application should be within 5 days of the initial
application, a third application may be required in some cases
April 2023 17

Benzyl Benzoate 25 % Emulsion (Adult) P03AX01000L2002XX C+ Scabies for adult and children more than 12 years old. After bath, apply over the whole body, neck down and leave on
for 24 hours then wash off. Reapply for another 24 hours, the
first repeat application should be within 5 days of the initial
application, a third application may be required in some cases.
Benzylpenicillin 1 mega unit (600 mg) Injection J01CE01702P4001XX B i) Infections caused by susceptible organisms ii) Infective i) Adult: 600mg - 3600mg (1 - 6 mega units) daily, divided into 4
endocarditis to 6 doses. Higher doses (24 mega units) in divided doses may be
given in serious infections such as meningitis. Child 1 month to 12
years old: 100mg/kg/day in 4 divided doses, not exceeding
4g/day; Infants 1 -4 weeks: 75mg/kg/day in 3 divided doses;
Newborn Infants: 50mg/kg/day in 2 divided doses ii)7.2 to 12g
(12 - 20 mega units) maybe given daily in divided doses
Benzylpenicillin 10,000 units/ml Eye Drops S01AA14-702-D20-02-XXX B Eye infection None 1-2 drops every 15 minutes or accordingly to needs of the patient
Benzylpenicillin 2,500 units/ml (1.5 mg/ml) Eye S01AA14-702-D20-01-XXX B Eye infection None 1-2 drops every 15 minutes or accordingly to needs of the patient
Drops
Benzylpenicillin 5 mega unit (3g) Injection J01CE01702P4002XX B i) Infections caused by susceptible organisms ii) Infective i) ADULT: 600 - 1200 mg IM 4 times daily, increased if necessary
endocarditis in more serious infections. CHILD: 50 - 100 mg/kg body weight
daily IV in 2 - 4 divided doses ii) ADULT: 7.2 g daily by slow IV
infusion in 6 divided doses
Beractant Intratracheal Suspension (200mg R07AA02-000-L80-01-XXX A* Treatment of newborn baby with birth weight of 700 g None 100 mg/kg (4 ml/kg) body weight intratracheally up to 4 doses in
phospholipids in 8 ml vial) or greater undergoing mechanical ventilation for 1st 48 hr. Doses should not be given more frequently than 6 hrly.
respiratory distress syndrome, whose heart rate and To be administered as soon as possible.
arterial oxygenation are continuously monitored
Betahistine Dihydrochloride 24 mg Tablet N07CA01110T1003XX A/KK i) Meniere's Syndrome as defined by the following core (Hanya terpakai untuk fasiliti kesihatan primer) Short term 24-48mg in divided doses daily
symptoms: - Vertigo (with nausea/vomiting). - Hearing (max. 2 months) treatment with Betahistine can be
loss (Hardness of hearing). - Tinnitus (ringing in the ears) initiated by Family Medicine Specialist (FMS) for patients
ii) Symptomatic treatment of vestibular vertigo with Menieres syndrome and vestibular vertigo, pending
referral/ evaluation by the Otorhinolaryngology team.
Betamethasone 17-Valerate 0.01-0.05% Cream D07AC01-256-G10-01-XXX B Topical corticosteroid indicated for the relief of None Apply sparingly to affected area 2 times daily then reduced to
inflammatory and pruritic manifestation of steroid- once daily when improvement occurs.
responsive dermatoses.
Betamethasone 17-Valerate 0.01-0.05% D07AC01-256-G50-01-XXX B Eczema, prurigo nodularis, limited psoriasis in None Apply sparingly to affected area 2 - 3 times daily then reduced to
Ointment appropriate in sites once daily when improvement occurs
Betamethasone 17-Valerate 0.1% Cream D07AC01-256-G10-02-XXX A Potent topical corticosteroid indicated for adults, elderly None Apply sparingly to affected area 2 times daily then reduced to
and child over 1 year for relief of inflammatory and once daily when improvement occurs
pruritic manifestation of steroid responsive dermatoses.
Betamethasone 17-Valerate 0.1% Ointment D07AC01-256-G50-02-XXX A Potent topical corticosteroid indicated for adults, elderly None Apply sparingly to affected area 2 times daily then reduced to
and child over 1 year for relief of inflammatory and once daily when improvement occurs.
pruritic manifestation of steroid responsive dermatoses
Betamethasone Disodium Phosphate and S03CA06-991-D10-01-XXX B Eye: Infected inflammatory conditions of the eyes. Ear: None Eye: 1 drops 3-4 times daily. Ear: 4 drops 3-4 times daily
Neomycin Sulphate 0.5% Ear/Eye Drops Allergic dermatosis in the ear
April 2023 18

Bicalutamide 50 mg Tablet L02BB03000T1001XX A* Androgen deprivation therapy in advanced prostate 50 mg once daily. (morning or evening), with or without food.
cancer in combination with luteinising hormone- Take on the same time each day. Adult: When used with
releasing hormone (LHRH) analogue therapy or surgical gonadorelin analogue: Usual dose: 50 mg once daily. May be
castration. started with or at least 3 days before starting gonadorelin
analogue therapy.
Bimatoprost 0.01% ophthalmic solution S01EE03-000-D20-02XXX A* Reduction of elevated intraocular pressure in chronic To be used as 2nd line One drop in the affected eye(s) once daily, administered in the
open-angle glaucoma and ocular hypertension in adults evening.
(as monotherapy or as adjunctive therapy to beta
blockers).
Bisacodyl 10mg Suppository A06AB02-000-S20-02-XXX C i) Constipation ii) Bowel preparation for radiological None i) ADULT and CHILD (over 10 years): 10 mg per rectal; CHILD (4 to
procedures and surgery 10 years): 5 mg per rectal. ii) ADULT and CHILD (over 10 years: )10
to 20 mg; CHILD (4 to 10 years): 5 mg the following morning
before procedures insert rectally
Bisacodyl 5 mg Tablet A06AB02-000-T10-01-XXX C i) Constipation ii) Bowel preparation for radiological None i) ADULT and CHILD (over 10 years): 5 to 10 mg; CHILD (4 to 10
procedures and surgery years): 5 mg. To be taken at night for effect on the following
morning. ii) ADULT and CHILD (over 10 years): 10 mg in the
morning and 10 mg in the evening the day before procedures;
CHILD (4 to 10 years): 5 mg the night before procedures.
Bisacodyl 5mg Suppository A06AB02-000-S20-01-XX C i) Constipation ii) Bowel preparation for radiological None i) ADULT and CHILD (over 10 years): 10 mg per rectal; CHILD (4 to
procedures and surgery 10 years): 5 mg per rectal. ii) ADULT and CHILD (over 10 years: )10
to 20 mg; CHILD (4 to 10 years): 5 mg the following morning
before procedures insert rectally
Bismuth Subnitrate, Iodoform and Liquid R01AX30-984-G60-01-XXX B As a mild antiseptic for wounds and abscesses. Sterile None As directed for local application
Paraffin Paste gauze impregnated with paste for packing cavities after
otorhinological surgery
Bisoprolol Fumarate 2.5 mg Tablet C07AB07-000-T10-01-XXX B i) Hypertension ii)Coronary heart disease (angina None 1.25 mg once daily, gradually titrate to maximum tolerable dose
pectoris) iii) Treatment of stable congestive cardiac (i) & (ii): Max: 20mg/ day (iii): Max 10mg/ day
failure in addition to ACEI's and diuretics
Bisoprolol Fumarate 5 mg Tablet C07AB07-000-T10-02-XXX B i) Hypertension ii)Coronary heart disease (angina None 1.25 mg once daily, gradually titrate to maximum tolerable dose
pectoris) iii) Treatment of stable congestive cardiac (i) & (ii): Max: 20mg/ day (iii): Max 10mg/ day
failure in addition to ACEI's and diuretics
Bleomycin 15 mg Injection L01DC01110P4001XX A Solid tumours; Lymphomas 15 - 30 mg weekly in divided doses or 10 - 20 mg/m2 once or
twice weekly or 10 mg/m2 slow bolus in 15 minutes D1 and D15.
Total dosage:should not exceed 300 mg. CHILD: 10 - 15 mg/m2
over 6 hours every 3 - 4 weeks (Routes: SC, IM, IV (either as bolus
or as infusion over 24 hours), intra-arterial, intra-pleural)
Bortezomib 3.5 mg Injection L01XX32000P3001XX A* Treatment of multiple myeloma 1.3 mg/m2 bodysurfacearea twice weekly for two weekson days
1, 4, 8, and 11 in a 21-day treatment cycle. At least 3 days should
elapse between consecutive doses of bortezomib.
Bosentan 125 mg tablet C02KX01-000-T10-01-XXX A* Treatment of pulmonary arterial hypertension (PAH) in None Initially 62.5 mg bd for 4 weeks, then increase to the
patients of WHO functional class II-IV. maintenance dose of 125 mg bd
Brimonidine Tartrate 0.15% Ophthalmic S01EA05-123-D20-01-XXX A* Lowering of intraocular pressure in patients with open- None 1 drop in the affected eye(s) 3 times daily
angle glaucoma or ocular hypertension
Brinzolamide 1% and Brimonidine Tartrate S01EC54-990-D20-01-XXX A* Decrease of elevated intraocular pressure (IOP) in adult None 1 drop in the affected eye(s) 2 times daily.
0.2% ophthalmic suspension patients with open-angle glaucoma or ocular
hypertension for whom monotherapy provides
insufficient IOP reduction.
April 2023 19

Brinzolamide 1% ophthalmic suspension S01EC04-000-D20-01-XXX A* Indicated for the treatment of elevated intraocular For patients who require carbonic anhydrase inhibitor 1 drop 2 times daily. Some patients may have a better response
pressure (IOP) in patients with open-angle glaucoma or (CAI) but could not tolerate Dorzolamide. with one drop three times a day. The dose should not exceed 1
ocular hypertension. drop in the affected eye(s) 3 times daily.
Brolucizumab 120mg/mL solution for Injection S01LA06-000-P30-01-XXX A* Indicated in adults for the treatment of neovascular • For refractory cases of nAMD despite prior anti-VEGF • The recommended dose is 6 mg brolucizumab (0.05 ml solution)
(wet) age related macular degeneration (nAMD). To be prescribed by Ophthalmology Retina Specialist only administered by intravitreal injection every 4 weeks (monthly) for
the first 3 doses. Thereafter, the physician may individualise
treatment intervals based on disease activity as assessed by
visual acuity and/or anatomical parameters. A disease activity
assessment is suggested 16 weeks (4 months) after treatment
start. In patients without disease activity, treatment every 12
weeks (3 months) should be considered. In patients with disease
activity, treatment every 8 weeks (2 months) should be
considered. If visual and anatomical outcomes indicate that the
patient is not benefiting from continued treatment, brolucizumab
should be discontinued.
Bromazepam 3 mg Tablet N05BA08000T1002XX A Anxiety disorders Adult: Initially, 6-18 mg daily in divided doses. Doses up to 60 mg
daily have been used. Elderly: Max initial dose: 3 mg daily
Bromhexine HCl 4mg/2ml Injection R05CB02-110-P30-01-XXX A Secretolytic therapy in acute and chronic None 4mg IM or IV 2 - 3 times daily (maximum 12mg/day).
bronchopulmonary diseases associated with abnormal
mucous secretion and impaired mucous transport
Bromhexine HCl 4mg/5ml Oral Solution R05CB02-110-L10-01-XXX B Secretolytic therapy in acute and chronic None Adult: 8-16 mg three times daily. Children: By body weight: 0.3
bronchopulmonary diseases associated with abnormal mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or
mucous secretion and impaired mucous transport Based on age: 6-12 years – 4mg three times daily; 2-6 years –
2mg three times daily; Less than 2 years – 1mg three times daily.
Bromhexine HCl 8mg Tablet R05CB02-110-T10-01-XXX C Secretolytic therapy in acute and chronic Medical Assistant in health settings without Medical Adult: 8-16 mg three times daily. Children: By body weight: 0.3
bronchopulmonary diseases associated with abnormal Officer is allowed to prescribe this medicine for adult use mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or
mucous secretion and impaired mucous transport. only. Based on age: 6-12 years – 4 mg three times daily; 2-6 years – 2
mg three times daily
Bromocriptine Mesilate 2.5mg Tablet G02CB01-196-T10-01-XXX A/KK i) Hypogonadism, galactorrhoea, infertility in men and None i) Initial dose of 1.25-2.5mg once daily at bedtime. Dose may be
women, cyclical benign breast and menstrual disorders increased by 2.5mg/day every 3 to 7 days as tolerated to a total
ii) Acromegaly iii) Hyperprolactinaemia, prolactinomas of 5 to 7.5mg daily in divided doses ii) 1.25 - 2.5 mg at bedtime
iv) Parkinson's disease for 3 days and may be increased by 1.25 - 2.5 mg every 3 to 7
days up to 30 mg a day in divided doses iii) Initial dose of 1.25mg,
two or three times a day. Increase dosage gradually over several
weeks to 10 - 20mg a day in divided doses. Higher doses may be
required iv) Initial dose of 1.25 mg one or two times a day. Dose
may be increased by 2.5mg/day increments in 2 -to 4-week
intervals as needed. Maintenance dose ranges from 10 to 30mg
daily in divided doses. Dosing is individualised and according to
Budesonide 100mcg/dose Inhaler R03BA02-000-A21-01-XXX B Maintenance treatment of asthma as prophylactic None ADULT:200 - 1600 mcg daily in 2-4 divided doses. Maintenance
therapy especially if not fully controlled by with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2
bronchodilators - 7 years: 200-400 mcg. To be inhaled in 2 - 4 divided doses.
April 2023 20

Budesonide 160mcg and Formoterol 4.5mcg R03AKO7-989-A21-01-XXX A/KK Category of prescriber A/KK: i) Regular treatment of None i) Asthma Maintenance therapy: Adult ≥18 yr 160 mcg to 320 mcg
Inhalation asthma where use of a combination (inhaled bd. Some patients may require up to a max of 640 mcg bd.
corticosteroid and long-acting beta2-agonist) is Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160
appropriate: - Patients not adequately controlled with mcg bd, <6 yr Not recommended. Maintenance & relief Adult and
inhaled corticosteroids and "as needed" inhaled short- adolescent ≥12 yr 320 mcg/day either as 160 mcg bd or 320 mcg
acting beta2-agonists. or - Patients already adequately od either morning or evening. For some patients a maintenance
controlled on both inhaled corticosteroids and long- dose of 320 mcg bd may be appropriate. Patients should take 160
acting beta2-agonists. ii) As a reliever treatment for mild mcg additional inhalation as needed in response to symptoms. If
asthma patients who do not adhere to regular inhaled symptoms persist after a few minutes, an additional inhalation
corticosteroid Category of prescriber A*: iii) Treatment should be taken. Not more than 960 mcg should be taken on any
of COPD patients with a blood eosinophil count of 300 single occasion. A total daily dose of more than 1280 mcg is not
cells/microliter and more iv) Treatment of COPD patients normally needed, however a total daily dose of up to 1920 mcg
with blood eosinophil count of 100 cells/microliter and could be used for a limited period. Patients using more than 1280
more with history of repeated exacerbation despite mcg daily should seek medical advice, should be reassessed &
regular treatment with long-acting bronchodilators. their maintenance therapy reconsidered. ii) Asthma reliever-only
therapy: 160 mcg as needed, but no more than 960 mcg to be
taken on any single occasion. Children <12 yr: Not recommended
iii & iv) COPD: Adult ≥18 yr 320 mcg bd.
Budesonide 1mg/2ml Nebuliser Solution R03BA02-000-A30-02-XXX B Treatment of asthma in patients where use of a None ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of
pressurized inhaler or dry powder formulation is age : 500 mcg - 1 mg. Maintenance dose : half of the above doses
unsatisfactory or inappropriate.
Budesonide 200mcg/dose Inhalation R03BA02-000-A21-02-XXX B Maintenance treatment of asthma as prophylactic None ADULT: 200-1600 mcg daily in 2-4 divided doses. Maintenance
therapy especially if not fully controlled by with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2
bronchodilators - 7 years: 200-400 mcg. To be inhaled in 2-4 divided doses.
Budesonide 500 mcg/2 ml Nebuliser Solution R03BA02-000-A30-01-XXX B Treatment of asthma in patients where use of a None ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of
pressurized inhaler or dry powder formulation is age : 500 mcg - 1 mg. Maintenance dose : half of the above doses
unsatisfactory or inappropriate.
Budesonide 64mcg Nasal Spray R01AD05-000-A41-03-XXX A/KK Seasonal allergic, perennial rhinitis and nasal polyposis None ADULT and CHILD 6 years and older. Rhinitis : 2 spray into each
nostril once daily in the morning or 1 spray into each nostril twice
daily. Nasal polyps : 2 spray twice daily
Bumetanide 0.5 mg/ml Injection C03CA02-000-P30-01-XX A* Oedema used in furosemide allergic patient None IV injection: 1 - 2 mg repeated after 20 mins. IV infusion: 2 - 5 mg
over 30 - 60 mins
Bumetanide 1 mg Tablet C03CA02000T1001XX A* Oedema used in furosemide allergic patient None 1 mg in the early evening. Up to 5 mg daily in severe cases
Bupivacaine 0.5 % Heavy Injection N01BB01110P3003XX A Used for spinal anaesthesia None ADULT: 2 - 4 ml. Not to exceed 2 mg/kg in a single dose
Bupivacaine 0.5 % Injection N01BB01110P3002XX B For peripheral sympathetic nerve and epidural None Regional nerve block or epidural block: 15 - 30 ml. Nerve block of
(excluding caudal) anaesthesia and obstetrics finger or toe: 2 - 6 ml. Maximum: 2 mg/kg body weight in any 4
anaesthesia hours period, equivalent to 25 - 30 ml in adults of average weight
Bupivacaine 0.5 % with Adrenaline 1:200,000 N01BB51975P3001XX B Regional nerve block or epidural block. None 10 - 40 ml (0.25 %) or maximum : 2 mg/kg body weight in any 4
Injection hours period, equivalent to 25 - 30 ml of 0.5% solution
April 2023 21

Buprenorphine 10mcg/hr transdermal patch N02AE01110M7001XX A* Treatment of non-malignant pain of moderate intensity For elderly patients or patients with Once weekly transdermal patch/for hospital use only. Patient
when an opioid is necessary for obtaining adequate comorbidities/difficult to swallow aged 18 years and over. Initial dose: 5 mcg/hr For elderly: Renal
analgesia. Not suitable for the treatment of acute pain. impairment. No special dose adjustments necessary in patients
with renal impairment Hepatic impairment Patients with hepatic
insufficiency should be carefully monitored during the treatment
with buprenorphine patch. Alternate therapy should be
considered. Patch should be used with cautions in severe hepatic
impairment patient
Buprenorphine 5mcg/hr transdermal patch N02AE01110M7003XX A* Treatment of non-malignant pain of moderate intensity For elderly patients or patients with Once weekly transdermal patch/for hospital use only. Patient
when an opioid is necessary for obtaining adequate comorbidities/difficult to swallow aged 18 years and over. Initial dose: 5 mcg/hr For elderly: Renal
analgesia. Not suitable for the treatment of acute pain. impairment. No special dose adjustments necessary in patients
with renal impairment Hepatic impairment Patients with hepatic
insufficiency should be carefully monitored during the treatment
with buprenorphine patch. Alternate therapy should be
considered. Patch should be used with cautions in severe hepatic
impairment patient
Busulfan 2 mg Tablet L01AB01000T1001XX A i) Chronic myeloid leukaemia (CML) and other i) ADULT: Initial: 2 - 4 mg daily. Maintenance: 0.5 - 2 mg daily.
myeloproliferative diseases ii) Haemopoietic stem cell Stop when white blood cell less than 20 x 109/L. CHILD: 60
transplant (HSCT)- refer to specific protocols mcg/kg body weight daily ii) CHILD: Induction 60 mcg/kg body
weight daily (maximum 4 mg) if leucocytes more than
20,000/mm3 and platelets more than 100,000/mm3.
Maintenance 10 - 30mcg/kg (maximum 2 mg daily)
Busulfan 6 mg/ml Injection L01AB01000P3001XX A* For use in combination with cyclophosphamide as a In selected cases with high risk of liver toxicity and 0.8 mg/kg of ideal body weight or actual body weight, whichever
conditioning regimen prior to allogeneic hematopoietic intolerance to oral busulfan. is lower via central venous catheter as a 2-hour infusion on the
stem cell transplantation (HSCT) for chronic basis of every 6 hours for 4 days, for a total of 16 doses. For
myelogenous leukemia. To be prescribed by paediatric obese or severely obese patients, IV Busulfan should be
oncologist and consultant haematologist trained in administered based on adjusted ideal body weight
transplant only.
Cabergoline 0.5mg Tablet G02CB03-000-T10-01-XXX A* i) Inhibition of physiological lactation soon after None i) 1 mg as a single dose during the first post-partum day ii) 0.25
parturition ii) Suppression of established lactation iii) mg every 12 hours for 2 days iii) Initial: 0.5 mg/week given in one
Treatment of hyperprolactinaemic disorders or two divided weekly doses. May gradually increase dose by 0.5
mg/week no sooner than every 4 weeks until an optimal
therapeutic response is achieved. Usual dose range: 0.25 mg to 2
mg/week (higher doses >1 mg /week may be divided in as many
as 3 to 4 divided doses)
Calamine Cream D04AX00000G1001XX C+ Soothes and relieves nappy rashes, prickly heat, minor Apply to the affected area as required, 1-3 times daily
skin irritations, insect bites and sunburn, Pruritic skin
conditions.
Calamine Lotion D04AX00000L8001XX C+ Soothes and relieves nappy rashes, prickly heat, minor Apply to the skin as required and allow to dry, 1-3 times daily
conditions.
Calamine with 0.25 - 0.5% Menthol Lotion D04AX00952L6001XX C Soothes and relieves nappy rashes, prickly heat, minor Apply to the skin as required and allow to dry, 1 - 3 times daily
conditions.
Calamine with 0.5% Phenol Cream D04AX00-952-G10-01-XXX C Relief symptoms of mild sunburn and other minor skin None Apply to the affected area as required
conditions (such as dry and itchy skin)
April 2023 22

Calamine with 2 - 6% Precipitated Sulphur D04AX00952L6002XX C Acne vulgaris Apply to the skin as required and allow to dry, 1 - 3 times daily
Lotion
Calcipotriol 50mcg/g Cream D05AX02-000-G10-01-XXX A* Psoriasis vulgaris. None ADULT Apply to the affected skin lesions twice daily.
Maintenance therapy may be achieved with less frequent
application. The weekly dose should not exceed 100 g. CHILD
over 6 years, apply twice daily. 6-12 years maximum 50gm
weekly, over 12 years maximum 75gm weekly. The dosing is
individualized according to product insert / protocol
Calcipotriol 50mcg/g Ointment D05AX02-000-G50-01-XXX A* Psoriasis Vulgaris None ADULT Apply to the affected skin lesions twice daily.
Maintenance therapy may be achieved with less frequent
application. The weekly dose should not exceed 100g. CHILD over
6 years, apply twice daily. 6-12 years maximum 50gm weekly,
over 12 years maximum 75gm weekly The dosing is individualized
according to product insert / protocol
Calcipotriol Hydrate 50 mcg/g & D05AX52-952-G50-01-XXX A* Resistant plaque psoriasis None Apply once daily up to 4 weeks with maximum weekly dose of
Betamethasone Dipropionate 0.5 mg/g 100g and maximum treatment area 30% of body surface
Ointment
Calcipotriol Monohydrate 50 mcg/g & D05AX52-952-G30-01-XXX A* Topical treatment of scalp and non-scalp plaque None Should be applied to affected areas once daily. The
Betamethasone Dipropionate 0.5 mg/g Gel psoriasis vulgaris in adults recommended treatment period is 4 weeks for scalp areas and 8
weeks for non-scalp areas. The body surface area treated with
calcipotriol containing products should not exceed 30% and
maximum dose should not exceed 15g or 100g/ week
Calcipotriol Monohydrate 50mcg/g & D05AX52-946-L62-01-XXX A* Resistant plaque psoriasis Second line topical treatment when unresponsive to Apply once daily up to 4 weeks with maximum daily dose of 15g
Betamethasone Dipropionate 0.5mg/g topical steroid and coal tar and maximum treatment area 30% of body surface
Cutaneous Foam
Calcitonin (synthetic Salmon) 100 IU Injection H05BA01000P3002XX A* Acute hypercalcaemia 5-10 IU per kg body weight in 500mL physiological saline daily by
i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4
divided doses spread over the day. Renal impairment: Dosage
adjustment needed.
Calcitonin (Synthetic Salmon) 50 IU Injection H05BA01000P3001XX A* Acute hypercalcaemia 5-10 IU per kg body weight in 500mL physiological saline daily by
i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4
divided doses spread over the day. Renal impairment: Dosage
adjustment needed.
Calcitriol 0.25 mcg Capsule A11CC04-000-C10-01-XXX A/KK i) Osteoporosis ii) Chronic kidney disease-mineral bone - i) 0.25 mcg 2 times daily ii) ADULT and CHILD 3 years and older:
disorder iii) Hypoparathyroidism and Initial dose: 0.25 mcg. In patients with normal or only slightly
pseudohypoparathyroidism iv) Rickets and osteomalacia reduced serum calcium levels, doses of 0.25 mcg every other day
is sufficient. Dosage may be increased if necessary to 0.5
mcg/day. Maintenance dose: 0.5-1mcg daily CHILD less than 3
years: 10 to 15 ng/kg/day iii) and iv) 0.25 mcg/day given in the
morning
Calcitriol 1 mcg/ml Injection A11CC04000P3001XX A* Management of hypocalcaemia and/or secondary Initially dose, depending on severity, 1 mcg (0.02 mg/kg) to 2 mcg
hyperparathyroidism in patients undergoing chronic 3 times weekly, approximately every other day
renal dialysis
Calcitriol 2 mcg/ml Injection A11CC04000P3002XX A* Management of hypocalcaemia and/or secondary Initially dose, depending on severity, 1 mg (0.02 mg/kg) to 2 mg 3
hyperparathyroidism in patients undergoing chronic times weekly, approximately every other day
renal dialysis
April 2023 23

Calcium Carbonate 500 mg Capsule A12AA04-121-C10-01-XXX B i) Hyperphosphatemia (phosphate binder) in chronic None i) Total dose of elemental calcium from calcium-based phosphate
kidney disease patients ii) Calcium supplementation binder not to exceed 1,500 mg/day. Dosing is individualised
based on serum phosphate level and according to product
insert/protocol ii) 500 mg to 4g per day as calcium carbonate in 1-
3 divided doses (500mg capsule contains 200mg elemental
calcium) Dosing is individualised based on serum calcium level
and according to product insert/protocol
Calcium Carbonate 500 mg Tablet A12AA04-121-T10-01-XXX B i) Hyperphosphatemia (phosphate binder) in chronic None i) Total dose of elemental calcium from calcium-based phosphate
kidney disease patients ii) Calcium supplementation binder not to exceed 1,500 mg/day. Dosing is individualised
based on serum phosphate level and according to product
insert/protocol ii) 500 mg to 4g per day as calcium carbonate in 1-
3 divided doses (500mg capsule contains 200mg elemental
calcium) Dosing is individualised based on serum calcium level
Calcium Chloride Dihydrate, Sodium Chloride, B05BB01-905-P60-02-XXX A Replacement of extracellular fluid losses in the case of None The maximum infusion rate depends on the needs of the patient
Magnesium Chloride Hexahydrate, Sodium isotonic dehydration, where acidosis is present or in fluid replacement and electrolytes, patient's weight, clinical
Acetate Trihydrate,Potassium Chloride, and imminent. condition, and biological status. Adults, elderly,
Malic Acid Solution adolescents:500ml-3L/24hr. Babies, children: 20ml to
100ml/kg/24 hr.
Calcium Disodium Edetate 200 mg Injection V03AB03-999-P30-01-XXX A Lead Poisoning None IM (Lead encephalopathy): 1000 mg/m(2)/day IM in divided
equal doses 8 to 12 hours apart, for 5 days. Therapy is
interrupted for 2 to 4 days, and followed by an additional 5-day
course of therapy, if indicated. Do not exceed the recommended
daily dosage. IV: 1000 mg/m(2)/day administered IV over 8 to 12
hours for 5 days. Therapy is interrupted for 2 to 4 days, and
followed by an additional 5-day course of therapy, if indicated.
Calcium Gluconate 10% Injection A12AA03-000-P30-01-XXX B i)Acute hypocalcaemia ii)Hypocalcaemic tetany None i) ADULT: 1 to 2 g (2.2 to 4.4 mmol). CHILD: 50mg/kg/dose
iii)Cardiac resuscitation (0.5ml/kg/dose) IV short infusion over at least 10 to 20 minutes,
per dose. Max: 20ml per dose; ii) ADULT: 1g (2.2 mmol) by slow
IV injection followed by continuous infusion of 4 g (8.8 mmol)
daily; iii) IV or intracardiac injection, 1g (2.2mmol). Dosing is
Calcium Lactate 300 mg Tablet A12AA05-125-T10-01-XXX C For prophylaxis of calcium deficiency and treatment of None ADULT: 300mg - 600mg (as elemental Ca) daily in in divided
chronic hypocalcaemia doses; Dosing is individualised and according to product
insert/protocol
Calcium Polystyrene Sulphonate Powder V03AE01-999-F21-01-XXX A*, A/KK PRESCRIBER CATEGORY A*: Hyperkalemia resulting from None ADULT: 15 – 30g daily in 2-3 divided doses. Each dose should be
acute or chronic renal failure PRESCRIBER CATEGORY suspended in 30 – 50ml of water and administered orally at least
A/KK: For asymptomatic mild hyperkalemia without ECG 3 hours before or 3 hours after other oral medications. CHILD:
changes 0.125-0.25g/kg orally or rectally 4 times per day (max: 10g/dose).
NEONATE: 0.125-0.25g/kg rectally 4 times/day. Evacuate the
resin 8-12 hours after the last dose with glycerine enema. (Oral
route is CONTRAINDICATED in neonates). Dosing is individualised
April 2023 24

Calfactant 35mg/ml intratracheal suspension R07AA02-000-L91-04-XXX A* For the prevention of Respiratory Distress Syndrome None 3mL/kg body weight at birth to be administered every 12 hours
(RDS) in premature infants at high risk for RDS and for for total up to 3 doses.
the treatment (“rescue”) of premature infants who
develop RDS. Prophylaxis: Indicated for premature
infants <29 weeks of gestational age at significant risk
for RDS. Should be administered as soon as possible,
preferably within 30 minutes after birth. Treatment:
Indicated for infants ≤72 hours of age with RDS
(confirmed by clinical and radiologic findings) and
requiring endotracheal intubation.
Capecitabine 150 mg Tablet L01BC06000T1002XX A* i) Metastatic breast cancer; ii) Treatment of colorectal i) & ii) 1250 mg/m2 twice daily (morning and evening) for 2
cancer in adjuvant and metastatic setting; iii) advanced weeks, every 21 days. iii) Recommended for a total of 24 weeks
oesophagogastric cancer in combination with a platinum- (8 cycles of 2 weeks of drug administration and 1 week rest
based regimen. period. Iv) In combination with a platinum on day 1, give
capecitabine 1250 mg/m2 twice daily for 14 days. Repeated every
3 weeks for 8 cycles or optimum number of cycles
Capecitabine 500 mg Tablet L01BC06000T1001XX A* i) Metastatic breast cancer; ii) Treatment of colorectal i) & ii) 1250 mg/m2 twice daily (morning and evening) for 2
cancer in adjuvant and metastatic setting; iii) advanced weeks, every 21 days iii) Recommended for a total of 24 weeks (8
oesophagogastric cancer in combination with a platinum- cycles of 2 weeks of drug administration and 1 week rest period
based regimen. iv) In combination with a platinum on day 1, give capecitabine
1250 mg/m2 twice daily for 14 days. Repeated every 3 weeks for
8 cycles or optimum number of cycles
Captopril 25 mg Tablet C09AA01000T1002XX B i) Hypertension ii) Congestive heart failure iii) Post- None i) Initial: 25-75mg in 2-3 divided doses Maintenance: 100-150mg
myocardial infarction iv) Diabetic kidney disease in 2-3 divided doses ii) Initial: 6.25-12.5mg 2-3 times daily
Maintenance: 75-150mg daily in divided doses iii) Initial: 6.25mg
followed by 12.5mg and then 25mg Maintenance: 75-150mg
daily in 2-3 divided doses iv) 75-100 mg in divided doses Dosing is
individualised and according to product insert / protocol.
Carbachol 0.01% Intraocular Solution S01EB02-100-D20-01-XXX A For intraocular use for miosis during surgery None Instill no more than 0.5 ml gently into the anterior chamber
Carbamazepine 100 mg/5 ml (2% w/v) Syrup N03AF01-000-L90-01-XXX A Epilepsy None ADULT: Initially, 100-200 mg once or twice daily gradually
increased by increments of 100-200 mg every 2 week.
Maintenance: 0.8-1.2 g daily in divided doses. Max: Adult: 1.6 g
daily CHILD: 10-15 years: 0.6-1 g daily 5-10 years: 400-600 mg
daily 1-5 years: 200-400 mg daily less than or equal to 1 year: 100-
200 mg daily. Alternatively, 10-20 mg/kg body weight daily in
divided doses.
Carbamazepine 200 mg CR Tablet N03AF01-000-T50-01-XXX A i) Epilepsy ii) Trigeminal Neuralgia iii) Idiopathic None ADULT: Initial, 200 mg twice daily for the first week, may increase
glossopharyngeal neuralgia iv) Acute mania and dosage by 200 mg/day at weekly intervals until optimal response
maintenance of bipolar affective disorder to prevent or is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage
attenuate recurrence 1000 mg/day in children 12-15 years of age, 1200 mg/day in
patients above 15 years of age
April 2023 25

Carbamazepine 200 mg Tablet N03AF01-000-T10-01-XXX B i) Epilepsy ii) Trigeminal neuralgia i) ADULT: 100 - 200 mg 1 - 3 times daily increased gradually to
usual dose of 0.8 - 1.2 g daily in divided doses. CHILD: Up to 1
year: 100 - 200 mg daily 1 - 5 yrs: 200 - 400 mg daily 5 - 10 years:
400 - 600 mg daily 10 - 15 years: 0.6 - 1 g daily ii) The initial
dosage of 200 to 400mg should be slowly raised daily until
freedom from pain is achieved (normally at 200mg 3 to 4 times
daily). The dosage should then be gradually reduced to the
lowest possible maintenance level. In elderly patients, an initial
dose of 100mg twice daily is recommended.
Carbamazepine 400 mg CR Tablet N03AF01-000-T50-02-XXX A i) Epilepsy ii) Trigeminal Neuralgia iii) Idiopathic None ADULT: Initial, 200 mg twice daily for the first week, may increase
glossopharyngeal neuralgia iv) Acute mania and dosage by 200 mg/day at weekly intervals until optimal response
maintenance of bipolar affective disorder to prevent or is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage
attenuate recurrence 1000 mg/day in children 12-15 years of age, 1200 mg/day in
patients above 15 years of age
Carbamide (Urea) 10 % Cream D02AE01000G1001XX B Contact irritant dermatitis, infantile eczemas, acute and Apply sparingly and rub into affected area 2 - 3 times daily and
chronic allergic eczemas, icthyosis, hyperkeratotic when required after cleansing skin
Carbetocin 100 mcg/ ml Injection H01BB03000P2001XX A* Prevention of uterine atony and postpartum A single IV dose of 100mcg (1ml) is adminitered by bolus
hemorrhage following elective cesarean section under injection, slowly over 1minute, only when delivery of the infant
epidural or spinal anaesthesia has been completed by caesarean section under epidural or
spinal anaesthesia, before or after delivery of the placenta.
Carbimazole 5 mg Tablet H03BB01000T1001XX B Hyperthyroidism ADULT: Initially, 10-60mg daily in divided doses given 8 hourly.
Maintenance: 5 to 20mg daily. CHILDREN > 6 years: Initially 15mg
daily in divided doses. CHILDREN 1-6 years: Initially 7.5mg daily in
divided doses
Carboplatin 10mg/mL Injection L01XA02000P4001XX A* i) Solid tumours; ii) Salvage therapy for lymphoma 360 - 400 mg/m2 BSA, by IV infusion over 15 mins to 1 hour on
Day 1 every 4 weeks. Alternatively, prescription may be based on
Area Under Curve (AUC) calculations. CHILD: 500-600 mg/m2
over 1 hour once every 3 weeks. Salvage regimes in lymphomas -
refer to specific protocols. Starting dose in renal impairment,
please refer to product insert.
Carboprost Tromethamine 250mcg Injection G02AD04-999-P30-01XXX A* Treatment of refractory postpartum haemorrhage None Initially 250 mcg deep IM inj. The dose may be repeated at
unresponsive to conventional methods of management. intervals of 15-90 min if necessary. Max total dose: 2000 mcg (8
doses).
Cardioplegia solution containing Potassium B05XA16-934-P30-01-XXX A* For myocardial preservation(prevent myocardial None Dilute 20 ml to 1 L of Ringer solution (cooled to 2-8 ∞C prior to
Chloride, Magnesium chloride & Procaine HCl damage) during cardiac surgery use). Initial rapid instillation into aortic root at 300 ml/m≤ body
Injection surface area/min for 3 minutes. Should myocardial activity persist
or recur instill at 300ml/m≤ body surface area/min for 2 minutes
Carvedilol 25mg Tablet C07AG02-000-T10-02-XX A/KK i) Treatment of all patients with stable and symptomatic, None i) Initial: 3.125mg twice daily for 2 weeks Maintenance: Titrate up
mild, moderate and severe chronic heart failure in to as tolerated Max: <85 kg: 25 mg twice daily >85 kg: 50 mg
combination with ACEis and diuretics ii) Hypertension iii) twice daily ii) Initial: 12.5mg once daily Maintenance: 25mg once
Angina pectoris daily Max. 50mg daily in 1 or 2 divided doses iii) Initial: 12.5mg
once daily Maintenance: 25mg once daily Max. 100mg daily in 1
or 2 divided doses Dosing is individualised and according to
product insert / protocol.
April 2023 26

Carvedilol 6.25mg Tablet C07AG02-000-T10-01-XX A/KK i) Treatment of all patients with stable and symptomatic, None i) Initial: 3.125mg twice daily for 2 weeks Maintenance: Titrate up
mild, moderate and severe chronic heart failure in to as tolerated Max: <85 kg: 25 mg twice daily >85 kg: 50 mg
combination with ACEis and diuretics ii) Hypertension iii) twice daily ii) Initial: 12.5mg once daily Maintenance: 25mg once
Angina pectoris daily Max. 50mg daily in 1 or 2 divided doses iii) Initial: 12.5mg
once daily Maintenance: 25mg once daily Max. 100mg daily in 1
or 2 divided doses Dosing is individualised and according to
Caspofungin Acetate 50 mg Injection J02AX04122P4001XX A* i) Confirmed systemic fungal infection in patients who i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70
are refractory or intolerant to other fungal therapies. ii) mg infused over 1 hour followed by subsequent doses of 50
For pediatric patient (12 month and older) for the mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV
following indications : a) Empirical therapy for presumed infusion over approximately 1 hour ii) For all indications, a
fungal infections in febrile, neutropenic patients b) loading dose of 70mg/m2 on D1 followed by maintenance dose
Treatment of invasive candidiasis, including candidemia of 50mg/m2 od.
and the following Candida infections ; intra-abdominal
abscesses, peritonitis and pleural space infections c)
Treatment of esophageal candidiasis d) Treatment of
invasive Aspergillosis in patients who are refractory to or
intolerant of others therapy (eg : Amphotericin B)
Caspofungin Acetate 70 mg Injection J02AX04122P4002XX A* i) Confirmed systemic fungal infection in patients who i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70
are refractory or intolerant to other fungal therapies. ii) mg infused over 1 hour followed by subsequent doses of 50
For pediatric patient (12 month and older) for the mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV
following indications : a) Empirical therapy for presumed infusion over approximately 1 hour daily ii) Child (12months to 17
fungal infections in febrile, neutropenic patients b) years) : For all indication) A single 70mg/m2 loading dose (not to
Treatment of invasive candidiasis, including candidemia exceed an actual dose of 70mg) by slow IV infusion over 1hour;
and the following Candida infections ; intra-abdominal followed by 50mg/m2 (not to exceed an actual dose of 70mg)
abscesses, peritonitis and pleural space infections c)
Treatment of esophageal candidiasis d) Treatment of
invasive Aspergillosis in patients who are refractory to or
intolerant of others therapy (eg : Amphotericin B)
Cefaclor 125 mg/5 ml Suspension J01DC04000F2101XX A Infections caused by susceptible organisms including CHILD:>1 mth: 20 mg/kg daily in 3 divided doses, increased to 40
Staphylococcus aureus and H. influenzae, treatment of mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5
sinusitis and infections involving the respiratory tract, yr: 250 mg tid. Maximum: 1 g daily
skin and skin structure, bone and joint, and urinary tract
Cefaclor 500 mg Capsule J01DC04000C1002XX A Infections caused by susceptible organisms including ADULT: 250 mg 3 times daily for 10 days. For severe infections,
Staphylococcus aureus and H. influenzae, treatment of double the dosage. Maximum: 4 g daily. CHILD:>1 mth: 20 mg/kg
sinusitis and infections involving the respiratory tract, daily in 3 divided doses, increased to 40 mg/kg daily if necessary,
skin and skin structure, bone and joint, and urinary tract <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid .
Maximum: 1 g daily
Cefazolin Sodium 1 g Injection J01DB04520P3001XX A Infection caused by cefazolin-sensitive microorganism, ADULT: Uncomplicated infections: 500 - 1000 mg 2 - 3 times
infection of the respiratory tract, urogenital tract, skin daily. Moderately severe and severe infections: 500 - 1000 mg 3 -
and soft tissue, bile duct, bones and joint, endocarditis, 4 times daily. Severe life-threatening infections: 1 - 1.5 g 4 times
systemic septic infection, peri-operative/ surgical daily. Rarely, dose up to 12 g daily. CHILDREN >1 month: 25-
prophylaxis 50mg/kg/day in 3-4 divided dose
April 2023 27

Cefepime 1 g Injection J01DE01110P4002XX A* Febrile neutropenia, septicaemia, lower respiratory tract ADULT: 1 - 2 g twice daily for most infections. For severe
infection, urinary tract infection, skin and skin structure infections including febrile neutropenia: 2 g 3 times daily. CHILD:2
infections, gynaecologic and intra-abdominal infections mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days
Cefoperazone Sodium 1g Injection J01DD12-520-P40-02-XXX A Infections due to gram-negative bacteria None ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be
doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT:
50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8
days: 50 - 200 mg/kg/day 12 hourly
Cefoperazone Sodium 2g Injection J01DD12-520-P40-03-XXX A Infections due to gram-negative bacteria None ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be
doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT:
50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8
days: 50 - 200 mg/kg/day 12 hourly
Cefoperazone Sodium 500mg & Sulbactam J01DD62-000-P40-01-XXX A i) Treatment of infections due to multi-drug resistance None ADULT: 1 - 2 g twice daily. In severe or refractory infections the
Sodium 500mg Injection pathogens producing B-lactamase ii) Treatment of daily dosage of sulbactam/cefoperazone may be increased up to
infections caused by Acinetobacter species 8g (4g cefoperazone activity) CHILD: 40 - 80 mg/kg/day in 2 to 4
equally divided doses; in serious or refractory infections, may
increase to 160mg/kg/d in 2 - 4 equally divided doses.
Cefotaxime 1 g Injection J01DD01520P4002XX A Infections due to gram-negative bacteria ADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 -
180 mg/kg/day in 4 - 6 divided doses
Cefotaxime 500 mg Injection J01DD01520P4001XX A Infections due to gram-negative bacteria ADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 -
180 mg/kg/day in 4 - 6 divided doses
Ceftaroline Fosamil 600mg Powder for J01D102-000-P40-01-XXX A* Treatment of complicated skin and soft tissue infections Restricted for only complicated SSTI in patients who are 600mg administered every 12 hours by intravenous infusion over
concentrate for solution for infusion (cSSTI) in adults unable to tolerate or not responding to vancomycin. 60 minutes for 5-14 days. Dose adjustment in renal impairment: -
CrCl > 30 to ≤50 ml/min : 400mg (IV) every 12 hours (over 60
minutes) - CrCl ≥ 15 ≤ 30 ml/min: 300mg (IV) every 2 hours (over
60 minutes) - CrCl < 30ml/min including hemodialysis*: 200mg
(IV) every 12 hours (over 60 minutes) * Ceftaroline is
hemodialyzable, thus should be administered after hemodialysis.
Ceftazidime 1 g Injection J01DD02520P4003XX A Severe gram negative bacterial infections ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8
hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
Ceftazidime 2 g Injection J01DD02520P4004XX A Severe gram negative bacterial infections ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8
hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
Ceftolozane 1000mg & Tazobactam 500mg J01DI54-000-P40-01-001 A* For the treatment of patients 18 years or older with the Indication (i) & (ii): Confirmed carbapenem-resistant 1.5g (ceftolozane 1g and tazobactam 0.5g) administered every 8
Injection following infections. i) Treatment of complicated Intra- Pseudomonas aeruginosa as an alternative to Polymyxins hours by intravenous infusion over 1 hour in patients 18 years or
abdominal Infections (cIAI), to be used in combination (Polymyxin sparing). Indication (iii): i) Confirmed older with normal renal function or mild renal impairment. i) 1.5g
with metronidazole. ii) Treatment of complicated Urinary carbapenem-resistant Pseudomonas aeruginosa as an every 8 hours for 4-14 days ii) 1.5g every 8 hours for 7 days iii) 3g
Tract Infections (cUTI) including Pyelonephritis. iii) alternative to Polymyxins (Polymyxin sparing). ii) (Ceftolozane 2g and Tazobactam 1g) every 8 hours by
Nosocomial Pneumonia, including Ventilator Associated Treatment initiated after proven susceptibility to intravenous infusion over 1 hour in patients 18 years or older, for
Pneumonia ceftolozane/tazobactam via C&S testing iii) To be 8 to 14 days
prescribed by Infectious Disease Specialist only
Ceftriaxone 0.25 g Injection J01DD04520P4001XX A/KK i) Gonorrhoea ii) Chancroid i) 250 mg by deep IM injection ii) single IM injection 250 mg only.
For severe infection up to 100 mg/kg/day
Ceftriaxone 0.5 g Injection J01DD04520P4002XX A Infections caused by susceptible organisms ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour
intervals. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight
daily, not to exceed 50 mg/kg INFANT & CHILD, 3 weeks - 12
years: 20 - 80 mg/kg body weight daily. CHILD with body weight
50 kg or more: adult dose.
April 2023 28

Ceftriaxone 1g Injection J01DD04520P4003XX A Infections caused by susceptible organisms ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour
intervals. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight
daily, not to exceed 50 mg/kg INFANT & CHILD, 3 weeks - 12
years: 20 - 80 mg/kg body weight daily. CHILD with body weight
50 kg or more: adult dose.
Cefuroxime Axetil 125 mg Tablet J01DC02233T1001XX A/KK Upper and lower respiratory tract, genito-urinary tract, ADULT: 250 mg twice daily ;UTI: 125 mg twice daily. CHILD:30
skin & soft tissue and urinary tract infections (UTI) mg/kg/day in 2 divided doses, up to 500 mg daily
Cefuroxime Axetil 125 mg/5 ml Suspension J01DC02233F2101XX A Infections caused by susceptible organisms 30 mg/kg/day in 2 divided doses, up to 500 mg daily.
Cefuroxime Axetil 250 mg Tablet J01DC02233T1002XX A/KK Upper and lower respiratory tract, genito-urinary tract, ADULT: 250 mg twice daily ;UTI: 125 mg twice daily. CHILD:30
skin & soft tissue and urinary tract infections (UTI) mg/kg/day in 2 divided doses, up to 500 mg daily
Cefuroxime Sodium 1.5 g Injection J01DC02520P4003XX A Infections caused by susceptible organisms, surgical ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections:
prophylaxis 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4
divided doses or 2-3 divided doses in neonates. Surgical
prophylaxis: 1.5 g IV
Cefuroxime Sodium 750 mg Injection J01DC02520P4002XX A Infections caused by susceptible organisms, surgical ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections:
prophylaxis 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4
divided doses or 2-3 divided doses in neonates. Surgical
prophylaxis: 1.5 g IV
Celecoxib 200 mg Capsule M01AH01-000-C10-01-XXX A/KK i) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) i) ADULTS: 200 mg once daily. May increase to 200 mg bid, if
Ankylosing Spondylitis necessary. CHILD not recommended ii) 100mg twice daily,
increased if necessary to 200 mg 2 times daily; CHILD not
recommended iii) 400mg as a single dose on first day followed by
200mg once daily on subsequent days iv) Initial, 200 mg once
daily or 100 mg twice daily; if no effect after 6 weeks, may
increase to max. 400 mg daily in 1-2 divided doses. If no response
following 2 weeks of treatment with 400 mg/day, consider
discontinuation and alternative treatment
Celecoxib 400 mg Capsule M01AH01-000-C10-02-XXX A* i) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) i) ADULTS: 200 mg once daily. CHILD not recommended ii) 100
Ankylosing Spondylitis mg twice daily, increased if necessary to 200 mg 2 times daily;
CHILD not recommended iii) 400 mg as a single dose on first day
followed by 200 mg once daily on subsequent days iv) Initial, 200
mg once daily or 100 mg twice daily; if no effect after 6 weeks,
may increase to max. 400 mg daily in 1-2 divided doses. If no
response following 2 weeks of treatment with 400 mg/day,
consider discontinuation and alternative treatment
Cephalexin Monohydrate 125 mg/5 ml Syrup J01DB01010F2101XX B Respiratory tract infections, ear, nose and throat CHILD: 25 - 100 mg/kg/day every 6 hourly. Maximum: 4 g daily
infections, urinary tract infections, obstetric and
gynaecologic infections
Cephalexin Monohydrate 250 mg Capsule J01DB01010C1001XX B i) Respiratory tract infection, urinary tract infection ii) i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times
Complicated, recurrent or chronic infections, bronchitis daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg
iii) Pneumonia daily in divided doses. Max: 4 g daily.
Cephalexin Monohydrate 250 mg Tablet J01DB01010T1001XX B i) Respiratory tract infection, urinary tract infection ii) i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times
April 2023 29

Cephalexin Monohydrate 500 mg Capsule J01DB01010C1002XX B i) Respiratory tract infection, urinary tract infection ii) i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times
Complicated, recurrent or chronic infections, bronchitis daily or 4 times daily. Maximum: 6 g/day
iii) Pneumonia
Cephalexin Monohydrate 500 mg Tablet J01DB01010T1002XX B i) Respiratory tract infection, urinary tract infection ii) i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times
Ceritinib 150mg Hard Capsules L01XE28-000-C11-01-XXX A* Monotherapy, first-line treatment of adult patients with None 450mg orally once daily with food until disease progression or
anaplastic lymphoma kinase (ALK)-positive advanced unacceptable toxicity
non-small cell lung cancer (NSCLC)
Cetirizine HCl 10mg Tablet R06AE07-110-T10-01-XXX B Urticaria, allergic dermatoses (insect bites, atopic ADULT and CHILD over 6 years:10 mg daily or 5 mg twice daily.
eczema), perennial rhinitis, allergic rhinitis Child 2-6 years: 5 mg once daily or 2.5 mg twice daily
Cetrimide 1-2% Lotion. D08AJ04000L6001XX C+ As shampoo and cleansing agent Apply to affected area
Cetrorelix 0.25 mg Injection H01CC02122P4001XX A* Prevention of premature ovulation in patients Given by SC 0.25 mg/day, given either in the morning beginning
undergoing a controlled ovarian stimulation, followed by on the day 5 or 6 of ovarian stimulation or in the evening
oocyte pick-up and assisted reproductive techniques beginning on day 5, and continued until ovulation induction
Cetuximab 5 mg/ml Solution for Infusion L01XC06000P5002XX A* For neo-adjuvant treatment of KRAS wild type To be prescribed in patients with the following conditions: Administered once a week. The very first dose is 400mg
metastatic colorectal cancer with the aim of liver i) The primary colorectal tumour has been resected or is cetuximab per m2 body surface area with a recommended
resection. potentially resected. ii)The metastatic disease is confined infusion period of 120 minutes. All subsequent weekly doses are
to the liver and is unresectable iii) Patient is fit enough to 250mg per m2 body surface area each with a recommended
undergo surgery to resect the primary colorectal tumour infusion period of 60 minutes. The maximum infusion rate must
and to undergo liver surgery if the metastases become not exceed 10mg/min.
resectable after treatment with cetuximab. - The
treatment is limited to 16 weeks
Charcoal, Activated 250mg Tablet A07BA01-000-T10-01-XXX C i) Diarrhoea and food poisoning; ii) Reduce absorption of None i) ADULT: 500mg -1000mg given 3-4 times daily. CHILD (up to 12
drugs, plant, inorganic poison and chemicals in poisoning years): 250-500mg 3-4 times daily. ii) ADULT and CHILD over 12
cases. years: initial 25-100 g or 1-2g/kg; repeat initial dose as soon as
possible or 25-50 g every 4-6 hours. CHILD (up to 12 years): 0.5 to
1 g/kg/dose (Maximum: 50 g/dose). Dose may be repeated every
2-6 hours as needed.
Charcoal, Activated 50 g Granules A07BA01-000-F10-01-XXX A Emergency treatment of acute oral poisoning and drug None ADULT and CHILD 12 years and above: Acute poisoning: 50 to
overdose 100g in suspension. Severe poisoning: 50 to 100g as an initial
dose followed by 20g every 4 to 6 hours. CHILD up to 12 years: 1
g/kg/dose (Maximum: 50 g/dose). Dose may be repeated every 4
to 6 hours as needed. Dosing is individualised and according to
product insert/protocol.
Chloral Hydrate 200 mg/5 ml Mixture N05CC01010L2101XX B Preoperative sedation ADULT : 0.5 - 1 g (max 2 g) with plenty of water at bedtime.
CHILD : Neonate: 30-50 mg/kg; up to 100 mg/kg may be used
with respiratory monitoring. 1 mth-12 yr: 30-50 mg/kg (max: 1 g);
up to 100 mg/kg (max: 2 g) may be used; 12-18 yr: 1-2 g. Doses to
be taken 45-60 minutes before procedure. May be given rectally
if oral route is not available.
April 2023 30

Chlorambucil 2mg Tablet L01AA02000T1001XX A Low grade lymphoma, chronic lymphocytic leukaemia. None General : Initial :0.1 -0.2 mg/kg body weight daily for 4 - 8 weeks
Ovarian cancer maintenance : given either by reduced daily dosage or
intermittent course of treatment. Chronic Lymphocytic
Leukaemia: initial : 0.15mg/kg/day until total leukocyte count has
fallen to 10,000peruL, then resumed treatment until 4 weeks
after the end of the first course then continued at a dosage
0.1mg/kg/day.
Chloramphenicol 0.5% Eye Drops S01AA01-000-D20-01-XXX C Ophthalmic infections None Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage
interval upon improvement.
Chloramphenicol 1% Eye Ointment S01AA01-000-G51-01-XXX C Treatment of ocular infections involving the conjunctiva None ADULT and CHILD : Apply to the conjunctiva, a thin strip
and/or cornea caused by chloramphenicol susceptible (approximately 1 cm) of ointment every 3 hours or more
organisms frequently
Chloramphenicol 250 mg Capsule J01BA01126C1001XX B Treatment of typhoid, paratyphoid fevers, ADULT: 500 mg 4 times daily or 50 mg/kg/day in 4 divided doses.
bronchopneumonia and enteric infection Maximum dose: 4 g/day. CHILD: 25 - 100 mg/kg/day in 4 divided
doses
Chloramphenicol 5% w/v Ear Drops S02AA01-000-D10-01-XXX C Acute otitis media, otitis externa with perforation None Apply 2 - 3 drops into the ear 2 - 3 times daily. Not to be used for
long term
Chloramphenicol Sodium Succinate 1 g Injection J01BA01520P4001XX B Treatment of typhoid, paratyphoid fevers, Adult:50 to 100 mg/kg/day in 4 divided doses. Premature and full-
bronchopneumonia and enteric infection term neonates: 25 mg/kg/day in 4 divided doses. Full-term
infants >2 wk: 50 mg/kg/day in 4 divided doses. Children: 50-100
mg/kg/day in 4 divided doses
Chlorhexidine 1:200 (0.5%) in Alcohol (Hand D08AC52-137-L99-01-XXX C+ Use as hand disinfectant for pre-surgical operation and None Pre-op surgical hand disinfection: Spread 5ml throughly over both
Disinfectant). skin disinfectant. hands and forearms, rubbing vigorously. When dry apply a
further 5ml and repeat procedure. Antiseptic hand disinfection
on the ward: Spread 3ml throughly over the hands and wrist
rubbing vigorously until dry. Disinfection of patient's skin: Prior to
surgery, apply to a sterile swab and rub thoroughly over the
operation site for a minimum of 2 mins
Chlorhexidine Gluconate 0.2 % Mouthwash R02AA05-137-M20-01-XXX C As a gargle None Rinse mouth with 10 ml for about 1 minute twice daily
Chlorhexidine Gluconate 1% cream D08AC02-137-G10-01-XX C+ For disinfection or lubricating during gynaecological and None Apply as required on affected area after cleaning
obstetric procedures or childbirth.
Chlorhexidine Gluconate 2% in Alcohol 70% D08AC52137L9902XX C Use as disinfectant in central venous catheter care Skin Preparation: Use Chlorhexidine Gluconate 2% in Isopropyl
Solution bundle Alcohol 70% and allow to dry. Catheter access: Apply to catheter
ports or hubs prior to accessing the line for administering fluids
or injections
Chlorhexidine Gluconate 4% Scrub D08AC02137M9901XX C+ Surgical hand scrub/disinfection, pre-op skin preparation Surgical hand disinfection: Apply 5ml to clean hands and
forearms for 1 min. Rinse and repeat with another 5ml for a
further 2 mins and then rinse and dry. General skin disinfection:
Apply appropriate quantity to wet area and scrub for 1 min. Rinse
thoroughly & dry
Chlorhexidine Gluconate 5% Solution D08AC02-137-L99-01-XXX C+ Use as antiseptic and disinfectant in: i) Preoperative skin None To be used as diluted solution: (i) 0.5 % w/v Aqueous solution :
disinfection; ii) Emergency disinfection of instruments; Dilute 10 ml of solution with 70% alcohol up to 100ml. (ii) 0.5 %
iii) Wounds or burns. w/v Aqueous solution : Dilute 10 ml of solution with 70% alcohol
up to 100ml. Immerse for 2 minutes (iii) 0.05 % w/v aqueous
solution : Dilute 1 ml of solution with 100 ml of sterile water.
Chlorinated Lime Powder V07AV00-000-F99-01-XXX C Antiseptic and disinfectants None Not applicable
Chlorinated Lime Solution & Buffered Acetate D08A000-999-G99-01-XXX C Use as skin disinfectant for wound and ulcer cleansing None Apply to affected areas undiluted as a cleansing agent
Solution
April 2023 31

Chloroquine Phosphate 250 mg Tablet (150 mg P01BA01162T1001XX C Treatment of malaria - acute attack None ADULT 600 mg base stat, 300 mg 6 - 8 hours later and a further
Chloroquine base) 300 mg on each of 2 following days. CHILD 3 - 4 years : 150 mg
base stat, 75 mg 6 hours later, then 75 mg daily for 2 days. CHILD
5 - 8 years : 300 mg stat, 150 mg 6 hours later, then 150 mg daily
for 2 days
Chlorpheniramine Maleate 10mg/ml Injection R06AB04-253-P30-01-XX B Allergic conditions None 10 - 20 mg IM or SC, repeated if required. Not to exceed 40 mg in
24 hours. 10 - 20 mg over 1 minute by slow IV
Chlorpheniramine Maleate 2mg/5ml Syrup R06AB04-253-L90-01-XXX C Symptomatic treatment of allergic conditions responsive None CHILD 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily) 6
to antihistamine - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)
Chlorpheniramine Maleate 4mg Tablet R06AB04-253-T10-01-XXX C Symptomatic treatment of allergic conditions responsive None ADULT : 4 mg every 4 - 6 hours. Maximum 24 mg daily. CHILD 2 -
to antihistamines 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily) 6 - 12
years : 2 mg every 4 - 6 hours (maximum 12 mg daily)
Chlorpromazine HCl 100 mg Tablet N05AA01110T1002XX B i) Psychotic conditions ii) Anti-emetic ADULT: Initial: 25-50mg two- three times daily Maintenance: 25-
100mg two- three times daily CHILD: Not recommended Dosing is
Chlorpromazine HCl 25 mg Tablet N05AA01110T1001XX B i) Psychotic conditions ii) Anti-emetic ADULT: Initial: 25-50mg two- three times daily Maintenance: 25-
100mg two- three times daily CHILD: Not recommended Dosing is
Chlortetracycline 1-3 % Cream D06AA02000G1001XX B Bacterial skin infections Apply directly to affected area twice daily as required for 1 - 2
weeks
Cholera Vaccine Oral Suspension J07AE01000P3001XX B Immunisation against cholera. Two doses of vaccines should be given at an interval of two
weeks.
Cholestyramine Resin 4G C10AC01-000-M40-01-XX A i) Hypercholesterolemia ii) Familial hypercholesterolemia None Hypercholesterolemia: Adjunct: initial, 4 g orally 1-2 times daily,
- heterozygous iii) Generalized atherosclerosis iv) maintenance, 8 to 16 g in divided doses, max 24 g daily CHILD: 50
Diarrhoea due to bile acid malabsorption v) Pruritus of - 150 mg/ kg 6 - 8 hourly oral
skin associated with partial biliary obstruction
Choline Salicylate 8.7%, Cetylkonium Chloride N02BA03-900-G30-01-XXX B For relief of the pain and discomfort in mouth ulcers and None Apply to area 4 times daily
0.01% Dental Gel sores, infant teething and denture irritation
Choriogonadotropin Alfa 250mcg/0.5 ml G03GA01-000-P50-01-XXX A* Indicated in the treatment of: i. Adult women None 250 mcg 24-48 hours after optimal stimulation of follicular
Injection in Prefilled Syringe undergoing superovulation prior to assisted growth is achieved Dosing is individualised and according to
reproductive technologies (ART), to trigger final follicular product insert/protocol
maturation and luteinisation after stimulation of
follicular growth ii. Anovulatory or oligo-ovulatory
women, to trigger ovulation and luteinisation after
stimulation of follicular growth
April 2023 32

Chorionic Gonadotrophin Human (HCG) 5000IU G03GA01-000-P40-01-XXX A* In the female: i. Ovulation induction in subfertility due to None i & ii: 5,000-10,000 IU stat once optimal stimulation of follicular
Injection anovulation or impaired follicle-ripening. ii. Preparation growth is achieved. iii: Up to three repeat injections of 1000 to
of follicles for puncture in controlled ovarian 3000 IU may be given within 9 days following ovulation or
hyperstimulation (for assisted reproductive embryo transfer (E.g.: on day 3, 6 and 9 after ovulation induction)
technologies). iii. Luteal phase support. In the male: iv) 1000 - 2000 IU, two to three times per week v)1500IU two to
iv)Hypogonadotropic hypogonadism(also cases of three times weekly for at least six months vi) < 2 years of age:
idiopathic dysspermias have shown a positive response 250 IU twice weekly for six weeks < 6 years of age: 500 - 1000 IU
to gonadotropins), v) Delayed puberty associated with twice weekly for six weeks > 6 years of age: 1500 IU twice weekly
insufficient gonadotropic pituitary function vi) for six weeks. Dosing is individualised and according to product
cryptorchidism not due to an anatomic obstruction. insert / protocol.
Ciclesonide 160mcg/dose Inhaler R03BA08-000-A21-01-XXX A* Prophylactic treatment of asthma in adults, adolescents The use of this drug in MOH is restricted to pediatric For adults and adolescents over 12 years of age with mild to
and children over 6 years. patient only. moderate asthma is 160 to 640mcg per day: severe asthma dose
may be increased to 1280mcg per day.
Ciclosporin 100 mg Capsule L04AD01000C1002XX A* i) Patients in whom donor specific transplantation i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before
cannot be carried out and in young children to minimise transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months
side-effects of steroids ii) Follow-up cases of bone before being tapered off to zero by 1 year of transplantation iii) 3
marrow transplant iii) Patients with severe rheumatoid mg/kg/day in 2 divided doses for first 6 weeks. May increased
arthritis not responding to other second line drugs iv) gradually to maximum 5 mg/kg. Treatment withdrawn if no
Patients with idiopathic nephrotic syndrome who are response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided
steroid toxic or poor response to cyclophosphamide v) doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with
Severe aplastic anemia, pure red cell aplasia vi) Cases of permitted levels of kidney failure, the starting dose must not
recalcitrant psoriasis and atopic eczema vii) Treatment of more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2
chronic ocular inflammatory disorders/uveitis divided doses increasing if there is no improvement after 4 weeks
by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5
mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in
resistant cases. Maintenance: Less than 5 mg/kg/day especially
during remission
Ciclosporin 100 mg/ml Oral Solution L04AD01000L5002XX A* i) Patients in whom donor specific transplantation i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before
marrow transplant iii) Patients with severe Rheumatoid mg/kg/day in 2 divided doses for first 6 weeks. May increased
Severe aplastic anaemia, pure red cell aplasia vi) Cases of permitted levels of kidney failure, the starting dose must not
recalcitrant psoriasis and atopic eczema more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2
divided doses increasing if there is no improvement after 4 weeks
by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day
April 2023 33

Ciclosporin 25 mg Capsule L04AD01000C1001XX A* i) Patients in whom donor specific transplantation i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before
marrow transplant iii) Patients with severe rheumatoid mg/kg/day in 2 divided doses for first 6 weeks. May increased
Severe aplastic anemia, pure red cell aplasia vi) Cases of permitted levels of kidney failure, the starting dose must not
recalcitrant psoriasis and atopic eczema vii) Treatment of more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2
chronic ocular inflammatory disorders/uveitis divided doses increasing if there is no improvement after 4 weeks
by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5
mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in
resistant cases. Maintenance: Less than 5 mg/kg/day especially
during remission
Ciclosporin 50 mg/ml Injection L04AD01000P3001XX A* i) Post bone marrow transplant ii) Solid organ transplant i) 3 - 5 mg/kg/day until tolerate orally ii) 2 - 3 mg/kg/day for
recipients who are unable to take orally
Ciclosporin Ophthalmic Emulsion 0.05% S01XA18-000-D20-01-XXX A* To increase tear production in patients whose tear None 1 drop twice a day in each eye approximately 12 hours apart.
production is presumed to be suppressed due to ocular
inflammation associated with keratoconjunctivitis sicca.
Increased tear production was not seen in patients
currently taking anti inflammatory drugs or using punctal
plugs.
Cilostazol 100 mg Tablet B01AC00000T1002XX A* Improvement of the maximal and pain-free walking 100 mg twice daily
distances in patients with intermittent claudication, who
do not have rest pain and who do not have evidence of
peripheral tissue necrosis.
Cimicifuga Racemosa Rhizome Extract Tablet HG03WA5-001-T10-01-XXX A Traditionally used for the relief of hot flushes, sweating, None 1 tablet twice a day (morning and evening)
restlessness associated with menopause
Cinacalcet Hydrochloride 25mg tablet H05BX01-110-T10-01-XXX A* Secondary hyperparathyroidism in patients undergoing For treatment of refractory secondary The starting dose for adults is 25mg once daily to be
maintenance dialysis with hypercalcaemia. hyperparathyroidism in patients with end-stage renal administered orally. Depending on the serum parathyroid
disease (including those with calciphylaxis) only in those: hormone (PTH) and calcium levels, the dose may be adjusted
i) who have 'very uncontrolled' plasma levels of intact within a range of 25-75mg once daily. If no improvement in PTH,
parathyroid hormone (defined as greater than 85pmol/L the dose may be increased up to 100 mg once daily. Dose can be
[800 pg/mL] that are refractory to standard therapy, and increased by 25mg at a time at intervals of at least 3 weeks.
an adjusted serum calcium level at upper limit of normal
or high, despite appropriate adjustment of phosphate
binders including non-calcium based phosphate binders.
ii) in whom surgical parathyroidectomy is contraindicated
in that the risks of surgery are considered to outweigh the
benefits, or if there is likely to be a significant delay for
surgery.
Cinnarizine 25 mg Tablet N07CA02000T1001XX B i) Vestibular disorders ii) Motion sickness i) ADULT and CHILD > 12years: 25mg three times a day ii) 25mg 2
hours before travel and 12.5mg every 8 hours during journey
CHILD 5-12 years: Half the adult dose Dosing is according to
product insert.
April 2023 34

Ciprofloxacin 100 mg/50 ml Injection J01MA02125P3001XX A Treatment of infections due to susceptible bacterial ADULT: the dosage range is 100-400mg twice daily Gonorrhoea:
strains 100mg single dose Upper and Lower Urinary Tract Infection:
100mg bd Upper and Lower Respiratory Tract Infection: 200mg
bd-400mg twice daily Cystic Fibrosis with psuedomonal Lower
RTI: 400mg bd Others: 200-400mg bd inhalation Anthrax: 400mg
bd
Ciprofloxacin 200 mg/100 ml Injection J01MA02125P3002XX A Treatment of infections due to susceptible bacterial Suggest to rephrase ADULT: the dosage range is 100-400mg twice
strains daily Gonorrhoea: 100mg single dose Upper and Lower Urinary
Tract Infection: 100mg bd Upper and Lower Respiratory Tract
Infection: 200mg bd-400mg twice daily Cystic Fibrosis with
psuedomonal Lower RTI: 400mg bd Others: 200-400mg bd
inhalation Anthrax: 400mg bd
Ciprofloxacin 250 mg Tablet J01MA02110T1001XX A Treatment of infections due to susceptible bacterial ADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose
strains of 250 mg
Ciprofloxacin 500 mg Tablet J01MA02110T1002XX A Treatment of infections due to susceptible bacterial ADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose
strains of 250 mg
Ciprofloxacin HCl 0.3% Ophthalmic Solution S01AX13-110-D20-01-XXX A* Treatment of bacterial infections caused by susceptible None i) 2 drops every 15 minutes for the first 6 hours, then 2 drops
strains in: i) corneal ulcers ii) bacterial conjunctivitis every 30 minutes for the rest of the first day. Second day : 2
drops every hour. Subsequent days (3rd - 14th day) : 2 drops
every 4 hours. Treatment may be continued after 14 days if
corneal re-epithelialization has not occured, ii) 1 - 2 drops every 2
hours into the conjunctival sac while awake for 2 days and 1-2
drops every 4 hours while awake for the next 5 days
Cisatracurium Besylate 2 mg/ml Injection M03AC11197P3001XX A* As an adjunct to general anaesthesia to facilitate Administered as bolus intravenous injection. May be
endotracheal intubation, to provide skeletal muscle administered as infusion in ICU patients at a rate of 3mcg/kg/min.
relaxation during surgery and to facilitate mechanical Adult dose: a) Induction: 0.15mg/kg over 5-10 secs, b)
ventilation. Restricted to patients with lung problem Maintenance: 0.03 mg/kg. Children 2-12 years: a) Induction: 0.1
such as asthma. mg/kg over 5-10 secs, b) Maintenance: 0.02 mg/kg
Cisplatin 1 mg/mL Injection L01XA01000P3001XX A i) Solid tumours ii) lymphomas Germ cell tumours: 20 mg/m2 daily for 5 days every 3 weeks for 3
- 4 courses. Ovarian tumours: 75 mg/m2 once every 3 weeks as
part of combination therapy with paclitaxel or 50-60mg/m2 IV
once every 3 weeks as a single agent. Baseline creatinine
clearance, pretreatment hydration and forced diuresis are
mandatory. CHILD: 100mg/m2 over 6 hours once every 3 weeks.
Lymphomas: Refer to protocols CHILD: 100mg/m2 over 6 hours
once every 3 weeks. Lymphomas: Refer to protocols
Clarithromycin 125 mg/5 ml Granules J01FA09000F1001XX A* Treatment of complicated respiratory tract infections CHILD: 8 - 12 years: 30 - 40 kg 10 mL, 4 - 8 years: 20 - 29 kg 7.5
not responding to standard macrolides mL, 2 - 4 years: 12 - 19 kg 5 mL, 1 - 2 years: 8 - 11 kg 2.5 mL, less
than 8 kg: 7.5 mg/kg. To be given twice daily. Maximum dose:
1g/day
Clarithromycin 250 mg Tablet J01FA09000T1001XX A* Only for i) treatment of complicated respiratory tract i) 250 - 500 mg twice daily. Up to 6 - 14 days ii) 500 mg twice
infection not responding to standard macrolides ii) daily with omeprazole & amoxicillin. Up to 2 weeks
eradication of Helicobacter pylori infection
April 2023 35

Clarithromycin 500 mg Injection J01FA09000P3001XX A* Only for treatment of complicated respiratory tract Susceptible infections Adult: 500 mg bid for 2-5 days. Dose to be
infection not responding to standard macrolides infused over 60 minutes in a 0.2% solution; revert to oral therapy
whenever possible. Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr.
Dose to be given via infusion into proximal vein. Dosage
Recommendation CrCl (ml/min)<30 : Half the dosage or double
dosing interval
Clindamycin HCl 300 mg Capsule J01FF01110C1001XX A* i) Skin and soft tissue infections, bone& joint infections i) ADULT: 150 - 300 mg every 6 hours; up to 450 mg every 6 hours
ii) Cerebral toxoplasmosis iii) Children less than 8 years in severe infections; Max: 1.8g/day CHILD: 3 - 6 mg/kg every 6
old: Treatment and prophylaxis of malaria in hours. Children weighing <10 kg should receive at least 37.5 mg
combination with quinine, as an alternative to doxycline every 8 hr. ii) 600 mg 6 hourly for 6 weeks iii) 10mg/kg twice a
day, in combination with quinine. The combination to be given
for 7 days
Clindamycin Phosphate 150 mg/ml Injection J01FF01162P3001XX A* i) Skin and soft tissue infections, bone & joint infections i) ADULT: 0.6 - 2.7 g daily (in 2 - 4 divided doses); up to 4.8 g
ii) Cerebral toxoplasmosis daily; CHILD over 1 month, 20 - 40 mg/kg/day or 350 mg/m2/day
in 3 - 4 divided doses ii) 1200 mg every 6 hours for 3 weeks
followed by 300 mg orally every 6 hours for another 3 weeks
Clobazam 10 mg tablet N05BA09000T1001XX A* As adjunctive therapy in patients with epilepsy not The initial dose in adults and adolescents >15 yr should be low (5
adequately stabilised with their basic medication. to15mg daily), if necessary, increased gradually to a maximum
daily dose of about 80mg. Doses of up to 30mg may be taken as a
single dose in the evening. The initial dose in children from 3 to15
yr is normally 5mg. A maintenance dose of 0.3 to 1.0mg/kg body
weight daily is usually sufficient.
Clobetasol Propionate 0.05% Cream D07AD01133G1001XX A Short term treatment only of more resistant dermatoses Apply sparingly once or twice daily, changing to lower potency
eg. psoriasis, recalcitrant eczemas, lichen planus, discoid therapy as soon as condition is controlled. For mild to moderate
lupus erythematosus and other conditions which do not use maximum for 2 weeks. For moderate to severe maximum
respond satisfactorily to less potent steroids duration 4 consecutive weeks. Max: 50 g/week
Clobetasol Propionate 0.05% Ointment D07AD01133G5001XX A Short term treatment only of more resistant dermatoses Apply sparingly once or twice daily, changing to lower potency
eg. psoriasis, recalcitrant eczemas, lichen planus, discoid therapy as soon as condition is controlled. For mild to moderate
lupus erythematosus and other conditions which do not use maximum for 2 weeks. For moderate to severe maximum
respond satisfactorily to less potent steroids duration 4 consecutive weeks. Max:50 g/week
Clobetasone Butyrate 0.05% Cream D07AB01-255-G10-01-XXX A/KK For the relief of the inflammatory and pruritic None Apply to 1-2 times a day
manifestations of steroid responsive dermatoses.
Clobetasone Butyrate 0.05% Ointment D07AB01-255-G50-01-XX A/KK For the relief of the inflammatory and pruritic None Apply to 1-2 times a day
manifestations of steroid responsive dermatoses.
Clodronate 800 mg Tablet M05BA02011T1011XX A* Treatment of hypercalcaemia due to malignancy 2 tablets in single or two divided doses
Clofazimine 100 mg Capsule J04BA01000C1002XX B i) Previously untreated leprosy patients ii) Leprosy i) ADULT: 100 mg each other day or 50 mg daily with 100mg
patients resistant to sulphones iii) Suppression of lepra Dapsone & 300mg once a month with 600mg rifampicin under
reactions supervision. Maximum: 200 mg/day. CHILD: 10-14 yr: 50mg
clofazimine on alternate days with 50mg dapsone & 150 mg
clofazimine with 450 mg rifampicin once a month.Maximum: 100
mg/day. ii) 100 mg daily iii) 200-300mg usually effective.
Treatment with minimum suppression dose continued for at least
6 months
April 2023 36

Clofazimine 50 mg Capsule J04BA01000C1001XX B i) Previously untreated leprosy patients ii) Leprosy i) ADULT: 100 mg each other day or 50 mg daily with 100mg
patients resistant to sulphones iii) Suppression of lepra Dapsone & 300mg once a month with 600mg rifampicin under
reactions supervision. Maximum: 200 mg/day. CHILD: 10-14 yr: 50mg
clofazimine on alternate days with 50mg dapsone & 150 mg
clofazimine with 450 mg rifampicin once a month.Maximum: 100
mg/day. ii) 100 mg daily iii) 200-300mg usually effective.
Treatment with minimum suppression dose continued for at least
6 months
Clomiphene Citrate 50mg Tablet G03GB02-136-T10-01-XXX A Treatment of ovulatory failure in women desiring None Initial: 50 mg once daily for 5 days. Increase to 100mg OD for 5
pregnancy days if there is no response (commence as early as 30 days after
the previous course).
Clomipramine HCI 25 mg Tablet N06AA04110T1001XX A Depression, obsessive-compulsive disorder. Initially 10 mg daily, increased gradually as necessary to 30 - 150
mg daily in divided doses or as a single dose at bedtime; max 250
mg daily. ELDERLY initially 10 mg daily increased carefully over
approximately 10 days to 30 - 75 mg daily;Child: ≥10 yr: Initially,
25 mg daily, increased gradually over 2 wk. Max: 3 mg/kg/day or
100 mg daily, whichever is smaller. Give in divided doses. Once
titrated, dose may be given as a single dose at bedtime.
Clonazepam 0.5mg Tablet N03AE01-000-T10-01-XX B i) Epilepsy ii) Non-epileptic myoclonus None i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided
into 3 doses, may be increased in increments of 0.5mg every 3
days until seizures are controlled. Maintenance dose: 3-6mg/day.
Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03
mg/kg/day in 2-3 divided doses, increased by no more than 0.25-
0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16
years: initial dose 1-1.5mg/day in 2-3 divided dose, may be
increased by 0.25-0.5mg every third day until individual
maintenance dose of 3-6mg/day is reached.
Clonazepam 2mg Tablet N03AE01-000-T10-02-XX B i) Epilepsy ii) Non-epileptic myoclonus None i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided
into 3 doses, may be increased in increments of 0.5mg every 3
days until seizures are controlled. Maintenance dose: 3-6mg/day.
Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03
mg/kg/day in 2-3 divided doses, increased by no more than 0.25-
0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16
years: initial dose 1-1.5mg/day in 2-3 divided dose, may be
increased by 0.25-0.5mg every third day until individual
maintenance dose of 3-6mg/day is reached.
Clonidine HCl 0.025 mg Tablet N02CX02110T1001XX A Rapid opiod detoxification combination use with Rapid detoxification in 4-5 days (use with naltrexone): 6 mcg/kg
naltrexone ORALLY divided in 3 doses 6 to 8 hours apart the first day,
increasing to 11 mcg/kg divided in 3 doses given day two,
tapering to 0.6 mcg/kg the third day. Rapid opioid detoxification
for 7 days ( use with naltrexone) : 0.1 to 0.2 mg every 4 hours as
needed
April 2023 37

Clopidogrel 75 mg Tablet B01AC04192T1001XX A/KK Secondary prevention of atherothrombotic events in: i) 75 mg once daily
Adult patients suffering from myocardial infarction (from
a few days until less than 35 days), ischaemic stroke
(from 7 days until less than 6 months) or established
peripheral arterial disease. Prescribing restriction: as
second/third line treatment in patients who are sensitive
or intolerant to acetylsalicylic acid and/or ticlopidine). ii)
Adult patients suffering from acute coronary syndrome:
• Non-ST segment elevation acute coronary syndrome
(unstable angina or non-Q-wave myocardial infarction),
including patients undergoing a stent placement
following percutaneous coronary intervention. • ST
segment elevation acute myocardial infarction, in
combination with acetylsalicylate acid (ASA) in medically
treated patients eligible for thrombolytic therapy.
Clostridium Botulinum Toxin Type A 100 units M03AX01-000-P40-01-XXX A* i) Focal dystonias ii) Hemifacial spasm iii) Spasticity 20 - 200 units 3 months once
including cerebral palsy iv) Neurogenic bladder
Clostridium Botulinum Type A toxin M03AX01000P4003XX A* i) Focal dystonias ii) Hemifacial spasm iii) Spasticity Initially 20 U/kg divided between both calf muscles. May be
haemagglutinin complex 300 units/vial powder including cerebral palsy titrated 10-30 U/kg up to max of not >1000 U/patient. Should
for injection only be used in children > 2 years of age. Repeat injections given
not less than 3 months from previous injection.
Clostridium botulinum Type A toxin M03AX01000P4002XX A* i) Focal dystonias ii) Hemifacial spasm iii) Spasticity Initially 20 U/kg divided between both calf muscles. May be
haemagglutinin complex 500U/vial powder for including cerebral palsy titrated 10-30 U/kg up to max of not >1000 U/patient. Should
injection only be used in children > 2 years of age. Repeat injections given
not less than 3 months from previous injection.
Clotrimazole 1% Cream D01AC01-000-G10-01-XXX B For treatment of fungal infection (eg: cutaneous None Apply on affected area twice daily, optimally for 4 weeks
candidiasis, tinea orporis, tinea cruris, tinea pedis and including 2 weeks after lesions have cleared.
tinea versicolor).
Clotrimazole 1% Ear Drop S02AA00-000-D10-02-XXX B Otomycosis; concomitant therapy with antibiotics and None 4 to 5 drops 3 to 4 times daily
corticosteroid ear drops
Clotrimazole 1% Solution D01AC01-000-L42-01-XXX A For treatment of large lesion of fungal infection (eg: None Apply on affected area by rubbing for 2-3 times daily after
cutaneous candidiasis, tinea orporis, tinea cruris, tinea cleaning. Continue treatment up to 2-4 weeks
pedis and tinea versicolor).
Clotrimazole 500mg Vaginal Tablet G01AF02-000-S10-03-XXX B Vaginal candidiasis None 500 mg as a single one-time dose
Cloxacillin Sodium 125 mg/5 ml Suspension J01CF02520L8001XX B Treatment of susceptible bacterial infections, notably Child: 50-100 mg/kg in divided doses every 6 hr
penicillinase-producing staphylococci
Cloxacillin Sodium 250 mg Capsule J01CF02520C1001XX B Treatment of susceptible bacterial infections, notably ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in
penicillinase-producing staphylococci divided doses every 6 hr.
Cloxacillin Sodium 250 mg Injection J01CF02520P4001XX B Treatment of susceptible bacterial infections, notably ADULT: 250 to 500 mg every 6 hours depending on type and
penicillinase-producing staphylococci infections severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in
equally divided doses every 6 hours
Cloxacillin Sodium 500 mg Capsule J01CF02520C1002XX B Treatment of susceptible bacterial infections, notably ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in
penicillinase-producing staphylococci divided doses every 6 hr.
April 2023 38

Cloxacillin Sodium 500 mg Injection J01CF02520P4002XX B Treatment of susceptible bacterial infections, notably ADULT: 250 to 500 mg every 6 hours depending on type and
penicillinase-producing staphylococci infections severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in
equally divided doses every 6 hours
Clozapine 100 mg Tablet N05AH02000T1002XX A Treatment of resistant schizophrenia Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in
steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks.
Maximum 900 mg/day
Clozapine 25 mg Tablet N05AH02000T1001XX A Treatment of resistant schizophrenia Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in
steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks.
Maximum 900 mg/day
Coal Tar 1-9% Ointment D05AA00000G5001XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, Apply sparingly to the affected area 1-3 times daily starting with
eczema and psoriasis. Used as a mild astringent for the low strength preparations
skin, as a soothing and protective application in eczema
and as a protective to slight excoriation
Coal Tar 20% Solution D05AA00-000-L52-01-XXX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, None To dilute 1 cap (15 ml) into 10L of water and soak for 20 minutes.
eczema and psoriasis.
Coal Tar and Salicylic Acid (various D05AA00-946-G50-02-XXX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, None Apply to the affected area as required or as in package insert
concentrations) Ointment eczema and psoriasis
Coal Tar with Salicylic Acid (various D05AA00000L5202XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, Apply to the affected areas or as in product leaflet
concentrations) Solution eczema and psoriasis
Cocaine 10% Solution N01BC01110L5001XX B To produce local anaesthesia or vasoconstriction during Maximum total dose recommended for application to the nasal
endoscopic nasal surgery, turbinectomy septoplasty, mucosa in healthy adult is 1.5 to 2 mg/kg of a 10% cocaine
polypectomy etc solution
Cocois Co. Ointment D05AA00946G5001XX B Scalp psoriasis and severe seborrhoeic dermatitis Rub a small amount into the scalp gently
Colchicine 0.5mg Tablet M04AC01-000-T10-01-XXX B i) Acute gout and prophylaxis of recurrent gout. ii) None i) Acute gout: Initial dose, 1 mg, then 0.5 mg after 1 hour. No
Leucocytoclastic Vasculitis either cutaneous or systemic further tablets should be taken for 12 hours. After 12 hours,
involvement, Behcet's syndrome, Urticarial vasculitis, treatment can resume if necessary with a maximum dose of 500
Systemic sclerosis, Sweet's syndrome and severe micrograms (1 tablet) every 8 hours until symptoms are relieved.
recalcitrant aphthous stomatitis The course of treatment should end when symptoms are relieved
or when a total of 6 mg (12 tablets) has been taken. No more
than 6 mg (12 tablets) should be taken as a course of treatment.
After completion of a course, another course should not be
started for at least 3 days (72 hours). Prophylaxis of recurrent
gout: 0.5 mg bd. ii) 0.5 mg 1-3 times daily depends on disease
and severity, up to a maximum of 3 mg/day
Colistimethate Sodium 1 million IU per vial J01XB01-520-P40-01-XXX A* Intravenous administration for the treatment of serious None A minimum of 5 days treatment is generally recommended. For
(Polymyxin E) infections caused by Gram negative bacteria, when more the treatment of respiratory exacerbations in cystic fibrosis
commonly used systemic antibacterial agents may be patients, treatment should be continued up to 12 days. Children
contraindicated or may be ineffective because of and adults (including elderly): Up to 60kg: 50,000 units/kg/day to
bacterial resistance. a maximum of 75,000 units/kg/day. The total daily dose should
be divided into three doses given at approximately 8-hour
intervals. Over 60kg: 1-2 million units three times a day. The
maximum dose is 6 million units in 24 hours. Renal impairment:
In moderate to severe renal impairment, excretion of
colistimethate sodium is delayed. Dosage in Renal Impairment
(for over 60 kg body weight): - Mild (CrCl 20-50 ml/min): 1-2
million units every 8 hr. - Moderate (CrCl 10-20 ml/min): 1 million
units every 12-18 hr. - Severe (CrCl <10 ml/min): 1 million units
every 18-24 hr.
April 2023 39

Colloidal Bismuth Subcitrate 120 mg Tablet A02BX05136T1001XX A Eradication therapy for Helicobacter Pylori in 240 mg twice daily for 1-2 weeks
combination with antibiotics and antisecretory drugs
Compound Sodium Lactate (Hartmanns B05XA30125P6001XX C Replacement of extracellular losses of fluid and 100-1000 ml by IV or according to the needs of the patient
Solution) electrolytes, as an alkaliniser agent
Conjugated estrogens 0.3 mg Tablet G03CA57-000-T10-03-XXX A i. Prevention and management of osteoporosis None i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for
associated with estrogen deficiency. ii. Female 1 week iii) & iv) 0.3mg-1.25mg daily
hypoestrogenism. iii. Moderate to severe vasomotor
symptoms associated with estrogen deficiency. iv.
Atrophic vaginitis and atrophic urethritis.
Conjugated Estrogens 0.625 mg Tablet G03CA57-000-T10-01-XXX A i. Prevention and management of osteoporosis None i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for
associated with estrogen deficiency. ii. Female 1 week iii) & iv) 0.3mg-1.25mg daily
hypoestrogenism. iii. Moderate to severe vasomotor
symptoms associated with estrogen deficiency. iv.
Atrophic vaginitis and atrophic urethritis.
Conjugated Estrogens 0.625mg/g Cream G03CA57-000-G10-01-XXX A Treatment of atrophic vaginitis, dyspareunia and None i. Atrophic Vaginitis and Kraurosis Vulvae: Initial dose:
kraurosis vulvae Intravaginal 0.5g daily for 21 days and then off for 7 days (cyclical
regimen). Dose range: 0.5- 2g daily based on individual response.
ii. Dyspareunia: 0.5g intravaginally twice weekly continuous
regimen or in a cyclic regimen of 21 days of therapy followed by 7
days off of therapy.
Continuous Ambulatory Peritoneal Dialysis B05DB00908H2504XX B For chronic renal diseases requiring dialysis and acute Dose depending on clinical cases
(CAPD) Solution containing 2.3% glucose therapy-resistance renal failure eg. prior to transfer to a
(Calcium 1.75mmol/L) & (Calcium 1.25mmol/L) dialysis centre
Solution containing 1.5% Dextrose therapy-resistance renal failure eg. prior to transfer to a
dialysis centre
dialysis centre
dialysis centre
Copper 375mm2 Intrauterine Device G02BA02-000-M90-02-XXX B Intrauterine contraception. None Intrauterine insertion: 1 unit to be replaced within 5 years from
the date of insertion.
Copper Sulphate Crystal D08A000183F9901XX C Wounds The tip of the crystal should be moistened by dipping in water
and applied carefully to the lesion
Corifollitropin Alfa 100mcg/0.5ml solution for G03GA09-000-P50-01-XXX A* Controlled Ovarian Stimulation (COS) in combination None Women with Body Weight ≤60 kg: A single dose of 100 mcg
injection with a GnRH antagonist for the development of multiple should be administered. Women with Body Weight >60 kg: A
follicles in woman participating in an Assisted single dose of 150 mcg should be administered. Details : Refer to
Reproductive Technology (ART) program Product Information
Corifollitropin Alfa 150mcg/0.5ml solution for G03GA09-000-P50-02-XXX A* Controlled Ovarian Stimulation (COS) in combination None Women with Body Weight ≤60 kg: A single dose of 100 mcg
injection with a GnRH antagonist for the development of multiple should be administered. Women with Body Weight >60 kg: A
follicles in woman participating in an Assisted single dose of 150 mcg should be administered. Details : Refer to
Reproductive Technology (ART) program Product Information
April 2023 40

Crotamiton 10 % Cream P03A000000G1001XX B i) Pruritus ii) Scabies iii) Insect bite reactions i) and iii) Massage into affected area until the medication is
completely absorbed. Repeat as needed. Apply 2 or 3 times daily
ii) Apply to the whole body from below the chin. 2nd application
is applied 24 hr later. May need to use once daily for up to 5 days.
Cyanocobalamin 0.1 mg Injection B03BA01000P3001XX B i) Prophylaxis of anaemia ii) Uncomplicated pernicious i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii)
anaemia or Vitamin B12 malabsorption Uncomplicated pernicious anaemia or Vitamin B12
malabsorption: Initial 100 mcg daily for 5-10 days followed by
100-200 mcg monthly until complete remission is achieved.
Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for
2 or more weeks (to a total dose of 1-5mg). Maintenance: 100
mcg monthly to sustain remission OR AS PRESCRIBED.
Cyanocobalamin 1 mg Injection B03BA01000P3002XX B i) Prophylaxis of anaemia associated with Vitamin B12 i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii)
deficiency ii) Uncomplicated pernicious anaemia or Uncomplicated pernicious anaemia or Vitamin B12
Vitamin B12 malabsorption malabsorption: Initial 100 mcg daily for 5-10 days followed by
100-200 mcg monthly until complete remission is achieved.
Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for
2 or more weeks (to a total dose of 1-5mg). OR AS PRESCRIBED.
Cyanocobalamin 50 mcg Tablet B03BA01000T1002XX B Vitamin B12 deficiency of dietary origin ADULT 50-150 mcg daily. CHILD 50-105 mcg daily in 1-3 divided
doses
Cyclopentolate 0.2% with Phenylephrine 1% S01GA55-990-D20-01-XXX A Dilating agent for premature babies None 1 drop every 5 - 10 minutes; not exceeding three times to
Eye Drops produce rapid mydriasis. Observe infants closely for at least 30
minutes
Cyclopentolate 1% Eye Drops S01FA04-000-D20-02-XXX A Mydriasis and cycloplegia None ADULT : 1 drop of solution in eye(s); may repeat after 5-10
minutes if needed. CHILD : 1 drop of solution in eye(s); may
repeat after 5-10 minutes if needed. Pre-treatment on the day
prior to examination is usually not necessary. If desirable, 1 or 2
drops may be instilled the evening prior to examination.
Cyclophosphamide 1 g Injection L01AA01000P4002XX A i) Solid tumours; ii) Leukaemia, non-Hodgkin's i)& ii) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of
lymphoma, multiple myeloma; iii) Severe lupus nephritis combination regime. CHILD: Dose variable depending on disease
(Class III and IV); iv) Other systemic vasculitis; v) Systemic and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour
lupus erythematosus, rheumatoid arthritis, polyarteritis to 6 hours (lower doses can be given as bolus). Care with pre and
nodosa, wegener granulomatosis; vi) Pemphigus vulgaris. post-hydration. Mesna to be given with doses more than 1 g/m2.
Higher doses are used in haematopoetic stem cell transplant-
refer to specific protocols iii) 750 mg/m2 BSA monthly for 18
months iv) 750 mg/m2 BSA monthly for 6 months. Dose can be
adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte
suppression v) 500 - 1000 mg intravenously (Regime varies
according to indication). Starting dose may be given fortnightly
then at monthly intervals followed by 3 monthly intervals; vi) 500
mg infusion on the 2nd day of the dexamethasone-
cyclophosphamide pulsed regime, the cycle is repeated every 4
weeks up to 6 cycles or till remission followed by oral
cyclophosphamide
April 2023 41

Cyclophosphamide 200 mg Injection L01AA01000P4001XX A i) Solid tumours; ii) Leukaemia, non-Hodgkin's i)& ii) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of
lymphoma, multiple myeloma; iii) Severe lupus nephritis combination regime. CHILD: Dose variable depending on disease
(Class III and IV); iv) Other systemic vasculitis; v) Systemic and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour
lupus erythematosus, rheumatoid arthritis, polyarteritis to 6 hours (lower doses can be given as bolus). Care with pre and
nodosa, wegener granulomatosis; vi) Pemphigus vulgaris. post-hydration. Mesna to be given with doses more than 1 g/m2.
Higher doses are used in haematopoetic stem cell transplant-
refer to specific protocols iii) 750 mg/m2 BSA monthly for 18
months iv) 750 mg/m2 BSA monthly for 6 months. Dose can be
adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte
suppression v) 500 - 1000 mg intravenously (Regime varies
according to indication). Starting dose may be given fortnightly
then at monthly intervals followed by 3 monthly intervals; vi) 500
mg infusion on the 2nd day of the dexamethasone-
cyclophosphamide pulsed regime, the cycle is repeated every 4
weeks up to 6 cycles or till remission followed by oral
cyclophosphamide
Cyclophosphamide 50 mg Tablet L01AA01000T1001XX A i) Solid tumours, leukaemia, lymphoma, autoimmune i) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver
disorders, autoimmune bullous diseases, connective function, urine microscopy and renal function. CHILD, up to 1
tissue disease, pyoderma gangrenosum ii) For severe year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years:
lupus nephritis (Class III & IV), systemic vasculitis and 50 - 100 mg daily ii) 2 mg/kg/day for 3 - 4 months iii) 1 - 1.5
steroid resistant/dependent nephrotic syndrome iii) mg/kg/day orally in divided doses
Systemic lupus erythematosus (SLE), rheumatoid
arthritis, polyarteritis nodosa, wegener granulomatosis
Cycloserine 250 mg Capsule J04AB01000C1001XX A* Multi-Drug Resistance Tuberculosis treatment failure. ADULT: Initial: 250 mg every 12 hours for 14 days, then
(For respiratory physicians) administer 0.5 - 1 g daily in 2 divided doses for 18 - 24 months
(maximum daily dose: 1 g). CHILD: 2-12 yr: 5 mg/kg bid; 12-18 yr:
250 mg bid for 2 wk then adjusted to a max dose of 1 g daily
Cyproterone Acetate 2 mg & Ethinyloestradiol G03HB01-954-T10-01-XXX A* i. Treatment androgen dependent diseases (including None 1 tablet daily for 21 consecutive days, followed by a 7 -day tablet
0.035 mg Tablet PCOS) in women ii.Treatment of acne as second line free interval before the next pack is started
treatment following failure of topical therapy or
systemic antibiotic treatment iii.Hormonal contraceptive
Cyproterone Acetate 50mg Tablet G03HA01-122-T10-01-XXX A* Carcinoma of prostate None i) After orchidectomy, 100 mg once daily or twice daily ii) If used
together with LHRH agonists, the initial dose is 100 mg twice
daily for 5 to 7 days before the start of LHRH agonist, then 100
mg twice daily for 3 to 4 weeks together with the LHRH agonist
Cytarabine 100 mg/mL Injection L01BC01000P4002XX A i) Central nervous system lymphoma ii) Meningeal Standard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher
leukemia iii) Non Hodgkin's Lymphoma iv) High dose doses for intensification/consolidation: 1000 - 3000 mg/m2 daily
cytarabine as conditioning to cytoreduce the disease over 3 - 5 days depending on specific protocols. CHILD: Dose
before stem cell transplant for relapsed or refractory variable depending on disease and protocol. Range from 100
leukemia v) As salvage for acute lymphocytic leukemia mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or
vi) As salvage for acute myeloid leukemia vii) As infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20
palliative chemotherapy in elderly acute myeloid mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT
leukemia/ myelodysplastic syndrome PREPARATION IS SUITABLE FOR INTRATHECAL USE)
April 2023 42

Dabigatran Etexilate 110 mg Capsule B01AE07999C1002XX A* i) Prevention of venous thromboembolic events in i) Following total knee replacement: Initially ADULT 110mg
patients who have undergone total knee replacement or (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg
total hip replacement surgery. ii) Reduction of the risk of (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following
stroke and systemic embolism in patients with non- total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg)
valvular atrial fibrillation (AF). iii) Treatment of deep vein within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg)
thrombosis (DVT) and pulmonary embolism (PE) and once daily thereafter for 28-35 days ii) Recommended daily dose
prevention of recurrent DVT and PE in adults. is 300mg taken orally as 150mg hard capsule twice daily. Therapy
should be continued lifelong. iii) Recommended daily dose is
300mg taken as one 150mg capsule BD following treatment with
a parenteral anticoagulant for at least 5 days. The duration of
therapy should be individualized after careful assessment of the
treatment benefit against the risk for bleeding. ii) & iii) For the
following groups, the recommended daily dose is 220 mg taken
as one 110mg capsule twice daily: - Patients aged 80 years or
above -Patients who receive concomitant verapamil Special
patient population for renal impairment : Renal function should
be assessed by calculating the creatinine clearance (CrCl) prior to
initiation of treatment with Dabigatran to exclude patients for
treatment with severe renal impairment (i.e. CrCl < 30 ml/min).
Dabigatran Etexilate 75 mg Capsule B01AE07999C1001XX A* Prevention of venous thromboembolic events in patients Following total knee replacement: Initially ADULT 110 mg
who have undergone total knee replacement or total hip (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg
replacement surgery (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following
total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg)
within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg)
once daily thereafter for 28-35 days
Dabigatran Etexilate150 mg Capsule B01AE07999C1003XX A* i) Reduction of the risk of stroke and systemic embolism i) Recommended daily dose is 300mg taken orally as 150mg hard
in patients with non-valvular atrial fibrillation (AF) ii) capsule twice daily. Therapy should be continued lifelong. ii)
Treatment of deep vein thrombosis (DVT) and Recommended daily dose is 300mg taken as one 150mg capsule
pulmonary embolism (PE) and prevention of recurrent BD following treatment with a parenteral anticoagulant for at
DVT and PE in adults. least 5 days. The duration of therapy should be individualized
after careful assessment of the treatment benefit against the risk
for bleeding. For the following groups, the recommended daily
dose is 220 mg taken as one 110mg capsule twice daily: - Patients
aged 80 years or above -Patients who receive concomitant
verapamil Special patient population for renal impairment : Renal
function should be assessed by calculating the creatinine
clearance (CrCl) prior to initiation of treatment with Dabigatran
to exclude patients for treatment with severe renal impairment
(i.e. CrCl < 30 ml/min).
Dacarbazine 100 mg Injection L01AX04000P4001XX A* i) Malignant melanoma, sarcomas, neuroblastomas and i) 250 mg/m2 for 5 days, may be repeated every 3 weeks ii) 375
other childhood solid tumours ii) Hodgkin's Disease mg/m2 IV every 2 weeks
April 2023 43

Daclatasvir 30mg tablet J05AP07-110-T32-02-XXX A/KK To be used in combination with other medicinal 60 mg once daily, to be taken orally with or without meals. Dose
products for the treatment of chronic hepatitis C (CHC) recommendation when taking concomitant medicines: i. Strong
in adults. inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): Reduce
dose to 30 mg once daily when co-administered with strong
inhibitors of CYP3A4. ii. Moderate inducers of CYP3A4: Increase
dose to 90 mg once daily when co-administered with moderate
inducers of CYP3A4. Daclatasvir must be administered in
combination with other medicinal products for the treatment of
hepatitis C infection. Dose modification of daclatasvir to manage
adverse reactions is not recommended.
Daclatasvir 60mg tablet J05AP07-110-T32-01-XXX A/KK To be used in combination with other medicinal 60 mg once daily, to be taken orally with or without meals. Dose
products for the treatment of chronic hepatitis C (CHC) recommendation when taking concomitant medicines: i. Strong
in adults. inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): Reduce
dose to 30 mg once daily when co-administered with strong
inhibitors of CYP3A4. ii. Moderate inducers of CYP3A4: Increase
dose to 90 mg once daily when co-administered with moderate
inducers of CYP3A4. Daclatasvir must be administered in
combination with other medicinal products for the treatment of
hepatitis C infection. Dose modification of daclatasvir to manage
adverse reactions is not recommended.
Danazol 100mg Capsule G03XA01-000-C10-01-XXX A/KK i) Endometriosis ii) Benign breast disorders including None i. 400mg daily in 2 to 4 divided doses, starting on the 1st day of
gynaecomastia fibrocystic breast disease and pubertal the menstrual cycle; daily doses of 800mg are also employed. ii.
breast hypertrophy iii) Menorrhagia iv) Prophylaxis of 100mg to 400mg daily in divided dose. iii. 200 mg BD iv. 400 mg
hereditary angioedema daily. Reduce to 200 mg daily after 2 months attack free period.
General dosing range: 200-800mg daily in 2 or 4 divided doses.
Dosing is individualised and according to product insert/protocol
Danazol 200mg Capsule G03XA01-000-C10-02-XXX A/KK i) Endometriosis ii) Benign breast disorders including None i. 400mg daily in 2 to 4 divided doses, starting on the 1st day of
gynaecomastia fibrocystic breast disease and pubertal the menstrual cycle; daily doses of 800mg are also employed. ii.
breast hypertrophy iii) Menorrhagia iv) Prophylaxis of 100mg to 400mg daily in divided dose. iii. 200 mg BD iv. 400 mg
hereditary angioedema daily. Reduce to 200 mg daily after 2 months attack free period.
General dosing range: 200-800mg daily in 2 or 4 divided doses.
Dapagliflozin 10mg Tablet A10BX09-999-T32-01-XXX A* Indication 1: Dapagliflozin is indicated for use as an add- Indication 1: Patients with HbA1c between 6.5%-10.0% 10 mg once daily
on combination therapy in combination with other while on single / combination anti-diabetic therapy
glucose-lowering medicinal products including insulin, to Indication 2: Patients with HbA1c not more than 10.0%
improve glycemic control in adult patients with type 2 while on adequate trial of metformin.
diabetes mellitus when these, together with diet and
exercise, do not provide adequate glycaemic control.
Indication 2: Dapagliflozin is indicated to reduce the risk
of hospitalization for heart failure in adults with type 2
diabetes mellitus and established cardiovascular disease
(CVD).
Dapsone 100 mg Tablet J04BA02000T1001XX B i)Leprosy ii) Dermatitis herpetiformis i) ADULT: 6 - 10 mg/kg weekly/ 1.4mg/kg daily (around 50 - 100
mg daily). CHILD: 1 - 2 mg/kg/day. Maximum: 100 mg/day ii)
ADULT: 50 - 300 mg daily
April 2023 44

Darbepoetin alfa 120mcg/0.5ml injection B03XA02-000-P50-04-XXX A* i. Treatment of anaemia associated with chronic renal For indication (i): Patients who require higher doses of Indication (i): Haemodialysis patients: Initial dose: 20mcg IV once
failure, including patients on dialysis and patients not on erythropoietin if it is more cost saving to use a long-acting weekly Initial dose for switched ESA-treated patient: 15 – 60mcg
dialysis. ii. Anemia with myelodysplastic syndrome agent instead of short-acting agents. IV once weekly Maintenance dose: 15 – 60mcg IV once weekly,
then 30 – 120mcg IV biweekly. Peritoneal dialysis patients and
patients with chronic kidney disease not on dialysis: Initial dose:
30mcg IV or SC biweekly Initial dose for switched ESA-treated
patient: 30 – 120mcg IV or SC biweekly Maintenance dose: 30 –
120mcg IV or SC biweekly, then 60 – 180mcg IV or SC once every
four weeks. Indication (ii): Adults: 240mcg administered as a
single subcutaneous injection once weekly. The dose should be
decreased in view of the degree of anemic symptoms and the
patient’s age.
dialysis. ii. Anemia with myelodysplastic syndrome agent instead of short-acting agents IV once weekly Maintenance dose: 15 – 60mcg IV once weekly,
patient’s age.
dialysis. ii. Anemia with myelodysplastic syndrome agent instead of short-acting agents. IV once weekly Maintenance dose: 15 – 60mcg IV once weekly,
patient’s age.
Daunorubicin HCl 20 mg Injection L01DB02110P4001XX A* i) Acute myeloblastic leukaemia (AML) ii) Acute i) 45 - 60 mg/m2 IV daily for 3 - 5 days ii) 25 - 45 mg/m2 once a
lymphoblastic leukemia (ALL) week for first 4 weeks during induction phase. Caution: Total
cumulative dose of daunorubicin and doxorubicin must not
exceed 500 mg/m2 due to risk of cardiotoxicity. CHILD: 30-45
mg/m2/dose infusion over 6 hours. Schedule depends on
protocol. Need to check cardiac function closely by
echocardiography every cumulative dose of 100mg/m2 to max.
360 mg/m2
April 2023 45

Decitabine 50 mg Injection L01BC08000P3001XX A* Myelodysplastic syndromes (MDS) 3-day Regimen 15 mg/m2 by continuous IV infusion over 3 hours
repeated every 8 hours for 3 days. Repeat this treatment cycle
every 6 weeks for a minimum of 4 cycles. 5-day Regimen Dose of
20 mg/m2 by continuous intravenous infusion over 1 hour
repeated daily for 5 days. This cycle should be repeated every 4
weeks Dosing is according to product insert /protocol
Deferasirox 125mg Dispersible Tablet V03AC03-000-T40-01-XXX A* Treatment of chronic iron overload due to blood Initial 20 mg/kg/day. Starting dose can also be based on
transfusions (transfusional haemosiderosis) in adult and transfusion rate and existing iron burden. In patients not
pediatric patients aged 2 years and above. adequately controlled with doses of 30mg/kg/day (e.g serum
ferritin levels persistently above 2,500 microgram/L and not
showing a decreasing trend over time), doses up to 40mg/kg/day
may be considered.
Deferasirox 250mg Dispersible Tablet V03AC03-000-T40-02-XX A* Treatment of chronic iron overload due to blood None Initial 20 mg/kg/day. Starting dose can also be based on
may be considered.
Deferasirox 360mg film coated tablet V03AC03-000-T32-03- XXX A* Treatment of chronic iron overload due to blood None • Recommended initial dose is 14mg/kg body weight. • An initial
transfusions (transfusional haemosiderosis) in adult and dose of 21mg/kg may be considered for patients receiving more
paediatric patients aged 2 years and above. than 14ml/kg/month of packed red blood cells, and for whom the
objective is maintenance of the body iron level. • An initial dose
of 7mg/kg may be considered for patients receiving less than
7ml/kg/month of packed red blood cells, and for whom the
objective is maintenance of the body iron level. • For patients
already well-managed on treatment with Deferoxamine, a
starting dose of Deferasirox film- coated tablets that is
numerically one third of the Deferoxamine dose could be
considered. In patients not adequately controlled with doses of
21mg/kg (e.g. serum ferritin levels persistently above 2,500
mcg/L and not showing a decreasing trend over time), doses of
up to 28mg/kg may be considered. Doses above 28 mg/kg are not
recommended because there is only limited experience with
doses above this level.
Deferasirox 500 mg Dispersible Tablet V03AC03-000-T40-03-XXX A* Treatment of chronic iron overload due to blood None Initial 20 mg/kg/day. Starting dose can also be based on
may be considered.
April 2023 46

Deferasirox 90mg film coated tablet V03AC03-000-T32-01- XXX A* Treatment of chronic iron overload due to blood • Recommended initial dose is 14mg/kg body weight. • An initial
transfusions (transfusional haemosiderosis) in adult and dose of 21mg/kg may be considered for patients receiving more
paediatric patients aged 2 years and above. than 14ml/kg/month of packed red blood cells, and for whom the
objective is maintenance of the body iron level. • An initial dose
of 7mg/kg may be considered for patients receiving less than
7ml/kg/month of packed red blood cells, and for whom the
objective is maintenance of the body iron level. • For patients
already well-managed on treatment with Deferoxamine, a
starting dose of Deferasirox film- coated tablets that is
numerically one third of the Deferoxamine dose could be
considered. In patients not adequately controlled with doses of
21mg/kg (e.g. serum ferritin levels persistently above 2,500
mcg/L and not showing a decreasing trend over time), doses of
up to 28mg/kg may be considered. Doses above 28 mg/kg are not
recommended because there is only limited experience with
doses above this level.
Deferiprone 500 mg Tablet V03AC02000T1001XX A* Treatment of iron overload in patients with thalassemia 25 mg/kg 3 times a day for total daily dose of 75 mg/kg. Doses
major for whom desferrioxamine therapy is greater 100 mg/kg are not recommended
contraindicated or inadequate. Add on therapy to
desferrioxamine for thalassemia patients with cardiac
complication
Degarelix 120mg Injection L02BX02-000-P40-01-001 A* Treatment of adult male patients with advanced Patients who are contraindicated to Gonadotrophin 240 mg administered as two consecutive subcutaneous injections
hormone- dependent prostate cancer Releasing Hormone (GnRH) agonist of 120 mg each. Maintenance dose* – monthly administration:
80 mg administered as one subcutaneous injection *The first
maintenance dose should be given one month after the starting
dose.
Degarelix 80mg Injection L02BX02-000-P40-01-002 A* Treatment of adult male patients with advanced Patients who are contraindicated to Gonadotrophin 240 mg administered as two consecutive subcutaneous injections
hormone- dependent prostate cancer. Releasing Hormone (GnRH) agonist of 120 mg each. Maintenance dose* – monthly administration:
80 mg administered as one subcutaneous injection *The first
maintenance dose should be given one month after the starting
dose.
Denosumab in 1.0 mL solution (60 mg/mL) M05BX04000P4001XX A* Post-Menopausal Osteoporosis. To be used by Orthopaedic Specialist, Rheumatologist, A single subcutaneous injection of 60 mg administered once
Pre-filled syringe (subcutaneous injection) Endocrinologist and Geriatricians every 6 months. Patients should receive calcium and vitamin D
supplements whilst undergoing treatment.
Desferrioxamine B Methanesulphonate 0.5g V03AC01-196-P30-01-XX A i) Acute iron poisoning in children ii) Investigation and None i) 2 g by IM immediately and 5 g by mouth after gastric lavage ii)
Injection treatment of haemochromatosis iii) Diagnosis and 0.5 - 1.5 g by IM injection daily iii) Diagnosis: 5 mg per kg by slow
treatment of aluminium toxicity in patients with renal intravenous infusion during the last hour of haemodialysis.
failure and dialysis iv) Chronic iron toxicity or overload Treatment: 5 mg per kg once a week by slow intravenous infusion
during the last hour of dialysis iv) 30 - 50 mg/kg
Desflurane Liquid N01AB07000L5001XX A i) Induction and maintenance of anaesthesia in adult ii) ADULT: Induction , initially 3% in oxygen or nitrous oxide/oxygen
Maintenance of anaesthesia in infants & children and increased by 0.5%-1% every 2-3 breaths or as tolerated (up
to 11%), until loss of consciousness. Maintenance: 2.5%-8.5%
with or without concomitant nitrous oxide CHILD: maintenance,
inhaled in concentrations of 5.2%-10% with or without
concomitant nitrous oxide
April 2023 47

Desloratadine 2.5mg/5ml syrup R06AX27-000-L90-01-XXX A* Allergic rhinitis and chronic idiopathic urticaria. For use in children 1-2 years old only. For children only: 1-5 yrs: 2.5ml once a day (with or without
meal) 6-11 yrs: 5ml once a day (with or without meal)
Desloratadine 5mg Tablet R06AX27-000-T10-01-XXX A* Allergic rhinitis and chronic idiopathic urticaria None Adults and Adolescents (12 years of age and older): 5mg once a
day regardless of mealtime.
Desmopressin 0.1 mg Tablet H01BA02122T1001XX A i)Central diabetes insipidus ii)Primary nocturnal enuresis i)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg
iii)Treatment of nocturia associated with nocturnal daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg
polyuria in adult at night. May be increased to 0.2 mg and then to 0.4 mg by
means of weekly increase
Desmopressin 0.2 mg Tablet H01BA02122T1002XX A i)Central diabetes insipidus ii)Primary nocturnal enuresis i)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg
iii)Treatment of nocturia associated with nocturnal daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg
polyuria in adult at night. May be increased to 0.2 mg and then to 0.4 mg by
means of weekly increase
Desmopressin 100mcg/ml Nasal Spray H01BA02-122-A41-01-XXX A i) Central Diabetes Insipidus ii) Primary nocturnal None i) ADULT : 10 - 20 mcg 1-2 times daily. CHILD: 5 - 10mcg 1-2 times
enuresis daily ii) 10-40 mcg nocte
Desmopressin 120mcg Sublingual Tablet H01BA02-122-T70-02-001 A i) Central diabetes insipidus ii) Primary nocturnal i) 60mcg 3 times daily sublingually (daily dose range from 120mcg
enuresis iii) Treatment of nocturia associated with to 720mcg) ii) 120mcg once daily at bedtime, sublingually
nocturnal polyuria in adults (maximum dose 240mcg) iii) 60mcg once daily at bedtime (dose
range from 120mcg to 240mcg)
Desmopressin 60mcg Sublingual Tablet H01BA02-122-T70-01-001 A i) Central diabetes insipidus ii) Primary nocturnal i) 60mcg 3 times daily sublingually (daily dose range from 120mcg
enuresis iii) Treatment of nocturia associated with to 720mcg); ii) 120mcg once daily at bedtime, sublingually
nocturnal polyuria in adults (maximum dose 240mcg); iii) 60mcg once daily at bedtime (dose
range from 120mcg to 240mcg).
Desmopressin Acetate 4mcg/ml Injection H01BA02-122-P30-01-XXX A Central Diabetes Insipidus. None Adults 1-4 mcg 1-2 times daily. Children above the age of 1 year
0.4-1 mcg 1-2 times daily. Children below the age of 1 year 0.2-
0.4 mcg 1-2 times daily.
Desogestrel 0.075mg Tablet G03AC09-000-T10-01-XXX A* Contraception. Only for women who should not take None Tablets must be taken in the order directed on the package every
combined oral contraceptives (COCs) eg Obese, smoker, day at about the same time with some liquid as needed. One
migraine, breast feeding tablet is to be taken daily for 28 consecutive days. Each
subsequent pack is started immediately after finishing the
previous pack.
Desogestrel 150mcg & Ethinylestradiol 20mcg G03AA09-954-T10-02-XX A/KK Oral contraception None One tablet daily for 21 days starting on 1st day of menses
Tablet followed by 7 tablet-free days.
Desogestrel 150mcg & Ethinylestradiol 30mcg G03AB05-954-T10-01-XXX C+ Contraception None 1 tablet daily for 21 days, subsequent courses repeated after 7
Tablet day interval (during which withdrawal bleeding occurs)
Desvenlafaxine Succinate 50 mg Extended N06AX23999T5002XX A* Major depression Recommended dose is 50mg once daily, with or without food.
Release Tablet
Dexamethasone 0.5mg Tablet H02AB02-000-T10-01-XXX A i) Prophylaxis and management of nausea and vomiting None 0.5mg to 10mg daily is given for oral administration. Dose can be
in cancer chemotherapy, post-operation and palliative titrated up to 20mg daily in severe disease depending on the
care ii) Treatment of adrenocortical function condition being treated. The dosing is individualized according to
abnormalities iii) Any other treatment requiring product insert / protocol
corticosteroid therapy.
Dexamethasone 4mg Tablet H02AB02-000-T10-03-XXX A i) Prophylaxis and management of nausea and vomiting None 0.5mg to 10mg daily is given for oral administration. Dose can be
in cancer chemotherapy, post-operation and palliative titrated up to 20mg daily in severe disease depending on the
care ii) Treatment of adrenocortical function condition being treated. The dosing is individualized according to
abnormalities iii) Any other treatment requiring product insert / protocol
April 2023 48

Dexamethasone 700mcg intravitreal implant S01BA01-000-P11-01-XXX A* i) Treatment of adult patients with visual impairment For indication (ii): a) First line therapy for patient with Indication (i): The recommended dose is one dexamethasone
due to diabetic macular oedema (DME) who are contraindication to anti-VEGF treatment. b) Second line intravitreal implant to be administered to the affected eye.
pseudophakic. ii) Treatment of adult patients with therapy for patient refractory to anti-VEGF treatment. c) Administration to both eyes concurrently is not recommended.
macular oedema following either Branch Retinal Vein To be prescribed by Ophthalmologist only Patients treated with dexamethasone intravitreal implant who
Occlusion (BRVO) or Central Retinal Vein Occlusion have experienced an initial response and in the physician’s
(CRVO) opinion may benefit from retreatment without being exposed to
significant risk should be considered for retreatment.
Retreatment may be performed after approximately 6 months if
the patient experiences decreased vision and/or an increase in
retinal thickness, secondary to recurrent or worsening diabetic
macular oedema. There is currently no experience of the efficacy
or safety of repeat administrations in DME beyond 7 implants.
Indication (ii): 700 mcg injected intravitreally into one affected
eye. Administration to both eyes concurrently is not
recommended. Repeat doses at 6 months interval should be
considered when a patient experiences a response to treatment
followed subsequently by a loss in visual acuity.
Dexamethasone and Neomycin Sulphate and S01CA01-990-G51-01-XXX A Treatment of ocular inflammation when concurrent use None Apply a small amount into the conjunctival sac(s) 3 – 4 times
Polymyxin B Eye Ointment of an antimicrobial is judged necessary daily, may be used adjunctively with drops at bedtime
Dexamethasone and Neomycin Sulphate and S01CA01-990-D20-01-XXX A Treatment of ocular inflammation when concurrent use None 1 - 2 drops hourly for severe cases and 4 - 6 hourly for mild
Polymyxin B Sulphate Ophthalmic Suspension of an antimicrobial is judged necessary infection
Dexamethasone Sodium Phosphate 0.1% Eye S01BA01-162-D20-01-XXX A Acute steroid responsive inflammatory and allergic None 1 - 2 drops 4 - 6 times a day
Drops conditions
Dexamethasone Sodium Phosphate 4 mg/ml H02AB02-162-P30-01-XXX B i) Prophylaxis and management of nausea and vomiting None i-iii) Initial dosage: 0.5 mg to 20 mg per day depending on the
Injection in cancer chemotherapy, post-operation and palliative specific disease entity being treated. The total daily dosage
care ii) Treatment of adrenocortical function should not exceed 80 mg. The dosing is individualized according
abnormalities iii) Any other treatment requiring to product insert / protocol
Dexlansoprazole 30 mg delayed release capsule A02BC06-000-C30-01-XXX A* i) Treatment of erosive esophagitis (EE); ii) Maintenance As a second-line therapy for: i) Patients with refractory EE; i) Treatment of EE – 60 mg once daily for 8 weeks; ii)
of healed erosive esophagitis (EE); iii) Symptomatic ii) Geriatrics; iii) Patients with polypharmacy. Maintenance of healed EE – 30 mg once daily for 6 months; iii)
treatment of non-erosive gastroesophageal reflux Symptomatic non-erosive gastroesophageal reflux disease – 30
disease. mg once daily for 4 weeks.
Dexlansoprazole 60 mg delayed release capsule A02BC06-000-C30-02-XXX A* i) Treatment of erosive esophagitis (EE); ii) Maintenance As a second-line therapy for: i) Patients with refractory EE; i) Treatment of EE – 60 mg once daily for 8 weeks; ii)
of healed erosive esophagitis (EE); iii) Symptomatic ii) Geriatrics; iii) Patients with polypharmacy. Maintenance of healed EE – 30 mg once daily for 6 months; iii)
treatment of non-erosive gastroesophageal reflux Symptomatic non-erosive gastroesophageal reflux disease – 30
disease. mg once daily for 4 weeks.
Dexmedetomidine HCl 100 mcg/ml Injection N05CM18110P4001XX A* i) Sedation of intubated and mechanically ventilated ICU i) Not to be infused for more than 24 hours, 1 mcg/kg over 10
patients. For use only by specialist anaesthetist ii) For minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr
sedation of non-intubated patients prior to and/or ii) Not to be infused for more than 24 hours, 1 mcg/kg over 10
during surgical and other procedures minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr
Dextrose 10% Injection B05BA03000P6002XX B For parenteral replenishment of fluid and minimal According to the needs of the patient
carbohydrate calories as required by the clinical
condition of the patient
April 2023 49

Dextrose Powder V04CA02000F2101XX B Use as a diagnostic agent for diabetes 75 g stat
Diatrizoate Meglumine and Sodium V08AA01254L9901XX A i) Contrast medium for the radiological examination of i) ADULT and CHILD more than 10 year, ORALLY: 60 -100 ml
Amidotrizoate Solution the gastrointestinal tract (primarily in cases in which RECTALLY, contrast medium should be diluted with 3-4 times its
barium sulphate is contraindicated) ii) Computerised volume of water. ORALLY: CHILD less than 10 years,: 15- 30 ml
tomography in abdominal region iii) Treatment of NEWBORN, INFANT contrast medium should be diluted with 3
Mecolinium ileus times its volume of water. RECTALLY: CHILD more than 5 years,
contrast medium should be diluted with 4-5 times its volume of
water. Younger patients a dilution with 5 times its volume is
recommended ii) Adult, orally, 25-77 mL in 1000 mL tap water 15-
30 minutes prior to imaging
Diazepam 2mg Tablet N05BA01-000-T10-01-XXX B i) Muscle spasm of varied aetiology, including tetanus ii) None i) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older:
Anxiety disorders 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT
: 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg
daily in divided doses. ELDERLY (or delibitated) half adult dose.
CHILD (night terrors), 1 - 5 mg at bedtime
Diazepam 5mg Rectal Solution N05BA01-000-G20-01-XXX B i) Status epilepticus ii) Skeletal muscle spasm None Status epilepticus - ADULT: 0.5 mg/kg repeated after 12 hours if
necessary. CHILD (febrile convulsions, prolonged or recurrent):
0.5 mg/kg (maximum 10 mg), repeated if necessary. Not
recommended for children below 2 years
Diazepam 5mg Tablet N05BA01-000-T10-02-XXX B i) Muscle spasm of varied aetiology, including tetanus ii) None i) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older:
Anxiety disorders 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT
: 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg
daily in divided doses. ELDERLY (or debilitated) half adult dose.
CHILD (night terrors), 1 - 5 mg at bedtime
Diazepam 5mg/ml Injection N05BA01-000-P30-01-XXX B i) Status epilepticus ii) Skeletal muscle spasm iii) Anxiety None i) ADULT: initial dose 10-20mg IV, in the following hours 20mg IM
disorders or by intravenous drip infusion as necessary. CHILD 2 to 5 years of
age: slow IV 0.2 - 0.5mg every two to five minutes up to a
maximum of 5mg. If necessary, dose can be repeated in two to
four hours. CHILD 5 years and older: slow IV 1mg every two to
five minutes up to a maximum of 10mg. If necessary, dose can be
repeated in two to four hours. ii) ADULT: 10mg once or twice IV.
CHILD 2 to 5 years of age: IM or IV, 1 to 2mg the dosage being
repeated every three to four hours as needed. CHILD 5 years and
older: IM or IV, 5 to 10mg, the dosage being repeated every three
to four hours as needed. iii) ADULT: 10-20mg three times daily IM
or IV until acute symptoms subside.
April 2023 50

Diclofenac 1% Gel M02AA15-520-G30-01-XXX A i) Post-traumatic inflammation of the tendons,ligaments None Apply 3 - 4 times daily and gently rubbed in
& joints. ii) Localised forms of soft tissue rheumatism
and degenerative rheumatism
Diclofenac 12.5mg Suppository M01AB05-520-S20-01-XXX A Pain and inflammation in rheumatic disease and juvenile None ADULT: 100 mg usually at night, max total daily dose 150 mg.
arthritis CHILD ABOVE 1 YEAR AND ADOLESCENT: 0.5-2mg/kg daily
divided to 2-3 doses. Maximum dose for juvenile RA is
3mg/kg/day in divided doses
Diclofenac 25mg Suppository M01AB05-520-S20-02-XXX A Pain and inflammation in rheumatic disease and juvenile None ADULT: 100 mg usually at night, max total daily dose 150 mg.
Diclofenac 50mg Tablet M01AB05-520-T10-01-XXX B Pain and inflammation in rheumatic disease and of non- None ADULTS: Initial dose of 150 mg daily. Mild or long term: 75 - 150
rheumatic origin mg daily in 2 to 3 divided doses after food. Maximum:
200mg/day. CHILD more than 6 months : 1 - 3 mg/kg body weight
daily in divided doses. Maximum: 3mg/kg/day (150mg/day).
Diclofenac Sodium 50 mg Suppository M01AB05-520-S20-03-XXX A Pain and inflammation in rheumatic disease and juvenile None ADULT: 100 mg usually at night, max total daily dose 150 mg.
Diclofenac Sodium 75 mg/3ml Injection M01AB05-520-P30-01-XXX A/KK Pain and inflammation in rheumatic disease and of non- None IM 75 mg once daily (2 times daily in severe cases) for not more
rheumatic origin than 2 days. Max 150mg/day. Not suitable for children.
Didanosine 100 mg Tablet (ddI) J05AF02000T1002XX A* HIV infection, in combination with other antiretrovirals ADULT less than 60 kg: 125 mg twice daily or 250 mg once daily;
more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD:
2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8
months: 100mg/m2 twice daily
Didanosine 2 g Oral Solution (ddI) J05AF02000F2101XX A* HIV infection, in combination with other antiretrovirals ADULT less than 60 kg: 125 mg twice daily or 250 mg once daily;
Didanosine 25 mg Tablet (ddI) J05AF02000T1001XX A* HIV infection, in combination with other antiretrovirals ADULT less than 60 kg: 125 mg twice daily or 250 mg once daily;
Didanosine 250 mg Enteric Coated Capsule J05AF02000C1001XX A* HIV infection, in combination with other antiretrovirals ADULT less than 60 kg: 250 mg once daily; 60 kg or greater: 400
mg once daily. Dose may varies if taken in combination with
tenofovir
Didanosine 400 mg Enteric Coated Capsule J05AF02000C1002XX A* HIV infection, in combination with other antiretrovirals ADULT less than 60 kg: 250 mg once daily; 60 kg or greater: 400
mg once daily. Dose may varies if taken in combination with
tenofovir
Dienogest 2mg tablet G03DB08-000-T10-01-XXX A/KK Treatment of endometriosis None One tablet daily. Treatment can be started on any day of
menstrual cycle. Tablets must be taken continously without
regard to vaginal bleeding.
Diethylcarbamazine Citrate 50 mg Tablet P02CB02136T1001XX B i) Bancrofti filariasis, onchocerciasis, loasis, creeping i) 1 mg/kg on the first day and increased gradually over 3 days to
eruption ii) Ascariasis iii) Tropical eosinophilia 6 mg/kg daily in divided doses. This dosage is maintained for 21
days. ii) 13 mg/kg once daily for 7 days. CHILD : 6 - 10 mg/kg 3
times daily for 7 days iii) 6 mg/kg/day in 3 divided doses for 21
days
April 2023 51

Digoxin 0.25mg Tablet C01AA05-000-T10-01-XX B Heart failure , with atrial fibrillation, supraventricular None Rapid digitalisation: 0.75 -1.5 mg in divided doses over 24 hours;
arrhythmias (particularly, atrial fibrillation) less urgent digitalisation, 250 mcg-500 mcg daily (higher dose
may be divided). Maintenance : 62.5mg -500 mcg daily (higher
dose may be divided) according to renal function and , in atrial
fibrillation, on heart rate response; usual range, 125-250 mcg
daily (lower dose may be appropriate in elderly)
Digoxin 250mcg/ml Injection C01AA05-000-P30-01-XX A Heart failure with atrial fibrillation, supraventricular None Rapid digitilisation: ADULT & CHILD over 10 years, initially 0.75 -
arrhythmias (particularly atrial fibrillation) 1.5 mg, followed by 250 mcg 6 hourly until digitilisation is
complete
Digoxin 50mcg/ml Elixir C01AA05-000-L10-01-XX B Heart failure, supraventricular arrhythmias (particularly None Rapid digitalization, give in divided doses; PREMATURE: 20-30
atrial fibrillation) mcg/kg; FULLTERM: 25-35 mcg/kg; CHILD 1-2 years : 35 to 60
mcg/kg; CHILD 2-5 years: 30-40 mcg/kg; CHILD 5-10 years: 20- 35
mcg/kg; CHILD over 10 years: 10-15 mcg/kg. For daily
maintenance doses or for gradual digitalization, give 20% to 30%
of oral digitalizing dose for premature infants or 25% to 35% of
oral digitalizing dose for all other pediatric patients
Digoxin 62.5mcg Tablet C01AA05-000-T10-02-XX B Heart failure, with atrial fibrillation, supraventricular None Rapid digitalisation: 1-1.5 mg in divided doses over 24 hours; less
arrhythmias (particularly, atrial fibrillation) urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be
divided). Maintenance: 62.5 - 500 mcg daily (higher dose may be
divided) according to renal function, and in atrial fibrillation, on
heart-response; usual range :125 - 250 mcg daily (lower doses
may be appropriate in the elderly)
Dihydrocodeine Tartrate 30 mg Tablet N02AA08-123-T10-01-XXX B For the control of moderate to severe chronic pain None ADULT: 30 - 60 mg every 4 - 6 hours. CHILD, over 4 yrs: 0.5 - 1
mg/kg body weight every 4-6 hours
Diltiazem HCl 100mg sustained release capsule C08DB01-110-C20-05-001 A/KK Treatment of angina pectoris in the following cases: i. None Usually, for adults, 100 mg to 200 mg to be administered orally
Inadequate response or intolerance to beta-blockers and once daily. If the effect is insufficient, the dosage may be
Isosorbide Dinitrate ii. Contraindication to beta-blockers increased to 200 mg once daily.
iii. Coronary artery spasm
Diltiazem HCl 30 mg Tablet C08DB01-110-T10-01-XX B i) Treatment of angina ii) Hypertension None Initially 30mg tds, may increase to 60mg tds (elderly initially twice
daily; increased if necessary to 360 mg daily.
Dimenhydrinate Injection 10ml/vial (50mg/ml) N07CA00000P2001XX B Prevention and relief of motion sickness, treatment of Usual Adult & Adolescent Dose: Antiemetic; or Antivertigo agent
vertigo, nausea or vomiting associated with electroshock ? Intramuscular, 50 mg repeated every four hours as needed.
therapy, anaesthesia and surgery; labyrinthine Intravenous, 50 mg in 10 mL of 0.9% sodium chloride injection,
disturbances and radiation sickness. administered slowly over a period of at least two minutes,
repeated every four hours as needed. Usual Pediatric Dose:
Antiemetic; or Antivertigo agent ? Intramuscular, 1.25 mg per kg
of body weight or 37.5 mg per square meter of body surface,
every six hours as needed, not to exceed 300 mg per day.
Intravenous, 1.25 mg per kg of body weight or 37.5 mg per
square meter of body surface, in 10 ml of 0.9% sodium chloride
injection, administered slowly over a period of at least two
minutes, every six hours as needed, not to exceed 300 mg per
day.
April 2023 52

Dimenhydrinate Syrup 15mg/5ml N07CA00000L9003XX B For prevention and treatment of motion sickness. Also ADULT: 50-100 mg every 4 hours as needed. For motion sickness,
used as anti-emetic agent in irradiation sickness, take medicine at least 30 minutes, and preferably 1-2 hours
postoperative vomiting, drug induced nausea and before travelling. Usual adult prescribing limit: Up to 400 mg
vomiting, and for symptomatic treatment of nausea and daily. CHILD: Children 6-12 years: 25-50 mg every 6-8 hours as
vertigo due to Meniere`s disease and other labyrinthine needed (maximum of 150 mg daily).
disturbances.
Dimercaprol 50 mg/ml Injection V03AB09000P3001XX B Poisoning by antimony, arsenic, bismuth, gold, mercury, None By IM: 2.5 - 3 mg/kg every 4 hours for 2 days, 2 - 4 times on the
possibly thallium; adjunct (with calcium disodium third day, then 1 - 2 times daily for 10 days or until recovery. For
edetate) in lead poisoning ophthalmic use : instillation of 50 mg/ml oily solution in
conjunctival sac, within 5 minutes of contamination
Dinoprostone (Prostagladin E2) 3mg Vaginal G02AD02-000-S10-01-XXX A Induction of labour None 3 mg vaginal tablet to be inserted high into the posterior formix.
Tablet A second 3 mg tablet may be inserted after 6-8 hours if labour is
not established. Max 6 mg
Diosmin 450mg and Hesperidin 50mg Tablet C05CA533-931-T10-01-XX B i) Haemorrhoids ii) Chronic venous insufficiency None i) Acute attack: 6 tablets daily for the first 4 days, then 4 tablets
daily in 2 divided doses for 3 days and 2 tablets thereafter.
Chronic: 2 tablets daily ii) 2 tab daily with meals
Diphenhydramine Hydrochloride 14mg/5ml R06AA52-110-L21-01-XXX C Cough None ADULT : 5 - 10 ml 2 - 3 times daily.
Expectorant
Diphenhydramine Hydrochloride 7 mg/5 ml R06AA52-110-L90-03-XXX C Cough None CHILD 6-12 years: 2.5 to 5 ml 2-3 times daily CHILD 2-5 years: 2.5
Expectorant ml 2-3 times daily NOT to be used in children less than 2 years in
age
Diphenoxylate HCl 2.5mg with Atropine A07DA01-922-T10-01-XXX B Symptomatic treatment of acute and chronic diarrhoea None ADULT: 2 tablets 4 times daily, later reduced when diarrhoea is
Sulphate 0.025mg Tablet controlled. Maintenance: 2 tablets once daily as needed (Max: 8
tablets daily)
Diphtheria and Tetanus Vaccine Injection J07AM51963P3001XX C+ Immunisation against diphtheria and tetanus. 0.5ml by deep SC or IM injection. Dosing is according to
Immunisation Schedule under NIP.
Diphtheria Antitoxin Injection J07AF01000P3001XX B Diphtheria Therapeutic: 10,000 - 30,000 units by IM or IV. Increase to 40,000
- 100,000 units in severe cases. Doses up to 30,000 units may be
given IM
Diphtheria, Pertussis, Tetanus Vaccine Injection J07AJ52963P3001XX C+ Immunisation against diphtheria, pertussis and tetanus. 0.5ml by IM. Dosing is according to Immunisation Schedule under
NIP.
Diphtheria, tetanus and pertussis (acellular, J07AJ52-963-P30-01-XXX C+ Indicated for passive protection against pertussis in early None A single 0.5 ml dose of the vaccine is recommended for pregnant
component) vaccine (adsorbed, reduced infancy following maternal immunisation during women during the second or the third trimester of pregnancy.
antigen(s) content) Suspension for injection pregnancy. For deep intramuscular injection, preferably in the deltoid region
(Tdap)
Diphtheria, Tetanus, Acellular Pertussis, J07CA06963P3001XX C+ Immunisation of children against Diphtheria, Tetanus, 0.5ml by IM. Dosing is according to Immunisation Schedule under
Inactivated Polio Virus, Haemophilus Influenza Acellular Pertussis, Polio and Haemophilus Influenza NIP.
Type B (DTaP-IPV-HiB) Vaccine Injection Type B infection.
Diphtheria, Tetanus, Pertussis (Acellular, J07CA09-963-P30-02-001 C+ For primary and booster vaccination of infants and Not applicable Dosing is according to Immunisation Schedule under NIP:
component), Hepatitis B (rDNA), Poliomyelitis toddlers from six weeks to 24 months of age against Primary: Dose of 0.5ml to be given by IM at 2, 3 & 5 months of
(Inactivated) and Haemophilus Influenzae Type diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis age. Booster: Dose of 0.5ml to be given by IM at 18 months of
B Conjugate Vaccine (adsorbed) (DTaP- IPV-HB- and invasive diseases caused by Haemophilus influenzae age.
Hib) Injection type b (Hib).
Dipyridamole 75 mg Tablet B01AC07000T1001XX B As an adjunct to oral anticoagulation/ antiplatelet 75-150 mg 3 times daily to be taken 1 hour before meals
therapy in the prophylaxis of cerebrovascular events
Dithranol 0.1 - 5% in Vaseline/ Ointment D05AC01000G5001XX A Short contact treatment for plaque psoriasis and For application to skin or scalp. 0.1-0.5% suitable for overnight
alopecia areata treatment. 1-2% for max 1 hour.
April 2023 53

Dithranol 1 % in Lassars Paste D05AC01000G6001XX A Treatment of quiescent or chronic psoriasis of the skin, Apply liberally and carefully to the lesions with a suitable
scalp and alopecia areata applicator. A dressing may be applied
Dobutamine 12.5mg/ml Injection C01CA07-110-P30-01-XX A Hypotension and heart failure None Initial 0.5-1 mcg/kg/min by IV, maintenance 2.5-10mcg/kg/min.
Frequently,doses up to 20mcg/kg/min are required for adequate
hemodynamic improvement. On rare occasions,infusion rates up
to 40mcg/kg/min
Docetaxel 20mg/ml Injection L01CD02-000-P30-03-XXX A* i) Breast Cancer ii) Non-small cell lung cancer iii) Prostate Two dosing regimens: a. 50 mg/m2 every 2 weeks, intravenous b.
cancer iv) Gastric adenocarcinoma v) Head and neck 75 to 100 mg/m2 every 3 weeks, intravenous. Dosing is according
cancer vi)Ovarian cancer to product insert/protocol.
Docetaxel 40mg/ml Injection L01CD0-000-P30-02-XXX A* i) Breast Cancer ii) Non-small cell lung cancer iii) Prostate Two dosing regimens: a. 50 mg/m2 every 2 weeks, intravenous b.
cancer iv) Gastric adenocarcinoma v) Head and neck 75 to 100 mg/m2 every 3 weeks, intravenous. Dosing is according
cancer vi)Ovarian cancer to product insert/protocol.
Dolutegravir 50mg Tablet J05AX12000T3201XX A* Dolutegravir is indicated in combination with other anti- For patients who are : - not able to tolerate; or - failing i) HIV-1 patients without documented or clinically suspected
retroviral medicinal products for the treatment of treatment or resistant to first line therapy (efavirenz and resistance to the integrase class: 50 mg (one tablet), once daily,
Human Immunodeficiency Virus (HIV) infected adults nevirapine). orally. ii) HIV-1 patients with resistance to the integrase class: 50
and adolescents above 12 years of age. mg (one tablet), twice daily, orally.
Domperidone 1 mg/ml Suspension A03FA03000L8001XX B Nausea, vomiting, dyspepsia, gastro-esophageal reflux Adults and adolescents ≥ 12 years of age and weighing ≥ 35kg &
children < 12 years of age and weighing ≥ 35kg: 10ml three to
four times per day. Maximum dose: 40mg/day. Adults and
adolescents (≥ 12 years of age) weighing < 35kg: 0.25mg/kg three
to four times per day. Maximum dose: 35mg/day.
Domperidone 10 mg Tablet A03FA03253T1001XX B Nausea, vomiting, dyspepsia, gastro-esophageal reflux Adults and adolescents ≥ 12 years of age and weighing ≥ 35kg &
children < 12 years of age and weighing ≥ 35kg: 10mg three to
four times per day. Maximum dose: 40mg/day
Donepezil HCl 10 mg Tablet N06DA02-110-T10-02-XXX A Treatment of mild, moderate and severe dementia in Psychiatrists, neurologists and geriatricians only 5 - 10 mg once daily at bedtime. Maximum 10 mg daily
Alzheimer's disease
Donepezil HCl 10mg Orodispersible Tablet N06DA02-110-T40-02-XXX A* Treatment of mild to moderate dementia in Alzheimer's Psychiatrists, neurologists and geriatricians only Initiated at 5mg/day (one a day dosing), should be maintained for
disease, as well as in patients with severe Alzheimer's at least 1 month in order to allow the earliest clinical responses
disease and to allow steady state concentration to be achieved. The
maximum recommended daily dose is 10 mg.
Donepezil HCl 5 mg Tablet N06DA02-110-T10-01-XXX A Treatment of mild, moderate and severe dementia in Psychiatrists, neurologists and geriatricians only 5 - 10 mg once daily at bedtime. Maximum 10 mg daily
Alzheimer's disease.
Donepezil HCl 5mg Orodispersible Tablet N06DA02-110-T40-01-XXX A* Treatment of mild to moderate dementia in Alzheimer's Psychiatrists, neurologists and geriatricians only Initiated at 5mg/day (one a day dosing), should be maintained for
disease, as well as in patients with severe Alzheimer's at least 1 month in order to allow the earliest clinical responses
disease and to allow steady state concentration to be achieved. The
maximum recommended daily dose is 10 mg.
Dopamine HCl 40 mg/ml Injection C01CA04110P3001XX B Non-hypovolemic hypotension None Initial dose 2-5 mcg/kg/min with incremental changes of 5-10
mcg/kg/min at 10-15 minutes intervals until adequate response is
noted. Most patients are maintained at less than 20 mcg/kg/min.
If dosage exceeds 50 mcg/kg/min, assess renal function frequently
April 2023 54

Dorzolamide HCl 2% Ophthalmic Solution S01EC03-110-D20-01-XXX A* All glaucoma patients where beta-blockers are None Monotherapy : 1 drop 3 times daily. Adjunctive therapy with an
contraindicated and when intraocular pressure is not ophthalmic beta-blocker : 1 drop 2 times daily. When substituting
well controlled by other drugs for another ophthalmic antiglaucoma agent with this product,
discontinue the other agent after proper dosing on one day and
start Trusopt on the next day. If more than 1 topical ophthalmic
drug is used, the drugs should be administered at least 10 mins
apart
Dothiepin HCl 25 mg Capsule N06AA16110C1001XX A Depression of any aetiology Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single
dose at bedtime, increased gradually as necessary to 150 mg daily
(ELDERLY 75 mg may be sufficient), up to 225 mg daily in some
circumstances. CHILD is not recommended
Dothiepin HCl 75 mg Tablet N06AA16110T1001XX A Depression of any aetiology Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single
dose at bedtime, increased gradually as necessary to 150 mg daily
(ELDERLY 75 mg may be sufficient), up to 225 mg daily in some
circumstances. CHILD is not recommended
Doxazosin Mesilate 4mg CR Tablet C02CA04196T5001XX A* Benign Prostatic Hyperplasia None 4 mg once daily to maximum 8mg/day
Doxorubicin HCl 2mg/mL Injection L01DB01110P4002XX A i) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) i) 30 - 75 mg/m2 IV as a single dose at 21 day intervals ii) 25 - 45
Leukaemia (ALL induction) iii) Multiple myeloma mg/m2 once a week for the first 4 weeks during induction or re-
induction phase (refer to specific protocol. Caution: Total
cumulative dose of doxorubicin must not exceed 550 mg/m2 due
to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours
for 1 - 2 days. Need to check cardiac function closely by
echocardiography every cumulative dose of 100 mg/m2 to
maximum 360 mg/m2 iii) 9 mg/m2 over 24 hours infusion for 4
days at monthly intervals
Doxycycline 100 mg Capsule J01AA02000C1001XX B Prophylaxis and treatment for infections due to Prophylaxis 100-200mg daily or weekly Treatment 100-300mg
susceptible organisms. daily Dosing is individualised based on type of infections and
Doxycycline 100 mg Tablet J01AA02000T1001XX B Prophylaxis and treatment for infections due to Prophylaxis 100-200mg daily or weekly Treatment 100-300mg
susceptible organisms daily Dosing is individualised based on type of infections and
D-Penicillamine 0.25g Capsule M01CC01-000-C10-01-XX A i) Treatment of severe lead poisoning, it is used as None i) Heavy metal poisoning: 900mg-1800mg daily. Duration of
adjunctive treatment following initial treatment with treatment is dictated by the urinary heavy metal excretion.
another chelating agent. May also be used as sole Simultaneous oral vitamin B6 replacement with at least 40mg
therapy in the treatment of asymptomatic patients with daily is essential ii) Wilson's disease: 0.25g - 1.5g daily on an
moderately elevated blood concentrations ii) Wilson's incremental basis. Maximal daily dose: 2g. Maintenance dose:
Disease: to aid in elimination of copper ions 0.75g - 1g daily
Duloxetine 30 mg Capsule N06AX21110C1001XX A* i) Major depressive disorder ii) Diabetic peripheral i) & ii) ADULT: 60 mg once daily up to a maximum dose of
neuropathic pain iii) Generalised Anxiety Disorder 120mg/day (in divided doses) CHILD and ADOLESCENT under 18
years not recommended iii) Generalised Anxiety: Initial dose: 30
mg OD with or without food Maintenance dose: 60 mg OD
Duloxetine 60 mg Capsule N06AX21110C1002XX A* i) Major depressive disorder ii) Diabetic peripheral i) & ii) ADULT: 60 mg once daily up to a maximum dose of
neuropathic pain iii) Generalised Anxiety Disorder 120mg/day (in divided doses) CHILD and ADOLESCENT under 18
years not recommended iii) Generalised Anxiety: Initial dose: 30
mg OD with or without food Maintenance dose: 60 mg OD
April 2023 55

Dupilumab 300mg Solution for Injection in Pre- D11AH05-000-P50-01-XXX A* Indicated for the treatment of adult patients with severe As fourth line of treatment in patients who have failed / The recommended dose is an initial dose of 600 mg (two 300 mg
filled Syringe atopic dermatitis (AD) whose disease is not adequately have contraindications / experienced adverse events to: - injections), followed by 300 mg given every other week
controlled with systemic immunosuppressants and / or Intensive and optimized topical treatment - Phototherapy
phototherapy or when those therapies are not - At least two immunosuppressants (To be prescribed by
advisable. Dupilumab can be used with or without Dermatologists only)
topical corticosteroids.
Dutasteride 0.5mg and Tamsulosin 0.4mg G04CA52-953-C10-01-XXX A* Combination therapy for the treatment of moderate to None One capsule daily
Capsule severe symptoms of BPH with: i) Large prostate (>30g) ii)
Poor risk or not fit for surgery iii)Those who are awaiting
their turn for surgery
Dutasteride 0.5mg Capsule G04CB02-000-C10-01-XXX A* Benign prostatic hyperplasia in men with an enlarged None 0.5 mg daily
prostate gland
Dydrogesterone 10mg Tablet G03DB01-110-T10-01-XXX A/KK i) Dysmenorrhoea ii) Endometriosis iii) Dysfunctional None i) 10 mg bd from day 5 - 25 of cycle ii) 10 mg bd - tds from day 5 -
uterine bleeding (to arrest and to prevent bleeding) iv) 25 of the cycle or continuously iii) To arrest bleeding :10 mg bd
Threatened abortion v) Habitual abortion vi) Post with an estrogen once daily for 5 - 7 days, To prevent bleeding :
menopausal complaints (hormone replacement therapy 10 mg bd with an oestrogen once daily from day 11 - 25 of the
in combination with oestrogen) cycle iv) 40 mg at once, then 10mg 8hrly until symptoms remit v)
10 mg bd until 20th week of pregnancy vi) 10-20 mg daily during
last 12-14 days of each cycle
Ear Wax Softener S02DA30-900-D10-XX-XX B Occlusion or partial occlusion of the external auditory None Instill 5 drops into the ears. Refer product information leaflet
meatus by soft wax or wax plug
Edrophonium Chloride 10 mg/ml Injection N07AA00100P3001XX B i) For reversal of neuromuscular block ii) Diagnosis of i) Intravenous injection on over several minutes, 500 - 700
myasthenia gravis mcg/kg (after or with atropine sulphate 600 mcg) ii) Intravenous
injection 2 mg followed by 8 mg if no response occurs within 30
seconds. CHILD: 20 mcg followed by 80 mcg/kg after 30 seconds
Efavirenz 100 mg Capsule J05AG03000C1002XX A* Combination therapy for HIV infections with a protease ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17
inhibitor and or Nucleoside Reverse Transcriptase years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg:
Inhibitors (NRTIs) 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 -
less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg
once daily, 13 - less than 15 kg: 200 mg once daily. No studies in
children less than 3 years or less than 13 kg. Formulation
unsuitable for children less than 40 kg
Efavirenz 200 mg Capsule J05AG03-000-C10-03-XXX A/KK Combination therapy for HIV infections with a protease ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17
April 2023 56

Efavirenz 200 mg Tablet J05AG03-000-T10-03-XXX A/KK Combination therapy for HIV infections with a protease - ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17
Efavirenz 50 mg Capsule J05AG03000C1001XX A* Combination therapy for HIV infections with a protease ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17
Efavirenz 600 mg Tablet J05AG03000T1001XX A/KK Combination therapy for HIV infections with a protease ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17
Eltrombopag Olamine 25 mg Film-coated Tablet B02BX05999T1001XX A* Short term use in idiopathic thrombocytopenic purpura Individualised dosage based on the patient's platelet count. Adult
patients as bridging therapy for splenectomy or surgery Initially 50 mg once daily. East Asian patient 25 mg once daily.
and in cases of severe bleeding. Then, adjust dose to maintain platelet count ≥50,000/microliter.
Max: 75 mg daily.
Emicizumab 150mg/ml solution for Injection B02BX06-000-P30-02-XXX A* For routine prophylaxis of bleeding episodes in patients To be prescribed by consultant haematologists only 3 mg/kg once weekly for the first 4 weeks (loading dose),
with hemophilia A (congenital factor VIII deficiency) with followed by maintenance dose of either 1.5 mg/kg once weekly, 3
factor VIII inhibitors mg/kg every two weeks, or 6 mg/kg every four weeks
Emicizumab 30mg/ml solution for injection B02BX06-000-P30-01-XXX A* For routine prophylaxis of bleeding episodes in patients To be prescribed by consultant haematologists only 3 mg/kg once weekly for the first 4 weeks (loading dose),
with hemophilia A (congenital factor VIII deficiency) with followed by maintenance dose of either 1.5 mg/kg once weekly, 3
factor VIII inhibitors mg/kg every two weeks, or 6 mg/kg every four weeks
Empagliflozin 10mg tablet A10BK03-000-T32-01-XXX A/KK Indication 1: Indicated in the treatment of type 2 Indication 1: Patients with HbA1c between 6.5%-10.0% - Starting dose is 10 mg empagliflozin once daily for monotherapy
diabetes mellitus to improve glycaemic control in adults while on single / combination anti-diabetic therapy. and add-on combination therapy with other glucose-lowering
as: Add-on combination therapy: In combination with Indication 2: Patients with HbA1c not more than 10.0% medicinal products including insulin. - In patients tolerating
other glucose–lowering medicinal products including while on adequate trial of metformin empagliflozin 10 mg once daily and need tighter glycaemic
insulin, when these, together with diet and exercise, do control, the dose can be increased to 25 mg once daily. - The
not provide adequate glycaemic control. Indication 2: maximum daily dose is 25 mg
Indicated in patients with type 2 diabetes mellitus
(T2DM) and established cardiovascular disease (CVD) to
reduce the risk of cardiovascular (CV) death: As an
adjunct to diet, exercise and standard of care, to reduce
the risk of cardiovascular (CV) death.
April 2023 57

Empagliflozin 25mg tablet A10BK03-000-T32-02-XXX A/KK Indication 1: Indicated in the treatment of type 2 Indication 1: Patients with HbA1c between 6.5%-10.0% - Starting dose is 10 mg empagliflozin once daily for monotherapy
diabetes mellitus to improve glycaemic control in adults while on single / combination anti-diabetic therapy. and add-on combination therapy with other glucose-lowering
as: Add-on combination therapy: In combination with Indication 2: Patients with HbA1c not more than 10.0% medicinal products including insulin. - In patients tolerating
other glucose–lowering medicinal products including while on adequate trial of metformin. empagliflozin 10 mg once daily and need tighter glycaemic
insulin, when these, together with diet and exercise, do control, the dose can be increased to 25 mg once daily. - The
not provide adequate glycaemic control. Indication 2: maximum daily dose is 25 mg
Indicated in patients with type 2 diabetes mellitus
(T2DM) and established cardiovascular disease (CVD) to
reduce the risk of cardiovascular (CV) death: As an
adjunct to diet, exercise and standard of care, to reduce
the risk of cardiovascular (CV) death.
Emulsificants Ointment D02AC00-952-G50-01-XXX C As an emollient for the symptomatic relief of dry skin None Apply to the affected area as required or as in package insert
conditions and as soap-substitute for skin-bathing.
Enalapril 10mg Tablet C09AA02-253-T10-02-XX B i) Hypertension ii) Heart failure iii) Prevention of None i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max.
coronary ischemic events in patients with left ventricular 40mg daily in 1-2 divided doses ii) & iii) Initial: 2.5mg once daily
dysfunction Maintenance: 20mg in 1-2 divided doses Max. 40mg daily in 2
divided doses Dosing is individualised and according to product
insert / protocol.
Enalapril 20mg Tablet C09AA02-253-T10-03-XX B i) Hypertension ii) Heart failure iii) Prevention of None i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max.
insert / protocol.
Enalapril 5mg Tablet C09AA02253T1001XX B i) Hypertension ii) Heart failure iii) Prevention of None i) Initial: 5mg once daily. Maintenance: 10-20mg once daily Max.
insert / protocol.
Enoxaparin Sodium 20 mg Injection B01AB05520P5001XX A* i) Prevention of Deep Vein Thrombosis(DVT) especially in i) Prophylaxis fo DVT especially in surgical patients: moderate
perioperative and high risk surgical cases ii) Treatment of risk, 20 mg SC approximately 2 hours before surgery then 20 mg
DVT iii) Unstable angina and non Q wave Myocardial every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic
Infarction surgery, medical patients, 40mg every 24 hours for at least 6 days
until patient ambulant, max 14 days. ii) Treatment of DVT or
pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5
days and until adequate oral anticoagulation established. iii)
Unstable angina and non-ST-segment-elevation myocardial
infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
April 2023 58

Enoxaparin Sodium 40 mg Injection B01AB05520P5002XX A*, A/KK PRESCRIBER CATEGORY A*: i) Prevention of Deep Vein i) Prophylaxis for DVT especially in surgical patients: moderate
Thrombosis(DVT) especially in perioperative and high risk, 20 mg SC approximately 2 hours before surgery then 20 mg
risk surgical cases ii) Treatment of DVT iii) Unstable every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic
angina and non Q wave Myocardial Infarction. surgery, medical patients, 40mg every 24 hours for at least 6 days
PRESCRIBER CATEGORY A/KK: Prevention of DVT in until patient ambulant, max 14 days. ii) Treatment of DVT or
antenatal and/or postnatal women with VTE risk scoring pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5
of 3 or more. A written consent form by the patient is days and until adequate oral anticoagulation established. iii)
necessary prior treatment initiation. Healthcare facilities Unstable angina and non-ST-segment-elevation myocardial
are advised to refer to “Panduan Penggunaan Ubat- infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
Ubatan yang Mengandungi Unsur Tidak Halal”.
Enoxaparin Sodium 60 mg Injection B01AB05520P5003XX A*, A/KK PRESCRIBER CATEGORY A*: i) Prevention of Deep Vein i) Prophylaxis fo DVT especially in surgical patients: moderate
Thrombosis(DVT) especially in perioperative and high risk, 20 mg SC approximately 2 hours before surgery then 20 mg
risk surgical cases ii) Treatment of DVT iii) Unstable every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic
angina and non Q wave Myocardial Infarction surgery, medical patients, 40mg every 24 hours for at least 6 days
PRESCRIBER CATEGORY A/KK: Prevention of DVT in until patient ambulant, max 14 days. ii) Treatment of DVT or
antenatal and/or postnatal women with VTE risk scoring pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5
of 3 or more. A written consent form by the patient is days and until adequate oral anticoagulation established. iii)
necessary prior treatment initiation. Healthcare facilities Unstable angina and non-ST-segment-elevation myocardial
are advised to refer to “Panduan Penggunaan Ubat- infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
Ubatan yang Mengandungi Unsur Tidak Halal”.
Entacapone 200 mg Tablet N04BX02000T1001XX A Parkinson's Disease. An adjunct to standard 200 mg to be taken with each daily dose of levodopa/dopa-
levodopa/benserazide or levodopa/carbidopa for use in decarboxylase inhibitor. Max 2g daily. May be taken with or
patients with parkinson's disease and end of dose motor without food
fluctuations, who cannot be stabilised on those
combinations
Entecavir 0.5 mg Tablet J05AF10000T1001XX A* First line treatment of Chronic Hepatitis B in patients 0.5-1mg once daily. Renal Dose Adjustment: 0.5-1mg every
who satisfy the criteria for treatment and require long- 48hours (30-49ml/min); 0.5-1mg every 72hours (10-29ml/min);
term therapy or have a very high baseline viral load 0.5mg-1mg every 5-7 days (<10ml/min; HD or CAPD).
Eperisone HCl 50 mg Tablet M03BX09110T1001XX A Myotonic symptoms associated with cervical syndrome, 50 mg 3 times daily
periarthritis of shoulder and lumbago spastic paralysis
Ephedrine HCl 30mg/ml Injection R03CA02-110-P30-01XXX B Treatment of bronchial spasm in asthma, adjunct to None By IM, SC or IV. Severe, acute bronchospasm : 12.5-25 mg.
correct haemodynamic imbalances and treat Further dosage should be determine by patient response. When
hypotension in epidural and spinal anaesthesia used as a pressor agent : ADULT 25 - 50 mg SC/IM. If necessary, a
second IM dose of 50 mg or an IV dose of 25 mg may be given.
Direct IV injection, 10 - 25 mg may be given slowly. Maximum
parenteral ADULT dose : 150 mg in 24 hours. CHILD : 3 mg/kg or
100 mg/m2 SC or IV daily, in 4 - 6 divided doses
Epirubicin 2mg/mL Injection L01DB03-110-P40-02-XXX A* i. Solid tumour ii. Non-Hodgkin's lymphoma iii. 75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21
Leukaemia (ALL induction) iv. Lymphoma day intervals.Higher doses up to 135mg/m2 as single agent and
120mg/m2 as combination (effective in treatment of breast
cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on
protocol.Refer to specific product for dosing information
April 2023 59

Erlotinib 100 mg Tablet L01XE03-110-T10-03-XXX A* Second line treatment of patients with locally advanced Prescribing restrictions: - Adenocarcinoma histology - 150 mg taken at least one hour before or two hours after the
or metastatic non-small cell lung cancer (NSCLC) who ECOG Performance Status 0-1 - Must be prescribed by an ingestion of food once daily. Reduce in steps of 50 mg when
have previously failed one line of chemotherapy, and oncologist or oncology-trained respiratory physician. - necessary. Continue treatment until disease progression or
who have activating mutations of epidermal growth Must not have received prior TKI for this condition. unacceptable toxicity occurs. May require dose modifications
factor receptor (EGFR). when coadministered with strong CYP3A4 inhibitors or inducers;
or in cigarette smoking patients.
Erlotinib 150 mg Tablet L01XE03-110-T10-02-XXX A* Second line treatment of patients with locally advanced Prescribing restrictions: - Adenocarcinoma histology - 150 mg taken at least one hour before or two hours after the
or metastatic non-small cell lung cancer (NSCLC) who ECOG Performance Status 0-1 - Must be prescribed by an ingestion of food once daily. Reduce in steps of 50 mg when
have previously failed one line of chemotherapy, and oncologist or oncology-trained respiratory physician. - necessary. Continue treatment until disease progression or
who have activating mutations of epidermal growth Must not have received prior TKI for this condition. unacceptable toxicity occurs. May require dose modifications
factor receptor (EGFR). when coadministered with strong CYP3A4 inhibitors or inducers;
or in cigarette smoking patients.
Ertapenem 1g Injection J01DH03520P4001XX A* i) Patient with confirm ESBL producing gram-negative ADULT: 1 g once daily. CHILD 3 month to 12 years: 15 mg/kg
infection. ii) Empiric treatment for severe community twice daily. Not to exceed 1 g/ day
acquired pneumonia or other infections when
Pseudomonas aeruginosa is not suspected.
Erythromycin Ethylsuccinate 200 mg/5 ml J01FA01238F2101XX B Treatment of susceptible bacterial infections Child: 30-50 mg/kg daily, increased to twice the usual dose in
Suspension severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily
in divided doses.
Erythromycin Ethylsuccinate 400 mg Tablet J01FA01238T1001XX B Treatment of susceptible bacterial infections Adult 400 mg 6 hrly or 800 mg 12 hrly. Max: 4 g/day. Childn 30-50
mg/kg in divided doses. Childn 2-8 yr 1 g/day in divided doses in
severe cases. Infant & childn ≤2 yr 500 mg/day in divided doses.
Erythromycin Ethylsuccinate 400 mg/5 ml J01FA01238F2102XX B Treatment of susceptible bacterial infections Child: 30-50 mg/kg daily, increased to twice the usual dose in
Suspension severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily
in divided doses.
Erythromycin Lactobionate 500 mg Injection J01FA01129P3001XX A* Only for treatment of i) certain forms of meningitis ii) Adult & Child: 25 - 50mg/kg /day infusion every 6 hours.
septicaemia not responding to usual antibiotics iii) Maximum: 4 g/day.
mycoplasma pneumonia iv) infection with gram-positive
organisms (e.g. tetanus, streptococcal infection)
associated with Penicillin allergy, only when oral
erythromycin cannot be given
Erythropoietin Human Recombinant 10,000 IU B03XA01-000-P50-05-XXX A* i) Treatment of anaemia associated with chronic renal a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once
Injection failure. Dialysis patients who have haemoglobin less weekly b) EPO Beta: 450IU/kg once weekly or 30,000 IU once
than 10 g/dL or are exhibiting symptoms of anaemia weekly Dosing is according to product insert.
although haemoglobin more than 10 g/dL and pre-
transplant cases ii) Anaemia in cancer (non-myeloid
malignancies) with concomitant chemotherapy
Erythropoietin Human Recombinant 1000 IU B03XA01-000-P50-01-XXX A* i) Treatment of anaemia associated with chronic renal a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once
April 2023 60

Erythropoietin Human Recombinant 2000 IU B03XA01-000-P50-02-XXX A i) Treatment of anaemia associated with chronic renal a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once
Erythropoietin Human Recombinant 3000 IU B03XA01-000-P50-03-XXX A* i) Treatment of anaemia associated with chronic renal a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once
Erythropoietin Human Recombinant 4000 IU B03XA01-000-P50-04-XXX A i) Treatment of anaemia associated with chronic renal a) EPO Alfa: 150IU/kg three times weekly or 40,000IU once
Escitalopram 10 mg Tablet N06AB10-124-T10-01-XXX B i) Major depression ii) Treatment of panic disorder with None i) 10 mg once daily; may be increased to max 20 mg daily. ii) Panic
or without agoraphobia disorder with or without agoraphobia :Initially 5 mg for the first
week, thereafter increased to 10 mg daily. Max 20 mg daily,
ELDERLY initially half the adult dose, lower maintenance dose
may be sufficient. CHILD and ADOLESCENT under 18 years not
recommended
Esmolol HCl 10mg/ml Injection C07AB09-110-P30-01-XX A* i) Supraventricular tachycardia ii) Intraoperative and None i) & ii) 50-200 mcg/kg/min Dosing is invidualised and according to
postoperative tachycardia and/or hypertension product insert/protocol.
Esomeprazole 20 mg Tablet A02BC05-000-T10-02-XXX A i) Gastro-oesophageal reflux disease ii) H. pylori - First-line therapy for patients on Ryle’s tube or unable to i) 20mg daily for 4-8 weeks ii) 40mg daily for 10 days in
eradication tolerate oral therapy - Second-line therapy for patients combination with amoxicillin 1g twice daily or clarithromycin
who are not suitable to take or did not respond well to 500mg twice daily
pantoprazole despite optimal duration of treatment
Esomeprazole 40 mg Injection A02BC05-000-P30-01-XXX A* i) Acute erosive/ ulcerative oesophagitis ii) Non-variceal - i) 20- 40 mg once daily for 2-5 days ii) 80 mg by IV bolus followed
upper gastrointestinal bleeding by 8mg/hour infusion for 72 hours
Esomeprazole 40 mg Tablet A02BC05-000-T10-01-XXX A i) Gastro-oesophageal reflux disease ii) H. pylori - First-line therapy for patients on Ryle’s tube or unable to i) 20mg daily for 4-8 weeks ii) 40mg daily for 10 days in
eradication tolerate oral therapy - Second-line therapy for patients combination with amoxicillin 1g twice daily or clarithromycin
who are not suitable to take or did not respond well to 500mg twice daily
pantoprazole despite optimal duration of treatment
Essential Phospholipids, nicotinamide, A05BA00-924-C10-01-XXX A/KK Nutritional support in the management of damaged liver - 1-2 capsules 3 times a day
cyanocobalamine, tocopheryl, pyridoxine, (due to chronic liver disease, liver cirrhosis, fatty liver &
thiamine, riboflavine capsule intoxication by hepatotoxic substances).
Estradiol 1mg & Estradiol 1mg with G03FB08-954-T10-01-XXX A* Hormone Replacement Therapy for women with None One tablet daily without pill-free interval, starting with 1 mg of
Dydrogesterone 10mg Tablet disorders due to natural or surgically induced Estradiol for first 14 days, followed by 1mg Estradiol with 10 mg
menopause with intact uterus. Dydrogestrone daily for the next 14 days
April 2023 61

Estradiol 1mg with Dydrogesterone 5mg Tablet G03FB08-954-T10-02-XXX A* i) Hormone replacement therapy for the relief of None One tablet is to be taken daily for a 28-day cycle.
symptoms due to oestrogen deficiency in women with a
uterus ii) Prevention of postmenopausal osteoporosis in
women with a uterus
Estradiol Valerate 1mg Tablet G03CA03-256-T10-02-XXX A* i. Hormone replacement therapy (HRT) for the treatment None 1-2 mg daily continuously. Titrate to the minimum effective dose
of signs and symptoms of estrogen deficiency due to necessary to control symptoms.
natural menopause or castration. ii. Prevention of
postmenopausal osteoporosis.
Estradiol Valerate 2mg and Norgestrel 500mcg G03FB01-953-T10-01-XXX B i. Hormone replacement therapy (HRT) for the treatment None One white tablet daily for the first 11 days, followed by one light
with Estradiol Valerate 2mg Tablet of signs and symptoms of estrogen deficiency due to brown tablet daily for 10 days then stop for a 7- day tablet-free
menopause or hypogonadism, castration or primary interval before commencing next pack.
ovarian failure in women with an intact uterus. ii.
Prevention of postmenopausal osteoporosis. iii. Control
of irregular menstrual cycles. iv. Treatment of primary or
secondary amenorrhea.
Etanercept 25 mg Injection L04AA11-000-P40-01-XXX A* i)Moderately to severe rheumatoid arthritis as Adult & geriatric dose: Rheumatoid arthritis, psoriatic arthritis,
monotherapy or in combination with methotrexate in ankylosing spondylitis; 50 mg SC once-weekly for once-weekly
patients with inadequate response to methotrexate dosing or 25 mg SC twice weekly (individual doses should be
alone. ii)Active polyarticular-course juvenile idiopathic separated by 72 to 96 hours) for twice-weekly dosing. Paediatric
arthritis in children 2-17 years with inadequate response dose (2 to 17 years): Juvenile idiopathic arthritis; 0.8 mg/kg (max.
to, or who have proved intolerant of methotrexate. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg
iii)Psoriatic arthritis as monotherapy or in combination (max. 25 mg/dose) SC twice weekly (individual doses should be
with methotrexate in patients inadequate response to separated by 72 to 96 hours) for twice-weekly dosing.
methotrexate alone. iv)Active ankylosing spondylitis in
adults
Etanercept 50 mg Injection L04AB01-000-P40-02-XXX A* i) Moderately to severe rheumatoid arthritis as Adult & geriatric dose: Rheumatoid arthritis, psoriatic arthritis,
monotherapy or in combination with methotrexate in ankylosing spondylitis; 50 mg SC once-weekly for once-weekly
patients with inadequate response to methotrexate dosing or 25 mg SC twice weekly (individual doses should be
alone. ii) Active polyarticular-course juvenile idiopathic separated by 72 to 96 hours) for twice-weekly dosing. Paediatric
arthritis in children 2-17 years with inadequate response dose (2 to 17 years): Juvenile idiopathic arthritis; 0.8 mg/kg (max.
to, or who have proved intolerant of methotrexate. iii) 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg
Psoriatic arthritis as monotherapy or in combination (max. 25 mg/dose) SC twice weekly (individual doses should be
with methotrexate in patients inadequate response to separated by 72 to 96 hours) for twice-weekly dosing.
methotrexate alone. iv) Active ankylosing spondylitis in
adults
Ethambutol HCl 200 mg Tablet J04AK02110T1001XX B Tuberculosis Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly
(max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice
weekly.
Ethambutol HCl 400 mg Tablet J04AK02110T1002XX B Tuberculosis Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly
(max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice
weekly.
Ether Solvent N01AA01000L9901XX C To remove adhesive plaster from the skin Dose depending on the route and procedure
Ethinylestradiol 20mcg & Drospirenone 3mg G03AA12-954-T10-02-XXX A* i)Oral contraception ii)Treatment of acne vulgaris in None 1 tab daily for 28 consecutive days starting on 1st day of
Tablet women seeking oral contraception. iii) Treatment of menstrual bleeding.
symptoms of premenstrual dysphoric disorder (PMDD)
in women who choose to use an oral contraceptive as
their method of contraception.
April 2023 62

Ethinylestradiol 20mcg & Levonorgestrel G03AA07-954-T10-02-XXX A/KK i) Oral Contraceptive. ii) Treatment of moderate acne None 1 tablet daily for 21 consecutive days, followed by a 7 -day tablet
100mcg Tablet vulgaris not controlled by conventional therapy (e.g. free interval before the next pack is started
topical preparations and oral antibiotics) in post-
menarchal, premenopausal women more than or 14
years who accept contraception.
Ethionamide 250 mg Tablet J04AD03000T1001XX A* As second-line therapy in the treatment of Multi Drug ADULT: 15-20mg/kg daily, in divided doses if necessary;
Resistant Tuberculosis only in combination with other maximum dose 1g/day. CHILD: 10-20mg/kg in 2-3 divided doses
efficacious agents and only when therapy with isoniazid, or 15mg/kg/24hrs as a single daily dose.
rifampicin, or other first-line agents has failed.
Ethyl Chloride 100ml Spray N01BX01000A4001XX C For minor surgical procedures including lancing boils, Spray to affected area at a distance of about 30cm until a fine
incision and drainage of small abscesses, pain due to white film is produced
athletic injuries and pain due to injection administration
Etomidate 20 mg/10 ml Injection N01AX07000P3001XX A* Induction of general anaesthesia for haemodynamically Adult: 300 mcg/kg given slowly over 30-60 seconds into a large
unstable patients vein in the arm. Child: Up to 30% more than the standard adult
dose. Elderly: 150-200 mcg/kg, subsequently adjusted according
to effects.
Etonogestrel 68mg Implant G03AC08-000-P10-01-XXX A/KK Contraception None Subdermal insertion: A single implant is effective for 3 years (to
be removed 3 years from the date of insertion)
Etoposide 100 mg/5 ml Injection L01CB01000P3001XX A* i) For treatment of children with solid tumours, juvenile i) CHILD: 60-120 mg/m2/day by IV for 3 - 5 days every 3 - 6 weeks
myelomonocytic leukemia (JMML) and Langerhan cell depending on protocols ii) Maintenance or palliative
histiocytosis ii) Leukaemia, lymphoma iii) solid tumour chemotherapy for elderly acute myeloid leukemia, consolidation
therapy for acute lymphoblastic leukemia, stem cell mobilization
(Refer to protocol) iii) 100 mg/m2 by IV every other day for 3
doses repeated every 3-4 weeks
Etoposide 50mg capsule L01CB01000C1003XX A* Treatment of small cell lung cancer and malignant Normal adult dose is 175mg-200mg daily for 5 consecutive days
lymphomas orally, followed by recession (withdrawal) interval of 3 weeks.
Repeat administration as necessary. Increase or reduce dose as
appropriate, according to the particular disease or symptoms.
Etoricoxib 120 mg Tablet M01AH05000T1002XX A* i)Acute and chronic treatment of signs and symptoms of i) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty
osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute arthritis and acute pain: 120 mg once daily (Given the exposure
gouty arthritis iii)Acute pain to COX-2 inhibitors, doctors are advised to use the lowest
effective dose for the shortest possible duration of treatment)
Etoricoxib 60 mg Tablet M01AH05000T1003XX A* i)Acute and chronic treatment of signs and symptoms of i) OA: 60 mg once daily. RA: 60mg once daily and may be
osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute increased to 90mg once daily if needed.Once the patient is
gouty arthritis iii)Acute pain stabilized, down-titration to 60mg once daily may be appropriate.
ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily
(Given the exposure to COX-2 inhibitors, doctors are advised to
use the lowest effective dose for the shortest possible duration
of treatment)
April 2023 63

Etoricoxib 90 mg Tablet M01AH05000T1001XX A/KK i)Acute and chronic treatment of signs and symptoms of i) OA: 60 mg once daily. RA: 60mg once daily and may be
osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute increased to 90mg once daily if needed.Once the patient is
gouty arthritis iii)Acute pain stabilized, down-titration to 60mg once daily may be appropriate.
ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily
(Given the exposure to COX-2 inhibitors, doctors are advised to
use the lowest effective dose for the shortest possible duration
of treatment)
Everolimus 0.25mg tablet L04AA18000T1001XX A* Indicated for the prophylaxis of organ rejection in adult An initial dose regimen of 0.75 mg b.i.d., which is recommended
patients at low to moderate immunological risk receiving for the general kidney and heart transplant population. The daily
an allogeneic renal or cardiac transplant in combination dose of everolimus should always be given orally in two divided
with ciclosporin for microemulsion and corticosteroids. doses (b.i.d.).
Everolimus 0.75mg tablet L04AA18000T1003XX A* Indicated for the prophylaxis of organ rejection in adult An initial dose regimen of 0.75 mg b.i.d., which is recommended
patients at low to moderate immunological risk receiving for the general kidney and heart transplant population. The daily
an allogeneic renal or cardiac transplant in combination dose of everolimus should always be given orally in two divided
with ciclosporin for microemulsion and corticosteroids. doses (b.i.d.).
Exemestane 25 mg Tablet L02BG06000T1001XX A* Treatment of post-menopausal women with advanced 25 mg once daily
breast cancer whose disease has progressed following
tamoxifen and non-steroidal aromatase inhibitors
Ezetimibe 10 mg Tablet C10AX09000T1001XX A* i) Co-administration with statins for patients who have 10 mg once daily. Not recommended for children less than 10
chronic heart disease or are chronic heart disease years old
equivalent or familial hypercholesterolaemia with target
LDL-C not achieved by maximum dose of statins ii)
Monotherapy in patients with documented biochemical
intolerance to statins
Ezetimibe 10mg & Simvastatin 20mg Tablet C10BA02-000-T10-01-XX A* Primary hypercholesterolemia None Usual starting dose: 10/20 mg/day
Ezetimibe 10mg & Simvastatin 40mg Tablet C10BA02-000-T10-03-XX A* Primary hypercholesterolemia None Usual starting dose: 10/20 mg/day
Factor IX Injection B02BD04-000-P99-01-XXX A Prevention and control of bleeding in patients with Number of factor IX units required = body weight (kg) x desired
factor IX deficiency due to haemophilia B factor IX increase (%) x 1.0 IU/kg Dosing is individualised and
according to product insert/protocol.
April 2023 64

Factor IX, Factor II & Factor X in combination B02BD01000P4002XXX A* i) Treatment and perioperative prophylaxis of bleeding in 25 – 50 IU/kg, depending on the INR
500IU/vial injection acquired deficiency of prothrombin complex factors,
such as deficiency caused by treatment with vitamin K
antagonists, or in case of overdose of vitamin K
antagonists, when rapid correction of the deficiency is
required. ii) Treatment and prophylaxis of bleeding in
patients with single or multiple congenital deficiencies of
factor IX, II or X when purified specific coagulation factor
product is not available. Cautionary Notes: i) in serious
life threatening haemorrhage, or if urgent immediate
clinical requirement for reversal of anticoagulated state
is required (especially if baseline INR >4), a 3-factor PCC
lacking factor VII may not be as effective as 4-factor PCC
in providing timely haemostasis. ii) The use of pure
factor IX concentrates is recommended for the
treatment of Haemophilia B (factor IX deficiency) as
opposed to PCC in view of risks of thrombosis or
disseminated intravascular coagulation (DIC). PCC should
not be used in patients with inhibitors.
Factor IX, Factor II, Factor VII and Factor X In B02BD01000P4001XX A* i) Treatment and perioperative prophylaxis of bleeding in Amount and frequency of administration should be calculated on
Combination Injection acquired deficiency of the prothrombin complex an individual patient basis. Individual dosage requirements can
coagulation factors, such as deficiency caused by only be identified on the basis of regular determinations of the
treatment with vitamin K antagonists, or in case of individual plasma levels of the coagulation factors of interest or
overdose of vitamin K antagonists, when rapid on the global tests of the prothrombin complex levels (INR,
correction of the deficiency is required. ii) Treatment and Quick's test) and a continuous monitoring of the clinical condition
perioperative prophylaxis of bleeding in congenital of the patient. An approximate calculation is as follows: Required
deficiency of any of the vitamin K dependent coagulation dose (IU) = body weight (kg) x desired factor rise (IU/dl or % of
factors only if purified specific coagulation factor normal) x reciprocal of the estimated recovery, i.e. Factor II = 53
product is not available. Factor VII = 59 Factor IX = 77 Factor X = 56 As product may differ
from one to another, it is strongly advised to refer to the
manufacturer (product insert) in regards to dosing calculation.
Factor VIIa (Recombinant) eptacog alfa B02BD08000P4005XX A* Treatment of bleeding episodes and prevention of Initially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5
(activated) 100 KIU (2 mg) Injection excessive bleeding in connection with surgery in patients minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight
with inherited or acquired haemophilia with inhibitors to depending on type & severity of haemorrhage or surgery
coagulation factors VIII or IX performed. Dosing interval: initially 2-3 hour to obtain
haemostasis and until clinically improved. If continued therapy is
needed, dose interval can be increased successively to every 4, 6,
8 or 12 hours
Factor VIIa (Recombinant) eptacog alfa B02BD08000P4004XX A* Treatment of bleeding episodes and prevention of Initially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5
(activated) 50 KIU (1 mg) Injection excessive bleeding in connection with surgery in patients minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight
with inherited or acquired haemophilia with inhibitors to depending on type & severity of haemorrhage or surgery
coagulation factors VIII or IX performed. Dosing interval: initially 2-3 hour to obtain
haemostasis and until clinically improved. If continued therapy is
needed, dose interval can be increased successively to every 4, 6,
8 or 12 hours
April 2023 65

Factor VIII (Human blood coagulation factor) & B02BD06000P4002XX A* i)The treatment and prophylaxis of haemorrhage or i. Von Willebrand Disease: Spontaneous Bleeding Episodes:
Von Willebrand factor Injection surgical bleeding in Von Willebrand Disease (VWD) when Initially, factor VIII 12.5-25 IU/kg and ristocetin cofactor 25-50
1-deamino-8-D-arginine vasopressin (desmopressin, IU/kg followed by factor VIII 12.5 IU/kg and ristocetin cofactor 25
DDAVP) treatment alone is ineffective or IU/kg subsequently every 12-24 hrs. Minor Surgery: Factor VIII 30
contraindicated. ii)The treatment and prophylaxis of IU/kg and ristocetin cofactor 60 IU/kg daily. Major Surgery:
bleeding associated with factor VIII deficiency due to Initially, factor VIII 30-40 IU/kg and ristocetin cofactor 60-80 IU/kg
haemophilia A. followed by factor VIII 15-30 IU/kg and ristocetin cofactor 30-60
IU/kg subsequently every 12-24 hrs. Prophylaxis: Factor VIII 12.5-
20 IU/kg and ristocetin cofactor 25-40 IU/kg 3 times weekly. ii.
Hemophilia A therapy: Minor haemorrage: 10-15 IU/kg every 12-
24 hours. Moderate to severe haemorrhage: 15-40 IU/kg every 8
to 24 hours. Minor surgery: Loading dose 20-30 IU/kg,
maintenance dose 15-30 IU/kg. Major surgery: Loading dose 40-
50 IU/kg, maintenance dose 10-40 IU/kg. Prophylaxis: 25-40
IU/kg three times weekly As product may differ from one to
another, it is strongly advised to refer to the manufacturer
(product insert) in regards to dosing calculation.
Factor VIII Inhibitor Bypassing Activity Injection B02BD03000P4001XX A i)Treatment and prophylaxis of hemorrhages in As a general guideline, a dose of 50 to 100IU/kg body weight is
hemophilia A and B patients with inhibitors. ii) recommended, not exceeding an individual dose of 100IU/kg bw
Treatment and prophylaxis of hemorrhages in non- and a maximum daily dose of 200IU/kg bw.
hemophilic patients who have developed inhibitors to
Factors VIII, IX and XI. iii)Treatment of patients with
acquired inhibitors to Factors X and XIII. iv)In the
combination with Factor VIII concentrate for a long-term
therapy to achieve a complete and permanent
elimination of the Factor VIII inhibitor so as to allow for
regular treatment with Factor VIII concentrate as in
patients without inhibitor.
Factor VIII Injection B02BD02999P9901XX A Prevention and control of bleeding in patients with Dose varies according to the patient and the circumstances of the
factor VIII deficiency due to classical haemophilia A bleeding. i) Mild to moderate: Usually a single dose of 10-
15units/kg. ii) More serious haemorrhage/minor surgery:Initially
15-25 units/kg followed by 10-15 units/kg every 8 - 12 hours if
required iii) Severe haemorrhage/major surgery: Initial : 40 - 50
units/kg followed by 20 - 25 units/kg every 8-12 hrs.
Fat Emulsion 10% for IV Infusion Injection B05BA02000P6001XX A Source of lipid in patients needing IV nutrition Dose to be individualised. ADULT usual lipid requirement 2-3
g/kg/day. INFANT 0.5 - 1 g/kg/day
Fat Emulsion 20% for IV Infusion Injection B05BA02000P6002XX A Source of lipid in patients needing IV nutrition Dose to be individualised. ADULT usual lipid requirement 2-3
g/kg/day. INFANT 0.5-1 g/kg/day
Febuxostat 80 mg tablet M04AA03-000-T32-01-XXX A* Treatment of chronic hyperuricaemia in adult patients, As second line for patients who are allergic or intolerant The recommended starting dose is 40 mg once daily. The
in conditions where urate deposition has already to allopurinol. recommended oral dose is 40 mg or 80 mg once daily. If serum
occurred (including a history, or presence of, tophus uric acid is > 6.0 mg/dL (357 µmol/L) after 2-4 weeks, 80 mg once
and/or gouty arthritis). daily may be considered.
Felodipine 10mg Extended Release Tablet C08CA02-000-T10-02-XX A/KK Hypertension None Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the
morning
Felodipine 5mg Extended Release Tablet C08CA02-000-T10-01-XX A/KK Hypertension None Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the
morning
April 2023 66

Fenofibrate 145mg tablet C10AB05-000-T10-02-XXX A* Category of prescriber A/KK is approved for the For Diabetic retinopathy: To be initiated by 145mg once daily, with or without food
following indications ONLY: As second line therapy after endocrinologists and ophthalmologists only.
failed gemfibrozil in patients: i) Hypercholesterolemia
and hypertriglyceridemia alone or combined [type
IIa,IIb,III and V dysplipidemias] in patients unresponsive
to dietary and other non-pharmacological measures
especially when there is evidence of associated risk
factors ii) Treatment of secondary
hyperlipoproteinemias if hyperlipoprotenemia persists
despite effective treatment of underlying disease iii)
Dyslipidemia in Type 2 Diabetes Mellitus Category of
prescriber A* is approved for the following indication:
Diabetic retinopathy Indicated for the reduction in the
progression of diabetic retinopathy in patients with type
2 diabetes and existing diabetic retinopathy.
Fentanyl 12mcg/h Transdermal Patch N02AB03-136-M70-05-XXX A* As a second line drug in the management of opioid None ADULT and CHILD over 2 years previously treated with a strong
responsive, moderate to severe chronic cancer pain. opioid analgesic, initial dose based on previous 24-hour opioid
requirement (consult product literature). If necessary dose
should be adjusted at 72-hour intervals in steps of 12-25 mcg/hr
Fentanyl 25 mcg/h Transdermal Patch N02AB03-136-M70-01-XXX A* As a second line drug in the management of opioid None Patients who have not previously received a strong opioid
responsive, moderate to severe chronic cancer pain analgesic, initial dose , one 25 mcg/hour patch to be replaced
after 72 hours. Patients who have received a strong opioid
analgesic, initial dose based on previous 24 hours opioid
requirement (oral morphine sulphate 90 mg over 24 hours = one
25 mcg/hour patch). Not recommended in children.
Fentanyl 50mcg/h Transdermal Patch N02AB03-136-M70-02-XXX A* As a second line drug in the management of opioid None Patients who have not previously received a strong opioid
responsive, moderate to severe chronic cancer pain analgesic, initial dose , one 25 mcg/hour patch to be replaced
after 72 hours. Patients who have received a strong opioid
analgesic, initial dose based on previous 24 hours opioid
requirement (oral morphine sulphate 90 mg over 24 hours = one
25 mcg/hour patch). Not recommended in children.
Fentanyl Citrate 50 mcg/ml Injection N01AH01-136-P30-01-XXX A Short duration analgesia during pre-medication Dose should be individualized according to age, body weight,
induction and maintenance of anaesthesia, and in the physical status, underlying pathological conditions and type of
immediate post-operative period. surgery and anaesthesia. ADULT: Premedication: IM 50 - 100 mcg,
30 - 60 mins prior to surgery. Adjunct to general anaesthesia:
Induction IV 50 - 100mcg, repeat 2 - 3 mins intervals until desired
effect is achieved. IV/IM 25 - 50mcg in elderly and poor risk
patients. Maintenance: IV/IM 25 - 50mcg. Adjunct to regional
anaesthesia: IM/slow IV 50 - 100mcg when additinal analgesia is
required. Post-operatively (recovery room): IM 50 - 100mcg for
pain control, tachypnoea and emergency delirium. May be
repeated in 1- 2 hours as needed. CHILD (2 - 12 years): Induction
& maintenance: 2 - 3 mcg/kg.
April 2023 67

Ferric Ammonium Citrate 800 mg/10 ml B03AB06136L2101XX C Prevention and treatment of iron-deficiency anaemias CHILD up to 1 year 5 ml, 1 - 5 years 10 ml, taken well diluted with
Paediatric Mixture water
Ferric derisomaltose 100 mg/ml solution for B03AC00-000-P30-01-XXX A* Indicated for the treatment of iron deficiency in the To be prescribed by haematologists only Intravenous bolus injection: Up to 500 mg up to three times a
injection /infusion following conditions: - when oral iron preparations are week at an administration rate of up to 250 mg iron/minute.
ineffective or cannot be used - where there is a clinical Intravenous drip infusion: Up to 20 mg iron/kg body weight or as
need to deliver iron rapidly The diagnosis must be based weekly infusions until the cumulative iron dose has been
on laboratory tests. administered. If the cumulative iron dose exceeds 20 mg iron/kg
body weight, the dose must be split in two administrations with
an interval of at least one week.
Ferrous controlled release 525 mg, Vitamin B1, B03AE10903T1001XX A/KK Anemia due to iron deficiency, megaloblastic anemia One tablet daily
Vitamin B2, Vitamin B6, Vitamin B12, Vitamin where there is an associated deficiency of Vitamin C and
C, Niacinamide, Calcium Pantothenate, Folic Vitamin B-complex particularly in pregnancy. In primary
Acid 800 mcg Tablet health clinic, the indication is restricted to anemia due to
iron deficiency in pregnant women ONLY.
Ferrous Fumarate 200 mg Tablet B03AA02138T1001XX C+ Prevention and treatment of iron-deficiency anaemias Adult: Usual dose range: Up to 600 mg daily. May increase up to
1.2 g daily if necessary. Child: As syrup containing 140 mg(45 mg
iron)/5ml. Preterm neonate: 0.6-2.4 ml/kg daily; up to 6 years
old: 2.5-5ml twice daily
Ferrous iron (elemental iron ≥ 100mg), vitamin B03AE02-903-C10-01-XXX B i) Iron deficiency anaemia ii) Nutritional deficiency 1 capsule daily
& mineral Capsule anaemia and anaemia associated with pregnancy, worm
infestation etc. iii) Prophylaxis against iron deficiency
and megaloblastic anaemia of pregnancy during the
second and third trimester of pregnancy
Filgrastim (G-CSF) 30 MU/ml Injection L03AA02000P3001XX A* i) Prevention and treatment of febrile neutropenia due i) Adult: SC or IV 5 mcg/kg/day. Initiation: 24 - 72 hours after
to cancer chemotherapy (except chronic myeloid chemotherapy. Duration: Until a clinically adequate neutrophil
leukaemia and myelodysplastic syndrome) ii) recovery is achieved (absolute neutrophil count of at least 1 x
Haemopoeitic stem cell transplantation (HSCT)/stem cell 109/L on 2 consecutive days) ii) Refer to protocol
harvesting
Filgrastim 30 MU in 0.5 ml Injection L03AA02000P5001XX A* i) Prevention and treatment of febrile neutropenia due i) ADULT: 5 mcg/kg/day by SC or IV. Initiation: 24 - 72 hours after
to cancer chemotherapy (except chronic myeloid chemotherapy. Duration: Until a clinically adequate neutrophil
leukaemia and myelodysplastic syndrome) ii) recovery is achieved (absolute neutrophil count of at least 1 x
Haemopoeitic stem cell transplantation (HSCT)/stem cell 109/L on 2 consecutive days) ii) Refer to protocol
harvesting
Finasteride 5mg Tablet G04CB01-000-T10-01-XXX A* Treatment and control of benign prostatic hyperplasia Consultant/specialists for specific indications only, 5mg once daily.
including Geriatricians
Fingolimod 0.5mg Capsule L04AA27110C1001XX A* Treatment of patients with relapsing forms of multiple 0.5mg orally once daily
sclerosis to reduce the frequency of clinical
exacerbations and to delay the accumulation of physical
disability
Flecainide Acetate 100mg Tablet C01BC04-122-T10-01-XX A* i) Sustained monomorphic ventricular tachycardias ii) None Ventricular arrhythmias: 100 mg twice daily, maximum 400
Preexcited atrial fibrillation associated with Wolff- mg/day (usually reserved for rapid control or in heavily built
Parkinson White Syndrome iii) Reciprocating Atrio- patients), reduced after 3 - 5 days if possible. Supraventricular
Ventricular tachycardias (AVT) associated with Wolff- arrhythmias: 50 mg twice daily, increased if required to maximum
Parkinson White Syndrome iv) Supraventricular of 150 mg twice daily
tachycardias due to Intra-Atrio Ventricular Nodul Reentry
April 2023 68

Fluconazole 100 mg Capsule J02AC01000C1002XX A i) Cryptococcosis a) cryptococcal meningitis and i) a) 400mg on Day1 followed by 200mg to 400mg once daily
infections of other sites (e.g.,pulmonary, cutaneous) b) usually at least 6 to 8 weeks for cryptococcal meningitis. CHILD ≥4
Prevention of relapse of cryptococcal meningitis in weeks-11 years: Treatment:6-12mg/kgoncedaily. b) 200 mg once
patients in AIDS after a full course of primary therapy ii) daily indefinitely. CHILD:- Maintenance: 6mg/kg once daily ii) 400
Systemic candidiasis, including candidemia, mg on Day 1 followed by 200 mg once daily CHILD ≥ 4weeks-
disseminated candidiasis and other forms of invasive 11years: 6-12mg/kg once daily. iii) a) 50mg to 100mg once daily
candidal infections. These include infections of the for 7 to 14 days CHILD:- Loading dose: 6mg/kg on Day 1 followed
peritoneum, endocardium, eye, and pulmonary and by 3mg/kg daily. b) 50 mg once daily for 14 days concurrently
urinary tracts. iii) Mucosal candidiasis. a) Oropharyngeal with local antiseptic measures to the denture c) 50 mg to 100 mg
candidiasis b) Chronic oral atrophic candidiasis (denture once daily for 14 to 30 days. CHILD:- 0-14days: Initially, 6mg/kg,
sore mouth) c) Oesophageal, non-invasive followed by 3mg/kg every 72 hours. Max: 12 mg/kg 72 hourly. 15-
bronchopulmonary infections, candiduria, 27 days: Initially, 6mg/kg, followed by 3 mg/kg every 48 hours.
mucocutaneous candidiasis d) Prevention of relapse of Max: 12 mg/kg 48 hourly. 28 days-11 years: Initially, 6 mg/kg,
oropharyngeal candidiasis in patients with AIDS, after a followed by 3 mg/kg once daily. d)150 mg once weekly. iv) a) 150
full course of primary therapy iv) Genital candidiasis. a) mg as a single oral dose. b) 150 mg once-monthly dose may be
Vaginal candidiasis (acute or recurrent) b) Prophylaxis of used for usually4 to 12 months c) 150 mg as a single oral dose. v)
recurrent vaginal candidiasis (three or more episodes a 50 mg to 400 mg once daily vi) a) 150 mg once weekly or 50 mg
year) c) Candidal balanitis. v) Prevention of fungal once daily for normally 2 to 6 weeks b)300mg once weekly for
infections in patients with malignancy who are 2weeks; a third weekly dose of 300-400mg. An alternate dosing
predisposed to such infections as a result of cytotoxic regimen is 50mg once daily for 2 to 4 weeks. Dosing is
chemotherapy or radiotherapy. vi) Dermatomycosis a) individualised and according to product insert/protocol.
Tinea pedis, tinea corporis, tinea cruris and dermal
Candida infections b) Tinea versicolor
Fluconazole 2 mg/ml Injection J02AC01000P9901XX A i) Cryptococcosis a) cryptococcal meningitis and i) a) 400mg on Day1 followed by 200mg to 400mg once daily
April 2023 69

Fluconazole 50 mg Capsule J02AC01000C1001XX A i) Cryptococcosis a) cryptococcal meningitis and i) a) 400mg on Day1 followed by 200mg to 400mg once daily
Flucytosine 2.5 g/250 ml Injection J02AX01000P9901XX A* Treatment of systemic fungal infection ADULT: 100 - 200 mg/kg daily in 4 divided doses by IV infusion
over 20 - 40 minutes not more than 7 days
Flucytosine 500 mg Tablet J02AX01000T1001XX A* Only for the treatment of fungal meningitis ADULT: 50 - 150 mg/kg/day in 4 divided doses
Fludarabine Phosphate 50 mg Injection L01BB05162P4001XX A* B-cell chronic lymphocytic leukaemia who have not 25 mg/m2 daily for 5 consecutive days every 28 days. May be
responded to or whose disease had progressed during or administered up to the achievement of a maximal response
after treatment with at least one standard alkylating- (usually 6 cycles) and then the drug should be discontinued.
agent containing regimen Reduce dose by up to 50% in patients with mild to moderate
renal impairment (30-70ml/min)
Fludrocortisone Acetate 0.1 mg Tablet H02AA02122T1001XX A As an adjunct to glucocorticoids in the management of Adrenocorticoid insufficiency (chronic): ADULT 1 tablet daily. Salt-
primary adrenocortical insufficiency in Addison's disease losing adrenogenital syndrome: ADULT 1 - 2 tablets daily. CHILD
and treatment of salt-losing adrenogenital syndrome and INFANT 0.5 - 1 tablet daily
April 2023 70

Flumazenil 0.1mg/ml Injection V03AB25-000-P30-01-XX B i) Diagnosis and/or management of benzodiazepine None i) Initial, 0.2 mg IV over 30 seconds; if desired level of
overdose due to self-poisoning or accidental overdose ii) consciousness not obtained after an additional 30 seconds, give
Reversal of sedation following anaesthesia with dose of 0.3 mg IV over 30 seconds; further doses of 0.5 mg IV
benzodiazepine over 30 seconds may be given at 1-minutes intervals if needed to
maximum total dose of 3 mg; patients with only partial response
to 3 mg may require additional slow titration to a total dose of 5
mg; if no response 5 minutes after receiving total dose of 5 mg,
overdose is unlikely to be benzodiazepine and further treatment
with flumazenil will not help ii) 0.2 mg IV over 15 seconds; if
desired level of consciousness is not obtained after waiting 45
seconds, a second dose of 0.2 mg IV may be given and repeated
at 60-seconds intervals as needed (up to a maximum of 4
additional times) to a maximum total dose of 1 mg; most patients
respond to doses of 0.6 to 1 mg; in the event of resedation,
repeated doses may be given at 20-minutes intervals if needed;
for repeat treatment, no more than 1 mg (given as 0.5
mg/minute) should be given at any one time and no more than 3
mg should be given in any one hour
Flunarizine HCl 5 mg Capsule N07CA03-110-C10-01-XXX B i) Migraine prophylaxis ii) Maintenance treatment of - i) ADULT: 5 - 10 mg daily preferably at night. ELDERLY more than
vestibular disturbances and of cerebral and peripheral 65 years: 5 mg at night. Maintenance 5-day treatment at the
disorders same daily dose ii) 5 - 10 mg at night. If no improvement after 1
month, discontinue treatment
Fluorescein 1mg Ophthalmic Strip S01JA01-520-M99-01-XXX B Used in diagnostic examinations None Moisten tip with tear fluid from lower fornix, sterile water or
ophthalmic solution and gently stroke across the conjunctiva
Fluorescein Sodium 10% Injection S01JA01-520-P30-01-XXX A Diagnostic fluorescein angiography or angioscopy of the None ADULT: Inject 5 mL of Fluorescein 10% solution for injection
fundus and of the iris vasculature rapidly into the antecubital vein after taking precautions to avoid
extravasation. Dosing is individualised and according to product
insert/protocol
Fluorometholone 0.1% Ophthalmic Suspension S01BA07-000-D20-01-XXX A* Treatment of steroid responsive ocular inflammation None 1-2 drops 2 to 4 times daily. During the initial 24-48 hr, dose may
be increased to 2 drops 2 hourly.
Fluorouracil 50 mg/ml Injection L01BC02000P4001XX A* Solid tumours. Ophtalmological indication: Intravenous Infusion: 15 mg/kg bodyweight (to a maximum of 1 g
trabeculectomy daily) diluted in 300-500mL of 5% glucose given over a period of 4
hours. 12 mg/kg bodyweight daily for 3 consecutive days.
Providing there are no signs of toxic effects, the patient may then
be given 6mg/kg I.V. on the 5th, 7th and 9th days. If after the 9th
day there is still no sign of toxicity, the patient may be placed on
maintenance therapy. Maintenance Therapy: 5 - 10mg/kg
bodyweight by I.V. injection once a week.
Fluoxetine HCl 20 mg Capsule N06AB03-110-C10-01-XXX A/KK i) Depression ii) Obsessive-compulsive disorder None i) 20 mg once daily increased after 3 weeks if necessary, usual
dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily max 80 mg once
daily (ELDERLY max 60 mg once daily). ii) Initially 20 mg once daily
increased after 2 weeks if necessary, usual dose 20 - 60 mg
(ELDERLY 20 - 40 mg) once daily, max 80 mg (ELDERLY max 60
mg) once daily, discontinue if no improvement within 10 weeks.
CHILD and ADOLESCENT under 18 years are not recommended
April 2023 71

Flupenthixol Decanoate 20mg/ml lnjection N05AF01135P2001XX B Chronic psychoses By deep IM, initial test dose of 5-20 mg, then after at least 7 days.
20 - 40 mg repeated at intervals of 2 - 4 weeks. Maximum 400 mg
weekly. Usual maintenance dose 50 mg every 4 weeks to 300 mg
every 2 weeks. ELDERLY, initially quarter to half adult dose. CHILD
not recommended. Deep IM recommended. Not for IV use
Fluphenazine Decanoate 25 mg/ml Injection N05AB02135P3001XX B Long term management of psychotic disorders By deep IM : Test dose 12.5 mg (6.25 mg in ELDERLY), then after
4-7 days 12.5 mg-100 mg repeated at intervals of 14-35 days,
adjusted according to response. CHILD not recommended
Flutamide 250 mg Tablet L02BB01000T1001XX A* Androgen deprivation therapy in advanced prostate 250 mg 3 times daily
cancer in combination with luteinising hormone-
releasing hormone (LHRH) analogue therapy or surgical
castration.
Fluticasone Furoate 27.5mcg/dose Nasal Spray R01AD08-139-A41-01-XXX A* Treatment of nasal symptoms (rhinorrhea, nasal None Adults/Adolescents (≥12 years) : 1-2 sprays (27.5 mcg/spray) in
congestion, nasal itching and sneezing) and ocular each nostril once daily. Children (2-11 years) : 1-2 sprays (27.5
symptoms (itching/burning, tearing/watering, and mcg/spray) in each nostril once daily
redness of the eye) of seasonal and perennial allergic
rhinitis.
Fluticasone Propionate 125mcg and R03AK11-989-A21-01-XXX A/KK Indicated in the regular treatment of asthma where the None Two inhalations (puffs) twice daily normally taken in the morning
Formoterol Fumarate Dihydrate 5mcg per use of a combination product (an inhaled corticosteroid and in the evening.
actuation pressurized inhalation, suspension and a long-acting β2 agonist) is appropriate: - For
patients not adequately controlled with inhaled
corticosteroids and "as required" inhaled short-acting β2
agonist. - For patients already adequately controlled on
both an inhaled corticosteroid and a long-acting β2
agonist.
Fluticasone Propionate 125mcg/dose Inhaler R03BA05-133-A21-01-XXX B Prophylactic treatment for asthma None ADULT and CHILD more than 16 years i) Mild asthma : 100 mcg -
250 mcg twice daily ii) Moderate asthma : 250 - 500 mcg twice
daily iii) Severe asthma : 500 mcg - 1000 mcg twice daily.
Alternatively, the starting dose of fluticasone dipropionate may
be gauged at half the total daily dose of beclomethasone
dipropionate or equivalent administered by inhalation.
Fluticasone Propionate 250mcg and R03AK11-989-A21-02-XXX A/KK Indicated in the regular treatment of asthma where the None Two inhalations (puffs) twice daily normally taken in the morning
Formoterol Fumarate Dihydrate 10mcg per use of a combination product (an inhaled corticosteroid and in the evening.
actuation pressurized inhalation, suspension and a long-acting β2 agonist) is appropriate: i) For
patients not adequately controlled with inhaled
corticosteroids and 'as required' inhaled short-acting β2
agonist. ii) For patients already adequately controlled on
both an inhaled corticosteroid and a long-acting β2
agonist.
Fluvoxamine 100 mg Tablet N06AB08-253-T10-02-XXX B i) Depression ii) Obsessive Compulsive Disorder i) Initial: 50 - 100 mg daily in the evening, increased if necessary
to 300 mg daily (over 150 mg in divided doses); usual
maintenance dose 100 mg daily. CHILD and ADOLESCENT under
18 years not recommended ii) Starting dose is 50 mg per day for
3 – 4 days.(The effective dosage is 100-300 mg). The starting dose
for children from 8 years on and adolescents is 25mg per day,
preferably at bedtime. (Max: 200 mg) (>50mg divided dose)
April 2023 72

Fluvoxamine 50 mg Tablet N06AB08-253-T10-01-XXX B i) Depression ii) Obsessive Compulsive Disorder i) Initial: 50 - 100 mg daily in the evening, increased if necessary
to 300 mg daily (over 150 mg in divided doses); usual
maintenance dose 100 mg daily. CHILD and ADOLESCENT under
18 years not recommended ii) Starting dose is 50 mg per day for
3 – 4 days.(The effective dosage is 100-300 mg). The starting dose
for children from 8 years on and adolescents is 25mg per day,
preferably at bedtime. (Max: 200 mg) (>50mg divided dose)
Folic Acid 5 mg Tablet B03BB01000T1001XX C+ i) For the prevention and treatment of folate deficiency i) ADULT initially 10-20mg mg daily for 14 days or until
states ii) For the prevention of neural tube defect in the haematopoietic response obtained. Daily maintenance: 2.5 mg-
foetus 10mg .CHILD up to 1 year:250 mcg/kg daily; 1 to 5
years:2.5mg/day;6-12 years: 5mg/day ii) 5 mg daily starting
before pregnancy and continued through the first trimester
Follitropin Alpha (Recombinant Human FSH) G03GA05-000-P30-02-XXX A* For the treatment of infertility in the following clinical None i) 75 - 150 IU daily, should commence within the first 7 days of
300IU/0.5ml Injection situations: i. Anovulation, including polycystic ovarian the menstrual cycle and increased by 37.5 IU or 75 IU at 7 or 14
syndrome (PCOS), in women who have been days interval. Max daily dose 225 IU ii) 150 - 225 IU daily
unresponsive to treatment with clomiphene citrate. ii. commencing on days 2 or 3 of the cycle. Max daily dose 450 IU.
Controlled ovarian hyperstimulation to induce the Dosing is individualised and according to product insert/protocol.
development of multiple follicles for assisted
reproductive technologies (ART).
Follitropin Alpha (Recombinant Human FSH) G03GA05-000-P30-01-XXX A* For the treatment of infertility in the following clinical None i) 75 - 150 IU daily, should commence within the first 7 days of
75IU Injection situations: i. Anovulation, including polycystic ovarian the menstrual cycle and increased by 37.5 IU or 75 IU at 7 or 14
syndrome (PCOS), in women who have been days interval. Max daily dose 225 IU ii) 150 - 225 IU daily
unresponsive to treatment with clomiphene citrate. ii. commencing on days 2 or 3 of the cycle. Max daily dose 450 IU.
Controlled ovarian hyperstimulation to induce the Dosing is individualised and according to product insert/protocol
development of multiple follicles for assisted
reproductive technologies (ART).
Follitropin Beta (Recombinant Human FSH) G03GA06-000-P30-02-XXX A* In females: For the treatment of infertility in the None i. Recommended starting dose: 50 IU daily, maintaining the
300IU Injection following clinical situations: i. Anovulation, including starting dose for at least 7 days. ii. Recommended starting dose:
polycystic ovarian syndrome (PCOS), in women who 100-225IU daily, maintaining the starting dose for at least the
have been unresponsive to treatment with clomiphene first 4 days. iii. 450 IU per week preferrably divided into 3 doses
citrate. ii. Controlled ovarian hyperstimulation to induce i.e. 150 IU three times a week (concomitantly with hCG). Dosing
the development of multiple follicles for assisted is individualised and according to product insert/protocol
reproductive technologies (ART). In males: iii.Deficient
spermatogenesis due to hypogonadotrophic
hypogonadism.
Follitropin Beta (Recombinant Human FSH) G03GA06-000-P30-01-XXX A* In females: For the treatment of infertility in the None i. Recommended starting dose: 50 IU daily, maintaining the
50IU Injection following clinical situations: i. Anovulation, including starting dose for at least 7 days. ii. Recommended starting dose:
polycystic ovarian syndrome (PCOS), in women who 100-225IU daily, maintaining the starting dose for at least the
have been unresponsive to treatment with clomiphene first 4 days. iii. 450 IU per week preferrably divided into 3 doses
citrate. ii. Controlled ovarian hyperstimulation to induce i.e. 150 IU three times a week (concomitantly with hCG). Dosing
the development of multiple follicles for assisted is individualised and according to product insert/protocol.
reproductive technologies (ART). In males: iii.Deficient
spermatogenesis due to hypogonadotrophic
hypogonadism.
April 2023 73

Fondaparinux Sodium 12.5 mg/ml Injection in B01AX05520P5002XX A* i) Treatment of acute Deep Vein Thrombosis (DVT) ii) The recommended dose to be administered by SC injection once
Prefilled Syringe Treatment of acute Pulmonary Embolism (PE) daily is: 5mg for body weight less than 50kg, 7.5mg for body
weight 50 to 100kg, 10mg for body weight greater than 100kg.
Treatment should be continued for at least 5 days and until
adequate oral anticoagulation is established (INR 2 to 3).
Concomitant treatment with vitamin K antagonists should be
initiated as soon as possible, usually within 72 hours. The usual
duration of treatment is 5 to 9 days
Fondaparinux Sodium 2.5 mg/0.5 ml Injection B01AX05520P5001XX A* i) Prevention of venous thromboembolic events (VTE) in i) 2.5 mg once daily given by SC, administered 6 hr following
orthopedic surgery (e.g. hip fracture, major knee or hip surgical closure provided homeostasis has been established.
replacement surgery), abdominal surgery in patients at Usual duration of therapy is 5 to 9 days; for hip fracture patients,
risk of thromboembolic complication. ii) Treatment of an extended course of up to 24 days is recommended. ii) ADULT
unstable angina or non-ST segment elevation myocardial more than 18 years: 2.5 mg once daily given by SC, initiated as
infarction [UA/NSTEMI] in patients for whom urgent soon as possible after diagnosis and continued for up to 8 days or
invasive management (PCI) is not indicated. iii) until hospital discharge. If patient needs to undergo PCI,
Treatment of ST segment elevation myocardial infarction unfractionated heparin to be admin as per local practice protocol,
(STEMI) in patients managed with thrombolytics or are taking into account the patient's bleeding risk and time of last
not receiving other forms of reperfusion therapy dose of fondaparinux. Fondaparinux may be restarted no earlier
than 2 hr after sheath removal. iii) ADULT more than 18 years: 2.5
mg once daily; first dose to be given IV (directly through an
existing IV line or as infusion in 25 or 50 ml of 0.9% saline over 1-
2 min), subsequent doses to be given SC. Treatment to be
initiated as soon as diagnosis is made and continued up to a max
of 8 days or until hospital discharge, whichever comes earlier. If
patient needs to undergo non-primary PCI, unfractionated
heparin to be admin as per local practice protocol, taking into
account the patient's bleeding risk and time of last dose of
fondaparinux. Fondaparinux may be restarted no earlier than 3 hr
after sheath removal
Fosfomycin trometamol 3g granules J01XX01-239-F10-01-XXX A* Treatment of acute uncomplicated lower urinary tract Acute uncomplicated lower UTI: - 1 sachet as single dose.
infections (acute cystitis) in females of 18 years of age Recurrent or other clinically problematic cystitis - Up to 2 doses
and older caused by multidrug resistant (MDR) every 24 hr. On empty stomach at bedtime.
Escherichia coli or Enterococcus faecalis who are
candidates for carbapenems or colistin.
Frusemide 10mg/ml Injection C03CA01-000-P30-01-XXX B Oedema None Initial: 20-50mg once via slow IV or IM Maintenance: Increase by
20mg every 2 hours and titrate to an effective dose if necessary.
CHILD: 0.5 - 1.5 mg/kg 6-24hourly. Dosing is individualised and
Frusemide 10mg/ml oral solution C03CA01-000-L90-01-XXX B Oedema None ADULT: Initial: 20-80mg daily. Max. 600mg/day. CHILD: 1-3mg/kg
daily. Max. 40mg/day. Dosing is individualised and according to
Frusemide 40mg Tablet C03CA01000-T10-01-XXX B Oedema None ADULT: Initial: 20-80mg daily Max. 600mg/day CHILD: 1-3mg/kg
daily Max. 40mg/day Dosing is individualised and according to
April 2023 74

Fuller's Earth Powder V03AB00000F2101XX C Adsorbent in pesticide poisoning Adult: 100-150g every 2-4 hours. Child: 1-2g/kg. (100g of Fuller's
Earth is mixed with 200ml water. Repeat until Fuller's Earth is
seen in stool (normally between 4-6 hours)
Fusidic Acid 1% Eye Drops S01AA13-000-D20-01-XXX A Bacterial eye infections caused by susceptible organisms None 1 drop in conjunctival sac 12 hourly. To be continued for 2 days
after the eye appears normal. On the first day of treatment, may
be applied more frequently : 1 drop 4 hourly. Surgical prophylaxis
: 1 drop every 12 hours, 24 - 48 hours before operation
Fusidic Acid 2% Cream D06AX01-000-G10-01-XXX B Treatment of impetigo, infected wounds, folliculitis, None Apply to affected area 2 - 3 times daily for a duration of 7 days.
boils, sycosis barbae, carbuncles, hidradenitis, Do not use for more than 2 weeks.
paronychia and erythrasma where skin infections caused
by Staphylococci, Streptococci, Propionibacterium acnes,
Corynebacterium minutissimum, and other organisms
sensitive to fusidic acid.
Fusidic Acid 2% in Betamethasone Valerate D07CC01-948-G10-01-XXX A/KK Inflammatory dermatosis where bacterial infection is None Uncovered lesion- Apply 2 to 3 times daily. Covered lesions- Less
0.1% Cream likely to occur eg atopic eczema, discoid eczema, stasis frequent applications may be adequate
eczema, seborrhoic dermatitis, contact dermatitis, lichen
simplex chronicus, psoriasis, discoid lupus erythematosus
Fusidic Acid 50 mg/ml Suspension J01XC01000L8001XX A* Treatment of infections caused by staphylococcal ADULT : 15 ml 3 times daily. CHILD 1 - 5 years: 5 ml 3 times daily;
especially Methicillin Resistant Staphylococcus aureus 5 - 12 years: 10 ml 3 times daily. INFANT : 1 ml/kg body weight
(MRSA) daily in 3 - 4 divided doses
Fusidic Acid 500 mg Injection J01XC01520P4001XX A* Treatment of severe staphylococcal infections especially ADULT : 500 mg 3 times daily diluted to 250 - 500 ml infused
Methicillin Resistant Staphylococcus aureus (MRSA). To slowly over 2 hours. Maximum : 2 g daily. CHILD and INFANT : 20
be used in combination therapy only mg/kg/day divided into 3 equal doses infused slowly over 2 - 4
hours
Gabapentin 100 mg Tablet N03AX12-000-T10-02-XXX A* i) Add-on therapy for intractable partial epilepsy, None ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be
refractory to standard anti-epileptic drugs ii) Treatment initiated by administering 300mg TDS on day 1, or by titrating the
of various types of neuropathic pain, both peripheral dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS
(which includes diabetic neuropathy, post-herpetic on day 3. Thereafter, then dose may be increased in 3 equally
neuralgia, trigeminal neuralgia) in adult more than 18 divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-
years 15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less
than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-
35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3
equally divided doses. Max 3600mg/day
Gabapentin 300 mg Capsule N03AX12-000-C10-01-XX A*, A/KK PRESCRIBER CATEGORY A*: Add-on therapy for None ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be
intractable partial epilepsy, refractory to standard anti- initiated by administered 300mg TDS on day 1, or by titrating the
epileptic drugs. PRESCRIBER CATEGORY A/KK: Treatment dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS
of various types of neuropathic pain, both peripheral on day 3. Thereafter, may be increased in 3 equally divided doses
(which includes diabetic neuropathy, post-herpetic up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day
neuralgia, trigeminal neuralgia) in adult more than 18 in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs:
years. 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day
in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided
doses. Max 3600mg/day
April 2023 75

Gabapentin 600 mg Tablet N03AX12-000-T10-01-XXX A* i) Add-on therapy for intractable partial epilepsy, None ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be
refractory to standard anti-epileptic drugs ii) Treatment initiated by administered 300mg TDS on day 1, or by titrating the
of various types of neuropathic pain, both peripheral dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS
(which includes diabetic neuropathy, post-herpetic on day 3. Thereafter, may be increased in 3 equally divided doses
neuralgia, trigeminal neuralgia) in adult over 18 years up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day
in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs:
40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day
in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided
doses. Max 3600mg/day
Gadobenate Dimeglumine Injection Solution V08CA08996P3001XX A* i) MRI of the liver for the detection of focal liver lesions i) MRI of liver: 0.05ml/kg body weight. This corresponds to
in patients with known or suspected primary liver cancer 0.1ml/kg of the 0.5M solution ii) MRI of brain & spine:
(e.g. Hepatocellular carcinoma) or metastatic disease; ii) 0.1mmol/kg body weight. This corresponds to 0.2ml/kg of the
MRI of the brain and spine where it improves the 0.5M solution iii) MRA: 0.1mmol/kg body weight. This
detection of lesion and provides diagnostic information corresponds to 0.2ml/kg of the 0.5M solution
additional to that obtained with unenhanced MRI; iii)
Contrast-enhanced MR-angiography where it improves
the diagnostic accuracy for detecting clinically significant
steno-occlusive vascular disease in patients with
suspected or known vascular disease of the abdominal
or peripheral arteries.
Gadobutrol 1 mmol/ml injection V08CA09000P3001XX A* In adults, adolescents and children aged 2 years and A single intravenous injection of 0.1 mmol/kg (equivalent to 0.1
older with diagnostic difficulty especially in patients with ml/kg body weight). Max: 0.3 mmol/kg (equivalent to 0.3 ml/kg
renal impairment for: i) Contrast enhancement in cranial body weight)
and spinal magnetic resonance imaging (MRI). ii)
Contrast enhanced MRI of liver or kidneys in patients
with high suspicion or evidence of having focal lesion to
classify these lesions as benign or malignant. iii)Contrast
enhancement in Magnetic Resonance Angiography (CE-
MRA).
Gadoterate Meglumine (Gadoteric Acid) 0.5 V08CA02254P3001XX A High risk patients undergoing Magnetic Resonance The recommended dose is 0.1 mmol/kg (equivalent to 0.2 mL/kg
mmol/ ml Injection Imaging for cerebral and spinal disease, diseases of the in adults, children and infants. In angiography, depending on the
vertebral column and other whole body pathology results of the examination being performed, a second injection
may be administered during the same session if necessary
Gadoxetic acid disodium 0.25 mmol/ml V08CA10520P3001XX A* For use in adults for the enhancement of magnetic 0.1ml/kg body weight (equivalent to 25 µmol per kg body
solution for injection (10ml pre-filled syringe) resonance imaging (MRI) of focal liver lesions weight). Not recommended for patients younger than 18 years
Gamma Benzene Hexachloride 0.1 % Lotion P03AB02100L6001XX B For treatment of head lice Leave lotion on hair for exactly 4 minutes. Then wash off of the
hair and skin with warm water.
Gamma Benzene Hexachloride 1% P03AB02100G1002XX A/KK i) Only for scabies in adult weighing more than 50kg. Use i) Only for single application. Adult: Apply a thin layer of 1%
Cream/Lotion should be restricted to patients who have failed topical preparation onto all skin areas from the neck to toes.
treatment with or cannot tolerate other medications Completely wash off from the body with warm water after 8-12
that pose less risk. ii) Treatment of head lice. hr. ii) Apply lotion into the scalp and hair. Leave the lotion for 4
minutes. Remove the lice using comb afterwards.
April 2023 76

Ganciclovir Sodium 50 mg/ ml Injection J05AB06520P3001XX A* Treatment of cytomegalovirus (CMV) disease in Initial: 5 mg/kg infused over 1 hour 12 hourly for 14 - 21 days
immunocompromised patients, prevention of CMV (CMV retinitis treatment) or 7 - 14 days (CMV disease
disease during immunosuppressive therapy following prevention). Long term maintenance: 6 mg/kg daily for 5
organ transplantation days/week or 5 mg/kg daily for 7 days/week
Ganirelix 0.25 mg/0.5 ml Injection H01CC01000P2001XX A* Prevention of premature luteinizing hormone surges in Given by SC 0.25 mg once daily, starting on day 6 of ovarian
women undergoing controlled ovarian hyperstimulation stimulation and continued until ovulation induction
for assisted reproduction technique
Gefitinib 250 mg tablet L01XE02000T1001XX A* i) First line treatment of adult patients with locally Indication (i): - Adenocarcinoma histology - Patient's 250mg tablet once a day, taken with or without food
advanced or metastatic Non Small Cell Lung Cancer ECOG Performance Status 0-1 - Must be prescribed by an
(NSCLC) who have activating mutations of the EGFR TK. oncologist or oncology-trained respiratory physician.
ii) For second line treatment of patients with locally Indication (ii) - Adenocarcinoma histology - Patient's ECOG
advanced or metastatic non-small cell lung cancer Performance Status 0-1 - Must be prescribed by an
(NSCLC) who have previously failed chemotherapy, and oncologist or oncology-trained respiratory physician. -
who have activating mutation of epidermal growth Must not have received prior TKI for this condition.
factor receptor (EGFR).
Gemcitabine HCl 1 g Injection L01BC05110P4002XX A* i) Non-small cell lung cancer ii) pancreatic cancer iii) i) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every 3 weeks or
ovarian cancer iv) breast cancer v) bladder cancer 1000 mg/m2 day 1, day 8, day 15 every 4 weeks ii) Initially 1000
mg/m2 weekly for 7 weeks followed by 1 week rest. Subsequent
cycles 1000 mg/ m2 weekly for 3 weeks followed by 1 week rest
iii) Gemcitabine 1000 mg/m2 as 30 minutes IV infusion day 1 & 8
of each 21-day cycle followed by carboplatin on day 1 to attain a
target AUC of 4 mg/ml/minute iv) 1250 mg/m2 on days 1 and 8 of
each 21-day cycle, with paclitaxel 175 mg/m2 given as a 3-hour
infusion before gemcitabine on day 1 of each 21- day cycle v)
With cisplatin: 1000 mg/m2, given by 30 minutes intravenous
infusion on days 1, 8 and 15, followed by one-week rest period
for a 28- day cycle. This four-week cycle is then repeated. Dosing
is according to product insert/ protocol.
Gemcitabine HCl 200 mg Injection L01BC05110P4001XX A* (i) Non-small cell lung cancer (ii) pancreatic cancer (iii) i) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every 3 weeks or
ovarian cancer (iv) breast cancer (v) bladder cancer 1000 mg/m2 day 1, day 8, day 15 every 4 weeks ii) Initially 1000
mg/m2 weekly for 7 weeks followed by 1 week rest. Subsequent
cycles 1000 mg/ m2 weekly for 3 weeks followed by 1 week rest
iii) Gemcitabine 1000 mg/m2 as 30 minutes IV infusion day 1 & 8
of each 21-day cycle followed by carboplatin on day 1 to attain a
target AUC of 4 mg/ml/minute iv) 1250 mg/m2 on days 1 and 8 of
each 21-day cycle, with paclitaxel 175 mg/m2 given as a 3-hour
infusion before gemcitabine on day 1 of each 21- day cycle v)
With cisplatin: 1000 mg/m2, given by 30 minutes intravenous
infusion on days 1, 8 and 15, followed by one-week rest period
for a 28- day cycle. This four-week cycle is then repeated. Dosing
is according to product insert/ protocol.
April 2023 77

Gemeprost (Prostagladin E1 Synthetic G02AD03-000-S10-01-XXX A i. Softening and dilatation of the Cervix uteri prior to None i. One pessary 3 hours before surgery ii & iii. One pessary 3-
Analogue) 1mg Pessary trans-cervical intra-uterine operative procedures in hourly to a maximum of 5 administrations over 24 hours. A
pregnant patients in the first trimester of gestation. ii. second course may be given after 24 hours from the initial
Therapeutic termination of pregnancy in patients in the commencement of treatment.
second trimester of gestation, in licensed institutions. iii.
Induction of abortion of second trimester pregnancies
complicated by intrauterine foetal death.
Gemfibrozil 300mg Capsule C10AB04-000-C10-01-XX A/KK Treatment of hyperlipoprotinaemias (TYPES IIA, IIB, III, None ADULT: 1200 mg/day in 2 divided doses, 30 minutes before
IV, V) breakfast and dinner. Dose range from 0.9-1.5 g daily
Gentamicin 0.1% Cream D06AX07-183-G10-01-XXX A* For the treatment of primary and secondary skin None Apply 2 - 3 times daily
infections caused by susceptible bacteria.
Gentamicin 0.3% Eye Drops S01AA11-183-D20-01-XXX A/KK Bacterial eye infections caused by susceptible organisms None 1 drops every 4 hours, in severe infection dosage may be
increased up to 1 drops every hour Dosing is individualised and
Gentamicin 0.3% Eye Ointment S01AA11-183-G51-01-XXX A/KK Bacterial eye infections caused by susceptible organisms None Apply a small amount (approx. 1/2-inch ribbon) into affected
eye(s) 2-3 times daily.
Gentamicin 3% Fortified Eye Drops S01AA11-183-D20-02-XXX A Broad spectrum antibiotic in superficial eye infections None Dose according to the needs of the patient
and also for Pseudomonas aeruginosa
Gentamicin Sulphate 10 mg/ml Injection J01GB03183P3002XX B Infections due to susceptible organisms ADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks:
3mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly
Gentamicin Sulphate 40 mg/ml Injection J01GB03183P3003XX B Infections due to susceptible organisms ADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks:
3mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly
Gentamicin Sulphate and Betamethasone S01CA05-990-D20-01-XXX A/KK Eye: i. Corticosteroid-responsive allergic and None Eye: Mild to moderate infections: 1 drop to the eye(s) every 4
Disodium Phosphate Eye/Ear Drops inflammatory conditions of the palpebral and bulbar hours. Severe infections: 1 drop to the eye(s) every hour. Ear: 3 or
conjunctiva, cornea and anterior segment of the globe 4 drops to the ear canal 3 times a day, with dosage gradually
such as allergic conjunctivitis, corneal injuries, superficial being decreased as inflammation subsides.
punctuate keratitis, vernal keratoconjunctivitis and as an
adjunct in the treatment of superficial occular infections
caused by susceptible organisms. ii. Topical treatment of
blepharitis, blepharoconjunctivitis, conjunctivitis,
dacryocystitis, keratitis, keratoconjunctivitis and acute
meibomianitis. Ear: i. Allergic otitis externa, infective
otitis and other corticosteroid-responsive disorders of
the external auditory meatus. ii. Indicated in the
treatment of mastoidectomy cavity infections, chronic
suppurative otitis media, subacute purulent otitis media
with tympanic membrane perforation and external otitis.
Gliclazide 30 mg Modified Release Tablet A10BB09000T5002XX B Diabetes mellitus type 2 Initially, 30mg daily at breakfast time, may increase in successive
steps to 60, 90 or 120mg daily at 1 month intervals. Max daily
dose: 120mg
Gliclazide 60 mg Modified Release Tablet A10BB09000T5001XX B Diabetes mellitus type 2 Initially, 30mg daily at breakfast time, may increase in successive
steps to 60, 90 or 120mg daily at 1 month intervals (except in
patients whose blood glucose level was not reduced after 2
weeks of treatment). Max daily dose: 120mg
April 2023 78

Gliclazide 80 mg Tablet A10BB09000T1001XX B Diabetes mellitus type 2 Initially 40-80mg daily. A single dose should not exceed 160mg
and when higher doses are required, a twice daily split dosage is
advised and should be divided. Maximum daily dose: 320mg. For
elderly, starting dose should be 40mg twice daily.
Glucagon (Lyophilised) 1 mg/ml Injection H04AA01000P4001XX B Management of hypoglycaemia Adult, children > 20kg: 1mg by SC, IM or IV. Children < 20kg :
0.5mg. If patient does not respond within 10 minutes, administer
IV glucose. Repeat in 20 minutes if necessary.
Glutaraldehyde 2% Solution V07AV00000L9905XX A High level disinfection for heat sensitive equipments 20 minutes or more immersion is recommended for endoscopes
such as endoscopes before the session and between patients after thorough cleaning
based on manufacturer recommendation
Glycerin A06AX01000L5001XX C+ As a lubricant and osmotic dehydrating agent Apply to area when required
Glycerin 25% and Sodium Chloride 15% Enema A06AG20921G2001XX C+ Constipation 1 enema as required
Glycerin 25% w/w in aqueous cream D02AX000G1001XXX C As an emollient for the symptomatic relief of dry skin None Apply to the affected area as required
conditions and as soap-substitute for skin-bathing.
Glyceryl Trinitrate 0.5mg Sublingual Tablet C01DA02-221-T10-01-XXX C Prophylaxis and treatment of angina and left ventricular None 0.5-1 mg sublingually may be repeated every 5 minutes until
failure relief is obtained. Seek physician if the pain persists after a total
of 3 tablets in a 15 minutes period.
Glyceryl Trinitrate 5mg/ml Injection C01DA02-221-P30-01-XXX A i) Angina pectoris. ii) Congestive heart failure. ii) Control None Initial: 5-25mcg/min Dosing is individualised and according to
of hypertensive episodes. iv) Production of controlled product insert or protocol.
hypotension during surgery.
Glyceryl Trinitrate Aerosol Spray 400mcg C01DA02-221-A10-01-XXX B i) Angina pectoris ii) Variant angina None 1-2 metered sprays sublingual every 5 minutes as required or 5-
(metered dose) 10minutes prior to activities that might precipitate an acute
attack. Dosing is according to product insert or protocol.
Glycine 1.5% Irrigation Solution B05CX03000H3001XX A Bladder irrigation during genitourinary surgery The dosage depends on the extent of the procedure and its
duration
Glycopyrrolate 200 mcg/ml Injection A03AB02-320-P30-01-XXX A* i) To reduce secretions (respiratory tract) for certain None i) ADULT: Pre-op: 4 mcg/kg via IM administration 30-60 mins
types of surgery ii) Reversal of neuromuscular block in before procedure. Intraoperative: 100 mcg via IV administration,
patients where atropine is contraindicated repeat at 2-3 min intervals when needed. Max: 400 mcg/dose.
CHILD: 4 to 8 mcg/kg IM or IV (maximum 200mcg), may be
repeated if necessary, during operation; ii) ADULT: 200 mcg by IV
for each 1 mg of neostigmine or 5 mg pyridostigmine CHILD: 10
mcg/kg IV for each 50 mcg/kg neostigmine or equivalent dose of
pyridostigmine. Dosing is individualised and according to product
insert/protocol
Glycopyrronium 50mcg, Inhalation Powder R03BB06-320-A20-01-XXX A/KK For maintenance bronchodilator treatment to relieve The diagnosis of COPD should be confirmed by spirometry. One capsule daily. The recommended dose is the inhalation of
Hard Capsules symptoms in adult patients with chronic obstructive the content of one capsule once daily using inhaler. It is
pulmonary disease (COPD). recommended to be administered, at the same time of the day
each day. No relevant use of glycopyrronium in pediatric
population (<18 years) for COPD.
April 2023 79

Golimumab 50mg (0.5ml) solution for injection L04AB06000P5001XX A* i) Rheumatoid arthritis (RA): In combination with i) Rheumatoid arthritis 50mg given as a subcutaneous injection
in a pre-filled syringe methotrexate (MTX), is indicated for: - The treatment of once a month, on the same date each month. ii)Psoriatic arthritis
moderate to severe active rheumatoid arthritis in adult 50mg given as a subcutaneous injection once a month, on the
patients when the response to DMARD therapy same date each month. iii) Ankylosing spondylitis 50mg given as a
including MTX has been inadequate. - The treatment of subcutaneous injection once a month, on the same date each
active, severe and progressive rheumatoid arthritis in month.
adult patients not previously treated with MTX. ii)
Psoriatic arthritis (PsA): Golimumab alone or in
combination with MTX, is indicated for: The treatment of
active psoriatic arthritis in adult patients when the
response to previous DMARD therapy has been
inadequate. iii) Ankylosing spondylitis (AS):
Golimumab(used alone) is indicated for: The treatment
of active ankylosing spondylitis in adult patients when
the response to conventional therapy has been
inadequate.
Goserelin 10.8 mg Depot Injection L02AE03000P2002XX A Androgen deprivation therapy in prostate cancer. One 10.8 mg depot injected subcutaneously into the anterior
abdominal wall, every 12 weeks.
Goserelin 3.6 mg Depot Injection L02AE03000P2001XX A Androgen deprivation therapy in prostate cancer, One 3.6 mg depot injected subcutaneously into the anterior
endometriosis,leiomyoma uteri and assisted abdominal wall, every 28 days.
reproduction,breast cancer in premenopausal and
perimenopausal women suitable for hormonal
manipulation
Granisetron HCl 1mg Tablet A04AA02-110-T10-01-XX A Prevention and treatment of nausea and vomiting None ADULT 1 mg twice daily or 2 mg once daily with the first dose to
associated with chemotherapy and radiotherapy be administered within 1 hour prior to cytostatic therapy and can
be given for up to 1 week following radiotherapy. Maximum 9
mg/day
Granisetron HCl 1mg/ml Injection A04AA02-110-P30-01-XX A i) Prevention and treatment of nausea and vomiting None i) ADULT 1-3 mg as an IV bolus not not less than 30 seconds;
associated with chemotherapy and radiotherapy ii) Post- maximum 9 mg/day. CHILD over 2 years; single dose of 10-40
operative nausea and vomiting mcg/kg as an IV infusion; maximum 3 mg/day ii) ADULT 1 mg by
slow IV injection over 30 seconds prior to induction of anaesthesia
Griseofulvin 125mg Tablet D01BA01-000-T10-01-XXX B Dermatophyte infections of the skin, scalp, hair and None Adults: 500mg-1000mg daily, taken as a single dose or in divided;
nails, where topical therapy has failed or inappropriate Children: 10mg-20mg/kg daily in divided doses. The dosing is
Guselkumab 100mg/ml Solution for Injection L04AC16-000-P30-01-XXX A* Guselkumab is indicated for the treatment of adult i) Severe plaque psoriasis as defined by PASI>20 or 100 mg to be given as subcutaneous injection at week 0, week 4
patients with severe plaque psoriasis. BSA>30 or DLQI>20 and who have at least one of the and every 8 weeks thereafter. Consideration should be given to
following clinical categories: - Contraindications to discontinuing treatment in patients who have shown no response
phototherapy and standard systemic therapies AND/OR - after 16 weeks of treatment
Intolerance/inaccessibility to phototherapy and standard
systemic therapies AND/OR - Failed phototherapy and
standard systemic therapies ii) As third-line biologic
therapy iii) To be prescribed by Dermatologists only
April 2023 80

Haemato Polyvalent Snake Antivenom Injection Nil B Passive immunisation against poisonous of a range of For initial does, at least 20mL of reconstituted serum should be
haematotoxic snakebites or neurotoxic snakebites, given by slow intravenous infusion (not more than 1mL/minute).
based on the type of snake identified. If symptoms still persist, the second dose should be repeated 2
hours or even earlier after the initial dose. The further dose
should be repeated every 6 hours according to the clinical
symptoms. Administration: Draw 10mL of the sterile water for
injection to the freeze-dried antivenin, shake well to dissolve the
contents until the serum became clear colourless or pale yellow
liquid, ready for administration.
Haemodialysis Concentrate with Acetate B05ZA00908H1001XX A For acute renal failure, chronic renal failure, Dose depending on clinical cases
overhydration, intoxication, adjustment of acid-base and
electrolyte balance
Haemodialysis Concentrate with Bicarbonate B05ZA00908H1002XX A For acute renal failure, chronic renal failure, Dose depending on clinical cases
overhydration, intoxication, adjustment of acid-base and
electrolyte balance
Haemophilus Influenza Type B Conjugate J07AG01000P4001XX C+ Immunisation of infants against Haemophilus Influenzae 0.5ml by IM. In patients with thrombocytopenia or bleeding
Vaccine Injection Type B disorders, vaccine can be administered by SC.
Haloperidol 1.5 mg Tablet N05AD01-000-T10-01-XXX B i) Psychotic disorder – management of acute and chronic None ADULT: moderate symptoms: 0.5mg to 2.0mg bid/tid; severe
psychotic disorders including schizophrenia, manic states symptoms, chronic or resistant: 3.0mg to 5.0mg bid/ tid Geriatric
and drug-induced psychoses ii) Management of / dehabilitated : 0.5mg to 2.0mg bid/tid maximum up to 100mg
aggressive and agitated patients, including patients with daily CHILD: 3-13 years old (15 to 40 kg): 0.5mg/day increase by
chronic brain syndrome or mental retardation. iii) Gilles 0.5mg at 5 to 7 days in bid/tid, dosing range 0.05mg/kg/day to
de la Tourette’s syndrome - for the control of tics and 0.15mg/kg/day Dosing is according to product insert.
vocalisations of Tourette’s syndrome in children and
adults.
Haloperidol 5 mg Tablet N05AD01-000-T10-02-XXX B i) Psychotic disorder – management of acute and chronic None ADULT: moderate symptoms: 0.5mg to 2.0mg bid/tid; severe
psychotic disorders including schizophrenia, manic states symptoms, chronic or resistant: 3.0mg to 5.0mg bid/ tid Geriatric
and drug-induced psychoses ii) Management of / dehabilitated : 0.5mg to 2.0mg bid/tid maximum up to 100mg
aggressive and agitated patients, including patients with daily CHILD: 3-13 years old (15 to 40 kg): 0.5mg/day increase by
chronic brain syndrome or mental retardation. iii) Gilles 0.5mg at 5 to 7 days in bid/tid, dosing range 0.05mg/kg/day to
de la Tourette’s syndrome - for the control of tics and 0.15mg/kg/day Dosing is according to product insert.
vocalisations of Tourette’s syndrome in children and
adults.
Haloperidol 5 mg/ml Injection N05AD01-000-P30-01-XXX B i) Management of acute psychotic disorders including None ADULT: IM or IV , 2 mg - 10 mg then every 4 - 8 hours according
schizophrenia, manic states, and drug-induced to response to total maximum 18 mg daily. Use in child is not
psychosis. ii) Management of aggressive and agitated recommended
patients, including patients with chronic brain syndrome
or mental retardation.
April 2023 81

Heparin 1000 units/ml Injection B01AB01520P3001XX B i) Prophylaxis and treatment of venous thrombosis and i) By IV injection, loading dose of 5000 units (10,000 units in
pulmonary embolism. ii) Treatment of myocardial severe pulmonary embolism) followed by continuous infusion of
infarction and arterial embolism. iii) Prevention of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every
clotting in arterial and heart surgery and for prevention 12 hours (laboratory monitoring on daily basis essential to adjust
of cerebral thrombosis dose). Small adult or child, lower loading dose then, 15-25
units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC
injection. ii) As i), for unstable angina and acute peripheral
arterial occlusion. iii) Prophylaxis in general surgery, by SC
injection, 5000 units 2 hour before surgery, then every 8-12
hours for 7 days or until patient is ambulant, during pregnancy
(with monitoring), 5000-10000 units every 12 hours. An adjusted
dose regimen may be used for major orthopaedic surgery or low
molecular weight heparin may be selected
Heparin 5000 units/ml Injection B01AB01520P3002XX B i) Prophylaxis and treatment of venous thrombosis and i) By IV injection, loading dose of 5000 units (10,000 units in
pulmonary embolism. ii) Treatment of myocardial severe pulmonary embolism) followed by continuous infusion of
infarction and arterial embolism. iii) Prevention of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every
clotting in arterial and heart surgery and for prevention 12 hours (laboratory monitoring on daily basis essential to adjust
of cerebral thrombosis dose). Small adult or child, lower loading dose then, 15-25
units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC
injection. ii) As i), for unstable angina and acute peripheral
arterial occlusion. iii) Prophylaxis in general surgery, by SC
injection, 5000 units 2 hour before surgery, then every 8-12
hours for 7 days or until patient is ambulant, during pregnancy
(with monitoring), 5000-10000 units every 12 hours. An adjusted
dose regimen may be used for major orthopaedic surgery or low
molecular weight heparin may be selected
Heparin Sodium 50 units in Sodium Chloride B01AB01930P3001XX B To maintain patency of peripheral venous catheters Flush with 5 ml (50 units) every 4 hours or as required
Injection
Hepatitis A Vaccine Injection J07BC02000P5001XX A Immunisation against Hepatitis A. 0.5 – 1.0 ml by IM. Dosing is according to product insert.
Hepatitis B Immunoglobulin (Human) Injection J06BB04000P3001XX A i) For post-exposure prophylaxis of hepatitis B ii) i) Adults: Recommended Dose: 1000-2000 IU IM and if necessary,
Prophylaxis against recurrence of hepatitis B infection in the dose should be increased or repeated. Children: Inject 32-48
chronic hepatitis B post liver transplantation IU/kg of body weight, should be administered within 7 days after
exposure to HBsAg (preferably within 48 hrs). Neonates:
Recommended Initial Dose: 100-200 IU. The 1st dose should be
administered within 5 days after birth (preferably within 48 hrs)
and booster dose should be 32-48 IU/kg body weight. The
booster dose should be administered between 2 and 3 months
after the 1st administration. ii) Different regimens depending on
hepatitis B virus (HBV) DNA positivity
Hepatitis B Vaccine Injection J07BC01000P4001XX C+ Immunisation against infections caused by Hepatitis B 0.5 – 1.0 ml by IM. Dosing is according to Immunisation Schedule
virus. under NIP and product insert.
April 2023 82

Homatropine 2% Eye Drops S01FA05-330-D20-03-XXX B i) Mydriasis and cycloplegia for refraction ii) Treatment None i) Adult: Instill 1 or 2 drops of 2% solution immediately before the
of anterior segment inflammation procedure, repeat at 5-10-minute intervals if necessary. Child:
Instill 1 drop of 2% soln immediately before the procedure,
repeat at 10-min intervals if necessary. ii) Adult: Instill 1-2 drops
of 2% bd-tds up to every 3-4 hr as needed. Child: 3 mth- 2 yr:
instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr:
instill 1 drop of 1% or 2% soln bd.
Human Albumin Injection B05AA01000P3001XX B i) Acute hypovolemic shock ii) Hypoproteinaemia iii) Dosing is according to product insert/ protocol.
Restoration and maintenance of circulating blood
volume in cases of volume deficiency where the use of a
colloid is indicated.
Human Normal Globulin Injection J06BA02-000-P30-01-XXX A i) Hypogammaglobulinaemia and other deficiency states i) 50 mg/kg body weight daily for 5 days, then 25 - 50 mg/kg
ii) Severe refractory idiopathic thrombocytopenia weekly for maintenance according to the severity of the
purpura (platelet less than 20,000) with internal condition ii) 400 mg/kg daily for 5 days with a further dose of 400
bleeding, particularly central nervous system iii) mg/kg as required iii) Septicaemia in immunocompromised
Septicaemia in immunocompromised patients or patients or patients not responding to antibiotics iv) 250 mg/kg
patients not responding to antibiotics iv) Chronic per month Dose varies depending on brand used v) Adult dose:
lymphocytic leukaemia not responding to conventional 0.4 gm/kg/day for 5 days via intravenous infusion
therapy v) Guillain-Barré Syndrome (GBS).
Human Papillomavirus (Types 16, 18) Vaccine J07BM02000P3001XX C+ For the prevention of cervical cancer due to papilloma To be used as part of NIP only. Given by IM into deltoid region. ADULT and CHILD 10 - 25 years, 3
Injection virus. doses of 0.5 mL, at 0, 1 and 6 months
Human Papillomavirus (Types 6, 11, 16, 18) J07BM01000P3001XX C+ For the prevention of cervical cancer due to papilloma To be used as part of NIP only. Given by IM into deltoid region or higher anterolateral thigh.
Vaccine Injection virus. ADULT and CHILD 9 - 26 years, 3 doses of 0.5 mL, at 0, 2 and 6
months
Hydralazine HCl 20mg Injection C02DB02-110-P30-01-XX B Hypertensive crisis in pregnancy None i) Slow IV injection, ADULT: 5-10 mg diluted with 10ml sodium
chloride 0.9%. May be repeated after 20-30 minutes if necessary.
ii) IV infusion 200-300 mcg/minutes. Maintenance dose 50-150
mcg/minutes
Hydrochlorothiazide 25mg Tablet C03AA03-000-T10-01-XX B Diuretic, hypertension None ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily
CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY
daily in single or two divided doses; Children 2-12 years old MAX
dose, not to exceed 100 mg ORALLY daily; Infants less than 6
months old, may require doses up to 3 mg/kg ORALLY daily in
two divided doses, Infants up to 2 yrs old: MAX dose, not to
exceed 37.5 mg ORALLY daily
Hydrochlorothiazide 50mg Tablet C03AA03-000-T10-02-XX B Diuretic, hypertension None ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily
CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY
daily in single or two divided doses; Children 2-12 years old MAX
dose, not to exceed 100 mg ORALLY daily; Infants less than 6
months old, may require doses up to 3 mg/kg ORALLY daily in
two divided doses, Infants up to 2 yrs old: MAX dose, not to
exceed 37.5 mg ORALLY daily
Hydrocortisone 1% & Neomycin 0.5% Cream D07CA01-952-G10-01-XXX B Inflammatory and pruritic manifestations of None Apply sparingly to the affected area. Adult: 3-4 times daily.
corticosteroid responsive dermatoses Children: 1-2 times daily
Hydrocortisone 1% Cream D07AA02-000-G10-01-XXX B Inflammatory and pruritic manifestations of None Apply sparingly to the affected area. Adult: 3-4 times daily.
Hydrocortisone 1% Ointment D07AA02-000-G50-01-XX B Inflammatory and pruritic manifestations of None Apply sparingly to the affected area. Adult: 3-4 times daily.
April 2023 83

Hydrocortisone 10mg Tablet H02AB09-000-T10-01-XXX B i) Glucocorticoid replacement therapy in primary or None ADULT: 20 - 30 mg daily in divided doses. CHILD: 10-
secondary adrenal insufficiencies ii) Congenital adrenal 15mg/m2/day in 3 divided dose The dosing is individualized
hyperplasia in children according to product insert / protocol
Hydrocortisone Enema 0.1% A07EA02000G2001XX B Adjunctive treatment for ulcerative colitis and proctitis ADULT 100 mg 1-2 times/day for 2-3 weeks. If used for longer
than 3 weeks, taper treatment over 2-3 weeks
Hydrocortisone Sodium Succinate 100mg H02AB09-520-P40-01-XXX C Conditions responsive to systemic or local glucocorticoid None ADULT: Initially 100 - 500 mg IV over 30 seconds to more than 10
Injection injection therapy. minutes. Dose may be repeated at intervals of 2, 4 or 6 hours
CHILD: 2-4mg/kg/dose every 6 hourly. The dosing is
Hydrogen Peroxide 1.5% Ear Drops S02AA06-241-D10-01-XX C To soften impacted ear wax None Instill 1 - 2 drops into the ear as required (leave for a few
minutess)
Hydrogen Peroxide 20 volume Solution D08AX01241L9901XX C Skin disinfection, particularly cleansing and deodorising Hydrogen Peroxide 6% (=approx. 20 vol) shall be dispensed. For
wounds and ulcers cleansing wounds: 1.5% to 6% solution apply 2-3 times daily or
when necessary. As a mouthwash: rinse the mouth for 2-3
minutes with 15ml of hydrogen peroxide 6% diluted in half a
tumblerful of warm water 2-3 times daily. Disinfecting cleaned
equipment: immersion for 30 minutes in 6% solution. As ear drop
for removal of wax: hydrogen peroxide 6% diluted with 3 parts of
water preferably just before use
Hydroxychloroquine Sulphate 200 mg Tablet P01BA02183T1001XX A i) SLE and mixed connective tissue disease for skin, joint None i) Initially 400 mg daily in divided dose. Maintenance : 200 - 400
and serosa ii) Second line therapy for acute rheumatoid mg daily ii) ADULT : 400 - 600 mg daily. Maintenance: 200 - 400
arthritis mg daily. CHILD : up to 6.5 mg/kg daily (maximum 400mg daily)
Hydroxyethyl Cellulose Jelly V07AY00250G4001XX B For lubricating purpose Apply sufficiently for lubricating purpose
Hydroxyethyl Starch 6% Injection B05AA07000P9901XX B Therapy and prophylaxis of hypovolaemia and shock in ADULT daily dose up to 20 ml/kg/day. Normally 500-1500 ml. The
connection with surgery trauma, infections and burns rate of infusion may approach 20 ml/kg/hour in acute
haemorrhagic shock, slower rates in burns and septic shock.
CHILD under 10 years do not exceed 15 ml /kg/hour.
Hydroxyprogesterone Caproate 250mg/ml G03DA03-128-P20-01-XXX A Habitual abortion None IM: 250-500mcg weekly as soon as pregnancy has been
Injection confirmed by diagnosis.
Hydroxyurea 500 mg Capsule L01XX05-000-C10-01-XXX A i)Solid tumours ii) Chronic myelocytic leukaemia and - i) Intermittent therapy: 80 mg/kg orally as a single dose every 3rd
myeloproliferative disease day. Continuous therapy: 20 - 30 mg/kg orally as a single dose
dly. Concomitant therapy with irradiation: 80 mg/kg orally as a
single dose every 3rd day (administration of hydroxyurea should
be started at least 7 days before initiation of irradiation and
continued during radiotherapy as well). ii) Continuous therapy 20
- 30 mg/kg orally as a single dose daily
Hydroxyzine HCl 25 mg Tablet N05BB01110T1001XX A Allergic pruritus Initially 25 mg at night, increased if necessary up to 25 mg 3-4
times daily. ADULT and CHILD more than 10 years : 50 - 75 mg; 6 -
10 years: 25 - 50 mg; 2 - 5 years: 12.5 - 25 mg; to be taken daily in
divided doses
Hyoscine N-Butylbromide 10 mg Tablet A03BB01320T1001XX C Gastrointestinal tract and genito-urinary tract spasm, Medical Assistant in health settings without Medical ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3
dyskinesia of the biliary system. Officer is allowed to prescribe this medicine for adult use times a day.
only.
Hyoscine N-Butylbromide 1mg/ml Liquid A03BB01-320-L50-01-XX B Gastrointestinal tract and genito-urinary tract spasm, None ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3
dyskinesia of the biliary system times a day.
April 2023 84

Hyoscine N-Butylbromide 20mg/ml Injection A03BB01-320-P30-01-XXX B Gastrointestinal tract and genito-urinary tract spasm, None ADULT: 20 mg IM/IV repeated after 30 min if needed. Max: 100
dyskinesia of the biliary system mg daily. Not recommended for CHILD below 12 years. Dosing is
individualised and according to product insert/protocol
Ibandronic Acid 150 mg Tablet M05BA06000T1003XX A* Treatment of postmenopausal osteoporosis to reduce 150 mg once monthly
the risk of fracture. Review treatment after 2 years and if
there is positive response, treatment may be continued
up to 5 years and then re-evaluate. Treatment should be
stopped if there is no positive response after 5 years.
Otherwise, patient needs to be given drug holiday for 1
to 2 years and then continue treatment shall the benefit
outweigh the risk.
Ibuprofen 100mg/5ml Suspension M01AE01-000-L80-01-XXX B i. Anti-inflammatory for rheumatic disease ii. Analgesic Not indicated in fever due to infection Children: 5 - 10 mg/kg/dose (max 2.4 gm/day) every 6-8 hourly.
for treatment of mild to moderate pain Not recommended for <7kg
Ibuprofen 200 mg Tablet M01AE01000T1001XX B Pain and inflammation in rheumatic disease None Dosage: ADULT : 200 - 400 mg 3 times daily after food, maximum
3.2 g daily. CHILD : 30-50 mg/kg body weight daily in divided
doses, maximum 2.4g daily. Lowest effective dose for the
shortest possible duration.
Ichthammol Glycerin 10% Ear Drops S02AA30-000-D10-01-XXX C Ear wick for otitis externa with oedema None 2 - 3 drops 3 - 4 times daily and in ear wick for otitis externa
Idarubicin 1mg/mL Injection L01DB06110P4002XX A* i) Acute non-lymphocytic leukemia (ANLL) in adults for i) Adult: 12mg/m2 IV daily for 3 days in combination with
remission induction in untreated patients or for cytarabine. Idarubicin may also be administered as a single agent
remission induction in relapsed or refractory patients. ii) and in combination, at a dose of 8mg/m2 IV daily for 5 days. ii)
Acute lymphocytic leukemia (ALL) as second line Adult: 12mg/m2 IV daily for 3 days as a single agent. Children:
treatment in adult and children. 10mg/m2 IV daily for 3 days as a single agent. All of these
dosages should take into account the hematological status of the
patient and the dosages of other cytotoxic drugs when used in
combination.
Idursulfase 2 mg/ml Injection A16AB09000P3001XX A* Hunter syndrome (Mucopolysaccharidosis II, MPS II). 0.5 mg/kg of body weight administered every week as an
intravenous infusion.
Ifosfamide 1 g Injection L01AA06000P4001XX A* i) Solid tumours ii) Leukaemia iii) Lymphoma i) 1.2 - 2.4 g/m2/day for 3 - 7 days as a 30 - 120 minutes infusion.
Alternatively, can also be given as a single high dose, eg. 5 g/m2
in a 24 hour infusion. Cycles may be repeated every 3 - 4 weeks ii)
CHILD: 400 - 3000 mg/m2/day for 3 - 5 days according to protocol
iii) Refer to protocols
Imatinib Mesylate 100mg Tablet L01XE01-196-T10-01-XXX A* i) ADULT and CHILD: Philadelphia positive (Ph+) chronic i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once
myeloid leukaemia in chronic phase and in early daily. Accelerated phase or blast crisis chronic myeloid leukemia:
acceleration after failure of interferon therapy ii) 600 mg once daily. CHILD more than 2 years, chronic and
Treatment of patients with unresectable and/or advanced phase chronic myeloid leukemia: 340 mg/m2 daily.
metastatic malignant gastrointestinal stromal tumours Max: 800 mg/day ii) ADULT : 400mg/day
(GIST) who are positive for CD117/c-kit
Imatinib Mesylate 400mg Tablet L01XE01-196-T10-02-XXX A* i) ADULT and CHILD: Philadelphia positive (Ph+) chronic i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once
myeloid leukaemia in chronic phase and in early daily. Accelerated phase or blast crisis chronic myeloid leukemia:
acceleration after failure of interferon therapy ii) 600 mg once daily. CHILD more than 2 years, chronic and
Treatment of patients with unresectable and/or advanced phase chronic myeloid leukemia: 340 mg/m2 daily.
metastatic malignant gastrointestinal stromal tumours Max: 800 mg/day ii) ADULT : 400mg/day
(GIST) who are positive for CD117/c-kit
April 2023 85

Imiglucerase 400 IU Injection A16AB02000P4002XX A* Non-neuronopathic (Type 1) or chronic neuronopathic Dosage should be individualized to each patient. Initial dosages
(Type 3) Gaucher disease and who exhibit clinically range from 2.5 units/kg of body weight 3 times a week to 60
significant non-neurological manifestations of the units/kg once every 2 weeks. Administered by intravenous
disease. The non-neurological manifestations of Gaucher infusion over 1-2 hours.
disease include one or more of the following conditions: -
anemia, after exclusion of other causes, such as iron
deficiency - thrombocytopenia - bone disease, after
exclusion of other causes, such as Vitamin D deficiency -
hepatomegaly or splenomegaly
Imipenem 500 mg and Cilastatin 500 mg J01DH51961P4002XX A* Severe infections caused by susceptible pathogens Based on type or severity of infection, susceptibility of
Injection especially useful in infections involving ESBL organisms. pathogen(s) and patient condition including body weight and
Not to be used for prophylaxis renal function. ADULT: 1 - 2 g/day in 3 - 4 divided doses.
Maximum: 4 g/day or 50 mg/kg/day. Infusion rate: less than 500
mg dose: over 20 - 30 minutes, more than 500 mg: dose over 40 -
60 minutes. CHILDREN: ≥ 40kg body weight should receive adult
doses. CHILDREN AND INFANTS: <40kg body weight should
receive 15mg/kg at six hour intervals. The total daily dose should
not exceed 2g.
Imiquimod 5 % w/w Cream D06BB10000G1001XX A* Treatment of external genital and perianal warts or Apply to affected area at bedtime for 3 times a week for up to 16
condyloma acuminata in adults weeks; leave on skin for 6-10 hours
Immunoglobulin Tetanus Human 250 J06BB02000P3001XX B Passive immunization against tetanus Prophylaxis of tetanus: IM 250 units. Treatment of tetanus: IM 30
Units/Vial Injection - 300 units/kg
Indacaterol Maleate 110mcg & Glycopyrronium R03AL04-989-C11-01-XXX A/KK As a once-daily maintenance bronchodilator treatment Patients with inhaler coordination problem. (Only applies One capsule inhalation daily.
Bromide 50mcg inhalation powder hard to relieve symptoms and reduce exacerbations in adult to Primary Care settings)
capsules patients with chronic obstructive pulmonary disease
(COPD).
Indacaterol Maleate 150mcg Inhalation Capsule R03AC18-253-C99-01-XXX A/KK Maintenance bronchodilator treatment of airflow The diagnosis of COPD should be confirmed by spirometry Once-daily inhalation of the content of one 150/300 microgram
obstruction in adult patients with chronic obstructive capsule. Maximum dose is 300 microgram once-daily.
pulmonary disease (COPD).
Indomethacin 25 mg Capsule M01AB01000C1001XX B Pain and inflammation in rheumatic disease 50 - 200 mg daily in divided doses, with food. Child not
recommended.
Infliximab 100 mg Injection L04AB02000P4001XX A* i) Rheumatoid arthritis (moderate to severe), in i) Rheumatoid arthritis: ADULT over 18 years old: 3 mg/kg at 0, 2,
combination with methotrexate ii) Ankylosing 6 weeks, then every 8 weeks; May increase to 10 mg/kg or
spondylitis in patients with active disease despite increase dosing frequency to 4 weekly for patients with
treatment with methotrexate iii) Crohn's Disease in incomplete response. Discontinue if no response by 12 weeks of
patients who have an inadequate response to initial infusion or after dose adjustment ii) Ankylosing spondylitis:
conventional therapies. iv) Fistulizing Crohn's Disease in ADULT over 18 years: 5 mg/kg IV over 2 hour given at week 0, 2,
patients who have an inadequate response to and 6 then every 6-8 weeks. Discontinue if no response by 6
conventional therapies v) Ulcerative Colitis in patients weeks of initial infusion. iii), iv) & v)5 mg/kg given as an
who have an inadequate response to conventional intravenous infusion over a 2-hour period followed by additional
therapies 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion,
then every 8 weeks thereafter
Influenza Vaccine (Inactivated) Injection J07BB02963P30XXXX B i) Prophylaxis of influenza for frontliners (KKM staff and 0.25ml to 1.0ml by IM. Dosing is according to product insert and
essential services personnel). ii) Prophylaxis of influenza WHO recommendations.
in high risk groups. Refer to current recommendation by
WHO for selection of product of inactivated influenza
vaccines.
April 2023 86

Insulin Aspart 100 IU/ml Injection A10AB05000P3001XX A* Diabetic Type 1 and 2 in patients that still experienced Dose to be individualised. The average daily insulin requirement
hypoglycaemia with use of human insulin is between 0.5 to 1.0 units/kg body weight
Insulin Aspart 30% and Protaminated Insulin A10AD05000P3001XX A/KK Diabetic type 1 and 2 in patients that still experienced Dose to be individualised. The average daily insulin requirement
Aspart 70% 100 U/ml Injection hypoglycaemia with use of human insulin is between 0.5 to 1.0 units/kg body weight
Insulin Degludec/ Insulin Aspart 70/30 Solution A10AD06-925-P50-01-001 A* Treatment of Type-2 Diabetes Mellitus in adults (A* - For patients who remained uncontrolled OR experienced Treatment initiation: 10 units with meal(s) followed by individual
for Injection in Pre- Filled Pen 100 Units/mL Must be prescribed by Endocrinologist) recurrent hypoglycaemia with multiple daily dosing of dosage adjustments. Once or twice daily with the main meal(s)
human/analogue basal-bolus/premixed insulin. Treatment switching: Can be administered alone, in combination
with oral antidiabetic medicinal products, and in combination
with bolus insulin. • Convert unit-to-unit to once or twice daily
Insulin Degludec/Insulin Aspart at the same total insulin dose as
the patient’s previous total daily basal or premix insulin dose. •
Patients switching from basal/bolus insulin therapy will need to
convert their dose based on individual needs. In general, patients
are initiated on the same number of basal units.
Insulin Detemir 100 IU/ml Injection in Prefilled A10AE05000P5001XX A/KK i)Type 1 Diabetes patients on basal bolus regimen, Individualized dose given via SC once or twice daily. Initiate at a
syringe/cartridge whom experience hypoglycaemia with conventional dose of 10IU or 0.1-0.2IU/kg. For twice daily dosing, the evening
insulin, to be used in combination with rapid or short- dose can be administered either with the evening meal, at
acting insulin. ii)Type 2 Diabetes patients on oral anti- bedtime, or 12 hours after the morning dose.
diabetics and basal insulin regimen or basal bolus insulin
regimen whom experience hypoglycaemia with
conventional basal insulin.
Insulin Glargine 300 IU/ 3 ml Injection (Prefilled A10AE04-000-P50-01-XXX A/KK i) Diabetes mellitus type I in adults and child over 6 years ADULT and CHILD over 6 years: individualised dose given by SC,
Pen) ii) Diabetes mellitus type II in adult once daily at the same time every day. Adult patients who are
insulin naive may be initiated with 10IU daily.
April 2023 87

Insulin Glargine 300 IU/ml injection (Prefilled A10AE04-000-P50-02-XXX A/KK Diabetes mellitus type I and II in adults For usage by Endocrinologists/Physicians (in hospitals): Initiation: Patient with type 1 diabetes: Once daily with mealtime
Pen) Patient must meet the following criteria: i) Patients on insulin and requires individual dose adjustments; Patient with
insulin not reaching treatment goals defined as high type 2 diabetes: 0.2units/kg followed by individual dose
fasting plasma glucose (FPG ≥ 7 mmol/L) and/or HbA1c ≥ adjustment. Please refer to the product information leaflet for
6.5% after 6 months of therapy and/or; ii) patients with a details of dosage information (switching, etc).
high risk of hypoglycaemia as determined by the following
risk factors: Advancing age; Severe cognitive impairment;
Poor health knowledge; Increased A1c; Hypoglycaemia
unawareness; long standing insulin therapy; Renal
impairment; Neuropathy. Note: Can be
prescribed/dispensed only to patients in diabetic
clinic/registered under DMTAC programme. For usage by
Family Medicine Specialists (in health clinics): Patient
must meet all the following criteria: i) Patient on high
dose insulin >30units per injection; ii) Patient with BMI
>35kg/m2; and iii) Patient who develops significant
hypoglycaemia with Insulin Glargine 100units/ml or
Insulin Detemir 100units/ml after ruling out other causes
of hypoglycaemia. Note: Used for a trial of 3 months, if
during this period patients still develop similar episodes of
hypoglycaemia, revert back to human insulins or refer
patients to Endocrinologist.
Insulin Glulisine 100u/ml solution for injection A10AB06000P5001XX A* Treatment of adults, adolescents and children 6 years or Glulisine should be given shortly (0-15 min) before or soon after
in pre-filled pen 3ml older with diabetes mellitus, where treatment with meals. Glulisine should be used in regimens that include an
insulin is required. intermediate or long acting insulin or basal insulin analogue and
can be used with oral hypoglycaemic agents. The dosage of
Apidra should be individually adjusted.
Insulin Lispro 100 IU/ml Injection in Prefilled A10AB04000P5001XX A* i) As initial therapy in children with Type 1 diabetes Dose to be individualized. The average daily insulin requirement
syringe/cartridge ii)Type 1 diabetes patients on basal bolus regimen, not is between 0.5 to 1.0 units/kg body weight, given within 15
controlled or experience hypoglycaemia with minutes before meal.
conventional insulin, to be used in combination with
long-acting insulin iii)Type 2 diabetes patients on basal
bolus or premixed regimen, not controlled or experience
hypoglycaemia with conventional insulin, to be used in
combination with intermediate-acting insulin or long-
acting insulin iv)Patients with diabetes in pregnancy with
poor postprandial control or experience hypoglycaemia
with conventional short-acting insulin
Insulin Lispro 25% & Insulin Lispro Protamine A10AD04000P5001XX A* Patients with Type 2 diabetes whom experience Dose to be individualized. The average daily insulin requirement
75% 100 U/ml Suspension for Injection in hypoglycemia with the use of human premixed insulin. is between 0.5 to 1.0 units/kg body weight
Prefilled Syringe/Cartridge
Insulin Lispro 50% & Insulin Lispro Protamine A10AD04000P5002XX A* Patients with Type 2 diabetes whom experience Dose to be individualized. The average daily insulin requirement
50% 100U/ml Suspension for Injection in hypoglycemia with the use of human premixed insulin. is between 0.5 to 1.0 units/kg body weight.
Prefilled Syringe/Cartridge
April 2023 88

Insulin Recombinant Neutral Human Short A10AB01000P3001XX B Diabetes mellitus Dose to be individualised. The average daily insulin requirement
Acting 100 IU/ml Injection in 10ml vial is between 0.3-1.0 units/kg body weight/day. Daily insulin
requirement may be higher in patients with insulin resistance,
and lower in patients with residual, endogenous insulin
production.
Insulin Recombinant Neutral Human Short- A10AB01000P5001XX B Diabetes mellitus Dose to be individualised. The average daily insulin requirement
acting 100IU/ml Penfill and Refill is between 0.3-1.0 units/kg body weight/day. Daily insulin
production.
Insulin Recombinant Synthetic Human A10AC01000P3001XX B Diabetes mellitus Dose to be individualised. The daily insulin requirement is usually
Intermediate-Acting 100IU/ml in Vial for between 0.3 and 1.0IU/kg /day
Injection
Insulin Recombinant Synthetic Human A10AD01000P3001XX B Diabetes mellitus Dose to be individualised. The average daily insulin requirement
Premixed 100IU/ml in Vial for Injection is between 0.3-1.0 units/kg body weight/day. Daily insulin
production.
Insulin Recombinant Synthetic Human, A10AC01000P5001XX B Insulin dependent diabetes mellitus, non insulin Dose to be individualised. The daily insulin requirement is usually
Intermediate-Acting 100 IU/ml Penfill and Refill dependent diabetes unresponsive to treatment to diet between 0.3 and 1.0IU/kg /day
or oral hypoglycaemics, hyperkalaemia to assure proper
utilisation of glucose and reduce glucosuria in non
diabetic patients receiving parenteral nutrition
Insulin Recombinant Synthetic Human, A10AD01000P5001XX B Insulin dependent diabetes mellitus, non insulin Dose to be individualised. The average daily insulin requirement
Premixed 100 IU/ml Penfill and Refill dependent diabetes unresponsive to treatment to diet is between 0.5-1.0 units/kg body weight
or oral hypoglycaemics, hyperkalaemia to assure proper
utilisation of glucose and reduce glucosuria in non
diabetic patients receiving parenteral nutrition
Interferon Alfa - 2a 3 MIU Injection L03AB04000P3001XX A* For the treatment of i) Hairy cell leukaemia ii) Chronic i) Initial : 3 MIU SC daily. If intolerant, 1.5 MIU daily or 3 MIU 3
myelogenous leukaemia iii) AIDS related Kaposi's times a week or 1.5 MIU 3 times a week. Maintenance : 1.5-3
Sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) MIU SC 3 times a week ii) Patient > 18 years : 3 MIU daily (days 1-
Advanced renal cell carcinoma 3), 6 MIU daily (days 4-6), 9 MIU daily (days 7-84) iii) Patient > 18
years : Initially escalating dose to 18-36 MIU SC/IM for 10-12
weeks. Maintenance: up to 36 MIU 3 times a week iv)2.5-5
MIU/m2 SC 3 times a week for 4-6 months. CHILD: up to 10
MIU/m2 BSA v) Monotherapy : Initial : 3 - 6 MIU SC 3 times a
week for 6 months. Maintenance : 3 MIU 3 times a week for an
additional 6 months. vi) As an adjunct to cytotoxic
chemotherapy: An escalating dose of 3 MIU 3 times a week for 1
week, then 9 MIU 3 times a week for 1 week, then 18 MIU 3
times a week thereafter for 3-12 months SC
April 2023 89

Interferon Alfa-2b 18 MIU Injection L03AB05000P5001XX A For the treatment of i) Hairy cell leukaemia ii) Chronic i) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 -
myelogenous leukaemia iii) AIDS related Kaposi's 9 MIU 3 - 5 times a week or daily depending on response iii)
sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Patient more than 18 years. Initially escalating dose to 18-36 MIU
Advanced renal cell carcinoma SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times
weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD:
up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to
cytotoxic chemotherapy: An escalating dose of 3 million IU 3
times/week for 1 week, then 9 million IU 3 times/week for 1
week, then 18 million IU 3 times/week thereafter for 3-12 month
SC or IM
Interferon Alfa-2b 30 MIU Multidose Injection L03AB05000P5002XX A For the treatment of i) Hairy cell leukaemia ii) Chronic i) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 -
Pen myelogenous leukaemia iii) AIDS related Kaposi's 9 MIU 3 - 5 times a week or daily depending on response iii)
sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Patient more than 18 years. Initially escalating dose to 18-36 MIU
SC or IM
Interferon Alpha - 2a 4.5 MIU Injection L03AB04000P3002XX A* For the treatment of i) Hairy cell leukaemia ii) Chronic i) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 -
myelogenous leukaemia iii) AIDS related Kaposi's 9 MIU 3 - 5 times a week or daily depending on response iii)
Sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Patient more than 18 years. Initially escalating dose to 18-36 MIU
SC or IM
Interferon Alpha 2b 3 MIU Injection L03AB05000P3001XX A* For the treatment of i) Hairy cell leukaemia ii) Chronic i) 2 MIU/m2 SC or IM 3 times a week ii) 4 - 5 MIU/m2 SC daily.
myelogenous leukaemia iii) AIDS related Kaposi's Treatment must be discontinued after 8 to 12 weeks of
sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) treatment if at least a partial haematological remission or a
Advanced renal cell carcinoma clinically meaningful cytoreduction has not been achieved iii)
Patient > 18 years : 30 MIU/m2 SC or IM three times a week until
disease progression or maximal response has been achieved after
16 weeks of treatment. iv) 5 MIU daily or 10 MIU three times a
week for 16 weeks. CHILD : 3 MIU/m2 three times a week for the
first week of therapy followed by dose escalation to 6 MIU/m2
(maximum of 10MIU) three times a week SC for a total duration
of 16 to 24 weeks v) 3 MIU SC or IM 3 times a week.
April 2023 90

Interferon beta -1b 250mcg (8MIU) Injection L03AB08000P4001XX A* i)Relapsing-remitting multiple sclerosis (RRMS): 0.25 mg (8 MIU) by SC injection every other day
Reduction of frequency and degree of severity of clinical
relapses in ambulatory patients characterized by at least
two attacks of neurological dysfunction over the
preceding two year period, followed by complete or
incomplete recovery ii)Secondary progressive multiple
sclerosis (SPMS):Reduction of frequency and severity of
clinical relapses and for slowing the progression of
disease
Interferon Beta-1a 22 mcg Injection L03AB07000P5001XX A* Multiple sclerosis of the relapsing remitting type with 2 22 mcg 3 times weekly
or more relapses within the last 2 years
Interferon Beta-1a 44 mcg Injection L03AB07000P5002XX A* Multiple sclerosis of the relapsing remitting type with 2 44 mcg 3 times weekly
or more relapses within the last 2 years
Iodine and Potassium Iodide Solution H03CA00-200-L99-01-XXX B i) Pre-operative treatment of thyrotoxicosis ii) None i) 1 ml daily in divided doses ii) 2 - 3 ml daily
Thyrotoxicosis crisis
Iodixanol 320 mg I/ml Injection V08AB09000P3001XX A X-ray contrast medium for cardioangiography, cerebral Depending on type of examination
angiography, peripheral arteriography, abdominal
angiography, uroloraphy, venography, CT enhancement,
lumbar, thoracic and cervical myelography
Iohexol Injection V08AB02-000-P30-01-XXX A X-ray contrast medium for use in adults and children for - Dose depending on the route and procedure
cardioangiography, arteriography, urography,
phlebography and CT-enhancement. Lumbar, thoracic,
cervical myelography and computed tomography of the
basal cisterns, following subarachnoid injection.
Arthrography, endoscopic retrograde pancreatography
(ERCP), herniography, hysterosalpingography,
sialography and studies of the gastrointestinal tract
Iopamidol Injection V08AB04000P3001XX A i) Neuroradiology: myeloradiculography, cisternography Dose depending on the route and procedure.
and ventriculography ii) Angiograph: cerebral
arteriography, thoracic aortography, abdominal
aortography, angiocardiography, selective visceral
arteriography, peripheral arteriography, venography,
digital subtraction angiography (DSA) iii) Urography iv)
Other diagnostic procedures: Contrast enhancement in
CT Scanning, arthrography, fistulography
Iopromide 300mg injection (623 mg of V08AB05000P3001XX A i) For angiography, urography, aortography and the Dose depending on the route and procedure
iopromide with 300 mg of iodine per mL) visualization of body cavities ii) Contrast enhancement
during computerized tomography iii) To check
functioning of a dialysis shunt
Iopromide 370mg injection (769 mg of V08AB05000P3002XX A i) For angiography, urography, aortography and the Dose depending on the route and procedure
iopromide with 370 mg of iodine per mL) visualization of body cavities ii) Contrast enhancement
during computerized tomography iii) To check
functioning of a dialysis shunt
April 2023 91

Ipratropium Bromide 0.0125% Nebulising R03BB01-320-A30-01-XXX B Maintenance treatment of bronchospasm associated None Maintenance treatment: i) Adult and adolescents over 12 years
Solution (125 mcg/ml) with chronic obstructive pulmonary disease, including old: 500mcg per dose, 3 to 4 times daily. ii) Children 6 - 12 years
chronic bronchitis and emphysema. Used concomitantly old: 250mcg per dose, 3 to 4 times daily. iii) Children less than 6
with inhaled beta-agonists in the treatment of acute years old: 100 - 250mcg per dose, 3 to 4 times daily. Acute
bronchospasm associated with chronic obstructive attacks (in combination with beta-agonist): i) Adult and
pulmonary disease including chronic bronchitis and adolescents over 12 years old: 500mcg per dose, time interval
asthma. between doses may be determined by the physician. ii) Children
6 - 12 years old: 250mcg per dose, time interval between doses
may be determined by the physician. iii) Children less than 6
years old: 100 - 250mcg per dose, time interval between doses
may be determined by the physician.
Ipratropium Bromide 0.025% Inhalation R03BB01-320-A30-02-XXX B Maintenance treatment of bronchospasm associated None Maintenance treatment: i) Adult and adolescents over 12 years
Solution (250mcg/ml) with chronic obstructive pulmonary disease, including old: 500mcg per dose, 3 to 4 times daily. ii) Children 6 - 12 years
chronic bronchitis and emphysema. Used concomitantly old: 250mcg per dose, 3 to 4 times daily. iii) Children less than 6
with inhaled beta-agonists in the treatment of acute years old: 100 - 250mcg per dose, 3 to 4 times daily. Acute
bronchospasm associated with chronic obstructive attacks (in combination with beta-agonist): i) Adult and
pulmonary disease including chronic bronchitis and adolescents over 12 years old: 500mcg per dose, time interval
asthma. between doses may be determined by the physician. ii) Children
6 - 12 years old: 250mcg per dose, time interval between doses
may be determined by the physician. iii) Children less than 6
years old: 100 - 250mcg per dose, time interval between doses
may be determined by the physician.
Ipratropium Bromide 0.5mg and Salbutamol R03AK04-320-A30-01-XXX B Management of reversible bronchospasm associated None Acute attacks : 1 unit dose vial. In severe cases not relieved by 1
2.5mg per UDV with obstructive airway diseases unit dose vial, 2 unit dose vials may require. Maintenance : 1 unit
dose vial 3 - 4 times daily
Ipratropium Bromide 20 mcg/dose Inhalation R03BB01-320-A10-01-XXX B Maintenance treatment of bronchospasm associated None Adult and children more than 6 years of age: 2 puffs 4 times daily.
with chronic obstructive pulmonary disease, including Total daily dose of 12 puffs.
chronic bronchitis, emphysema and asthma.
Ipratropium Bromide 20mcg and Fenoterol R03AK03-986-A21-01-XXX B Management of symptoms in chronic obstructive airway None ADULT & CHILD more than 6 years; Acute asthma 2 puffs. Severe
50mcg/dose Inhaler disorders with reversible bronchospasm such as cases: if breathing has not noticeably improved after 5 mins, 2
bronchial asthma and chronic bronchitis with or without further puffs may be taken. Intermittent and long-term treatment
emphysema 1-2 puffs for each administration, up to max 8 puffs/day (average:
1-2 puffs three times daily)
Ipratropium Bromide 20mcg and Salbutamol R03AK04-320-A10-01-XXX B Management of reversible bronchospasm associated None ADULT and ELDERLY : 2 inhalations 4 times daily. Maximum : 12
base 100mcg/dose Inhalation with obstructive airway diseases inhalations daily. CHILD under 12 years not recommended
Irinotecan HCl Trihydrate 20 mg/ml Injection L01XX19110P3002XX A* Metastatic colorectal cancer In combination therapy (for previously untreated patients): 180
mg/m2 once every 2 weeks as an IV infusion over 90 mins
followed by infusion with folinic acid and 5-fluorouracil. In
monotherapy (for previously treated patients): 350 mg/m2
administered as an intravenous infusion over 90 minutes period
once every 3 weeks
April 2023 92

Iron (III) hydroxide sucrose complex 20mg/ml B03AC02250P3001XX B Treatment of iron deficiency anaemia: a) where there is ADULT and ELDERLY: Cumulative dose is to be administered in
solution for injection a clinical need for rapid iron supply b) in patients who single doses of 100 - 200 mg of iron 2 - 3 times weekly depending
cannot tolerate oral iron therapy or who are non- on Hb level. Total cumulative dose: 1000 mg
compliant c) in active inflammatory bowel disease where
oral iron preparations are ineffective
Iron (III) Polymaltose Complex 10mg iron/ml B03AB05000L9001XX A Treatment of latent iron deficiency and iron deficiency Infants (up to 1 year): 2.5-5ml daily (25-50mg iron) Children (1-12
syrup anaemia (manifest iron deficiency). years old): 5-10ml daily (50-100mg iron) Children (>12 years),
adults: 10-30 ml daily (100-300mg iron) Pregnant woman 20-
30ml daily (200-300mg iron)
Iron (III)-hydroxide polymaltose complex (IPC) B03AD04-250-T20-01-XXX A/KK Treatment of iron deficiency without anaemia and iron Dosage and duration of therapy are dependent upon the extent
100mg iron and 0.35mg folic acid chewable deficiency anaemia of iron deficiency. Manifest iron deficiency: 1 chewable tablet
tablet two to three times daily until a normalization of the hemoglobin
value is achieved. Afterwards the therapy should be continued
with 1 chewable tablet daily at least until the end of pregnancy to
replenish the iron stores. Latent iron deficiency and prevention of
iron and folic acid deficiency: 1 chewable tablet daily
Iron Dextran 50 mg Fe/ml Injection B03AC06000P3001XX B Severe iron deficiency anaemia An initial test dose of 0.5 ml should be given over the desired
route. For severe iron deficiency anaemia, 1-2 ml daily given by
deep IM. Dosage is individualized according to total iron deficit
Isoflurane Liquid N01AB06000L5001XX B i) Induction and ii) Maintenance of anaesthesia i) Induction- Initiate at a concentration of 0.5 % ii) Maintenance-
1 - 2.5 % in oxygen or nitrous oxide mixture. 0.5 - 0.75 % with
oxygen and nitrous oxide for Caesarian section
Isoniazid 100 mg Tablet J04AC01000T1001XX B i) Tuberculosis ii)Tuberculous meningitis i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg
biweekly (max 1200mg)
Isoniazid 400 mg Tablet J04AC01000T1002XX B i) Tuberculosis ii)Tuberculous meningitis i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg
biweekly (max 1200mg)
Isoprenaline HCl 0.2mg/ml Injection C01CA02-110-P30-01-XX B Complete heart block (third-degree artrioventricular None If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed
block) not responding to atropine, while waiting for by 0.02-1 mg depending on clinical response. If given as SC: 0.2
cardiac pacing mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending
on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose
5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is
being monitored. The dose should be titrated to produce the
desired clinical response
Isoprenaline HCl 1mg/5 ml Injection C01CA02-110-P30-02-XX B Complete heart block (third-degree artrioventricular None If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed
block) not responding to atropine, while waiting for by 0.02-1 mg depending on clinical response. If given as SC: 0.2
cardiac pacing mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending
on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose
5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is
being monitored. The dose should be titrated to produce the
desired clinical response
Isosorbide Dinitrate 10mg Tablet C01DA08-221-T10-01-XXX B Prophylaxis and treatment for: i) Angina ii) Left None i) 30 - 120 mg daily in divided doses ii) 40 - 160 mg, up to 240 mg
ventricular failure if required
April 2023 93

Isosorbide Dinitrate 1mg/ml Injection C01DA08-221-P30-01-XX A Treatment for angina pectoris and left ventricular failure None 2-12mg IV per hour after dilution. Dosing is according to product
insert or protocol.
Isosorbide-5-Mononitrate 60mg SR Tablet C01DA14-221-T50-02-XXX A/KK Angina pectoris None Initial: 30mg daily. Maintenance: 30-60mg once daily. Max.
120mg once daily.
Isotretinoin 10 mg Capsule D10BA01000C1001XX A* Only for treatment of i) Severe nodulo-cystic acne ii) 0.5-1 mg/kg of body weight per day (in two divided doses) for 15
Acne conglobata iii) Acne fulminans iv) Severe acne to 20 weeks; the maximum recommended dose is 2mg/kg of
vulgaris failing conventional treatment. body weight per day. After about 4 weeks, therefore, dosage for
the maintenance treatment should be adjusted within the range
0f 0.1-1mg/kg daily to meet individual need. Treatment usually
lasts a total of 16 weeks. There should be an interval of at least 8
weeks before re-starting treatment.
Isotretinoin 20 mg Capsule D10BA01000C1002XX A* Only for treatment of i) Severe nodulo-cystic acne ii) 0.5-1 mg/kg of body weight per day (in two divided doses) for 15
Acne conglobata iii) Acne fulminans iv) Severe acne to 20 weeks; the maximum recommended dose is 2mg/kg of
vulgaris failing conventional treatment WARNING: THIS body weight per day. After about 4 weeks, therefore, dosage for
DRUG IS TERATOGENIC the maintenance treatment should be adjusted within the range
0f 0.1-1mg/kg daily to meet individual need. Treatment usually
lasts a total of 16 weeks. There should be an interval of at least 8
weeks before re-starting treatment.
Itopride HCl 50 mg Tablet A03FA00110T1001XX A* Treatment of gastrointestinal symptoms of functional, 50 mg 3 times daily before meal
non-ulcer dyspepsia (chronic gastritis) i.e sensation of
bloating, early satiety, upper abdominal pain or
discomfort, anorexia, heartburn, nausea and vomiting
Itraconazole 10 mg/ml Oral Solution J02AC02000L9901XX A* Treatment of: i) oral and/or oesophageal candidiasis ii) i) 200 mg daily for 1 week. If no response after 1 week, continue
fluconazole resistant and/or oesophageal candidiasis treatment for another week ii) 100 - 200 mg twice daily for 2
weeks. If no response after 2 weeks, continue treatment for
another 2 weeks. The 400 mg daily dose should not be used for
more than 14 days if there are no signs of improvement
Itraconazole 100 mg Capsule J02AC02000C1001XX A/KK i) Dermatomycosis including pityriasis versicolor ii) Oral i) 200 mg once daily for 7 days ii) 100 mg daily for 15 days iii) 200
candidiasis iii) Palmar tinea manus and plantar tinea mg twice daily for 7 days iv) 200mg twice daily for 1 week per
pedis iv) Fingernail onychomycosis v) Toenail month for 2 months v) 200 mg twice daily for 1 week per month
onychomycosis vi) Vulvovaginal candidiasis for 3 months vi)200 mg morning and evening for 1 day or 200 mg
once daily for 3 days
Ivabradine 5mg Tablet C01EB17-110-T10-01-XX A* i) Symptomatic treatment of chronic stable angina None Initial dose 5 mg twice daily. May increase dose after 3-4 weeks
pectoris in coronary artery disease adults with normal to 7.5 mg twice daily depending on response. ELDERLY, initial
sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice
indicated: - in adults unable to tolerate or with a daily
contraindication to the use of beta-blockers - or in
combination with beta-blockers in patients inadequately
controlled with an optimal beta-blocker dose. ii)
Treatment of chronic heart failure NYHA II to IV class
with systolic dysfunction, in patients in sinus rhythm and
whose heart rate is ≥ 75 bpm, in combination with
standard therapy including beta-blocker therapy or
when beta-blocker therapy is contraindicated or not
tolerated.
April 2023 94

Ivabradine 7.5mg Tablet C01EB17-110-T10-02-XX A* i) Symptomatic treatment of chronic stable angina None Initial dose 5 mg twice daily. May increase dose after 3-4 weeks
pectoris in coronary artery disease adults with normal to 7.5 mg twice daily depending on response. ELDERLY, initial
sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice
indicated: - in adults unable to tolerate or with a daily
contraindication to the use of beta-blockers - or in
combination with beta-blockers in patients inadequately
controlled with an optimal beta-blocker dose. ii)
Treatment of chronic heart failure NYHA II to IV class
with systolic dysfunction, in patients in sinus rhythm and
whose heart rate is ≥ 75 bpm, in combination with
standard therapy including beta-blocker therapy or
when beta-blocker therapy is contraindicated or not
tolerated.
Kanamycin 1 g Injection J01GB04183P4001XX A* i) Treatment of gonorrhoea and neonatal meningitis ii) i) ADULT: 1 - 2 g daily IM in 1 - 2 equally divided doses. CHILD: 30 -
Treatment of TB patients who require reserved second 50 mg/kg/day in 1 - 2 divided doses ii) ADULT: 2 g daily IM in 2
line drugs but have no pre-existing renal complications equally divided doses twice a week or 1 g once daily 3 days a
week
Ketamine 10 mg/ml Injection N01AX03110P3001XX B Sole anaesthetic for short procedures or induction of IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesth for
anaesthesia in certain types of patients (e.g in shock 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg
states) produces anesth for 12-25 mins.
Ketamine 50 mg/ml Injection N01AX03110P3002XX B Sole anaesthetic for short procedures or induction of IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesthesia
anaesthesia in certain types of patients (e.g in shock for 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg
states) produces anesthesia for 12-25 mins.
Ketoconazole 2% Shampoo D01AC08-000-L52-01-XXX A/KK Dandruff, seborrhoeic dermatitis and pityriasis versicolor. None Seborrhoeic dermatitis & dandruff: Apply twice weekly for 2 to 4
weeks. Pityriasis versicolor: Apply once daily for up to 5 days.
Prophylaxis: Once every 1 or 2 weeks. Both left for 3-5minutes
before rinsing.
Ketoconazole 200 mg Tablet J02AB02000T1001XX A/KK i) Pityriasis versicolor ii) Systemic mycosis (other skin i) 200 mg with meal once daily for 10 days ii) 200 - 400 mg daily
mycoses) iii) Nail infections for 4 weeks - 6 months iii) 200 - 400 mg daily for 6 - 12 months.
Ketoprofen 2.5% Gel M02AA10-000-G30-01-XXX A/KK Local treatment of osteoarticular & muscular painful - Apply onto affected areas 2-4 times daily up to 10 days.
disorders of rheumatic or traumatic origin: Contusions,
distortions, muscle strains, stiff neck, lumbago.
Ketoprofen 30 mg Transdermal Plaster M02AA10000M7001XX A Treatment of signs & symptoms of arthritis deformans, Apply 1 plaster to the affected area twice daily
periarthritis humero-scapularis, tendinitis, peritendinitis,
sore muscle, swelling, pain resulting from trauma (eg.
contusion, distorsion, sprain).
Ketoprofen 50 mg/ml Injection M01AE03000P3001XX A* To be used only in treatment of acute inflammatory By deep IM into gluteal muscle, 50-100 mg every 4 hours.
conditions Maximum 200 mg in 24 hours for up to 3 days. Child not
recommended
Ketorolac Tromethamine 30 mg/ml Injection M01AB15239P3001XX A* Short term management of moderate to severe ADULT : 60mg as a single dose via IM inj or 30mg as a single IV
postoperative pain dose. Alternatively, 30mg every 6 hr via IM or IV admin up to a
max of 120mg daily.
Labetalol HCl 100mg Tablet C07AG01-110-T10-01-XX B i) Mild, moderate or severe hypertension ii) None i) & ii) Initial: 100mg twice daily Maintenance: 200-400mg twice
Hypertension in pregnancy daily Max. 2400mg daily in 3 or 4 divided doses Dosing is
April 2023 95

Labetalol HCl 5mg/ml Injection C07AG01-110-P30-01-XX B Hypertension crisis None ADULT: 20mg injected slowly for at least 2 min, followed by 40-
80mg dose every 10 min, if necessary upto 300 mg. Patient
should remain supine during and 3 hr after the procedure.
Lactobacillus Acidophilus 100million viable cells G03CC06-953-T10-01-XXX A/KK i)Atrophic vaginitis due to estrogen deficiency during None Atrophic vaginitis : 1 vaginal tablet daily for 6-12 days followed by
& Estriol 0.03mg vaginal tablet menopause and post-menopause, or as co-medication to a maintenance dose of 1 vaginal tablet for 1-2 days per week
systemic hormone replacement therapy ii)Restoration of Restoration therapy: 1-2 vaginal tablet daily for 6-12 days
the Lactobacillus flora after local and/or systemic Administration The vaginal tablets should be inserted deeply into
treatment with anti-infective agents or the vagina in the evenings before bedtime. ?In cases of a very dry
chemotherapeutic agents vagina, vaginal tablet can be moistened with 1 or 2 drops of
water before insertion into the vagina. ?During menstruation,
treatment should be interrupted and resumed afterwards Should
not use vaginal douches or rinses during treatment
Lactulose 3.35g/5 ml Liquid A06AD11-000-L50-01-XXX C+ i) Constipation ii) Hepatic encephalopathy None i) ADULT 15-45 ml daily in 1-2 divided doses adjusted to patient's
need. Maintenance dose: 15-30ml daily in 1-2 divided doses.
CHILD 0.5 ml/kg/dose once or twice daily. ii) ADULT: 30-45 ml 2-4
times daily, dose adjusted to produce 2-3 soft stools daily. CHILD:
1 ml/kg/dose 3-4 times daily.
Lamivudine 10 mg/ml Oral Solution J05AF05000L9901XX A* HIV infection in combination with other antiretroviral ADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1
agents month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg
twice daily. Maximum 300 mg daily
Lamivudine 100 mg Tablet J05AF05000T1001XX A* Management of chronic hepatitis B infection associated Adult:†100 mg once daily. For patients with
with evidence of hepatitis B viral replication and active concomitant†HIV†infection: 300 mg once daily or in 2 divided
liver inflammation doses.†Child: >2 yr: 3 mg/kg once daily. Max: 100 mg/day.
Lamivudine 150 mg Tablet J05AF05000T1002XX A/KK HIV infection in combination with other antiretroviral ADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1
agents month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg
twice daily. Maximum 300 mg daily
Lamotrigine 100mg Tablet N03AX09-000-T10-02-XX A i) Adjunctive or monotherapy for partial seizures and None i) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg
generalised tonic-clonic seizures not satisfactorily daily
controlled with other antiepileptic drugs ii) Prevention of
mood episodes in adult 18 years and above with bipolar
disorder, predominately by preventing depressive
episodes
Lamotrigine 25mg Dispersible/Chewable Tablet N03AX09-000-T20-01-XX A Add-on therapy in intractable partial seizures None 25 mg daily - 50 mg twice daily
Lamotrigine 50mg Tablet N03AX09-000-T10-01-XX A i) Adjunctive or monotherapy for partial seizures and None i) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg
generalised tonic-clonic seizures not satisfactorily daily
controlled with other antiepileptic drugs ii) Prevention of
mood episodes in adult 18 years and above with bipolar
disorder, predominately by preventing depressive
episodes
April 2023 96

Lamotrigine 5mg Dispersible/Chewable Tablet N03AX09-000-T20-02-XX A Management of seizures in children aged 2 - 12 years None a) Add-on therapy in patients not taking Valproate: week 1 and 2:
2 mg/kg/day twice daily, week 3 and 4: 5 mg/kg/day twice daily.
Maintenance: 5 - 15 mg/kg/day twice daily b) Add-on therapy in
patients taking Valproate or other anti-epileptic drugs, week 1
and 2: 0.2 mg/kg/day as a single dose (children less than 25 kg
may take 5 mg on alternate days), week 3 and 4: 0.5 mg/kg/day
as a single dose. Maintenance dose: 1 -5 mg/kg/day once daily or
twice daily
Lanreotide acetate 120mg prolonged-release H01CB03-122-P30-04-XXX A* i) Treatment of grade 1 and a subset of grade 2 (Ki67 None i) 120 mg administered every 28 days ii) 60 mg to 120 mg
solution for injection index up to 10%) gastroenteropancreatic administered every 28 days
neuroendocrine tumours (GEPNETs) of midgut,
pancreatic or unknown origin where hindgut sites of
origin have been excluded, in adult patients with
unresectable locally advanced or metastatic disease ii)
Treatment of the clinical symptoms of neuroendocrine
(particularly carcinoid) tumours
Lanreotide acetate 60mg prolonged-release H01CB03-122-P30-02-XXX A* Treatment of the clinical symptoms of neuroendocrine None 60 mg to 120 mg administered every 28 days
solution for injection (particularly carcinoid) tumours
Lanreotide acetate 90mg prolonged-release H01CB03-122-P30-03-XXX A* Treatment of the clinical symptoms of neuroendocrine None Treatment of the clinical symptoms of neuroendocrine
solution for injection (particularly carcinoid) tumours (particularly carcinoid) tumours
Lansoprazole 30 mg Tablet A02BC03000T1001XX A* i) Peptic ulcer disease ii) Reflux oesophagitis iii) Zollinger- i) 30mg daily in the morning for up to 4 weeks (duodenal ulcer) or
Ellison Syndrome iv) For eradication of Helicobacter up to 8 weeks (gastric ulcer). Maintenance: 15mg/day. ii) 30mg
pylori in combination with antibiotic OD in the morning for up to 8 weeks if not healed. Maintenance:
15mg OD. iii) Initially 60mg OM & adjust as required. Daily doses
>120mg should be given in 2 divided doses. iv) 30 mg twice daily
in combination with any of the 2 antibiotics (clarithromycin 500
mg twice daily , amoxicillin 1 g twice daily or metronidazole 400
mg twice daily) for 1-2 weeks
Lanthanum Carbonate 1000mg Chewable V03AE03130T2004XX A* Phosphate binding agent for the treatment of Initial: 750 to 1500 mg/day in divided doses with meals, then
Tablet hyperphosphataemia in dialysis patients with sustained titrate in increments of 750 mg/day at intervals of 2 to 3 weeks.
hypercalcaemia of more than three months and Maintenance: 1500-3000 mg/day in divided doses. Max: 3750
secondary hyperparathyroidism g/day
Laronidase 2.9 mg/5ml Injection A16AB05000P3001XX A* Hurler and Hurler-Scheie forms of 0.58 mg/kg of body weight administered once-weekly as an
Mucopolysaccharidosis I (MPS I) and for patients with intravenous infusion
the Scheie form who have moderate to severe symptoms
L-Asparaginase 10,000 IU Injection L01XX02000P3001XX A* i) Acute lymphoblastic leukemia ii) Non-hodgkin's i) 5,000 iu/m2 for 10 days during induction, 10,000 iu/m2 also
lymphoma used with high dose methotrexate rescue in consolidation phase
of acute lymphoblastic leukemia ii) CHILD: 5,000 - 25,000 iu/m2
per dose depending on protocol
Latanoprost 0.005% and Timolol Maleate 0.5% S01ED51-990-D20-04-XXX A* For reduction of Intraocular Pressure (IOP) in patients None 1 drop in the affected eye(s) once daily
eye drops with Open-angle Glaucoma (OAG) and Ocular
Hypertension (OH) who are insufficiently responsive to
topical beta-blocker.
Latanoprost 0.005% Eye Drops S01EE01-000-D20-01-XXX A* Reduction of elevated intraocular pressure in patients None 1 drop in the affected eye(s) once daily.
with open-angle glaucoma
Leflunomide 10 mg Tablet L04AA13000T1001XX A* i) Persistent active rheumatoid arthritis ii) Active Loading dose: 100 mg once daily for 3 days. Maintenance: 10-20
psoriatic arthritis mg once daily
April 2023 97

Leflunomide 20 mg Tablet L04AA13000T1002XX A* i) Persistent active rheumatoid arthritis ii) Active Loading dose: 100 mg once daily for 3 days. Maintenance: 10-20
psoriatic arthritis mg once daily.
Lenalidomide 10 mg Capsule L04AX04000C1002XX A* In combination with dexamethesone is indicated for the Recommended starting dose: 25 mg once daily on days 1 to 21 of
treatment of multiple myeloma patients who have repeated 28 day cycle with dexamethasone 40 mg once daily on
received at least one prior therapy days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first
4 cycles of therapy, thereafter dexamethasone 40 mg once daily
on day 1 to 4 every 28 day cycle
Lenvatinib 4mg Hard Capsule L01EX08-196-C11-01-XXX A* Indicated as monotherapy for the treatment of adult Only for patients with Child-Pugh A The recommended daily dose of lenvatinib is 8 mg (two 4 mg
patients with advanced or unresectable hepatocellular capsules) once daily for patients with a body weight of < 60 kg
carcinoma (HCC) who have received no prior systemic and 12 mg (three 4 mg capsules) once daily for patients with a
therapy body weight of ≥ 60 kg. Dose adjustments are based only on
toxicities observed and not on body weight changes during
treatment (Refer package insert for dosage adjustments)
Treatment should continue as long as clinical benefit is observed
or until unacceptable toxicity occurs.
Letrozole 2.5 mg Tablet L02BG04000T1001XX A* Hormonal therapy in breast cancer in post-menopausal 2.5 mg once daily
women if failed /contraindicated to Tamoxifen
Leucovorin Calcium (Calcium Folinate) 15 mg V03AF03-390-T10-01-XXX A i) Treatment of folic acid antagonist overdose; ii) None i) 15 mg every 6 hours for the next 48 - 72 hours; ii) Metastatic
Tablet Leucovorin (folinic acid) plus tegafur-uracil combination stage: Leucovorin Calcium 30 mg TDS, Day 1-28, rest 7 days for 5
therapy is indicated for the treatment of colorectal cycles Adjuvant setting: Leucovorin Calcium 30 mg TDS, Day 1-28,
cancer in: a) Metastatic stage, b) Adjuvant setting, c) rest 7 days for 5 cycles; Concurrent setting: Leucovorin Calcium
Concurrent setting. 25 mg /day, D8- D36, for 4 weeks. Dosing is individualised and
April 2023 98

Leucovorin Calcium (Calcium Folinate) 50 mg V03AF03-237-P30-02-XXX A (i) Biochemical modulator for 5-Fluorouracil in the None i) 200mg/m2 by slow IV injection over a minimum 3 minutes,
Injection treatment of solid tumour; (ii) As rescue for high dose followed by 5-Fluorouracil or 20mg/m2 IV followed by 5-
methotrexate; (iii) Megaloblastic anaemias due to Fluorouracil. In both cases, treatment is repeated daily for 5 days;
deficiency of folic acid may repeat at 4-week intervals for 2 courses then 4- to 5-week
intervals ii) 15 mg (approximately 10mg/m2) every 6 hours for 10
doses, starting 24 hours after the beginning of the methotrexate
infusion iii) Up to 1 mg daily Dosing is individualised and
Leuprolide 22.5mg injection L02AE02122P2001XXX A* Hormonal therapy in advanced prostate cancer. 22.5mg SC every 3 months
Leuprolide Acetate 11.25 mg Injection L02AE02122P5002XX A* i) Endometriosis ii) Hormonal therapy in advanced 11.25 mg every 3 months
prostate cancer
Leuprolide Acetate 3.75 mg Injection L02AE02122P5001XX A* i) Endometriosis ii) Hormonal therapy in advanced i) 3.75 mg monthly for 3 - 6 months ii) 3.75 mg IM or SC injection
prostate cancer monthly
Levetiracetam 100 mg/ml Oral Solution N03AX14-000-L99-01-XXX A* As adjunctive therapy in the treatment of partial onset None CHILD: 4-11 years and adolescent (12-17 years) less than 50 kg:
seizures with or without secondary generalization in Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg
adults and children from 4 years of age with epilepsy twice daily. Dose changes should not exceed increments or
decrements of 10 mg/kg two times daily twice weekly
Levetiracetam 100mg/ml Injection N03AX14-000-P30-01-XXX A* i) Monotherapy therapy in the treatment of partial onset To be initiated when conventional IV antiepileptic drugs i) ADULTS and ADOLESCENT (from 16 years): Starting dose: 250
seizures with or without secondary generalization in failed to achieve control, or oral form is temporarily not mg twice daily, Increase dose to 500 mg twice daily after 2 week.
patients from age 16 years of age with newly diagnosed feasible in seizure emergencies Dose can be further increased by 250 mg twice daily every 2
epilepsy ii) Adjunctive treatment in partial onset seizures weeks depending upon the clinical response. Max: 1500 mg twice
with or without secondary generalization in adults and daily. ii) ADULT more than 18 years and ADOLESCENT (12 to 17
children from 4 years of age with epilepsy; juvenile years) more than or equal to 50 kg: Initially 500 mg twice daily
myoclonic epilepsy and idiopathic generalized tonic may be increased up to 1500 mg twice daily. Dose changes can be
clonic epilepsy from 12 years of age made in 500 mg twice daily increments or decrements 2 to 4
weekly. CHILD (4 to 11 years) and ADOLESCENT (12 to 17 years)
less than 50 kg : Initially 10 mg/kg twice daily, may be increased
up to 30 mg/kg twice daily. Dose changes should not exceed
increments or decrements of 10 mg/kg twice daily every 2 weeks.
CHILD more than or equal to 50 kg: Adult dose
Levetiracetam 250 mg Tablet N03AX14-000-T10-01-XXX A* i) Monotherapy therapy in the treatment of partial onset i) Monotherapy ADULTS and ADOLESCENT (from 16 years):
seizures with or without secondary generalization in Starting dose: 250 mg twice daily, Increase dose to 500 mg twice
patients from age 16 years of age with newly diagnosed daily after 2 week. Dose can be further increased by 250 mg twice
epilepsy ii) Adjunctive treatment in partial onset seizures daily every 2 week depending upon the clinical response. Max:
with or without secondary generalization in adults and 1500 mg twice daily. ii) ADULT more than 18 years and
children from 4 years of age with epilepsy; juvenile ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially
myoclonic epilepsy and idiopathic generalized tonic 500 mg twice daily may be increased up to 1500 mg twice daily.
clonic epilepsy from 12 years of age Dose changes can be made in 500 mg twice daily increments or
decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-
17 years) less than 50 kg: Initially 10 mg/kg twice daily, may be
increased up to 30 mg/kg twice daily. Dose changes should not
exceed increments or decrements of 10 mg/kg twice daily every 2
weeks. CHILD more than or equal to 50 kg: Adult dose
April 2023 99

Levetiracetam 500 mg Tablet N03AX14-000-T10-02-XXX A* i) Monotherapy therapy in the treatment of partial onset None i) Monotherapy ADULTS and ADOLESCENT (from 16 years):
seizures with or without secondary generalization in Starting dose: 250 mg twice daily, Increase dose to 500 mg twice
patients from age 16 years of age with newly diagnosed daily after 2 week. Dose can be further increased by 250 mg twice
epilepsy ii) Adjunctive treatment in partial onset seizures daily every 2 week depending upon the clinical response. Max:
with or without secondary generalization in adults and 1500 mg twice daily. ii) ADULT more than 18 years and
children from 4 years of age with epilepsy; juvenile ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially
myoclonic epilepsy and idiopathic generalized tonic 500 mg twice daily may be increased up to 1500 mg twice daily.
clonic epilepsy from 12 years of age Dose changes can be made in 500 mg twice daily increments or
decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-
17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be
increased up to 30 mg/kg twice daily. Dose changes should not
exceed increments or decrements of 10 mg/kg twice daily every 2
weeks. CHILD more than or equal to 50 kg: Adult dose
Levobupivacaine 5mg/ml Injection N01BB10110P3001XX A Production of local or regional anesthesia for surgery None Surgical anesthesia : Lumber epidural : 10 - 20 ml (50 - 150 mg) ,
and obstetrics, and for postoperative pain management caesarean section : 15 - 30 ml (75 - 150 mg), intrathecal: 3 ml (15
mg), peripheral nerve block : 1 - 40 ml, ilioinguinal/iliohypogastric
block. CHILD : 0.25 - 0.5 ml/kg (1.25-2.5 mg/kg)
Levocetirizine Dihydrochloride 5mg Tablet R06AE09-110-T10-01-XXX A* Symptomatic treatment of allergic rhinitis (including None Children above 12 years and adults: 5 mg orally once daily
persistent allergic rhinitis) and chronic idopathic urticaria (Swallow whole, do not chew/crush).
Levodopa 100 mg and Carbidopa 25 mg Tablet N04BA02000T1001XX B Parkinson's disease Patients not receiving Levodopa before, initially 100 - 125 mg 3 -
4 times daily adjusted according to response. Maintenance: 0.75 -
2 g in divided doses. In patients previously treated with Levodopa
the dose should be about 20 - 25% of the dose previously being
taken
Levodopa 100 mg, Benserazide 25 mg HBS N04BA02977C1001XX B Parkinson's Disease Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until
capsule therapeutic effect, optimal dosage: 400/100 mg to 800/200
mg/day divided into 4-6 doses. Dose: 200/50 mg used only when
maintenance therapy is reached and not to exceed levodopa
1000-1200 mg/benserazide 250-300 mg per day
April 2023 100


Levodopa 100 mg, Carbidopa 25 mg and N04BA03977T1002XX A* Idiopathic Parkinson's disease The optimum daily dosage must be determined by careful
Entacapone 200 mg Tablet titration of levodopa in each patient. The daily dose should
preferably be optimised using 1 of the 4 available tablet strengths
(50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or
200/50/200mg levodopa/carbidopa/entacapone). Patients
should be instructed to take only 1 tablet/dose administration.
While the experience with total daily dosage >200 mg carbidopa
is limited, the maximum recommended daily dose of entacapone
is 2000 mg and therefore the maximum dose, for the strengths of
50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10
tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg
equals carbidopa 375 mg/day. Therefore, using a maximum
recommended daily dose of carbidopa 375 mg, the maximum
daily dose of 200/50/200 mg is 7 tablets per day. The maximum
total daily levodopa dose administered should not exceed 1500
mg.
Levodopa 150 mg, Carbidopa 37.5 mg and N04BA03977T1003XX A* Idiopathic Parkinson's disease The optimum daily dosage must be determined by careful
(50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or
50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10
mg.
Levodopa 200 mg, Benserazide 50 mg Tablet N04BA02977T1001XX B Parkinson's Disease Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until
therapeutic effect, optimal dosage: 400/100 mg to 800/200
mg/day divided into 4-6 doses. Dose: 200/50 mg used only when
maintenance therapy is reached and not to exceed levodopa
1000-1200 mg/benserazide 250-300 mg per day
April 2023 101


Levodopa 200 mg, Carbidopa 50 mg & N04BA03977T1004XX A* Idiopathic Parkinson's disease The optimum daily dosage must be determined by careful
(50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or
50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10
mg.
Levodopa 250 mg and Carbidopa 25 mg Tablet N04BA02000T1002XX B Parkinson's disease Patients not receiving Levodopa before, initially 100 - 125 mg 3 -
4 times daily adjusted according to response. Maintenance: 0.75 -
2 g in divided doses. In patients previously treated with Levodopa
the dose should be about 20 - 25% of the dose previous being
taken
Levodopa 50 mg, Carbidopa 12.5 mg & N04BA03977T1001XX A* Idiopathic Parkinson's disease The optimum daily dosage must be determined by careful
(50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or
50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10
mg.
Levofloxacin 0.5% ophthalmic solution S01AX19-000-D20-01-XX A* For the treatment of bacterial conjunctivitis caused by None Adult dose: 1 drop a time 3 times daily. The dosage may be
susceptible strains of the designated microorganisms. adjusted according to the patient's symptoms. Route of
administration: ophthalmic use only.
Levofloxacin 250 mg Tablet J01MA12000T1001XX A* Community acquired pneumonia 500 mg daily for 7 - 14 days
Levofloxacin 500 mg Injection J01MA12000P3001XX A* Community Acquired Pneumonia 500 mg daily for 7 - 14 days
Levofloxacin 500mg Tablet J01MA12-000-T10-02-XXX A* Community acquired pneumonia 500 mg daily for 7 - 14 days
Levonorgestrel 1.5mg Tablet G03AC03-000-T10-01-XXX A* Emergency contraception within 72 hours of None 1.5 mg as a single dose as soon as possible, preferably within 12
unprotected sexual intercourse for the female victim of hours but no later than 72 hours after unprotected sexual
sexual violence to prevent unwanted pregnancy intercourse.
April 2023 102


Levonorgestrel 150mcg and Ethinyloestradiol G03AA07-954-T10-01-XXX C+ Contraception None 1 tablet daily for 21 days from first day of the cycle, followed by 7
30mcg Tablet tab free days
Levonorgestrel 52mg Intrauterine System G02BA03-000-P10-01-XXX A* i. Contraception. ii. Idiopathic menorrhagia. iii. None One unit intrauterine device to be inserted into the uterine cavity
Protection from endometrial hyperplasia during within 7 days of the onset of menstruation or immediately after
oestrogen replacement therapy. first trimester abortion. Postpartum insertion should be
postponed until 6 weeks after delivery.Can be inserted at any
time of amenorrheic woman. One unit IUD is effective for 5 years
Levothyroxine Sodium 100 mcg Tablet H03AA01520T1001XX B Hypothyroidism Start at low dose and increase at 2-4 weeks interval. Adult:
Initially, 50-100 mcg/day may increase by 25-50 mcg at
approximately 3 to 4 weeks intervals until the thyroid deficiency
is corrected. Maintenance: 100-200 mcg/day. CHILD; 0 - 3
months: 10 - 15 mcg/kg/day; 3 - 6 months: 8 - 10 mcg/kg/day; 6 -
12 months: 6 - 8 mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12
years: 4 - 5 mcg/kg/day; more than 12 years: 2 -3 mcg/kg/day
Levothyroxine Sodium 25 mcg Tablet H03AA01152T1003XX B Hypothyroidism Start at low dose and increase at 2-4 weeks interval. Usual
recommended dose for i) Treatment of benign euthyroid goitre:
75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid
goitre: 75-200mcg iii) Substitution therapy in hypothyroidism:
ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day.
CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-
150mcg/m2 body surface area iv) Concomitant supplementation
during anti-thyroid drug treatment of hyperthyroidism: 50-
100mcg v) Suppression therapy in thyroid cancer: 150-300mcg
Levothyroxine Sodium 50 mcg Tablet H03AA01520T1002XX B Hypothyroidism Start at low dose and increase at 2-4 weeks interval. Usual
recommended dose for i) Treatment of benign euthyroid goitre:
75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid
goitre: 75-200mcg iii) Substitution therapy in hypothyroidism:
ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day.
CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-
150mcg/m2 body surface area iv) Concomitant supplementation
during anti-thyroid drug treatment of hyperthyroidism: 50-
100mcg v) Suppression therapy in thyroid cancer: 150-300mcg
Lidocaine 25mg and Prilocaine 25mg Cream N01BB52974G1001XX A Surface anaesthesia of the skin in connection with Apply a thick layer under occlusive dressing Dosing is according to
needle insertion and for superficial surgical procedures product insert.
Lidocaine Medicated Plaster 5% w/w N01BB02-110-M60-01-XXX A* Indicated for the symptomatic relief of neuropathic pain i) For elderly patients with polymedication status whom 1 patch /day (Adults & elderly. Cover the painful area once daily
associated with previous herpes zoster infection (post- certain treatment was contraindicated or not tolerated. for up to 12 hr w/in 24-hr period. Subsequent plaster-free
herpetic neuralgia, PHN). ii)Prescribed by pain specialist only. interval: At least 12 hr. Not more than 3 plasters should be used
at the same time)
Lignocaine 10 % w/w Spray N01BB02110A4001XX B For surface anaesthesia in dental practice, in None Spray to affected part
otorhinolaryngology and paracentesis
Lignocaine 2% Jelly N01BB02110G4001XX B Use for endotracheal tubes and instruments, painful Apply to affected area 10 mins before catheterization.
procedures in the ear, nose and throat, burns, wounds,
abrasions, lacerations; catheterisation of the male and
female urethra and for symptomatic treatment of cystitis
and urethritis
April 2023 103


Lignocaine 2% Viscous Solution N01BB02110L5001XX A i) To relief pain associated with irritated or inflamed i) a) For anaesthesia of the mouth: Rinse the mouth with 5-15 ml
mucous membranes of the: a) mouth; b) pharynx (post- (100- 300 mg lignocaine), then the solution is spat out. In dental
tonsillectomy) c) upper gastrointestinal tract (e.g practice, 10 ml solution (200 mg lidocaine) are used. The solution
esophagitis). ii) Use for instrumentation of the should be spat out when adequate anaesthesia has been
respiratory and digestive tracts (e.g. bronchoscopy, achieved (after approx. 1 minute). b) For anaesthesia of the
oesophagoscopy). ii) Use for instrumentation of the pharynx: Gargle with 5-10 ml (100-200 mg lignocaine), after
respiratory and digestive tracts (e.g. bronchoscopy, which the solution is slowly swallowed. c) Painful conditions in
oesophagoscopy). the upper GI tract: 5-15 ml (100-300 mg lignocaine) are rapidly
swallowed all at once. *Daily dose should not exceed 1200 mg
(Total of 60 ml) ii) Instrumentations into the stomach: 10-15 ml
(200-300 mg lignocaine) are swallowed. Indications (i) & (ii): The
daily dose should not exceed 1200mg (60mL) If combined with
other lignocaine products, the total dose of lignocaine on one
dosing occasion should not exceed 400mg.
Lignocaine 2% with Chlorhexidine 0.05% Gel N01BB52974G3001XX B To provide local anaesthesia and lubrication during Adult Male: Instil 20 mL slowly into the urethra until it reaches
catheterization, exploration by sound and other external sphincter, proximal to the prostrate. Subsequently, apply
endourethral operations and examinations, cytoscopy compression at the corona for several mins. Fill the length of the
and symptomatic treatment of painful cystitis and urethra w/ the remaining gel. Sounding procedure or cytoscopy:
urethritis Instill 40 mL (in 3-4 portions) into the insertion area then allow 5-
10 mins for anaesthesia to take effect. Adult Female: Prior to
urological procedure, instill 5-10 mL in small portions to fill the
whole urethra & allow anaesth to take effect in 3-5 mins.
Children <12 yr: - Up to 6 mg/kg.
Lignocaine 4 % Solution N01BB02110L5002XX B i) Anaesthesia of mucous membranes ii) Use for i) & ii) Dosing is according to product insert/protocol.
instrumentation of the respiratory and digestive tracts
Lignocaine HCl (Lidocaine) 100 mg/ml Injection C01BB01110P3002XX B Ventricular tachycardia and ventricullar fibrillation. To be None 50-100 mg IV as a bolus, repeated after 5 minutes if necessary.
diluted before use Maintenance : 1-4 mg/min by IV infusion under ECG monitoring
Lignocaine HCl (Lidocaine) 2% N01BB02-110-P30-01-XXX B For local or regional anaesthesia and nerve block. Not for None Local anesthesia: ADULT Maximum: 100 mg; CHILD Maximum: 3
Intramuscular/Subcutaneous Injection IV use. mg/kg
Lignocaine HCl (Lidocaine) 20 mg/ml Injection C01BB01110P3001XX B Ventricular tachycardia and ventricular fibrillation. For IV None 50-100 mg IV as a bolus, repeated after 5 minutes if necessary.
use. To be diluted before use Maintenance : 1-4 mg/min by IV infusion under ECG monitoring
Lignocaine HCl 1% Injection N01BB02110P3002XX C+ Local or regional anaesthesia for episiotomy repairs None According to patients weight and nature of procedures,
maximum 200mg. For most obstetric procedures, the preparation
is diluted to 0.5%, which gives the maximum effect with the least
toxicity. [lignocaine 1%, 1 part and normal saline or sterile
distilled water, 1 part]
Lignocaine HCl 5% and Phenylephrine HCl 0.5% N01BB02984A4101XX A* Preparation of nasal mucosa for surgery (eg. Cautery to Adults and children over 12 years : 5 squirts per nostril. Children:
Nasal Spray Little's area), aid the treatment of acute nose bleeds and 8 to 12 years 3 squirts per nostril, 4 to 8 years 2 squirts per
removal of foreign bodies from the nose, topical nostril, 2 to 4 years 1 squirt per nostril. Doses are to be
anaesthesia of the pharynx prior to direct or indirect administered once only.
laryngoscopy, topical anaesthesia and local
vasoconstriction prior to endoscopy of the upper airways
Lignocaine, Aluminium Acetate, Zinc Oxide and C05AX03-931-G50-01-XXX A/KK Anorectal pain, pruritis, inflammation and irritation None Apply once or twice daily. Not for prolonged use
Hydrocortisone Ointment
April 2023 104


Lignocaine, Aluminium Acetate, Zinc Oxide and C05AX03-931-S20-01-XXX B Treatment of pain, itching and discomfort arising from None 1 suppository once or twice daily and as required after each
Hydrocortisone Suppository irritated anorectal issues bowel action. Max: 5 suppositories/day.
Linezolid 20 mg/ml Suspension J01XX08000L8001XX A* MRSA patients with severe sepsis requiring intensive CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than
care and not clinically responding to vancomycin 7 days: 10 mg/kg twice daily
Linezolid 2mg/ml Injection J01XX08000P3001XX A* MRSA patient with severe sepsis requiring intensive care ADULT: 600 mg twice daily for 10 - 14 days. CHILD: 10 mg/kg 3
and not clinically responding to vancomycin times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg
twice daily
Linezolid 600 mg Tablet J01XX08000T1001XX A* MRSA patient with severe sepsis requiring intensive care ADULT: Above 12 years 600 mg every 12 hours for 10-14 days.
and not clinically responding to vancomycin. CHILD :10 mg/kg 3 times daily. PREMATURE NEONATES less than
7 days: 10 mg/kg twice daily
Liquid Paraffin A06AA01-000-L50-01-XX C Constipation None ADULT: 10-30 ml daily at night. CHILD: not recommended.
Lithium Carbonate 300 mg Tablet N05AN01121T1001XX A i) Prophylaxis and treatment of acute mania and Dose depends on the preparation used. Doses should be adjusted
hypomania episodes ii)Prophylaxis of manic depression to produce a serum-lithium concentration of 0.4-1 mmol/l.
in bipolar illness or bipolar depression and recurrent
depression
Loperamide 2mg Capsule A07DA03-110-C10-01-XX B Adjunct to rehydration in acute diarrhoea in adult also in None Acute diarrhoea: ADULT: 4 mg stat, followed by 2 mg after each
chronic diarrhoea in adult unformed stool (up to 5 days). Usual 6- 8 mg daily. Max: 16 mg
daily. Chronic diarrhoea: Initially 4-8 mg daily in divided doses,
adjust according to response. Max: 16 mg daily
Lopinavir 100 mg and Ritonavir 25 mg Tablet J05AE06-964-T10-02-XXX A Second line treatment for HAART regimen in Adult: - Therapy-naive patients: 400/100 mg bd or 800/200 mg
combination with other anti-retroviral agents once daily; - Therapy-experienced patients: 400/100 mg bd. -
Concomitant therapy (efavirenz, nevirapine, amprenavir,
fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or
w/ BSA >1.4 m2 as adult dose.
Lopinavir 200 mg and Ritonavir 50 mg Tablet J05AE06-964-T10-01-XXX A Second line treatment for HAART regimen in Adult: - Therapy-naive patients: 400/100 mg bd or 800/200 mg
combination with other anti-retroviral agents once daily; - Therapy-experienced patients: 400/100 mg bd. -
Concomitant therapy (efavirenz, nevirapine, amprenavir,
fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or
w/ BSA >1.4 m2 as adult dose.
Lopinavir 80mg/Ritonavir 20mg (per ml) Oral J05AE06964L9901XX A Management of patients with asymptomatic and Tab Adult Therapy-naive patients 400/100 mg bd or 800/200 mg
Solution symptomatic (early or advanced) HIV Infection with CD4 once daily. Therapy-experienced patients 400/100 mg bd.
cell counts <50 cubic mm Concomitant therapy (efavirenz, nevirapine, amprenavir,
fosamprenavir or nelfinavir) 400/100 mg bd. Can be used w/ no
dose adjustment. Childn >40 kg or w/ BSA >1.4 m2 Adult dose.
Oral Soln Childn 6 mth-12 yr, 15-40 kg 10/2.5 mg/kg bd; 7 to <15
kg 12/3 mg/kg bd. Max: 5 mL bd in childn >40 kg. W/ efavirenz or
nevirapine 15-45 kg 11/2.75 mg/kg bd; 7 to <15 kg 13/3.25 mg/kg.
Loratadine 10mg Tablet R06AX13-000-T10-01-XXX B Allergic rhinitis and allergic dermatoses None ADULT and CHILD over 6 years 10 mg once daily. CHILD 2 - 6
years: 5 mg once daily
Loratadine 1mg/ml Syrup R06AX13-000-L90-01-XXX A Allergic rhinitis, chronic urticaria and other allergic None ADULT and CHILD over 6 years : 10 mg once daily. CHILD 2 - 6
dermatological disorders years: 5 mg once daily
Loratadine 5mg and Pseudoephedrine Sulphate R01BA52-988-T10-01-XXX A/KK For treatment of allergic rhinitis and allergic dermatoses None ADULT and CHILD over 12 years 1 tablet twice daily
120mg Tablet
Lorazepam 1 mg Tablet N05BA06-000-T10-01-XXX A/KK i) Severe anxiety ii) Insomnia - i) 1 - 4 mg increase to 10 mg daily in divided doses. ELDERLY (or
delibitated) half adult dose ii) 1 - 2 mg at bedtime Not
recommended in children
April 2023 105


Losartan 100 mg Tablet C09CA01-500-T10-02-XXX B Patients intolerant to ACE inhibitors in: i) Hypertensive - i), ii) & iii) Initial: 50mg once daily Max: 100mg once daily Dosing
patient with left ventricular hypertrophy ii) Type 2 is individualised and according to product insert / protocol.
Diabetes Mellitus with chronic kidney disease iii)
Hypertension
Losartan 100mg & Hydrochlorothiazide 25mg C09DA01-935-T10-04-XXX A* i) Hypertension in patients intolerant to ACE inhibitors ii) None i) & ii) Initial: Losartan/Hydrochlorothiazide 50/12.5mg once daily
Tablet Hypertensive patient with left ventricular hypertrophy Max: Losartan/Hydrochlorothiazide 100/25mg once daily Dosing
is individualised and according to product insert / protocol.
Losartan 100mg and Hydrochlorothiazide C09DA01-935-T10-03-XXX A* i) Hypertension in patients intolerant to ACE inhibitors ii) None i) & ii) Initial: Losartan/Hydrochlorothiazide 50/12.5mg once daily
12.5mg Tablet Hypertensive patient with left ventricular hypertrophy Max: Losartan/Hydrochlorothiazide 100/25mg once daily Dosing
Losartan 50 mg Tablet C09CA01-500-T10-01-XXX B Patients intolerant to ACE inhibitors in: i) Hypertensive - i), ii) & iii) Initial: 50mg once daily Max: 100mg once daily Dosing
patient with left ventricular hypertrophy ii) Type 2 is individualised and according to product insert / protocol.
Diabetes Mellitus with chronic kidney disease iii)
Hypertension
Losartan 50mg and Hydrochlorothiazide C09DA01-935-T10-01-XXX A/KK i) Hypertension in patients intolerant to ACE inhibitors ii) None i) & ii) Initial: Losartan/Hydrochlorothiazide 50/12.5mg once daily
12.5mg Tablet Hypertensive patient with left ventricular hypertrophy Max: Losartan/Hydrochlorothiazide 100/25mg once daily Dosing
Magnesium Sulphate 45% Paste D11AX05-183-G60-01-XXX C Inflammatory skin conditions such as boils and - Apply under dressing
carbuncles
Magnesium Sulphate 50% Injection B05XA05-183-P30-01-XXX C i)Treatment and prophylaxis of acute hypomagnesaemia None i)Mild hypomagnesemia (ADULT): 1gm magnesium sulphate
ii) Prevention and treatment of life-threatening seizures (8mEq) IM every 6 hours for 4 doses. Severe hypomagnesemia
in the treatment of toxemias of pregnancy (pre- (ADULT): 0.25 g/kg IM over 4 hours. Alternative dose of 5g may
eclampsia and eclampsia) be given by slow intravenous infusion over 3 hours ii) Toxemia of
pregnancy: An initial intravenous dose of 4gm of magnesium
sulphate is recommended. Followed by an intramuscular dose of
4-5gm into each buttock. This may be followed by a dose of 4-
5gm into alternate buttocks every 4 hours as needed.
Alternatively, the initial dose IV dose may be followed by an
infusion of 1-2gm/hr
Magnesium Trisilicate Mixture A02AA10-912-L21-01-XXX C Heartburn, dyspepsia None ADULT children over 12 years: 10-20ml 3 times daily or as
required; CHILD: 5-11 years: 5-10 ml three times a day or as
required
Magnesium Trisilicate Tablet A02AA10-912-T10-01-XXX C Heartburn, dyspepsia - ADULT 1-2 tablet to be chewed up to 6 times a day before meals.
CHILD over 6 years one tablet to be taken 3-4 times a day
Magnesium, Aluminium Hydroxide and V07AB00-900-L80-01-XXX C For the relief from gastric acidity, indigestion, heartburn, - 5 to 10ml as required or one hour after food and at bedtime
Simethicone Suspension flatulence and dyspepsia.
Malathion 1 % Shampoo P03AX03-000-L52-01-XXX C+ Lice infestation - Wet hair, apply shampoo and work up lather. Leave for 15
minutes and rinse, comb. Repeat if necessary after 7 - 9 days
Mannitol 10% Injection (10 g/100 ml) B05BC01-000-P30-01-XXX A Cerebral oedema 0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes.
Safety and efficacy not established in children under 12 years of
age
Mannitol 20% Injection (20 g/100 ml) B05BC01-000-P30-02-XXX A Cerebral oedema - 0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes.
Safety and efficacy not established in children under 12 years of
age
April 2023 106


Measles and Rubella Virus Live, Attenuated J07BD52-963-P40-02-XXX C+ Immunisation against measles and rubella. - 0.5ml by deep SC injection. Dosing is according to Immunisation
Vaccine Injection Schedule under NIP and product insert.
Measles Vaccine Injection J07BD01-000-P40-01-XX C+ Immunisation against measles. - 0.5ml by SC or IM. Dosing is according to Immunisation Schedule
under NIP.
Measles, Mumps and Rubella (MMR) Vaccine J07BD52-963-P40-01-XXX C+ For immunisation of children against measles, mumps - 0.5ml by SC or IM. Dosing is according to Immunisation Schedule
Injection and rubella under NIP.
Mebeverine HCl 135 mg Tablet A03AA04-110-T10-02-XXX B i) Irritable bowel syndrome ii) Treatment of gastro- - 135 mg 3 times daily
intestinal spasm secondary to organic diseases.
Meclozine HCl 25mg and Pyridoxine 50mg R06AE55-919-T10-01-XXX B Nausea and vomiting of pregnancy None Optimum dosing: 1 to 2 tablets OD. Maximum dosing: 4
Tablet tablets/day.
Mecobalamin 500 mcg Tablet M09AX00-000-T10-01-XXX B Peripheral neuropathies - 1 tablet 3 times daily. The dosage should be adjusted according
to age of patient and severity of symptoms
Medroxyprogesterone Acetate 100 mg Tablet L02AB02-122-T10-02-XXX A Breast carcinoma, endometrial carcinoma, renal - 200-500 mg orally daily
carcinoma
Medroxyprogesterone Acetate 10mg Tablet G03DA02-122-T10-02-XXX B i) Secondary amenorrhoea ii) Abnormal uterine bleeding None i) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10
due to hormonal imbalance mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum
secretory transformation 10 mg daily for 10 days from day 16 of
the cycle
Medroxyprogesterone Acetate 500 mg Tablet L02AB02-122-T10-01-XXX A Breast carcinoma, endometrial carcinoma, renal - 200-500 mg orally daily
carcinoma
Medroxyprogesterone Acetate 50mg/ml G03AC06-122-P30-01-XXX B Prevention of pregnancy and to provide long term None 150mg to be administered once every 3 month
Injection contraception
Medroxyprogesterone Acetate 5mg Tablet G03DA02-122-T10-01-XXX B i) Secondary amenorrhoea ii) Abnormal uterine bleeding None i) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10
due to hormonal imbalance mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum
secretory transformation 10 mg daily for 10 days from day 16 of
the cycle
Mefenamic Acid 250mg Capsule M01AG01-000-C10-01-XX C Mild to moderate pain None ADULT: 250 - 500 mg 3 times daily after meals.
Mefenamic Acid 250mg Tablet M01AG01-000-T10-01-XXX C Mild to moderate pain None ADULT: 250 - 500 mg 3 times daily after meals.
Mefloquine HCl 250 mg Tablet P01BC02110T1001XX A* For multi-drug resistant cases of malaria only Treatment of malaria : ADULT and CHILD 25 mg/kg usually given
over 2-3 days. Prophylaxis of malaria : ADULT 250 mg once a
week. CHILD over 5 kg : 5 mg/kg once a week; prophylaxis should
start 1-3 weeks before departure and continue for 4 weeks after
last exposure
Meloxicam 7.5 mg Tablet M01AC06-000-T10-01-XXX A/KK Only for patients not responding to other NSAIDs in the - i) initially 7.5 mg daily. May be increased to 15 mg daily ii) initially
treatment of: i) painful osteoarthritis ii) rheumatoid 15 mg daily. May be reduced to 7.5 mg daily. Maximum 15 mg
arthritis daily. Child under 12 years not recommended
Melphalan 2 mg Tablet L01AA03-000-T10-01-XXX A i) Multiple myeloma ii) Neuroblastoma, i) 8 - 10 mg/m2 for 4 days every 4 weeks ii) 10 - 35 mg/m2 once
rhabdomyosarcoma iii) Recurrent neuroblastoma every month For dose regimes, refer to protocols
(palliative)
Melphalan 50 mg Injection L01AA03-000-P40-01-XXX B High dose conditioning therapy for stem cell - 200 mg/ m2 IV infusions in divided doses for Day 1 to day 3
transplantation in multiple myeloma followed by IV infusions of autologous stem cells
Memantine HCI 10 mg Tablet N06DX01-110-T10-01-XXX A* Treatment of moderate to severe Alzheimer's disease. - Initial Week 1: 5mg daily Week 2: 10mg daily Week 3: 15mg daily
Week 4 and subsequent: 20mg daily Maintenance 20mg daily
Max. dose: 20mg daily
Memantine HCl 20 mg Tablet N06DX01-110-T10-02-XXX A* Treatment of moderate to severe Alzheimer's disease - nitial Week 1: 5mg daily Week 2: 10mg daily Week 3: 15mg daily
Week 4 and subsequent: 20mg daily Maintenance 20mg daily
Max. dose: 20mg daily
April 2023 107


Meningococcal Group A, C, Y, W 135 Vaccine J07AH04-000-P40-01-XXX B Immunisation against meningococcal diseases caused by - 0.5ml by IM.
Injection Neisseria meningitis Group A, Group C, Group Y or Group
W-135.
Menotrophin (highly purified, multidose) 600IU G03GA02-000-P40-01-XXX A* For the treatment of infertility in the following clinical None i. Recommended starting dose: 75-150 IU daily, maintaining the
injection situations: i. Anovulation, including polycystic ovarian starting dose for at least 7 days. Adjust the dose according to
syndrome (PCOS), in women who have been individual response at a minimum interval of 7 days. The
unresponsive to treatment with clomiphene citrate. ii. recommended dose increment is 37.5 -75 IU per adjustment.
Controlled ovarian hyperstimulation to induce the Maximum daily dose: 225 IU. ii. Recommended starting dose: 150-
development of multiple follicles for assisted 225 IU daily, maintaining the starting dose for at least the first 5
reproductive technologies (ART). days of treatment. Adjust the dose according to individual
response. The dose increment should not exceed more than 150
IU per adjustment. Maximum daily dose: 400 IU. Dosing is
Menotrophin, highly purified 150 IU injection G03GA02-954-P40-02-XXX A* i) Anovulation in women who have been unresponsive - i) Anovulation in women who have been unresponsive to
to treatment with clomiphene citrate ii) Stimulation of treatment with clomiphene citrate: The recommended initial
follicle growth as part of an assisted reproductive dose is 75-150 IU daily, which should be maintained for at least 7
technology (ART) days. The subsequent dosing should be adjusted according to
individual patient response. Adjustments in dose should not be
made more frequently than every 7 days. The recommended
dose increment is 37.5 IU per adjustment and should not exceed
75 IU. The maximum daily dose should not be higher than 225 IU.
If a patient fails to respond adequately after 4 weeks of
treatment, that cycle should be abandoned and the patient
should recommence treatment at a higher starting dose than in
the abandoned cycle. When an optimal response is obtained, a
single injection of 5,000 IU to 10,000 IU of Human Chorionic
Gonadotrophin (hCG) should be given 1 day after the last
menotrophin injection, The patient is recommended to have
coitus on the day of and the day following hCG administration. ii)
Stimulation of follicle growth as part of an assisted reproductive
technology (ART): The recommended initial dose is 150-225IU
daily injection for at least the first 5 days of treatment. Based on
clinical monitoring subsequent dosing should be adjusted
according to individual patient response and should not exceed
more than 150IU per adjustment. The maximum daily dose
should not be higher than 450 IU. In most cases, dosing beyond
20 days is not recommended.
April 2023 108


Menotrophin, Highly Purified 75 IU Injection G03GA02-954-P40-03-XXX A* For the treatment of infertility in the following clinical - i. Recommended starting dose: 75-150 IU daily, maintaining the
(Follicle Stimulating Hormone 75 IU and situations: i. Anovulation, including polycystic ovarian starting dose for at least 7 days. Adjust the dose according to
Luteinizing Hormone 75 IU) syndrome (PCOS), in women who have been individual response at a minimum interval of 7 days. The
unresponsive to treatment with clomiphene citrate. ii. recommended dose increment is 37.5 -75 IU per adjustment.
Controlled ovarian hyperstimulation to induce the Maximum daily dose: 225 IU. ii. Recommended starting dose: 150-
development of multiple follicles for assisted 225 IU daily, maintaining the starting dose for at least the first 5
reproductive technologies (ART). days of treatment. Adjust the dose according to individual
response. The dose increment should not exceed more than 150
IU per adjustment. Maximum daily dose: 400 IU. Dosing is
Menthol 1.6% in Industrial Methylated Spirit R01AX30-000-A99-01-XXX C Decongestion of the upper respiratory tract None As directed for local use
Inhalation
Mepivacaine HCl 2% with Adrenaline N01BB53-974-P30-01-XXX B For the production of local anaesthesia for dental - ADULT: 2.2ml for routine procedure. Max: 3 cartridges. CHILD: 6-
(1:100,000) Injection procedures including infiltration and nerve blocks 14 years: 1.6ml. Max: 3.3mL. 3-6 years 1.1 to 2.2ml. Dosing is
according to product insert.
Mepivacaine HCl 3% Injection N01BB03-110-P30-01-XXX B For the production of local anaesthesia for dental - ADULT: 1 cartridge for routine procedure. Max: 3 cartridges.
procedures by infiltration injection or nerve block. CHILD: 6-14 years: 1.35ml. Max: 2.7ml. 3-6 years: maximum
1.8ml. Dosing is according to product insert
Mercaptopurine 50 mg Tablet L01BB02-000-T10-01-XXX A i) Langerhan's cell histocytosis ii) Acute lymphoblastic - "Leukaemia adults: 2.5mg/kg or 80-00mg/m2 p.o per day, given
leukaemia iii) Acute promyelocytic leukaemia APML as a single dose. To be increased at the end of 4 weeks, If
(maintenance) necessary, up to 5mg/kg p.o per day. Maintainance dosage are
1.5mg/kg -2.5mg/kg p.o per day Children age 5 and older:
Induction: 2.5mg/kg/day p.o once daily. Maintanance dose:
1.5mg/kg -2.5mg.kg p.o once daily or 70-100mg/m2 p.o once
daily."
Meropenem 1 g Injection J01DH02-000-P40-02-XXX A* i) Nosocomial pneumonia ii) Bacterial Meningitis iii) - ADULT: 1-2g every 8hourly (refer to specific indication dosing)
Empirical treatment for presume infections in patients CHILD (aged 3 months and over): 10-40mg/kg 8 hourly, if body
(adult and children) with febrile neutropenia, used as weight over 50kg, adult dosage should be used. Dosing is
monotherapy or in combination with anti-virals or according to product insert/ protocol.
antifungal agent iv) Septicaemia v) Urinary tract
infections vi) Intra-abdominal infections vii)
Gynaecological infections
Meropenem 500 mg Injection J01DH02-000-P40-01-XXX A* i) Nosocomial pneumonia ii) Bacterial Meningitis iii) - ADULT: 1-2g every 8hourly (refer to specific indication dosing)
Empirical treatment for presume infections in patients CHILD (aged 3 months and over): 10-40mg/kg 8 hourly, if body
(adult and children) with febrile neutropenia, used as weight over 50kg, adult dosage should be used. Dosing is
monotherapy or in combination with anti-virals or according to product insert/ protocol.
antifungal agent iv) Septicaemia v) Urinary tract
infections vi) Intra-abdominal infections vii)
Gynaecological infections
Mesalazine 1 g Suppository A07EC02-259-S20-02-XXX A Inflammatory bowel disease of ulcerative colitis and - Ulcerative colitis: 1 g suppository insert rectally once daily at
Crohn's disease. bedtime. To achieve maximum benefit, it is recommended that
the suppository be retained in the rectum for a minimum of 1 to
3 hours or longer. The usual course of therapy, depending upon
response, may last from 3 to 6 weeks. CHILD not recommended
Mesalazine 1200mg Gastro-Resistant A07EC02-000-T55-01-XXX A* In patients with mild to moderate active ulcerative - Adults: i. Induction of remission: 2.4 to 4.8g once daily. ii. For
Prolonged Release Tablets colitis: i. For the induction of clinical and endoscopic maintenance of remission: 2.4g once daily.
remission ii. For the maintenance of remission
April 2023 109


Mesalazine 1g/100ml enema A07EC02-259-G20-02-XXX A Inflammatory bowel disease of ulcerative colitis and 1 tube of enema at bedtime
Crohn's disease.
Mesalazine 250mg MR Tablet A07EC02-259-T10-01-XXX A Inflammatory bowel disease of ulcerative colitis and - ADULT: 250 - 500 mg 3 - 4 times daily for 3 - 6 weeks. CHILD up 2
Crohn's disease. years with Crohn's disease: 20 - 30 mg/daily in divided doses
Mesalazine 500mg MR Tablet A07EC02-259-T10-02-XXX A Inflammatory bowel disease of ulcerative colitis and - ADULT: 250 - 500 mg 3 - 4 times daily for 3 - 6 weeks. CHILD up 2
Crohn's disease. years with Crohn's disease: 20 - 30 mg/daily in divided doses
Mesalazine 6.67% w/w Enema A07EC02259G2001XX A Inflammatory bowel disease of ulcerative colitis and 60 ml (4g) at bedtime, retained overnight, approximately 8 hours
Crohn's disease.
Mesna 100 mg/ml Injection V03AF01520P3001XX A For prevention of urotoxic effects of oxazaphosphorines IV injection at a dosage of 20% of the corresponding
e.g. ifosfamide and cyclophosphamide oxazaphosphorine dose at the times 0 hour (concurrently with
the oxazaphosphorine), 4 hours and 8 hours thereafter. CHILD:
Dose given at greater frequency (e.g. 6 times) and a shorter
intervals (e.g. 3 hours)
Metformin HCl 500 mg Extended Release Tablet A10BA02-110-T50-01-XXX B Diabetes mellitus who experienced gastrointestinal side 500 mg once daily. Maximum dose 2000 mg once daily with
effects with normal metformin evening meal
Metformin HCl 500 mg Tablet A10BA02110T1001XX B Diabetes mellitus Initial: 500mg orally twice daily with food. Maintenance: Titrate
in 500mg increments weekly, doses up to 2000 mg daily may be
divided into 2 equal doses.
Metformin HCl 750 mg Extended Release Tablet A10BA02110T5003XX A/KK Diabetes mellitus who experienced gastrointestinal side 500 mg once daily. Maximum dose 2000 mg once daily with
effects with normal metformin evening meal
Methadone 5mg/ml Syrup N07BC02-110-L90-01-XXX A/KK Detoxification treatment or maintenance treatment of None Initial 10-20mg per day, increasing by 10-20mg per day until
narcotic addiction. there are no signs of withdrawal or intoxication. Usual dose 40-
60mg/day
Methotrexate 100mg/mL Injection L01BA01520P3005XX A i) Solid tumours ii) Gestational trophoblastic disease iii) i) 50 mg/m2 once every 3 weeks in combination with other drugs
Acute leukaemias, lymphomas (for this dose, use the 50 mg preparation) ii) 50 mg IV Day 1, 3, 5,
9 every 3 weeks. For high risk gestational trophoblastic disease,
use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes:
500 - 3000 mg/m2 per dose may be used, employing the 500 mg
preparations. CHILD: Central nervous system prophylaxis for
acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue,
3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks.
Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36
hours with folinic acid rescue every 3 weeks for 9 doses,
maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3
gm/m2 over 3 hours with folinic acid rescue for three doses.
Methotrexate level monitoring recommended when using high
dose regimens. THE 500 MG STRENGTH IS NOT FOR
INTRATHECAL USE
April 2023 110


Methotrexate 2.5 mg Tablet L01BA01000T1001XX A i) Solid tumours particularly breast, lung, head and neck, i) ADULT: 20 mg/m2 weekly. CHILD: 20 - 30 mg/m2 weekly
bladder, cervical, ovarian, and testicular carcinoma. ii) according to protocol ii) Relapsed acute lymphoblastic leukaemia
Acute lymphoblastic leukaemia and acute promyelocytic (ALL): 100 mg/m2/day for 5 days 6 weekly according to protocol
leukemia (maintenance) iii) Extensive plaque psoriasis, iii) Dose used by dermatologist: 5 - 25 mg weekly. Liver biopsy
erythrodermic psoriasis, pustular psoriasis, Reiter's after cumulative dose of 1.5 gram and repeat liver biopsy with
syndrome, connective tissue disease additional gram received. Maximum cumulative dose is 4 gram.
Monitor full blood count (FBC), renal and liver function iv)
Rheumatoid arthritis, psoriatic arthropathy: dose used by
rheumatologist: 2.5 mg/week orally starting dose, increasing to
7.5 - 20 mg/weekly
Methotrexate 25mg/mL Injection L01BA01520P3001XX A i) Solid tumours ii) Gestational trophoblastic disease iii) i) 50 mg/m2 once every 2 - 3 weeks in combination with other
Acute leukaemia/lymphomas iv) Rheumatoid arthritis, drugs ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk
psoriatic arthropathy, severe/erythrodermic psoriasis gestational trophoblastic disease, use 100 mg/m2 as part of EMA-
CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose
may be used, employing the 500 mg preparations. CHILD: Central
nervous system prophylaxis for acute leukaemia 2 gm/m2 over 24
hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses
for T-lineage all every 3 weeks. Relapse acute lymphoblastic
leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue
every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2
weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid
rescue for three doses. Methotrexate level monitoring
recommended when using high dose regimens. The 500 mg
strength is not for intrathecal (IT) use. Dosage for intrathecal
treatment and prophylaxis in leukaemia: less than 1 year: 5 mg, 1
- 2 years: 7.5 mg, 2 - 3 years: 10 mg, more than 3 years: 12.5 mg.
IT preparation must be clearly stated/verified. ENSURE THAT
PREPARATION IS SUITABLE FOR INTRATHECAL USE iv) Dose used
by rheumatologist: 10 - 15 mg IM injection or oral weekly. Dose
used by dermatologist: 10 - 25 mg IM injection weekly
Methoxsalen 1% Lotion D05AD02000L6001XX A Repigmenting agent in vitiligo in conjuction with Apply 0.1% lotion to area to be exposed to the UVA light ( need
controlled doses of UVA or sunlight to dilute the 1% lotion to 0.1% lotion, otherwise the skin will
burn)
Methoxsalen 10 mg Capsule D05BA02000C1001XX A Protection before exposure to sunlight, psoriasis and 0.2 - 0.6 mg/kg/body weight. For repigmentation of larger lesions
vitiligo (greater than 6 cm sq): 20 mg/day 2 hours before exposure. Take
with food or milk
Methoxy Polyethylene Glycol-epoetin Beta 100 B03XA03000P5001XX A* Treatment of anaemia associated with chronic renal Non Erythropoiesis Stimulating Agent (ESA)-treated patients : 0.6
mcg/0.3 ml Injection in Prefilled Syringe failure. Prescribing restriction: Patients who require mcg/kg, once every two weeks (IV or SC). When the Hb is
higher doses of erythropoietin if it is more cost saving to >11g/dl, administration can be reduced to once monthly using
use a long-acting agent instead of short-acting agents. the dose equal to twice the previous two weekly dose. ESA-
treated patients : 120-360 mcg once monthly or 60-180 mcg
every two weeks.
April 2023 111


every two weeks.
every two weeks
every two weeks.
every two weeks
every two weeks
Methyl Salicylate 25% Cream M02AC00-969-G10-09-XXX C+ Relief of minor aches and pains of muscles and joints None Apply to the affected area, 3-4 times daily.
associated with simple backache, arthritis and rheumatic
conditions.
Methyl Salicylate 25% Ointment M02AC00-259-G54-01-XXX C+ Relief of minor aches and pains of muscles and joints None Apply to the affected area, 3-4 times daily.
associated with simple backache, arthritis and rheumatic
conditions.
Methyldopa 250 mg Tablet C02AB01110T1001XX B Hypertension Adult: 250 mg 2 - 3 times daily, gradually increased at intervals of
2 or more days, maximum; 3 g/day. Elderly: initially 125 mg twice
daily, increased gradually, maximum; 2 g daily. Child: Initially, 10
mg/kg or 300 mg/m2 daily in 2-4 divided doses; increase as
necessary. Max: 65 mg/kg, 2 g/m2 or 3 g daily, whichever is least.
Methylene Blue 1%Injection V03AB17-100-P30-01-XX B For treatment of idiopathic and drug-induced None Adult and children: 1 to 2 mg/kg (0.1 to 0.2 mL/kg of a 1%
methaemoglobinemia solution) IV very slowly over 5 minutes. This dosage can be
repeated if necessary after one hour.
April 2023 112


Methylphenidate HCl 10 mg Tablet N06BA04110T1001XX A Attention deficit hyperactivity disorder (ADHD) CHILD over 6 years, initially 5 mg 1 - 2 times daily, increased if
necessary at weekly intervals by 5 - 10 mg daily to maximum of
60 mg daily in divided doses; discontinue if no response after 1
month, also suspend periodically to assess child's condition
(usually finally discontinued during or after puberty)
Methylphenidate HCl 18 mg Extended-release N06BA04110T5002XX A* Attention deficit hyperactivity disorder (ADHD) CHILD over 6 years: Individualize dosage, to be taken once daily in
Tablet the morning. Dose may be adjusted in increments to a maximum
of 54 mg/day, at weekly interval. Patient new to
methylphenidate: starting dose 18 mg once daily; adults 18mg or
36mg once daily. Patient currently using methylphenidate: 18 -
36 mg. Maximum 54 mg/day. Discontinue if no response after 1
month
Methylphenidate HCl 20 mg LA Capsule N06BA04110C2003XX A* Attention deficit hyperactivity disorder (ADHD) 20 mg once daily to be taken in the morning. Dosage be adjusted
in increments to a maximum of 60 mg/day
Methylphenidate HCl 36 mg Extended-release N06BA04110T5003XX A* Attention deficit hyperactivity disorder (ADHD) CHILD over 6 years: Individualize dosage, to be taken once daily in
Tablet the morning. Dose may be adjusted in increments to a maximum
of 54 mg/day, at weekly interval. Patient new to
methylphenidate: starting dose 18 mg once daily; adults 18mg or
36mg once daily. Patient currently using methylphenidate: 18 -
36 mg. Maximum 54 mg/day. Discontinue if no response after 1
month
Methylphenidate HCl 40mg LA Capsule N06BA04110C2002XX A* Attention deficit hyperactivity disorder (ADHD) 20 mg once daily to be taken in the morning. Dosage be adjusted
in increments to a maximum of 60 mg/day
Methylprednisolone Acetate 40mg injection H02AB04-134-P30-01-XX A* i) Intramuscular administration: anti-inflammatory None i. Intramuscular route a) Asthma: may be used in place of a short
treatment, treatment of hematological and oncological burst of oral steroids in vomiting or non-adherent patients. The
disorders, endocrine disorders ii) Intrasynovial, recommended dose is 80- 120mg intramuscularly as a one-dose
periarticular, intrabursal or soft tissue administration: b) Adrenogenital syndrome: 40mg every two weeks c)
Indicated as adjunctive therapy for short term Rheumatoid arthritis (maintenance): 40-120mg weekly d)
administration in : Synovitis of osteoarthritis, Dermatologic lesions (acute severe dermatitis, chronic contact
rheumatoid arthritis, acute and subacute bursitis, acute dermatitis, seborrheic dermatitis): 40-120mg weekly for 1-4
gouty arthritis, epicondylitis, acute nonspecific weeks ii. Intraarticular route Recommended dose is 4 to 80
tenosynovitis, post-traumatic osteoarthritis iii) milligrams, depending upon the size of the joint. Injections may
Intralesional use in alopecia areata, discoid lupus be repeated at intervals of 1 to 5 or more weeks in chronic cases
erythematosus; keloids, localized hypertrophic, iii.Intralesional route 20 to 60 milligrams methylprednisolone
infiltrated inflammatory lesions of granuloma annulare, acetate injected into the lesion
lichen planus, psoriatic plaques, lichen simplex chronicus
(neurodermatitis) *Restricted to patients experiencing
side effects with triamcinolone acetonide
Methylprednisolone Sodium Succinate 0.5g H02AB04-520-P40-01-XX A Suppression of inflammatory and allergic disorders, None 15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for
Injection cerebral oedema, immunosuppression treatment of up to 48 hours
haematological and oncological disorders, treatment of
shock states and endocrine disorders
Methylprednisolone Sodium Succinate 1g H02AB04-520-P40-02-XX A Suppression of inflammatory and allergic disorders, None 15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for
Injection cerebral oedema, immunosuppression treatment of up to 48 hours
haematological and oncological disorders, treatment of
shock states and endocrine disorders
April 2023 113


Metoclopramide HCl 10 mg Tablet A03FA01110T1001XX B Use in adults for: i) Prevention of delayed chemotherapy Adult: The recommended single dose is 10mg, repeated up to
induced nausea and vomiting (CINV) ii) Prevention of three times daily. The maximum recommended daily dose is
radiotherapy induced nausea and vomiting (RINV) iii) 30mg or 0.5mg/kg body weight. The maximum recommended
Symptomatic treatment of nausea and vomiting, treatment duration is 5 days. Prevention of delayed CINV
including acute migraine induced nausea and vomiting (children aged 1-18 years): The recommended dose is 0.1-
Use in children aged 1-18 years for: i) Prevention of 0.5mg/kg body weight, repeated up to three times daily by oral
delayed chemotherapy induced nausea and vomiting route. The maximum dose in 24 hours is 0.5mg/kg body weight.
(CINV) as a second line option Dosing table CHILD age 1-3 years old (body weight 10-14kg): 1mg
TDS, 3-5 years old (body weight 15-19kg): 2mg TDS, 5-9 years old
(body weight 20-29kg): 2.5mg TDS, 9-18 years old (body weight
30-60kg): 5mg TDS, 15-18 years old (body weight > 60kg): 10mg
TDS. Tablets are not suitable for use in children weighing less
than 30kg. Other pharmaceutical forms may be more appropriate
for administration to this population.
Metoclopramide HCl 1mg/ml Syrup A03FA01-110-L90-01-XX B Use in adults for: i) Prevention of delayed chemotherapy None Adult: the recommended single dose is 10mg, repeated up to
induced nausea and vomiting (CINV) ii) Prevention of three times daily. The maximum recommended daily dose is
radiotherapy induced nausea and vomiting (RINV) iii) 30mg or 0.5mg/kg body weight. The maximum recommended
Symptomatic treatment of nausea and vomiting, treatment duration is 5 days. Prevention of delayed CINV
including acute migraine induced nausea and vomiting (children aged 1-18 years): The recommended dose is 0.1-
Use in children aged 1-18 years for: i) Prevention of 0.5mg/kg body weight, repeated up to three times daily by oral
delayed chemotherapy induced nausea and vomiting route. The maximum dose in 24 hours is 0.5mg/kg body weight.
(CINV) as a second line option Dosing table CHILD age 1-3 years old (body weight 10-14kg): 1mg
TDS, 3-5 years old (body weight 15-19kg): 2mg TDS, 5-9 years old
(body weight 20-29kg): 2.5mg TDS, 9-18 years old (body weight
30-60kg): 5mg TDS, 15-18 years old (body weight > 60kg): 10mg
TDS. Tablets are not suitable for use in children weighing less
than 30kg. Other pharmaceutical forms may be more appropriate
for administration to this population.
April 2023 114


Metoclopramide HCl 5mg/ml Injection A03FA01-110-P30-01-XX B Use in adults for: i) Prevention of post-operative nausea None All indications (adult): A single 10mg dose is recommended for
and vomiting ii) Symptomatic treatment of nausea and the prevention of post-operative nausea and vomiting. The
vomiting, including nausea and vomiting induced by recommended dose for the symptomatic treatment of nausea
migraine attacks iii) Prevention of radiotherapy-induced and vomiting, including nausea and vomiting induced by migraine
nausea and vomiting Use in children aged 1 to 18 years attacks and for the prevention of radiotherapy-induced nausea
for: i) Prevention of delayed chemotherapy-induced and vomiting is 10mg per dose, 1 to 3 times daily. The maximum
nausea and vomiting as a second-line option ii) recommended daily dose is 30mg or 0.5mg/kg. Treatment
Prevention of post-operative nausea and vomiting as a duration when administering by injection should be as short as
second-line option possible and a switch to administration via oral or rectal route
should be instituted as quickly as possible. All indications
(children aged 1 to 18 years of age) The recommended dosage is
0.1 to 0.15mg/kg, 1 to 3 times daily, by intravenous route. The
maximum daily dose is 0.5mg/kg. Dosing table: CHILD age 1-3
years old (body weight 10-14kg): 1mg TDS, 3-5 years old (body
weight 15-19kg): 2mg TDS, 5-9 years old (body weight 20-29kg):
2.5mg TDS, 9-18 years old (body weight 30-60kg): 5mg TDS, 15-
18 years old (body weight > 60kg): 10mg TDS. For the prevention
of delayed CINV, the maximum treatment duration is 5 days. For
the prevention of post-operative nausea and vomiting, the
maximum treatment duration is 48 hours.
Metolazone 2.5 mg Tablet C03BA08000T1002XX A* Oedema in congestive cardiac failure, nephrotic Adult: 5-10 mg daily, increased if necessary to 20 mg daily. Max:
syndrome and impaired renal function 80 mg in 24 hr. Elderly: Initially, 2.5 mg/day or every other day.
Should be taken with food. Take after breakfast.
Metoprolol Tartrate 100 mg Tablet C07AB02123T1002XX B i) Hypertension ii) Angina pectoris iii) Myocardial infarct i) Initial: 100mg daily in 1 or 2 divided doses Maintenance: 200mg
iv) Cardiac arrhythmias v) Migraine prophylaxis vi) daily in divided doses Max. 400mg daily ii) 50-100mg 2-3 times
Hyperthyroidism daily Max. 400mg daily iii) Initial: 50mg twice daily Maintenance:
100mg twice daily iv) Initial: 50mg 2-3 times daily Maintenance:
300mg daily in divided doses v) 100-200mg daily in 2 divided
doses vi) 150-200mg daily in 3-4 divided doses Dosing is
invidualised and according to product insert/protocol.
Metoprolol Tartrate 50 mg Tablet C07AB02123T1001XX B i) Hypertension ii) Angina pectoris iii) Myocardial infarct i) Initial: 100mg daily in 1 or 2 divided doses Maintenance: 200mg
iv) Cardiac arrhythmias v) Migraine prophylaxis vi) daily in divided doses Max. 400mg daily ii) 50-100mg 2-3 times
Hyperthyroidism daily Max. 400mg daily iii) Initial: 50mg twice daily Maintenance:
100mg twice daily iv) Initial: 50mg 2-3 times daily Maintenance:
300mg daily in divided doses v) 100-200mg daily in 2 divided
doses vi) 150-200mg daily in 3-4 divided doses Dosing is
invidualised and according to product insert/protocol.
April 2023 115


Metronidazole 200 mg Tablet P01AB01000T1001XX B Anaerobic infection Anaerobic bacterial infections Adult: Initially, 800 mg followed by
400 mg 8 hly for about 7 days. Other recommended doses: 500
mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr). Child: 7.5 mg/kg
8 hrly. Elderly: Use lower end of adult dose recommendations. Do
not admin as a single dose. Prophylaxis of postoperative
anaerobic bacterial infections Adult: 400 mg by mouth 8 hrly in
the 24 hr prior to surgery followed postoperatively by IV or rectal
admin until oral therapy is possible. Other sources recommend
that oral doses be initiated only 2 hr prior to surgery and that
number of doses for all admin routes be limited to a total of 4.
Elderly: Dose reduction may be necessary. Tab: Should be taken
with food.
Metronidazole 200 mg/5 ml Suspension P01AB01000L8001XX B Anaerobic infection CHILD: 7.5 mg/kg 3 times daily for 7 days
Metronidazole 500 mg/100 ml Injection J01XD01000P9901XX A Anaerobic infections ADULT: 500 mg IV infusion 8 hourly. CHILD: 7.5 mg/kg body
weight every 8 hours. Neonates: 15mg/kg LD, followed by
7.5mg/kg every 12 hourly. 1 month to 18 years: 7.5mg/kg
(maximum 500mg) every 8 hours.
Micafungin Sodium 50mg Injection J02AX05520P4101XX A* i) Treatment of invasive candidiasis, including i) Dosage for adults, adolescents ≥ 16 years of age and the elderly
candidemia in adults when intolerance or resistance to for the treatment of invasive candidiasis: - Body weight > 40kg:
Amphotericin B or Fluconazole. ii) Treatment of invasive 100mg/day* - Body weight ≤ 40kg: 2mg/kg/day* *If patient's
candidiasis in children. response is inadequate, e.g. persistence of cultures or if clinical
condition does not improve, the dose may be increased to 200
mg/day in patients weighing > 40kg or 4mg/kg/day in patients
weighing ≤ 40kg. Treatment duration for invasive candidiasis:
should be a minimum of 14 days. The antifungal treatment
should continue for at least one week after two sequential
negative blood cultures have been obtained and after resolution
of clinical signs and symptoms of infection. ii) Dosage for
children: - Body weight ≤ 40kg: 2mg/kg/day; - Body weight >
40kg: 100mg/day
Miconazole 2% Cream D01AC02221G1001XX C i) Fungal infections: Tinea pedis, Tinea corporis, Tinea To be used as 2nd line treatment at health facilities Apply sparingly and rub gently onto affected area 1-2 times daily
capitis and other dermatophyte infections caused by without medical officer. continuing for 14 days after lesions have healed
Trichophyton and Epidermophyton species; ii) Antifungal
agent that has been in various candida infections
including vaginal candidiasis.
Miconazole Nitrate 2% Powder D01AC02221F2001XX A Skin infections caused by dermatophytes or Candida Dust powder over infected area 1 - 2 times daily
Midazolam 5mg/5ml Injection N05CD08-110-P30-01-XX A Pre-operative sedation, induction of general None Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV
anaesthesia, premedication and sedation in ICU and injection over 30 seconds). Premedication by IM injection 70 -
sedation for minor procedures 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5
mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg
(ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200
mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2
mg/kg/hour
April 2023 116


Midazolam 5mg/ml Injection N05CD08110P3002XX A Pre-operative sedation, induction of general None Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV
anaesthesia, premedication and sedation in ICU and injection over 30 seconds). Premedication by IM injection 70 -
sedation for minor procedures 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5
mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg
(ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200
mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2
mg/kg/hour
Midazolam 7.5mg Tablet N05CD08253T1001XX A/KK Pre and post-operative sedation None ADULT: Usually 7.5 - 15 mg at bedtime; or for premedication, 30 -
60 minutes before the procedure. For ELDERLY, debilitated or
impaired liver/kidney function: 7.5 mg
Minocycline 100 mg Capsule J01AA08110C1002XX A* As second-line treatment for leprosy only 100 mg daily 6 - 18 months
Minocycline 50 mg Capsule J01AA08110C1001XX A* As second-line treatment for leprosy only 100 mg daily 6 - 18 months
Minoxidil 5 mg Tablet C02DC01000T1001XX A* Severe hypertension ADULTS and CHILD above 12 years old: Initially 5 mg daily in
single or divided doses (elderly 2.5 mg). May increase by 5 - 10
mg daily at intervals of 3 or more days until optimum control is
achieved. Maximum 50 mg daily
Mirabegron 50mg Prolonged Release Tablet G04BD12-000-T52-01-001 A* Symptomatic treatment of urgency, increased For patients who are not responsive, intolerant or 50mg once daily. Should be taken once daily, with liquid,
micturition frequency and/or urgency incontinence as unsuitable to use other existing agents. swallowed whole and is not to be chewed, divided, or crushed
may occur in adult patients with overactive bladder
(OAB) syndrome.
Mirtazapine 15mg Orodispersible Tablet N06AX11-000-T40-01-XXX A* Major depression Consultant/specialists for specific indications only, Initially 15 mg daily at bedtime increased according to response
including Geriatricians and Neurologists up to 45 mg daily as a single dose at bedtime or in 2 divided
doses. CHILD and ADOLESCENT under 18 years not recommended
Mirtazapine 30mg Orodispersible Tablet N06AX11-000-T40-02-XXX A* Major depression Consultant/specialists for specific indications only, Initially 15 mg daily at bedtime increased according to response
including Geriatricians and Neurologists up to 45 mg daily as a single dose at bedtime or in 2 divided
doses. CHILD and ADOLESCENT under 18 years not recommended
Mirtazapine 30mg Tablet N06AX11-000-T32-01-XXX A* Major depression Consultant/specialists for specific indications only, Initial: 15mg daily at bedtime Maintenance: 15-45mg daily
including Geriatricians and Neurologists
Mitomycin C 0.02% Eye Drops S01AX00-000-D20-01-XXX A Pterygium, conjunctival tumour, glaucoma surgery None 1 - 2 drops several times a day
Mitomycin C 0.04% Eye Drops S01AX00-000-D20-02-XXX A Pterygium, conjunctival tumour, glaucoma surgery None 1 - 2 drops several times a day
Mitomycin-C 10 mg Injection L01DC03000P4001XX A* i) Gastrointestinal, lung, breast, cervical cancers ii) i) 10 - 20 mg/m2 body surface area (BSA) given as a single dose
Bladder tumours iii) Opthalmological conditions: through a running IV infusion repeated every 6 - 8 weeks. The
conjunctival squamous neoplasia, squamous cell whole schedule may be repeated depending on the bone marrow
carcinoma of conjunctiva, trabeculectomy chronic ii) 10 - 40 mg daily or every other day (intravesical) iii) 0.4 mg
lymphocytic leukaemia, chronic myelogenous leukaemia. topically as a single application for opthalmological conditions,
Gastric, colorectal, lung cancer duration: 1 to 3 minutes
Mitoxantrone 20 mg/10ml Injection L01DB07110P3001XX A* Acute leukaemia, elderly patients with acute myeloid 10 - 12 mg/m2 IV daily for 3 days, in combination with other
leukaemia (AML), relapsed/resistant acute leukaemia, cytotoxic agents. Refer to protocol. CHILD: 5 - 10 mg/m2 daily for
non-Hodgkin's lymphoma (NHL) 3 - 5 days according to protocol. Treatment of acute leukaemia,
ADULT: 8 - 12 mg/m2/day once daily for 4 - 5 days. CHILD more
than 2 years: same as adult dose. CHILD 2 years: 0.4 mg/kg/day
once daily for 3 - 5 days
Mixed Gas-Gangrene Antitoxin 25,000 units/5 J06AA05000P3001XX B Mixed gas-gangrene Prophylactic: 25,000 units IM or IV. Therapeutic: Not less than
ml Injection 75,000 units IV
April 2023 117


Moclobemide 150 mg Tablet N06AG02000T1001XX A* Treatment of depressive syndrome Initially 300 mg daily in divided doses. Gradually to increase up to
600 mg daily in divided doses depending on response. Usual
range 150 - 600 mg daily. Not recommended in children
Modified Fluid Gelatin 4% Injection B05AA06905P9901XX B For primary volume replacement in hypovolaemia, peri- ADULT 500 - 1500 ml given as IV infusion
operative stabilization of the circulation, haemodilution,
extracorporeal circulation (haemodialysis and heart-lung
machine)
Mometasone Furoate 0.1% Cream D07AC13139G1001XX A* Steroid responsive dermatosis and vitiligo. Used where a Apply thin layer to the affected skin areas once daily until the
potent steroid is required for short duration not more lesion heals or for a duration of 3 weeks whichever is
than 6 weeks sooner.Massage gently and thoroughly until the medication
disappears.
Mometasone Furoate 50mcg Aqueous Nasal R01AD09-139-A41-01-XX A* i) Allergic rhinitis. ii) For the treatment of nasal polyps in None ALLERGIC RHINITIS: ADULT and CHILD, 12 years and above: 100
Spray patients 18 years of age and older. mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg
(4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when
control achieved. CHILD 3 - 11 years old: 50 mcg (1 spray) to each
nostril once daily. TREATMENT OF NASAL POLYPS: Two sprays (50
micrograms/spray) in each nostril twice daily (total daily dose of
400 mcg). Once symptoms are adequately controlled, dose
reduction to two sprays in each nostril once daily (total daily dose
200 mcg) is recommended.
Monobasic Sodium Phosphate 48%, Dibasic A06AG01162L5001XX A Bowel cleansing prior to colonoscopy, radiological 45 ml diluted with half a glass (120 ml) of water, followed by one
Sodium Phosphate 18% examination or bowel surgery full glass (240 ml) of water to be taken depending on the time of
the procedure. For morning procedure, 45 ml dilute with half
glass of water should be taken at 7 am and the second 45 ml at 7
pm on the day before the procedure. For afternoon procedure,
the first dose should be taken at 7 pm on the day before and the
second dose at 7 am on the day of the procedure. Solid food
must not be taken during the preparation period; clear fluids or
water can be taken liberally. Not recommended for use in children
Montelukast Sodium 10 mg Tablet R03DC03-520-T10-01-XX A/KK Chronic treatment of asthma and relief of symptoms of None CHILD more than 15 years and ADULT: 10 mg daily at bedtime
seasonal allergic rhinitis for children more than 15 years
and adults
Montelukast Sodium 4mg Oral Granules R03DC03-520-F10-01-XXX A* Asthmatics, not controlled on high dose inhaled None 12 months - 5 years: 1 packet of 4mg oral granules daily at
corticosteroids more than 1600 mcg/day and with co- bedtime
morbid allergic disorders. Chronic treatment of asthma
Montelukast Sodium 5mg Tablet R03DC03-520-T20-01-XXX A* Asthmatics, not controlled on high dose inhaled None CHILD 6 - 14 years: One 5 mg chewable tablet daily at bedtime
corticosteroids more than 1600 mcg/day and with co-
morbid allergic disorders. Chronic treatment of asthma
Morphine HCl 10mg/5 ml Solution N02AA01110L9901XX B For use in management of moderate to severe pain None 5-20 mg or more regularly every 4 hours as needed in terminal
especially that associated with neoplastic disease pain
Morphine Sulphate 10mg Prolonged Release N02AA01-183-T50-01-XXX A i) Prolonged relief of severe pain associated with Indication (ii): Initiated by Pain or Palliative Specialists only 10 - 60 mg 12 hourly intervals, depend upon the severity of the
Tablet neoplastic disease ii) As a second line treatment of pain. Children (more than 1 year of age) with severe cancer pain:
chronic non-cancer pain when treatments with adjuvant 0.2 - 0.8mg/kg 12 hourly.
analgesics and non-pharmacological approach failed
April 2023 118


Morphine Sulphate 10mg Suppository N02AA01-183-S20-01-XXX A* Relief of severe chronic pain (cancer patient) None 15 - 30 mg regularly every 4 hours
Morphine Sulphate 10mg/ml Injection N02AA01-183-P30-01-XXX B i) For moderate to severe pain especially that associated None ADULT: 5 to 20 mg every 4 hours, intravenously (IV or IM), 2.5 to
with neoplastic disease ii) As an analgesic adjunct in 15mg should be given by slow injection. CHILD: - Adjusted
general anaesthesia. according to body weight, 0.1 – 0.2 mg /kg every 4 hours. No
dose should exceed 15 mg. - Analgesic Indication (i)
subcutaneous, 100 mcg to 200 mcg (0.1 to 0.2 mg) per kg of body
weight every four hours as needed, not to exceed 15mg per dose.
Indication (ii) Intravenous, 50 to 100 mcg (0.05 mg to 0.1 mg) per
kg of body weight, administered very slowly.
Morphine Sulphate 20 g Suppository N02AA01-183-S20-02-XXX A* Relief of severe chronic pain (cancer patient) None 15 - 30 mg regularly every 4 hours
Morphine Sulphate 30mg Prolonged Release N02AA01-183-T50-02-XXX A i) Prolonged relief of severe pain associated with Indication (ii) Initiated by Pain or Palliative Specialists only 10 - 60 mg 12 hourly intervals, depend upon the severity of the
Tablet neoplastic disease ii) As a second line treatment of pain
chronic non-cancer pain when treatments with adjuvant
Morphine Sulphate 30mg Suppository N02AA01-183-S20-03-XXX A* Relief of severe chronic pain (cancer patient) None 15 - 30 mg regularly every 4 hours
Morphine Sulphate 5mg Immediate Release N02AA01-183-T60-01-XXX A* Relief of moderate to severe pain (cancer patient) None 5-10 mg every four hours. The dose may be increased according
Tablet to needs
Morphine Sulphate 60mg Prolonged Release N02AA01-183-T50-03-XXX A i) Prolonged relief of severe pain associated with Indication (ii): Initiated by Pain or Palliative Specialists only 10 - 60 mg 12 hourly intervals, depend upon the severity of the
Tablet neoplastic disease ii) As a second line treatment of pain. Children (more than 1 year of age) with severe cancer pain:
chronic non-cancer pain when treatments with adjuvant 0.2 - 0.8mg/kg 12 hourly.
Moxifloxacin 0.5% Ophthalmic Solution S01AX22-110-D20-01-XXX A* Treatment of conjunctivitis caused by susceptible None CHILD more than 1 year and ADULT: 1 drop to affected eye(s) 3
organism times daily for 7 days
Moxifloxacin 400 mg Injection J01MA14110P3001XX A* Second line therapy for Severe Community Acquired IV or Oral: 400 mg once daily. The recommended total treatment
Pneumonia (CAP) patients with co-morbidity or with duration for sequential administration (intravenous followed by
recent antibiotic therapy, suspected infections of oral therapy) is 7 to 14 days
resistant pathogens including Streptococcus
pneumoniae, Haemophilus influenzae & Mycoplasma
pneumoniae.
Moxifloxacin 400mg Tablet J01MA14110T1001XX A* Second line therapy for Severe Community Acquired IV or Oral: 400 mg once daily. The recommended total treatment
Pneumonia (CAP) patients with co-morbidity or with duration for sequential administration (intravenous followed by
recent antibiotic therapy, suspected infections of oral therapy) is 7 to 14 days
resistant pathogens including Streptococcus
pneumoniae, Haemophilus influenzae & Mycoplasma
pneumoniae.
Multivitamin Drops A11BA00901D5001XX B For prevention and treatment of vitamin deficiencies INFANT less than 1 year: 1 ml daily
Multivitamin Injection A11BA00901P3001XX B For prevention and treatment of vitamin deficiencies Initially 2 - 4 pairs IV 4 - 8 hourly, reducing to 1 pair IV daily. For
less serious cases, 1 pair IV 1 - 2 times daily or based on individual
requirements
Multivitamin Syrup A11BA00901L9001XX C+ For prevention and treatment of vitamin deficiencies CHILD 5 ml daily or based on manufacturer
Multivitamin Tablet A11BA00901T1001XX B For prevention and treatment of vitamin deficiencies 1 - 2 tablets daily or based on individual requirements
Mupirocin 2% Cream D06AX09000G1001XX A Skin infection by Staphylococcus aureus (including Adults and child over 1 year, apply up to 3 times daily for up to 10
MRSA), Staphylococcus epidermidis and beta-haemolytic days
streptococcus
April 2023 119


Mupirocin 2% Ointment D06AX09000G5001XX A For MRSA infections only ADULT and CHILD: Apply up to three times daily for up to 10 days
Mycophenolate Mofetil 250 mg Capsule L04AA06236C1001XX A* i) Prophylaxis of acute organ rejection in patients i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3
receiving allogenic renal, cardiac and hepatic transplant months and older): 600 mg/m(2)/dose, twice daily; maximum
ii) Used with steroids for induction and maintenance of daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice
severe lupus nephritis daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction
phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose
gradually tapers to 1 g/day
Mycophenolate Mofetil 500 mg tablet L04AA06236T1002XX A* i) Prophylaxis of acute organ rejection in patients i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3
receiving allogenic renal, cardiac and hepatic transplant months and older): 600 mg/m(2)/dose, twice daily; maximum
ii) Used with steroids for induction and maintenance of daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice
severe lupus nephritis daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction
phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose
gradually tapers to 1 g/day
Mycophenolate Sodium 180mg Tablet L04AA06520T1001XX A* Prophylaxis of acute transplant rejection in adult 720 mg twice daily
patients receiving allogenic renal transplant in
combination with ciclosporin and corticosteroids
Mycophenolate Sodium 360mg Tablet L04AA06520T1002XX A* Prophylaxis of acute transplant rejection in adult 720 mg twice daily
patients receiving allogenic renal transplant in
combination with ciclosporin and corticosteroids
Nalbuphine HCl 10 mg/ml Injection N02AF02110P3001XX B i) Management of pain severe enough to require an i) ADULT: 10mg SC, IM or IV repeated every 3-6 hours as
opioid analgesic and for which alternative treatments necessary. Max. single dose: 20mg Max. total daily dose: 160mg
are inadequate ii) As a supplement to balanced ii) Induction: 0.3 – 3 mg/kg IV to be administered over 10 to 15
anesthesia, for preoperative and postoperative analgesia min Maintenance: 0.25 – 0.50 mg / kg in single IV administration
and for obstetrical analgesia during labor and delivery as required.
Naloxone HCl 0.02mg/ml Injection V03AB15-110-P30-01-XX B For the complete/partial reversal of narcotic depression None 0.005 - 0.01 mg/kg body weight repeated at intervals of 2 - 3
including respiratory depression induced by opioids such minutes according to the patient's needs by IM, IV or SC
as natural and synthetic narcotics. Diagnosis of
suspected acute opioids overdosage
Naloxone HCl 0.4mg/ml Injection V03AB15-110-P30-02-XX B For the complete/partial reversal of narcotic depression None Initially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes
including respiratory depression induced by opioids such according to patient's needs
as natural and synthetic narcotics. Diagnosis of
suspected acute opioids overdosage
Naltrexone HCl 50 mg Tablet N07BB04110T1001XX A Adjunct in relapse prevention treatment in detoxified Initial 25 mg may be increased to 50 mg. Maintenance: 350 mg
formerly opioid-dependant patients weekly; administered as 50 mg daily. Dosing interval may be
lengthened to improve compliance; 100 mg on alternate days or
150 mg every third day
Naproxen 250mg Tablet M01AE02-000-T10-01-XXX A/KK i) Rheumatic arthritis, osteoarthritis and ankylosing None i) 0.5 - 1 g daily in 2 divided doses ii) 750 mg initially then 250 mg
spondylitis ii) Acute gout iii) Muscular skeletal disorder, 8 hourly iii) 500 mg initially then 250 mg every 6 - 8 hour as
dysmenorrhoea required Max: 1g daily
Naproxen Sodium 275mg Tablet M01AE02-520-T10-01-XXX A i) Rheumatic arthritis, osteoarthritis and alkylosing None i: 275mg bd ii: Initial: 825mg followed by 275mg every 8 hrs as
spondylitis ii) Acute gout iii) Muscular skeletal disorder necesssary iii. Initial: 550mg followed by 275 every 6-8 hrs as
and dysmenorrhoea necessary.
Neomycin 0.5% Cream D06AX04256G1001XX B Infections of the skin due to susceptible organisms Apply sparingly to affected area up to 3 times daily (For short
term use, 1 - 2 weeks)
April 2023 120


Neomycin 0.5% in Betamethasone 17-Valerate D07CC01-947-G10-01-XXX B Treatment of the following conditions where bacterial None Apply sparingly to affected area 2 - 3 times daily. (May cause
0.01% Cream infection is present or likely to occur: eczemas, prurigo sensitisation to neomycin. Use with caution)
nodularis, psoriasis (excluding widespread plaque
psoriasis), neurodermatoses, anal and genital intertrigo
Neomycin 0.5% in Betamethasone 17-Valerate D07CC01-947-G50-01-XXX B Treatment of the following conditions where bacterial None Apply sparingly to affected area 2 to 3 times daily. (May cause
0.01% Ointment infection is present or likely to occur: eczemas, prurigo sensitisation to Neomycin. Use with caution)
Neomycin 0.5% in Betamethasone 17-Valerate D07CC01-947-G10-02-XXX A Treatment of the following conditions where bacterial None Apply sparingly to affected area 2 - 3 times daily (May cause
0.1% Cream infection is present or likely to occur: eczemas, prurigo sensitisation to neomycin. Use with caution)
Neomycin 0.5% in Betamethasone 17-Valerate D07CC01-947-G50-02-XXX A Treatment of the following conditions where bacterial Apply sparingly to affected area 2 to 3 times daily. (May cause
0.1% Ointment infection is present or likely to occur: eczemas, prurigo sensitisation to neomycin. Use with caution)
Neomycin 0.5% Ointment D06AX04256G5001XX B Infections of the skin due to susceptible organisms Apply sparingly to affected area up to 3 times daily (For short
term use, 1- 2 weeks)
Neostigmine Methylsulphate 2.5 mg/ml N07AA01-183-P30-02-XXX B i) Symptomatic treatment of myasthenia gravis where i) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual
Injection oral therapy is impractical ii) Reversal of the effects of total daily dose 5 - 20 mg. CHILD: 0.1mg IM. Titrated in the range
non-depolarizing neuromuscular blockade iii)The of 0.05mg - 0.25mg. NEONATE: 50 - 250 mcg every 4 hours ii) By
management of post-operative distension, paralytic ileus IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg and
and urinary retention, where mechanical obstruction has 2.5mg for children) after or with atropine sulphate 0.6 - 1.2 mg iii)
been out-ruled Adults: SC or IM 0.5 - 2.5mg. Children: SC or IM 0.125mg - 1mg
Nepafenac 0.1% ophthalmic solution S01BC10-000-D20-01-XXX A* Reduction in the risk of postoperative macular oedema None One drop 3 times/day beginning 1 day prior to cataract surgery,
associated with cataract surgery in diabetic patients. continued on the day of surgery and up to 60 days of the
postoperative period as directed by the clinician. An additional
drop should be administered 30 to 120 minutes prior to surgery.
Netilmicin Sulphate 100 mg/2 ml Injection J01GB07183P3002XX A Systemic infections ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses
for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5
mg/kg/day 8 - 12 hourly depending on gestation and age.
Maximum: 7.5 mg/kg/day
April 2023 121


Neuro Polyvalent Snake Antivenom Injection Nil B Passive immunisation against poisonous of a range of For initial dose, at least 20mL of reconstituted serum should be
haematotoxic snakebites neurotoxic snakebites, based given by slow intravenous infusion (not more than 1mL/minute).
on the type of snake identified. If symptoms still persist, the second dose should be repeated 2
hours or even earlier after the initial dose. The further dose
should be repeated every 6 hours according to the clinical
symptoms. Administration: Draw 10mL of the sterile water for
injection to the freeze-dried antivenin, shake well to dissolve the
contents until the serum became clear colourless or pale yellow
liquid, ready for administration.
Nevirapine 200 mg Tablet J05AG01000T1001XX A/KK Treatment of HIV-1 infection in combination with other Combined with other antiretrovirals: 200 mg once daily for the
antiretroviral agents 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-
introduce at a lower dose for the 1st 14 days if treatment is
interrupted for >7 days,necessitate reintroduction at a lower
dose for the first 14 days.
Nevirapine 50mg/5ml Oral Suspension J05AG01000L8001XX A/KK Treatment of HIV-1 infection in combination with other The total daily dose should not exceed 400mg. Nevirapine may be
antiretroviral agents dosed in paediatric patients either by body surface area (BSA) or
by body weight. i)By BSA using the Mosteller formula: the
recommended oral dose for paediatric patients of all ages is 150
mg/m2 once daily for 2 weeks followed by 150 mg/m2 twice daily
thereafter. ii)By body weight: <8 years of age: 4 mg/kg once daily
for 2 weeks followed by 7 mg/kg twice daily thereafter. ≥8 years:
4 mg/kg once daily for 2 weeks followed by 4 mg/kg twice daily
thereafter.
Nicotine 10mg/16hr Transdermal Patch N07BA01000M7005XX A/KK For the treatment of tobacco dependence by relieving The patch should be apply to an intact area of the skin upon
nicotine withdrawal symptoms, thereby facilitating waking up in the morning and removed at bedtime. Heavy
smoking cessation in smokers motivated to quit. smoker (those smoking 15 or more cigarettes in a 24-hour
period): Step 1: 25mg/16 hours patch and use one patch daily for
8 weeks. Step 2: One 15mg/16hours patch should be daily for 2
weeks Step 3: One 10mg/16 hours patch daily for 2 weeks. Light
smokers (those smoking less than 15 cigarettes in a 24-hour
period): Step 1: 15mg/16hours patch for 8 weeks Step 2:
10mg/16hours for the final 4 weeks. Combination therapy with
the patch (Flexible smoking cessation format) for fast relief of
cravings in: i) Highly dependent smokers; or ii) Smokers who
experience breakthrough cravings; or iii) Those who have failed
single NRT treatment
nicotine withdrawal symptoms, thereby facilitating waking up in the morning and removed at 24hrs. Smokers of >10
smoking cessation in smokers motivated to quit. cigarettes/day: 21 mg/day for 6 wk, then 14 mg/day for 2 wk;
finish w/ 7 mg/day for 2 wk. Smokers of ≤10 cigarettes/day: 14
mg/day for 6 wk, then 7 mg/day for 2 wk.
April 2023 122


nicotine withdrawal symptoms, thereby facilitating waking up in the morning and removed at bedtime. Heavy
smoking cessation in smokers motivated to quit. smoker (those smoking 15 or more cigarettes in a 24-hour
period): Step 1: 25mg/16 hours patch and use one patch daily for
8 weeks. Step 2: One 15mg/16hours patch should be daily for 2
single NRT treatment.
Nicotine 2 mg Gum N07BA01000M9901XX A/KK For the treatment of tobacco dependence by relieving Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20
nicotine withdrawal symptoms, thereby facilitating sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12
smoking cessation in smokers motivated to quit. week.)
Nicotine 25mg/16hr Transdermal Patch N07BA01-000-M70-07-001 A/KK For the treatment of tobacco dependence by relieving The patch should be apply to an intact area of the skin upon
nicotine craving and withdrawal symptoms thereby waking up in the morning and removed at bedtime. Heavy
facilitating smoking cessation in smokers motivated to smoker (those smoking 15 or more cigarettes in a 24-hour
quit. Advice and support normally improve the success period): Step 1: 25mg/16 hours patch and use one patch daily for
rate. 8 weeks. Step 2: One 15mg/16hours patch should be daily for 2
single NRT treatment.
Nicotine 4 mg Gum N07BA01000M9902XX A/KK For the treatment of tobacco dependence by relieving Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,
nicotine withdrawal symptoms, thereby facilitating chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)
smoking cessation in smokers motivated to quit.
April 2023 123


Nicotinic Acid 50 mg Tablet A11HA01000T1001XX B For prophylaxis and treatment of Vitamin B3 deficiency Prophylactic: 15 - 30 mg daily. Therapeutic: 50 - 250 mg daily.
Maximum single dose: 200 mg. Maximum dose in 24 hours: 800
mg
Nicotinic Acid 500 mg Tablet C10AD02000T1001XX B Hyperlipidaemia 100 - 200 mg 3 times daily, gradually increased over 2 - 4 weeks
to 1 - 2 g 3 times daily with or after meals. CHILD: 100 - 250
mg/day in 3 divided doses with meals, increase 100 mg/day
weekly or 250 mg/day every 2 - 3 weeks as tolerated. Maximum:
10 mg/kg/day
Nifedipine 10 mg Tablet C08CA05000T1001XX B Hypertension Initial dose of 10 mg twice daily. Usual range 10 - 30 mg 3 times
daily. Maximum: 120 - 180 mg per day. Elderly: Dose reduction
may be necessary.
Nilotinib 150mg capsule L01XE08110T1001XX A* For the treatment of adult patients with newly 300mg twice daily. Dose adjustments or modifications:For
diagnosed Philadelphia chromosome positive chronic neutropenia & thrombocytopenia
myelogenous leukemia in the chronic phase (CP).
Nilotinib 200 mg Capsule L01XE08110C1001XX A* Treatment of chronic phase and accelerated phase 400 mg twice daily, 12 hours apart. No food should be taken two
Philadelphia chromosome positive chronic myelogenous hours before and 1 hour after taking the dose
leukaemia (CML) in adults who: i) Failed imatinib ie no
cytogenic response and no haematological response by
12 months ii) Have molecular resistance to Imatinib as
shown by molecular mutation studies iii) Are intolerant
to Imatinib
Nimodipine 10 mg/50 ml Infusion Solution C08CA06000P9901XX A* Prophylaxis & treatment of ischaemic neurological IV infusion of 1 mg/hour for a period of 2 hours (about 15
deficits caused by cerebral vasospasm following mcg/kg/hour). IV therapy should be started no later than 4 days
subarachnoid haemorrhage of aneurysmal origin after haemorrhage & continue for up to 10 - 14 days
Nimodipine 30 mg Tablet C08CA06000T1001XX A* Prophylaxis & treatment of ischaemic neurological 360 mg daily in divided doses for 7 days
deficits caused by cerebral vasospasm following
subarachnoid haemorrhage of aneurysmal origin
Nintedanib 100mg Capsule L01XE31-189-C40-01-XXX A* For the treatment of Idiopathic Pulmonary Fibrosis (IPF) The recommended dose is 150 mg twice daily administered
in adults approximately 12 hours apart. The 100 mg twice daily dose is
only recommended to be used in patients who do not tolerate
the 150 mg twice daily dose.
Nintedanib 150mg Capsule L01XE31-189-C40-02-XXX A* For the treatment of Idiopathic Pulmonary Fibrosis (IPF) The recommended dose is 150 mg twice daily administered
in adults approximately 12 hours apart. The 100 mg twice daily dose is
only recommended to be used in patients who do not tolerate
the 150 mg twice daily dose.
Nitrazepam 5 mg Tablet N05CD02000T1001XX B Epilepsy (infantile spasms) 5 - 10 mg at bedtime. ELDERLY or debilitated 2.5 - 5 mg. CHILD
not recommended. Increasing slowly according to response
Nitrofurantoin 100 mg Tablet J01XE01000T1002XX B Uncomplicated lower urinary tract infections Acute uncomplicated urinary tract infections Adult: 50-100 mg 4
times daily for 7 days. Dual-release preparation: 100 mg bid.
Child: >3 mth and older children: 3 mg/kg daily in 4 divided doses.
Prophylaxis of uncomplicated urinary tract infections Adult: 50-
100 mg at bedtime. Child: >3 mth and older children: 1 mg/kg
once daily.
April 2023 124


Noradrenaline Acid Tartrate (Norepinephrine C01CA03-123-P30-01-XXX A i) For blood pressure control in certain acute Infuse and titrate to desired pressure response. Range: 0.05 - 0.5
Bitartrate) 1 mg/ml Injection hypotensive states (e.g.pheochromocytomectomy, mcg/kg/minute
sympathectomy, poliomyelitis, spinal anesthesia,
myocardial infarction, septicemia, blood transfusion, and
drug reactions). ii) As an adjunct in the treatment of
cardiac arrest and profound hypotension
Norethisterone 0.35 mg Tablet G03AC01000T1001XX C+ Contraception 1 tablet daily starting on the first day of the menstrual bleeding
Norethisterone Enanthate 200 mg/ml Injection G03AC01257P3001XX B Contraception By deep IM injection only. First injection is within first 5 days of
the cycle. The next 3 injections are given at 8 weeks interval after
which the injection interval should be extended to 12 weeks
Nystatin 100,000 units/g Cream D01AA01000G1001XX C Prevention and treatment of cutaneous infections Apply liberally to affected area twice daily or as required. After
caused by Candida albicans lesion has disappeared continue treatment for 10 days to prevent
relapses. Nail infection: Cut nails as short as possible. Apply
cream once daily until growth of new nail has set in
Nystatin 100,000units/ml Suspension A07AA02-000-L80-01-XXX B Prevention and treatment of candidiasis of the skin and None Treatment: Adult & Children: 100,000 to 600,000 units 6 hourly;
mucous membranes, protection against candidas Infant: 100,000 – 200,000 units 6 hourly; Neonates: 100,000 units
overgrowth during antimicrobial /corticosteroid therapy 8 hourly. Prophylaxis: Adult: 1,000,000 units daily; Neonates and
and as selective decontamination regimens Infants: 100,000 units 2-3 times a day; Children: 250,000 –
500,000 units 2-3 times a day.
Nystatin 500,000 units Tablet A07AA02000T1001XX B Prevention and treatment of candidiasis of the skin and ADULT: 500,000 -1,000,000 units 6 hourly, according to severity
mucous membranes, protection against candidas of infections. CHILD: 100,000-500,000 units 6 hourly
overgrowth during antimicrobial /corticosteroid therapy
and as selective decontamination regimens
Octreotide 0.05mg/ml Injection H01CB02-122-P30-02-XXX A i) Acromegaly treatment in patients in whom surgery or None i) Initially 0.05-0.1mg SC every 8 or 12 hours. Optimal daily dose is
radiotherapy is inappropriate or ineffective- based on 0.3mg, not to exceed maximum dose of 1.5mg/day. ii) Initially
level of growth hormone and high IGF-1 and residual 0.05 mg once or twice daily, gradually increase to 0.1-0.2mg 3
pituitary tumor ii) Relief of symptoms associated with times daily. Higher doses may be required in exceptional
functional gastro-entero-pancreatic (GEP) endocrine circumstances. iii) 0.1 mg 3 times daily for 7 consecutive days,
tumors: • Carcinoid tumors with features of the starting on the day of operation, at least 1 hour before
carcinoid syndrome. • VIPomas, Glucagonomas • laparotomy iv) ADULT: 50mcg bolus, followed by continuous
Gastrinomas/Zollinger-Ellison syndrome • Insulinomas • infusion of 25-50mcg/hour for 2-5 days. CHILD: IV 1-5
GRFomas. iii) Prevention of complications following mcg/kg/hour The dosing is individualized according to product
pancreatic surgery iv) Emergency management of insert / protocol
bleeding gastro-eosophageal varices in patients with
cirrhosis
April 2023 125


Octreotide 0.1mg/ml Injection H01CB02-122-P30-01-XXX A i) Acromegaly treatment in patients in whom surgery or None i) Initially 0.05-0.1mg SC every 8 or 12 hours. Optimal daily dose is
radiotherapy is inappropriate or ineffective- based on 0.3mg, not to exceed maximum dose of 1.5mg/day. ii) Initially
level of growth hormone and high IGF-1 and residual 0.05 mg once or twice daily, gradually increase to 0.1-0.2mg 3
pituitary tumor ii) Relief of symptoms associated with times daily. Higher doses may be required in exceptional
functional gastro-entero-pancreatic (GEP) endocrine circumstances. iii) 0.1 mg 3 times daily for 7 consecutive days,
tumors: • Carcinoid tumors with features of the starting on the day of operation, at least 1 hour before
carcinoid syndrome. • VIPomas, Glucagonomas • laparotomy iv) ADULT: 50mcg bolus, followed by continuous
Gastrinomas/Zollinger-Ellison syndrome • Insulinomas • infusion of 25-50mcg/hour for 2-5 days. CHILD: IV 1-5
GRFomas. iii) Prevention of complications following mcg/kg/hour The dosing is individualized according to product
pancreatic surgery iv) Emergency management of insert / protocol
bleeding gastro-eosophageal varices in patients with
cirrhosis
Octreotide Acetate 20mg Injection H01CB02-122-P20-01-XXX A* i) Acromegaly treatment in patients in whom surgery or None 10 - 30 mg every 4 weeks as deep intragluteal injection
radiotherapy is inappropriate or ineffective- based on
level of growth hormone and high IGF-1 and residual
pituitary tumor. ii)Treatment of patients with symptoms
associated with functional gastro-entero-pancreatic
endocrine tumors: • Carcinoid tumors with features of
the carcinoid syndrome. • VIPomas, Glucagonomas •
Gastrinomas/Zollinger-Ellison syndrome. • Insulinomas,
GRFomas. iii) Treatment of patients with advanced
neuroendocrine tumors of the midgut or of unknown
primary origin where non-midgut sites of origin have
been excluded.
Octreotide Acetate 30mg Injection H01CB02-122-P20-02-XXX A* i) Acromegaly treatment in patients in whom surgery or None 10 - 30 mg every 4 weeks as deep intragluteal injection
radiotherapy is inappropriate or ineffective- based on
level of growth hormone and high IGF-1 and residual
pituitary tumor. ii) Treatment of patients with symptoms
associated with functional gastro-entero-pancreatic
endocrine tumors: • Carcinoid tumors with features of
the carcinoid syndrome. • VIPomas, Glucagonomas •
Gastrinomas/Zollinger-Ellison syndrome. • Insulinomas,
GRFomas. iii) Treatment of patients with advanced
neuroendocrine tumors of the midgut or of unknown
primary origin where non-midgut sites of origin have
been excluded.
Ofloxacin 0.3% Otic Solution S02AA00-000-D10-01-XXX A/KK i. Acute otitis media with tympanostomy tubes ii. None CHILD: 1 - 12 years: 5 drops twice daily for 10 days. ADULT and
Chronic suppurative otitis media with perforated CHILD over 12 years: 6 - 10 drops twice daily and remain in the
tympanic membranes and iii. Otitis externa ear about 10 minutes
Ofloxacin 100 mg Tablet J01MA01000T1001XX A i) As second-line treatment of leprosy ii) As second-line i) 400 mg/day ii) 400 mg twice daily iii) 200 mg twice daily
treatment for tuberculosis and multidrug resistant
tuberculosis (MDR-TB) iii) Sequential therapy for UTI and
pyelonephritis
Ofloxacin 200 mg Injection J01MA01000P4001XX A Sequential therapy for UTI and pyelonephritis 200 mg IV twice daily for 3 - 5 days followed with 200 mg tablet
twice daily for 3 - 5 days as maintenance dose (if necessary)
April 2023 126


Olanzapine 10 mg Disintegrating Tablet N05AH03-000-T40-02-XXX A* i) Acute and maintenance treatment of schizophrenia Consultant/specialists for specific indications only, i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7
and other psychoses where positive and or negative including Geriatricians days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20
symptoms are prominent ii) Short-term use for acute mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at
mania episodes associated with Bipolar 1 disorder iii) intervals of not less than 24 hours. Maintenance 5 - 20 mg/day;
Prevention of recurrence of manic, mixed or depressive maximum 20 mg/day iii) Starting dose is 10mg/day, daily dosage
episodes in Bipolar I Disorder. may subsequently be adjusted on the basis of individual clinical
status within the range 5-20 mg/day
Olanzapine 10 mg Tablet N05AH03-000-T10-02-XXX B i) Acute and maintenance treatment of schizophrenia None i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7
and other psychoses where positive and or negative days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20
Olanzapine 5 mg Tablet N05AH03-000-T10-01-XXX B i) Acute and maintenance treatment of schizophrenia None i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7
and other psychoses where positive and or negative days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20
Olanzapine 5mg Disintegrating Tablet N05AH03-000-T40-01-XXX A* i) Acute and maintenance treatment of schizophrenia Consultant/specialists for specific indications only, i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7
and other psychoses where positive and or negative including Geriatricians days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20
Olive Oil Ear Drops S02DC00-000-D10-01-XXX C Impacted wax softener None 3 - 4 drops 3 - 4 or as directed
Olopatadine Hydrochloride ophthalmic S01GX09-110-D20-02-XXX A* Temporary prevention of ocular itching due to allergic None One drop in each affected eye once a day
solution 0.2% conjunctivitis
Omalizumab 150mg powder and solvent for R03DX05-000-P30-01-XXX A* i) For adults and adolescents (≥12 years), for severe None i) Adult & adolescent ≥12 yr, 150-375 mg SC every 2-4 wk,
solution persistent allergic asthma whose symptoms are according to body wt & baseline serum total IgE level.. For
inadequately controlled with inhaled corticosetroids; ii) subcutaneous administration only. Do not administer by the
For Children (6 to <12 years of age): As add-on therapy intravenous or intramuscular route. ii) Appropriate dose and
to improve asthma control with severe persistent allergic dosing frequency of omalizumab is determined by baseline IgE
asthma who have positive skin test or in vitro reactivity (IU/ml), measured before the start of treatment, and body weight
to a perennial aero allergen and frequent daytime (kg). Prior to initial dosing, patients should have their IgE level
symptoms or night-time awakenings and who have had determined for their dose assignment. Based on these
multiple documented severe asthma exacerbations measurements 150-375mg in 1 -3 injections may be needed for
despite daily high-dose inhaled corticosteroids, plus a each administration. Patients whose baseline IgE levels or body
long-acting inhaled beta 2 agonist. weight in kilograms are outside the limits of the dosing table
should not be given omalizumab. For subcutaneous
administration only.
April 2023 127


Omeprazole 10 mg Capsule A02BC01000C1001XX A/KK i) Reflux oesophagitis ii) For eradication of Helicobacter i) 20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii) 20 mg twice
pylori infection iii) Benign peptic ulcer not responding to daily in combination with any of the 2 antibiotics (clarithromycin
conventional therapy iv) Zollinger-Ellison Syndrome 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole
400 mg twice daily) for 1 - 2 weeks iii) 20 mg once daily for 4 - 6
weeks iv) ADULT: 20 - 120 mg once daily adjusted according to
the patient's response. CHILD 0.4 - 0.8 mg/kg/day
Omeprazole 20 mg Capsule A02BC01000C1002XX A/KK i) Reflux oesophagitis ii) For eradication of Helicobacter i) 20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii) 20 mg twice
pylori infection iii) Benign peptic ulcer not responding to daily in combination with any of the 2 antibiotics (clarithromycin
conventional therapy iv) Zollinger-Ellison Syndrome 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole
400 mg twice daily) for 1 - 2 weeks iii) 20 mg once daily for 4 - 6
weeks iv) ADULT: 20 - 120 mg once daily adjusted according to
the patient's response. CHILD 0.4 - 0.8 mg/kg/day
Omeprazole 40 mg Injection A02BC01000P4001XX A* i) Reflux oesophagitis, eradication of H. Pylori infection, i) 40 mg IV once daily when oral therapy is inappropriate ii) 40-
benign peptic ulcer not responding to conventional 160 mg by IV in single or divided doses
therapy, Zollinger-Ellison Syndrome ii) Endoscopically
confirmed peptic ulcer
Ondansetron 2mg/ml Injection A04AA01-110-P30-01-XX A i)Prevention of nausea and vomiting induced by None i)8 mg given by IV infusion over 15 minutes or by IM immediately
chemotherapy and radiotherapy ii)Postoperative nausea before treatment followed by 8 mg orally every 12 hours for up
and vomiting to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes
immediately before chemotherapy followed by 4 mg orally every
12 hours for up to 5 days ii)Prevention : 4 mg given by IV at
induction of anaesthesia. CHILD over 2 years, 100 mcg/kg (max
4mg) by slow IV before, during or after induction of anaesthesia.
Treatment of postoperative: 4 mg by IM or slow. CHILD over 2
years 100 mcg/kg (maximum 4mg) by slow IV
Ondansetron 4mg Tablet A04AA01-110-T10-01-XX A i)Prevention of nausea and vomiting induced by None i)8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for
chemotherapy and radiotherapy ii) Postoperative nausea up to 5 days. CHILD, treatment by infusion followed by 4 mg by
and vomiting mouth every 12 hours for up to 5 days ii)Prevention of
postoperative nausea and vomiting, 16 mg 1 hour before
anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg
at intervals of 8 hours for a further 2 doses
Ondansetron 8mg Tablet A04AA01-110-T10-02-XX A i)Prevention of nausea and vomiting induced by None i)8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for
chemotherapy and radiotherapy ii) Postoperative nausea up to 5 days. CHILD, treatment by infusion followed by 4 mg by
and vomiting mouth every 12 hours for up to 5 days ii)Prevention of
postoperative nausea and vomiting, 16 mg 1 hour before
anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg
at intervals of 8 hours for a further 2 doses
April 2023 128


Ondansetron 8mg/4ml Injection A04AA01110P3002XX A i)Prevention of nausea and vomiting induced by None i)8 mg given by IV infusion over 15 minutes or by IM immediately
chemotherapy and radiotherapy ii)Postoperative nausea before treatment followed by 8 mg orally every 12 hours for up
and vomiting to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes
immediately before chemotherapy followed by 4 mg orally every
12 hours for up to 5 days ii)Prevention : 4 mg given by IV at
induction of anaesthesia. CHILD over 2 years, 100 mcg/kg (max
4mg) by slow IV before, during or after induction of anaesthesia.
Treatment of postoperative: 4 mg by IM or slow. CHILD over 2
years 100 mcg/kg (maximum 4mg) by slow IV
Oral Rehydration Salt A07CA00905F2101XX C Replacement of fluid and electrolytes loss in diarrhoea ADULT: 200 - 400 ml ( 1 - 2 sachets ) for every loose motion.
CHILD: 200 ml (1 sachet) for every loose motion. In severe
dehydration 100 ml/kg for 3 - 4 hours. INFANT: 1 - 1.5 times their
usual feed volume (50 ml per stool for small infant)
Orphenadrine 100mg Tablet M03BC01-110-T10-01-XXX A Painful muscle spasm None 100mg BD. In severe cases, doses may increase to 300mg in any
24-hour period.
Ortho-phthalaldehyde 0.55% Solution V07AV00000L9909XX A High level disinfectant for sensitive endoscopes or semi- Manual reprocessing, at least 12 minute immersion time at room
critical reusable medical devices temperature (20 degree celcius) is required. Automatic
endoscope reprocessor, at least 5 minute immersion time at a
minimum of 25 degree celcius is required
Oseltamivir 60mg/5ml oral suspension. J05AH02000L8001XX A/KK i) For treatment of patients with suspected or confirmed Children ≥ 1 year (for 5 days): a) ≤15 kg: 30mg twice daily b)
influenza and severe disease (requiring hospitalization or >15kg to 23kg:45mg twice daily c) >23kg to 40kg: 60mg twice
evidence of lower respiratory tract infection). ii) For daily Children with body weight more than 40kg who are able to
treatment of patients with suspected or confirmed swallow capsule is recommended to be dosed as adults.
influenza and with co-morbidity and associated with
increased risk of influenza complications. Not to be used
as prophylaxis.
Oseltamivir 75mg capsule. J05AH02000C1001XX A/KK i) For treatment of patients with suspected or confirmed Recommended dose in adults and adolescents ≥ 13 years of age
influenza and severe disease (requiring hospitalization or and body weight >40kg is 75mg twice daily for 5 days. Dosing
evidence of lower respiratory tract infection). ii) For adjustment for renal impaired patient, follow manufacturer's
treatment of patients with suspected or confirmed recommendations in product insert.
influenza and with co-morbidity and associated with
increased risk of influenza complications. Not to be used
as prophylaxis.
Osimertinib 40mg Tablet L01XE35-000-T32-01-XXX A* The treatment of adult patients with locally advanced or Second-line therapy, in patients who progressed from 80 mg once a day until disease progression or unacceptable
metastatic EGFR T790M mutation-positive NSCLC whose first-line EGFR TKI therapy. To be prescribed by toxicity, taken with or without food at the same time each day. If
disease has progressed on or after EGFR TKI therapy oncologists and oncology-trained respiratory physicians dose reduction is necessary, then the dose should be reduced to
40 mg taken once daily.
Osimertinib 80mg Tablet L01XE35-000-T32-02-XXX A* The treatment of adult patients with locally advanced or Second-line therapy, in patients who progressed from 80 mg once a day until disease progression or unacceptable
metastatic EGFR T790M mutation-positive NSCLC whose first-line EGFR TKI therapy. To be prescribed by toxicity, taken with or without food at the same time each day. If
disease has progressed on or after EGFR TKI therapy oncologists and oncology-trained respiratory physicians dose reduction is necessary, then the dose should be reduced to
40 mg taken once daily.
Oxaliplatin 5mg/mL Injection L01XA03000P4001XX A* Colorectal cancer 85 mg/m2 IV repeated every 2 weeks
April 2023 129


Oxybutynin Chloride 5 mg Tablet G04BD04110T1001XX A* For the relief of symptoms of bladder instability ADULT: Initially 5 mg 2 - 3 times daily increased if necessary to
associated with voiding in patients with uninhibited maximum 5 mg 4 times daily. ELDERLY: Initially 2.5 - 3 mg twice
neurogenic or reflex neurogenic bladder (ie urgency, daily, increased to 5 mg twice daily according to response and
frequency, urinary leakage, urge incontinence, dysuria) tolerance. CHILD over 5 years, neurogenic bladder instability: 2.5 -
3 mg twice daily increased to 5 mg twice daily to maximum 3
times daily
Oxycodone HCl 10mg Immediate Release N02AA05-110-C10-02-XXX A* i) Management of moderate to severe chronic cancer Indication (iii): Initiated by Pain, Palliative Specialists and Initially 5 mg every 4 to 6 hours, increased if necessary according
Capsules pain non-responsive to morphine in accordance with Geriatricians only to severity of pain. Usual max. 400 mg daily, but some patients
WHO step-wise ladder of chronic pain management ii) As may require higher doses
a step-down analgesic drug in post-operative procedures
iii) As a second line treatment of chronic non-cancer pain
when treatments with adjuvant analgesics and non-
pharmacological approach failed
Oxycodone HCl 1mg/ml Oral Solution N02AA05-110-L50-01-XXX A* As a second-line drug in the management of responsive, To be prescribed by palliative medicine physicians, Initial dose for opioid naïve patients or patients presenting with
moderate to severe pain in patients who i. have difficulty oncologist, anaesthesiologist, haematologist and pain severe pain uncontrolled by weaker opioids is 5 mg, 4-6 hourly.
swallowing or ii. require a low dose oxycodone (<5mg). specialists only The dose should then be carefully titrated, as frequently as once
a day if necessary, to achieve pain relief. Maximum daily dose is
400mg daily. Dosing is individualised and according to product
insert/protocol. Should not be used in patients under 18 years.
Oxycodone HCl 5mg Immediate Release N02AA05-110-C10-01-XXX A* i) Management of moderate to severe chronic cancer Indication (iii): Initiated by Pain, Palliative Specialists and Initially 5 mg every 4 to 6 hours, increased if necessary according
Capsules pain non-responsive to morphine in accordance with geriatricians only to severity of pain. Usual max. 400 mg daily, but some patients
WHO step-wise ladder of chronic pain management ii) As may require higher doses
a step-down analgesic drug in post-operative procedures
iii) As a second line treatment of chronic non-cancer pain
when treatments with adjuvant analgesics and non-
pharmacological approach failed
Oxycodone Hydrochloride 10mg and Naloxone N02AA55-900-T10-02-XXX A* The management of moderate to severe chronic pain Consultant/specialists for specific indications only, Adults and paediatric patients from 18 years of age: The usual
Hydrochloride Dihydrate 5mg Tablet unresponsive to non-narcotic analgesics. The opioid including Geriatricians starting dose for opioid-naive patients or patients presenting
antagonist naloxone in the fixed combination is added to with moderate to severe chronic pain uncontrolled by weaker
counteract and/or prevent opioid-induced constipation. opioids is one tablet 10mg/5mg at 12 hourly intervals, or one
tablet 5mg/2.5mg 12-hourly for patients with mild hepatic
impairment and patients with renal impairment. The dose should
then be cautiously titrated, as frequently as every 1-2 days if
necessary, to achieve pain relief.
Oxycodone Hydrochloride 10mg Controlled N02AA05-110-T53-01-XXX A* i) Management of moderate to severe chronic cancer Indication (ii): Initiated by Pain, Palliative Specialists or Adults, elderly and children over 12 years: Usual starting dose for
Release Tablet pain non-responsive to morphine in accordance with Geriatricians only opioid-naive patients or patients presenting with moderate to
WHO step-wise ladder of chronic pain management. ii) severe pain uncontrolled by weaker opioids (especially if they are
As a second line treatment of chronic non-cancer pain receiving concurrent sedatives, muscle relaxants or other CNS
when treatments with adjuvant analgesics and non- medicines):10mg 12 hourly. The dose should then be carefully
pharmacological approach failed titrated with longitudinal patient monitoring, assessing whether
the pain is opioid responsive and providing the patient significant
pain relief. Patients with renal or hepatic impairment: The
recommended adult starting dose should be reduced by 1/3 to
1/2, and each patient should be titrated to adequate pain control
according to their clinical situation.
April 2023 130


Oxycodone Hydrochloride 10mg/ml Injection N02AA05-110-P3-01XXX A* For the treatment of moderate to severe pain in patients Consultant/specialists for specific indications only, Adults over 18 years: The following starting doses are
with cancer and post-operative pain. For the treatment including Geriatricians recommended. A gradual increase in dose may be required if
of severe pain requiring the use of a strong opioid. analgesia is inadequate or if pain severity increases. IV Bolus:
Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for
injections. Administer a bolus dose of 1 to 10 mg slowly over 1-2
minutes. Doses should not be administered more frequently than
every 4 hours. IV Infusion: Dilute to 1 mg/ml in 0.9% saline, 5%
dextrose or water for injections. A starting dose of 2 mg/hour is
recommended. IV PCA: Dilute to 1 mg/ml in 0.9% saline, 5%
dextrose or water for injections. Bolus doses of 0.03 mg/kg
should be administered with a minimum lock-out time of 5
minutes. SC Bolus: Use as 10 mg/ml concentration. A starting
dose of 5 mg is recommended, repeated at 4-hourly intervals as
required. SC Infusion: Dilute in 0.9% saline, 5% dextrose or water
for injections if required. A starting dose of 7.5 mg/day is
recommended in opioid naive patients, titrating gradually
according to symptom control. Cancer patients transferring from
oral oxycodone may require much higher doses. Transferring
patients between oral and parenteral oxycodone: The dose
should be based on the following ratio: 2 mg of oral oxycodone is
equivalent to 1 mg of parenteral oxycodone. It must be
emphasised that this is a guide to the dose required. Inter-patient
variability requires that each patient is carefully titrated to the
appropriate dose.
Release Tablet pain non-responsive to morphine in accordance with Geriatricians only opioid-naive patients or patients presenting with moderate to
when treatments with adjuvant analgesics and non- medicines): 10mg 12 hourly. The dose should then be carefully
April 2023 131


Release Tablet pain non-responsive to morphine in accordance with geriatricians only opioid-naive patients or patients presenting with moderate to
when treatments with adjuvant analgesics and non- medicines): 10mg 12 hourly. The dose should then be carefully
Hydrochloride Dihydrate 2.5mg Tablet unresponsive to non-narcotic analgesics. The opioid including Geriatricians starting dose for opioid-naive patients or patients presenting
Oxymetazoline HCI 0.01% Nasal Drops R01AA05-110-D60-03-XXX A* Acute cold, paranasal sinusitis, syringitis, otitis media. None Newborn (up to 4 weeks): 1 drop. Infant (1 - 12 month): 1 - 2
drop. Doses to be given twice or three times daily
Oxymetazoline HCl 0.025% (Paediatric) Nasal R01AA05-110-D60-01-XXX A/KK Acute colds, paranasal sinusitis and otitis media None 1 - 2 drops twice daily in each nostril for child more than 1 year
Drops
Oxymetazoline HCl 0.025% (Paediatric) Nasal R01AA05-110-A41-01-XXX A Acute colds, paranasal sinusitis and otitis media None 2 - 3 sprays into each nostril twice daily for child more than 1 year
Spray
Oxymetazoline HCl 0.05% (Adult) Nasal Drops R01AA05-110-D60-02-XXX A/KK Acute colds, paranasal sinusitis and otitis media None 1 - 2 drops twice daily in each nostril
Oxymetazoline HCl 0.05% (Adult) Nasal Spray R01AA05-110-A41-02-XXX A Acute colds, paranasal sinusitis and otitis media None 2 - 3 sprays into each nostril twice daily, maximum 6 sprays per
nostril/day
Oxymetholone 50 mg Tablet A14AA05000T1001XX A Anaemias caused by the administration of myelotoxic ADULT and CHILD: 1 - 5 mg/kg daily in one daily dose. Usual
drugs, treatment of AIDS-wasting syndrome effective dose 1 - 2 mg/kg/day, given for a minimum trial of 3 - 6
months because response may be delayed
Oxytetracycline with Polymyxin B Sulphate Eye S01AA30-947-G51-01-XXX B Treatment of superficial ocular infections involving the None Apply into the conjunctival sac 4 times daily
Ointment conjunctiva and/or cornea due to susceptible
microorganisms
April 2023 132


Oxytocin 10units/ml Injection H01BB02-000-P30-01-XXX B i) Induction of labour ii) Inadequate uterine effort iii) None i & ii) Intiate at 2 milliunits/min, may be increased by 4
Management of third stage of labour iv) Post-partum miliunits/min gradually at 30 minute intervals. Dose may be
haemorrhage decreased once a contraction pattern similar to normal labour is
achieved and labor has progressed to 5 - 6 cm dilation. Maximum
dose of oxytocin for multiparae - 16 miliunits/min and nulliparae-
32 miliunits/min. iii) IV/IM: 5 -10 units. iv) IV : 5-10 units followed
by IV infusion at 10 units/hour. The dosing is individualized based
on maternal, fetal response and product insert / protocol
Oxytocin 5 units & Ergometrine Maleate 0.5 G02AC01-900-P30-01-XXX C+ i)Prevention and treatment of postpartum haemorrhage None i) 1 ml IM, may be repeated after 2 hours. Should not exceed 3 ml
mg/ml Injection associated with uterine atony. ii)Active management of within 24 hours ii) For routine management of third stage of
third stage of labour labour, 1 ml IM following delivery of the anterior shoulder or
immediately after delivery of the child
Paclitaxel 6mg/ml Injection L01CD01-000-P30-01-XXX A* i) Breast carcinoma: Initial treatment of advanced or i) 175 mg/m2 IV over 3 hours every 3 weeks ii) 175 mg/m2 IV
metastatic and also second line after failure of standard over 3 hour followed by cisplatin 75 mg/m2 in every 3 weeks or
therapy. ii) Ovarian carcinoma: First Line in combination 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2
with a platinum compound for advanced metastatic every 3 weeks iii) 135 mg/m2 IV over 24 hours followed by
carcinoma of the ovary; Second line for advanced cisplatin 75 mg/m2 every 3 weeks
metastatic carcinoma of the ovary iii) Non-small cell lung
carcinoma: First line in combination with platinum
compound or as single agent
Palbociclib 100mg capsules L01XE33-000-C11-02-XXX A* Indicated for the treatment of hormone receptor (HR)- None 125 mg capsule taken orally once daily for 21 consecutive days
positive, human epidermal growth factor receptor 2 followed by 7 days off treatment to comprise a complete cycle of
(HER2)-negative locally advanced or metastatic breast 28 days. Palbociclib should be taken with food. For dose
cancer in combination with an aromatase inhibitor as modification, refer package insert
initial endocrine based therapy in postmenopausal
women.
Palbociclib 125mg Capsules L01XE33-000-C11-03-XXX A* Indicated for the treatment of hormone receptor (HR)- None 125 mg capsule taken orally once daily for 21 consecutive days
women.
Palbociclib 75mg capsules L01XE33-000-C11-01-XXX A* Indicated for the treatment of hormone receptor (HR)- None 125 mg capsule taken orally once daily for 21 consecutive days
women.
Paliperidone 100mg Prolonged Release N05AX13-000-P20-04-XXX A* Second or third line treatment of acute and maintenance None Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM
Injection treatment of schizophrenia in adults 100 mg eq on one week later. Maintenance: Monthly dose of 75
mg eq ( this can be increased or decreased based on individual
patient's tolerability and/or efficacy). These monthly
maintenance dose can be administered in either the deltoid or
gluteal muscle
April 2023 133


Paliperidone 150mg Prolonged Release N05AX13-000-P20-05-XXX A* Second or third line treatment of acute and maintenance None Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM
Injection treatment of schizophrenia in adults 100 mg eq on one week later. Maintenance: Monthly dose of 75
patient?s tolerability and/or efficacy). These monthly maintenace
dose can be administered in either the deltoid or gluteal muscle
Paliperidone 175mg/0.875ml Prolonged- N05AX13-126-P20-01-001 A* For the maintenance treatment of schizophrenia in adult None Apply 3.5 as a dose multiplier to the previous 1-month injection
Release for Intramuscular Injection patients who have been adequately treated with the 1- dose, and administer every 3 months
month paliperidone palmitate injectable product for at
least four months.
Paliperidone 263mg/1.315ml Prolonged- N05AX13-126-P20-02-001 A* For the maintenance treatment of schizophrenia in adult Apply 3.5 as a dose multiplier to the previous 1-month injection
least four months.
Paliperidone 350mg/1.750ml Prolonged- N05AX13-126-P20-03-001 A* For the maintenance treatment of schizophrenia in adult None Apply 3.5 as a dose multiplier to the previous 1-month injection
least four months.
Paliperidone 3mg Extended Released Tablet N05AX13-000-T50-01-XX A* Second or third line treatment of schizophrenia ADULT 6 mg once daily in the morning, adjusted if necessary;
usual range 3 -12 mg daily. Renal impairment (creatinine
clearance between 10-50 mL/min) 3 mg once daily. Avoid if
creatinine clearance less than 10mL/min
Paliperidone 50mg Prolonged Release Injection N05AX13-000-P20-02-XXX A* Second or third line treatment of acute and maintenance Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM
treatment of schizophrenia in adults 100 mg eq on one week later. Maintenance: Monthly dose of 75
Paliperidone 525mg/2.625ml Prolonged- N05AX13-126-P20-04-001 A* For the maintenance treatment of schizophrenia in adult Apply 3.5 as a dose multiplier to the previous 1-month injection
least four months.
Paliperidone 6 mg Extended Released Tablet N05AX13000T5002XX A* Second or third line treatment of schizophrenia ADULT 6 mg once daily in the morning, adjusted if necessary;
Paliperidone 75 mg Prolonged Release Injection N05AX13000P2003XX A* Second or third line treatment of acute and maintenance Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM
treatment of schizophrenia in adults 100 mg eq on one week later. Maintenance: Monthly dose of 75
Paliperidone 9 mg Extended Released Tablet N05AX13000T5004XX A* Second or third line treatment of schizophrenia ADULT 6 mg once daily in the morning, adjusted if necessary;
Palivizumab 100mg Injection J06BB16000P3001XX A* For the prevention of serious lower respiratory tract 15 mg/kg IM once a month during season of RSV risk
disease caused by respiratory syncytial virus (RSV) in
paediatric patients at high risk of RSV disease
April 2023 134


Pamidronate Disodium 30 mg Injection M05BA03520P3001XX A* Hypercalcaemia of malignancy (tumour -induced Dose depends on the initial serum calcium levels. Doses range
hypercalcaemia) from a single infusion of 30 - 90 mg
Pamidronate Disodium 90 mg Injection M05BA03520P3002XX A* Hypercalcaemia of malignancy (tumour -induced Dose depends on the initial serum calcium levels. Doses range
hypercalcaemia) from a single infusion of 30 - 90 mg
Pancreatin 150 mg Capsule (equivalent to A09AA02-000-C10-01-XXX A/KK Treatment of pancreatic exocrine insufficiency - Initially 1 - 2 capsules with each meal. May increase to 5 - 15
amylase 8000 units, lipase 10,000 units and capsules daily Dosing is individualised and according to product
protease 600 units) insert/protocol
Pancuronium Bromide 2 mg / ml lnjection M03AC01320P3001XX B Muscle relaxant as an adjunct to general anaesthesia ADULT: Initially 50 - 100 mcg/kg IV, then 10 - 20 mcg/kg as
required. CHILD > 2 YEARS: Initially 60 - 100 mcg/kg then 10 - 20
mcg/kg. Intensive care, by IV, 60 mcg/kg every 60 - 90 minutes
Pantoprazole 40 mg Tablet A02BC02-000-T10-01-XXX B i) Helicobacter pylori eradication ii) Peptic ulcer disease - i) 40 mg twice daily in combination with any of the 2 antibiotics
iii) Erosive and non-erosive reflux oesophagitis (GERD (Clarithromycin 500 mg twice daily, Amoxicillin 1 g twice daily or
and NERD) iv) Zollinger-Ellison Syndrome v) Prevention Metronidazole 400 mg twice daily) for 1-2 weeks ii) 40 mg daily
of NSAID induced gastropathy for 2 - 4 weeks iii) 20 - 40 mg daily on morning for 4 weeks iv)
Initially 80 mg daily, dose can be titrated up or down as needed.
v) 20 mg daily. CHILD not recommended
Pantoprazole 40mg Injection A02BC02-000-P30-01-XXX A/KK Short term use for symptomatic improvement and - 40 mg twice daily until oral administration can be resumed. CHILD
healing of gastrointestinal diseases which require a not recommended
reduction in acid secretion: • Duodenal ulcer • Gastric
ulcer • Moderate and severe reflux esophagitis •
Zollinger-Ellison-Syndrome and other pathological
hypersecretory conditions
Papaverine HCl 120 mg/10ml Injection A03AD01110P3002XX A Relief of cerebral and peripheral ischaemia associated ADULT: 30 - 120 mg may be repeated every 3 hours as necessary.
with arterial spasm and myocardial ischaemia CHILD: 6 mg/kg daily in 4 divided doses
complicated by arrhythmias
Paracetamol 10mg/ml Solution for IV Infusion N02BE01000P3101XX A Mild to moderate pain and pyrexia Body Weight (BW) ≤ 10kg: 7.5mg/kg, max: 30mg/kg >10kg to ≤
33kg: 15mg/kg, max 60mg/kg not exceeding 2g >33kg to ≤ 50kg:
15mg/kg, max 60mg/kg not exceeding 3g >50kg (with risk of
hepatotoxicity): 1g, max 3g BW >50kg (without risk of
hepatotoxicity): 1g, max 4g OR as in the product leaflet
Paracetamol 120mg/5 ml Syrup N02BE01000L9001XX C+ Mild to moderate pain and pyrexia None CHILD: up to 1 year: 60 - 120 mg. 1 - 5 years: 120 - 240 mg. 6 - 12
years: 240 - 480 mg per dose. Repeat every 4 - 6 hours when
necessary. Maximum of 4 doses in 24 hours
Paracetamol 125mg Suppository N02BE01000S2002XX C+ Symptomatic relief of fever and post operative pain None ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6
whom cannot tolerate oral preparations. hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250
mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary,
maximum 4 doses in 24 hours. INFANTS under 3 months should
not be given Paracetamol unless advised by doctor; a dose of 10
mg/kg (5 mg/kg if jaundiced) is suitable.
Paracetamol 250 mg Suppository N02BE01000S2001XX B Symptomatic relief of fever and post operative pain None ADULT & CHILDREN more than 12 years old: 500mg - 1g every 4-6
whom cannot tolerate oral preparations. hours CHILD 6 - 12 years : 250 - 500 mg; 1 - 5 years : 125 - 250
mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary,
maximum 4 doses in 24 hours. INFANTS under 3 months should
not be given Paracetamol unless advised by doctor; a dose of 10
mg/kg (5 mg/kg if jaundiced) is suitable.
April 2023 135


Paracetamol 250 mg/5 ml Syrup N02BE01000L8002XX C+ Mild to moderate pain and pyrexia None CHILD: 6 - 12 years: 250 - 500 mg per dose. Repeat every 4 - 6
hours when necessary. Maximum of 4 doses in 24 hours
Paracetamol 500 mg Tablet N02BE01000T1001XX C+ Mild to moderate pain and pyrexia None ADULT: 500 - 1000 mg every 4 - 6 hours, maximum of 4 g daily
Paraffin Mole Alba (White Soft Paraffin) D02AC00000G5001XX C Xerosis and ichthyosis Apply to the affected area
Paraffin Mole Flava D02AC00000G5002XX C Xerosis and ichthyosis Apply to the affected area
Parecoxib Sodium 40mg Injection M01AH04520P3001XX A* Management of post operative pain in the immediate 40 mg followed by 20 or 40 mg every 6 to 12 hours, as required,
post operative setting only not exceeding daily dosage of 80 mg. There is limited clinical
experience with parecoxib treatment beyond three days. Reduce
the initial dose by 50% in elderly less than 50 kg, with a maximum
daily dosage of 40 mg.
Pazopanib Hydrochloride 200 mg Tablet L01XE11110T1001XX A* For treatment of advanced and/or metastatic renal cell Restriction: i) KPS ≥ 70% ii) Clear cell histology iii) No brain Recommended dose is 800 mg ORALLY once daily. Should be
carcinoma (RCC) metastasis iv) Haemoglobin ≥ 9g/dl v) Creatinine ≤2x the taken without food (at least one hour before or two hours after
ULN vi) Corrected calcium < 12mg/dl vii) Platelet count of meal). The dose should not exceed 800 mg.
>100x103/uL viii) Neutrophil count >1,500/mm3
Pazopanib Hydrochloride 400 mg Tablet L01XE11110T1002XX A* For treatment of advanced and/or metastatic renal cell Restriction: i) KPS ≥ 70% ii) Clear cell histology iii) No brain Recommended dose is 800 mg ORALLY once daily. Should be
carcinoma (RCC) metastasis iv) Haemoglobin ≥ 9g/dl v) Creatinine ≤2x the taken without food (at least one hour before or two hours after
ULN vi) Corrected calcium < 12mg/dl vii) Platelet count of meal). The dose should not exceed 800 mg.
>100x103/uL viii) Neutrophil count >1,500/mm3
Pegfilgrastim Pre-filled Syringe 6 mg/0.6 ml (10 L03AA13000P5001XX A* Reduction in the duration of neutropenia, the incidence Adults (≥18 years): One 6 mg dose (a single pre-filled syringe) of
mg/ml) of febrile neutropenia and the incidence of infection as pegfilgrastim for each chemotherapy cycle, administered as a
manifested by febrile neutropenia in patients treated subcutaneous injection approximately 24 hours following
with cytotoxic chemotherapy for malignancy (with the cytotoxic chemotherapy. Renal impairment: Pharmacokinetics of
exception of chronic myeloid leukaemia and pegfilgrastim is not expected to be affected by renal impairment.
myelodysplastic syndromes) Hepatic impairment: Pharmacokinetics of pegfilgrastim is not
expected to be affected by hepatic impairment. Paediatric
population: Insufficient data to recommend the use of
pegfilgrastim in children and adolescents under 18 years of age.
Peginterferon Alpha-2a 135 mcg Prefilled L03AB11-000-P50-02-XXX A* i) Chronic hepatitis C alone or in combination with other Initiated by Hepatologist and Gasteroenterologist only. i) 180 mg once weekly. Treatment duration may vary depending
Syringe antiviral drugs ii) For the treatment of both HbeAg- on HCV genotype. ii) 180 mcg weekly SC for 48 weeks Dosage,
positive and HbeAg-negative chronic hepatitis B with including treatment duration, is individualised and according to
compensated liver disease and evidence of viral product insert/protocol
replication who are not responding or tolerating oral
antiviral therapy
Peginterferon Alpha-2a 180 mcg Prefilled L03AB11-000-P50-01-XXX A* i) Chronic hepatitis C alone or in combination with other Initiated by Hepatologist and Gasteroenterologist only) i) 180 mg once weekly. Treatment duration may vary depending
Syringe antiviral drugs ii) For the treatment of both HbeAg- on HCV genotype. ii) 180 mcg weekly SC for 48 weeks Dosage,
positive and HbeAg-negative chronic hepatitis B with including treatment duration, is individualised and according to
compensated liver disease and evidence of viral product insert/protocol
replication who are not responding or tolerating oral
antiviral therapy
Pegylated Interferon Alpha-2b 100 mcg L03AB10000P5003XX A* Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for
Injection at least 6 months. Combination therapy: 1.5 mcg/kg/week SC in
combination with ribavirin capsules. ii) 1-1.5 mcg/kg once weekly
for at least 24 weeks and up to 52 weeks.
April 2023 136


Pegylated Interferon Alpha-2b 50 mcg Injection L03AB10000P5001XX A* Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for
at least 6 months. Combination therapy: 1.5 mcg/kg/week SC in
Pegylated Liposomal Doxorubicin HCl 20 L01DB01110P3003XX A* i) For patients with platinum-resistant ovarian cancer 50 mg/m2 IV every 4 weeks for as long as the disease does not
mg/vial where the disease relapses within 6 months after progress & patient continues to tolerate treatment.For doses <90
completion of the initial platinum-based chemotherapy mg: dilute in 250 ml Dextrose 5 % in Water. For doses >90 mg:
ii) For patients with platinum-sensitive ovarian cancer dilute in 500 ml Dextrose 5 % in Water. To minimize the risk of
where the disease responds to first-line platinum-based infusion reactions, the initial dose is administered at a rate no
therapy but relapses 12 months or more after greater than 1 mg/minute. Renal impairment: No dose
completion of the initial platinum based chemotherapy. adjustment required in patients with creatinine clearance 30-156
As third line therapy for very selected patients. (Gyne ml/min, no pharmacokinetic data are available in patients with
Oncology Specialist only) creatinine clearance of less than 30 ml/min. Hepatic impairment:
At initiation of therapy: Bilirubin 1.2 - 3.0 mg/dl, the first dose is
reduced by 25 %, Bilirubin > 3.0 mg/dl, the first dose is reduced
by 50 %.
Pemetrexed Disodium 100 mg Injection L01BA04-016-P30-02-XXX A* i) In combination with Cisplatin for the 2nd line Initial therapy 500 mg/m(2) IV over 10 minutes on day 1,
treatment of patients with locally advanced or followed 30 minutes later by cisplatin 75 mg/m(2) infused IV over
metastatic non-small cell lung cancer (NSCLC) other than 2 hours; repeat cycle every 21-days. Prior chemotherapy : 500
predominantly squamous cell histology ii) Malignant mg/m(2) IV, as a single-agent, over 10 minutes on day 1 of each
pleural mesothelioma 21-day cycle Dosing is according to product insert / protocol.
Pemetrexed Disodium 500 mg Injection L01BA04016P3001XX A* i) In combination with Cisplatin for the 2nd line Initial therapy 500 mg/m(2) IV over 10 minutes on day 1,
treatment of patients with locally advanced or followed 30 minutes later by cisplatin 75 mg/m(2) infused IV over
metastatic non-small cell lung cancer (NSCLC) other than 2 hours; repeat cycle every 21-days. Prior chemotherapy : 500
predominantly squamous cell histology ii) Malignant mg/m(2) IV, as a single-agent, over 10 minutes on day 1 of each
pleural mesothelioma 21-day cycle Dosing is according to product insert / protocol.
Pentamidine Isethionate 300 mg Injection P01CX01198P3001XX A* Only for the treatment of pneumonia due to 4 mg/kg once daily by slow IV infusion for at least 14 days
Pneumocytosis carinii
Pentoxifylline 400 mg Tablet C04AD03000T1001XX A/KK Peripheral vascular disease 400 mg 2 - 3 times daily
Peracetic Acid and Hydrogen Peroxide V07AV00000L9906XX A High level disinfectant or sterilant for heat labile Immersion time based on manufacturer recommendation
endoscopes
Perindopril 10mg and Indapamide 2.5mg film C09BA04-900-T10-03-XXX A/KK As substitution therapy for treatment of essential None 1 tablet daily
coated tablet hypertension, in patients already controlled with
perindopril and indapamide given concurrently at the
same dose level.
April 2023 137


Perindopril 4 mg and Indapamide 1.25 mg C09BA04-900-T10-01-XXX B Essential hypertension, for patients whose blood None One tablet daily, preferably taken in the morning and before a
Tablet pressure is insufficiently controlled by perindopril alone. meal.
Perindopril 4 mg Tablet C09AA04000T1001XX B i) Hypertension ii) Stable coronary artery disease iii) i) & ii) Initial: 4mg once daily Max. 8mg daily iii) Initial: 2mg once
Heart failure daily Maintenance: 4mg once daily Dosing is individualised and
Perindopril 8 mg Tablet C09AA04000T1002XX B i) Hypertension ii) Stable coronary artery disease Initial: 2-4mg once daily Maintenance: up to 8mg once daily
Peritoneal Dialysis Solution (1.5% Dextrose) B05DB00908H2001XX B For chronic renal disease requiring dialysis and for acute Dose depending on clinical cases
renal failure
Peritoneal Dialysis Solution (4.25% Dextrose) B05DB00908H2002XX B For chronic renal disease requiring dialysis and for acute Dose depending on clinical cases
renal failure
Peritoneal Dialysis with 7.5% Icodextrin B05DB00908H2003XX A* As a once replacement for a single glucose exchange as Administered as a single daily exchange for the long dwell in
Solution part of a continuous ambulatory peritoneal dialysis continuous ambulatory peritoneal dialysis or automated
(CAPD) or automated peritoneal dialysis (APD) regimen peritoneal dialysis. The recommended dwell time is 8 to 16 hours
for the treatment of chronic renal failure, particularly for
patients who have lost ultra filtration on glucose
solutions
Permethrin 1% w/v Lotion. P03AC04000L6002XX B For topical treatment of head lice. Apply lotion onto clean towel dried hair ensuring every strand
comes in contact with lotion for at least 10 minutes. Rinse
completely. Re-apply after 10 days to ensure total recovery.
Permethrin 5% w/v Lotion P03AC04000L6001XX A/KK Treatment of scabies Two applications needed one week apart. Apply thoroughly to all
body parts from neck down. Leave overnight for 8 - 14 hours.
Washed off. Reapply after one week. Not recommended for
children less than 2 months of age.
Perphenazine 4 mg Tablet N05AB03-000-T10-01-XXX B i) Treatment of psychotic disorders ii) Used in the ADULT: Initially 4 mg 3 times daily adjusted according to
treatment of behavioural disorders in adults, in the aged response, maximum 24 mg daily. ELDERLY: 1/4 to 1/2 adult dose.
and in children CHILD: The lower range of the adult dosage may be used in
children over 12. It should start with the smallest dose e.g 2mg,
then titrate accordingly.
Pethidine HCl 100 mg/2 ml Injection N02AB02110P3002XX B For relief of moderate to severe pain (medical and ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary.
surgical), pre-anaesthetic medication and obstetrical CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1
analgesia - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
Pethidine HCl 50 mg/ml Injection N02AB02110P3001XX B For relief of moderate to severe pain (medical and ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary.
surgical), pre-anaesthetic medication and obstetrical CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1
analgesia - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
Phenobarbitone 30mg Tablet N03AA02-000-T10-02-XX B Epilepsy None ADULT: 60 - 180 mg daily on. CHILD: Up to 8 mg/kg daily
Phenobarbitone Sodium 200mg/ml Injection N03AA02-520-P30-01-XXX B All forms of epilepsy except absence seizures. None ADULT: 10 mg/kg IV at a rate of not faster than 100 mg/minute.
Initial maximum dose does not exceeding 1 gm. Daily
maintenance of 1 - 4 mg/kg/day. CHILD: 3- 5mg per kg body
weight as a single dose by intramuscular injection. Dosing is
according to product insert.
Phenol 80% w/w Liquid D08AE03000L5001XX C As disinfectant Use in various dilutions
Phenoxybenzamine HCl 100 mg/2 ml Injection C04AX02110P3001XX A* Hypertensive episodes associated with 1 mg/kg daily over at least 2 hours into large vein. Do not repeat
phaeochromocytoma within 24 hours.
April 2023 138


Phenoxymethyl Penicillin 125 mg Tablet J01CE02500T1001XX C i) Treatment or prophylaxis of infections caused by i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 -
susceptible organisms ii) Prophylactic, rheumatic fever 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 -
250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6
- 8 hours. Maximum: 3 g/day
Phenoxymethyl Penicillin 125 mg/5 ml Syrup J01CE02500F2101XX C Treatment or prophylaxis of infections caused by CHILD: Up to 1 year: 62.5 mg 6 hourly; 1 - 5 years: 125 mg 6
susceptible organisms hourly; 6 - 12 years: 250 mg 6 hourly
Phenoxymethyl Penicillin 250 mg Tablet J01CE02500T1002XX C i) Treatment or prophylaxis of infections caused by i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 -
susceptible organisms ii) Prophylactic, rheumatic fever 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 -
250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6
- 8 hours. Maximum: 3 g/day
Phenylephrine HCI 2.5% Eye Drops S01FB01-110-D20-01-XXX B For pupillary dilation in uveitis, for refraction without None Mydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution,
cyclopegic. For fundoscopy and other diagnostic repeated in one hour if necessary. Chronic mydriasis: 1 drop of a
procedures 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior
synechiae (treatment) or synechiae, posterior (prophylaxis): 1
drop of a 2.5% or 10% solution, repeated in one hour if
necessary, not to exceed three times a day. Treatment may be
continued the following day, if necessary
Phenytoin Sodium 100mg Capsule N03AB02-520-C10-02-XX B Control of tonic-clonic (grand mal) and psychomotor None ADULT Initial: 300mg daily in 3 equally divided doses
seizures Maintenance: 300-400 daily in 3-4 equally divided doses Max.
dose: 600mg daily CHILD Initial: 5mg/kg/day in 2-3 equally
divided doses Maintenance: 4-8mg/kg/day Max. dose: 300mg
daily Dosing is according to product insert.
Phenytoin Sodium 125mg/5ml Suspension N03AB02-520-L80-01-XX B Control of tonic-clonic (grand mal) and psychomotor None ADULT: Initial: 125mg 2-3 times daily. Max. dose: 625mg daily
seizures CHILD: Initial: 5mg/kg/day in 2-3 divided doses Maintenance: 4-8
mg/kg/day in equally divided doses Max. dose: 300mg daily
Dosing is according to product insert.
Phenytoin Sodium 30mg Capsule N03AB02-520-C10-01-XX B Control of tonic-clonic (grand mal) and psychomotor None ADULT Initial: 300mg daily in 3 equally divided doses
seizures Maintenance: 300-400 daily in 3-4 equally divided doses Max.
dose: 600mg daily CHILD Initial: 5mg/kg/day in 2-3 equally
divided doses Maintenance: 4-8mg/kg/day Max. dose: 300mg
daily Dosing is according to product insert.
Phenytoin Sodium 50mg/ml lnjection N03AB02520P3001XX B i) Control of status epilepticus of the tonic-clonic (grand None i) ADULT Loading: 10-15mg/kg slow IV (max. 50mg per minute)
mal) type ii) Prevention and treatment of seizures Maintenance: 100mg orally or IV every 6-8 hours NEONATE &
occurring during or following neurosurgery. CHILD Loading: 15-20mg/kg IV slow IV (max. 1-3mg/kg/minute) ii)
100-200mg deep IM at approximately 4 hour intervals during
surgery and continued postoperative. Dosing is individualised and
Pilocarpine 1% Eye Drops S01EB01-110-D20-01-XXX B Miotics in chronic open-angle glaucoma None 1 drop 1 - 4 times a day
Pilocarpine 2% Eye Drops S01EB01-110-D20-02-XXX B Miotics in chronic open-angle glaucoma None 1 drop 1 - 4 times a day
Pimecrolimus 1% cream D11AH02-000-G10-01-XXX A* Short-term and intermittent long-term therapy of mild i) First line for periorbital eczema; ii) Second line for facial Apply a thin layer of the cream to the affected skin twice daily.
to moderate atopic dermatitis in non- eczema.
immunocompromised patients aged 2 years and older, in
whom the use of alternative, conventional therapies are
deemed inadvisable because of potential risks, or in the
treatment of patients who are not adequately
responsive to or intolerant of alternative, conventional
therapies.
April 2023 139


Piperacillin 4 g & Tazobactam 500 mg Injection J01CR05961P3001XX A* Febrile neutropenia, lower respiratory tract infection and Adult and children more than 12 years: 4.5g 6 hourly, for
severe sepsis neutropenia adult and children more than 50kg: 4.5g 6 hourly.
Children less than 50kg: 90mg/kg 6 hourly
Piperacillin Sodium 4 g Injection J01CA12520P4002XX A Infections due to Pseudomonas aeruginosa ADULT: 100 - 150 mg/kg IM/IV in divided doses. Increase to 200 -
300 mg/kg in severe infections & at least 16 g in life-threatening
infections. Single dose over 2 g: IV route only. Maximum: 24
g/day. CHILD: 50-75 mg/kg/dose every 6 - 8 hourly
Piracetam 1 g Injection N06BX03000P3001XX A* Treatment of cerebral functional impairment 30 - 160 mg/kg/day orally or parenterally 2 times daily or 3 to 4
times daily. Maximum: 24 g/day
Piracetam 1.2 g Tablet N06BX03000T1001XX A* Mild cognitive impairment, post concussional head Initially 7.2 g daily in 2 - 3 divided doses, increased according to
syndrome, head injury disorder, chronic vertigo and response by 4.8 g daily every 3 - 4 days to maximum of 20 g daily.
myoclonus CHILD under 16 years not recommended
Piracetam 20% Solution N06BX03000L5001XX A* Children with learning disability, progressive myoclonic 30 - 160 mg/kg/day orally. To be given 2 times daily or 3 - 4 times
epilepsy and hypoxia daily. Maximum 24 g/day
Piribedil 50 mg Tablet N04BC08000T5001XX A* Parkinson disease As monotherapy: 150 - 250 mg as 3 - 5 divided doses daily. As
combination with L-dopa therapy: 50 - 150 mg daily (50 mg per
250 mg of L-dopa)
Piroxicam 10 mg Capsule M01AC01-000-C10-01-XXX A/KK Musculoskeletal and joint disorders such as ankylosing - Max: 20 mg daily as a single dose, or in divided doses if necessary
spondylitis, osteoarthritis, rheumatoid arthritis, and
juvenile rheumatoid arthritis, in soft-tissue disorders.
Pizotifen 0.5 mg Tablet N02CX01253T1001XX B Prophylactic treatment of vascular headache Starting with 0.5mg daily, the dosage should be progressively
increased. The average maintenance dosage is 1.5mg daily in
divided doses or as a single dose at night. Max dose: 4.5 mg/day
and 3 mg/dose. Child: >2 yr: Up to 1.5 mg daily in divided doses.
Max dose: 1 mg/dose.
Pneumococcal Polysaccharide and Non- J07AL01-000-P30-01-XXX C+ Active immunisation of infants and children against Immunisation for newborn cohort eligible for National 2-dose primary series (2+1): A series consisting of 3 doses, each
Typeable Haemophilus Influenzae (NTHi) disease caused by Streptococcus pneumoniae vaccine Immunisation Programme (NIP) of 0.5 ml may be given. Dosing is according to Immunisation
Protein D Conjugate Vaccine (10-valent, serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross- Schedule under NIP
adsorbed) reactive serotype 19A (including sepsis, meningitis,
pneumonia, bacteraemia and acute otitis media) and
against acute otitis media caused by Non-Typeable
Haemophilus influenzae.
April 2023 140


Pneumococcal polysaccharide conjugate J07AL01-000-P30-02-XXX A*, C+ 1. Active immunisation for the prevention of INDICATION (1): i. Immunisation for newborn cohort For indication 1(i): 2-dose primary series (2+1): A series consisting
vaccine (adsorbed) 13-valent injection pneumococcal disease caused by Streptococcus eligible for National Immunisation Programme (NIP) of 3 doses, each of 0.5 ml may be given. Dosing is according to
pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, (Prescriber Category: C+) ii. Paediatric population without Immunisation Schedule under NIP. For other indications: ADULT:
19A, 19F and 23F (including invasive disease, pneumonia history of vaccination or not eligible for NIP, who have to be administered as a single dose to adults 18 years and older
and acute otitis media) in infants, children and associated risk in IPD with following conditions (Prescriber including those previously vaccinated with a pneumococcal
adolescents from 2 months to 17 years of age: - Category: A*): a) Infants/children from 2 months of age polysaccharide vaccine. The need for re-vaccination with a
PRESCRIBER CATEGORY C+: National Immunisation with one of the following conditions: • Functional or subsequent dose of PCV13 has not been established. INFANT:
Programme (NIP) - PRESCRIBER CATEGORY A*: anatomical asplenia; • Cochlear implant; • Congenital Infants aged 2-6 months: i) Three-dose primary series: The
Immunisation other than NIP 2. Active immunisation for immunodeficiency; • Haematopoietic and solid organ recommended immunisation series consists of four doses, each
the prevention of pneumococcal disease caused by transplant; • Cerebrospinal fluid leakage b) High risk of 0.5 mL. The primary infant series consists of three doses, with
Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, infants/children from 2 months old with one of the the first dose usually given at 2 months of age and with an
7F, 9V, 14, 18C, 19A, 19F and 23F in adults aged 18 years following conditions: • Immunosuppression (including interval of at least 1 month between doses. The first dose may be
and older. - PRESCRIBER CATEGORY A* asymptomatic HIV) • Nephrotic syndrome • Chronic lung given as early as six weeks of age. The fourth (booster) dose is
or heart disease (adapted from Paediatric Protocols for recommended between 12-15 months of age, or ii) Two-dose
Malaysia Hospital, 3rd Edition) • Chronic liver disease primary series: A series consisting of three doses, each of 0.5 mL
INDICATION (2) (Prescriber Category: A*): i. Adult may be considered. The first dose may be given from the age of 2
population aged 18 years and above with associated risk months, with a second dose 2 months later. The third (booster)
in IPD with following conditions: a) Functional or dose is recommended between 11-15 months of age. Preterm
anatomical asplenia; b) Cochlear implant; c) Congenital infants (<37 weeks gestation): The recommended immunisation
immune-deficiency; d) Haematopoietic and solid organ series consists of four doses, each of 0.5 mL. The primary infant
transplant. ii. Adult population aged 60 years and above series consists of three doses, with the first dose given at 2
with associated risk in IPD with following conditions: a) months of age and with an interval of at least 1 month between
Chronic lung diseases, including chronic obstructive doses. The first dose may be given as early as six weeks of age.
pulmonary disease (COPD), emphysema & asthma The fourth (booster) dose is recommended between 11 and 15
(requiring frequent hospital visit & use of multiple months of age. Unvaccinated infants and children ≥ 7 months of
medications); b) Chronic liver disease including cirrhosis, age Infants aged 7-11 months: Two doses, each of 0.5 ml, with an
biliary atresia, chronic hepatitis; c) Chronic cardiac interval of at least 1 month between doses. A third dose is
disease, including congestive heart failure, congenital recommended in the second year of life. CHILDREN: Children
heart disease, and cardiomyopathies. aged 12-23 months: Two doses, each of 0.5 ml, with an interval
of at least 2 months between doses. Children and adolescents
aged 2 years to 17 years: One single dose of 0.5 ml. Young
Children (12-59 months) completely immunized with PCV (7
Pneumococcal Vaccine (Polyvalent) J07AL01-000-P30-03-XXX A Prevention of pneumococcal infections in high risk None Primary injection: 1 single injection (0.5 ml) only. Booster: Must
subjects from the age of 2 years including patient with a not be given within 5 years except in very high risk patient who
history of splenectomy or scheduled splenectomy received the vaccine while under immunosuppressive treatment
Podophyllum 10 - 20% Paint D06BB04000L7001XX B External anogenital warts Apply 2 - 3 drops carefully to lesion after protecting surrounding
area with vaseline. Wash off after 6 hours or if feel burning
sensation and repeat 2 - 3 times weekly or once weekly
Poliomyelitis Oral Live Vaccine J07BF02000D5001XX C+ Immunisation against poliomyelitis 0.1ml (two drops) by oral. Dosing is according to local and WHO
recommendations.
Polycitra Syrup A12BA02955L9001XX C For treatment of calcium and uric acid stones The usual dose of potassium citrate is 30 - 60 mEq/day orally in 3
or 4 doses with meals or within 30 minutes after meals. ADULT:
15 ml 3 times daily well diluted with water. CHILD 5-15 ml 3 times
daily, after meals and at bedtime.
April 2023 141


Polyethylene Glycol/Macrogol 4000 Powder A06AD15-000-F21-01-XXX A Bowel cleansing prior to colonoscopy, radiological None 1 sachet dissolved in 1 L of water and to be consumed within 1
examination or colonic surgery. Suitable for patients hour. Usual dose: 3-4 L of oral solution are required. When
with heart failure or renal failure morning surgery is planned, the oral solution is given in the late
afternoon the day prior. If surgery is scheduled in afternoon, the
oral solution should be given on the same day for ingestion to be
completed three hours before surgery.
Polymyxin B Sulphate 10,000U, Neomycin S02CA03-991-D10-01-XXX B Treatment of bacterial infection and inflammation of the None 3-4 drops 3 – 4 times daily. Dosing is individualised and according
Sulphate 5mg and Hydrocortisone 10mg Ear external auditory meatus to product insert/protocol
Drops
Polymyxin B Sulphate 500,000 units Injection J01XB02-183-P40-01-001 A* i. Acute infections caused by susceptible strains of • Use as targeted therapy. As 2nd line for empirical Loading dose: 25,000 units/kg/dose. (Maximum dose: 2,000,000
Pseudomonas Aeruginosa. • Treatment of infections of therapy. • To be prescribed by Infectious Disease, General units / 2MU). Maintenance dose: 15,000 units/kg every 12 hours.
the meninges and blood stream, caused by susceptible Medicine & ICU specialist only (Maximum dose per day: 2,000,000 units / 2MU).
strains of Pseudomonas Aeruginosa. ii. Indicated in
serious infections caused by susceptible strains of the
following organisms, when less potentially toxic drugs
are ineffective or contraindicated: • H. influenzae,
specifically meningeal infections. • Aerobacter
aerogenes, specifically bacteremia. • Klebsiella
pneumoniae, specifically bacteremia.
Ponatinib 15mg Film-coated Tablet L01XE24-110-T32-02-XXX A* i) Adult patients suffering from Philadelphia-positive For indication (i): i) As third line treatment for Ph+ CML The recommended starting dose is 45 mg of ponatinib once daily.
(Ph+) chronic myeloid leukemia (chronic phase, resistant or intolerant to at least 2 tyrosine kinase Refer to the package insert for guidance on dose modifications or
accelerated phase or blast phase) for whom a treatment inhibitors with mutation other than T315I. ii) To be interruptions for the management of treatment-related toxicities,
with other c-abl tyrosine kinase inhibitors is not prescribed by Consultant Haematologist only. For drug-drug interactions as well as consideration for dose reduction
appropriate. ii) Adult patients suffering from T315I- indication (ii): To be prescribed by Consultant upon achievement of major cytogenetic response
positive Ph+ chronic myeloid leukemia (chronic phase, Haematologist only.
accelerated phase, or blast phase).
Posaconazole 100mg modified released (MR) J02AC04-000-T51-01-XXX A* Prophylaxis of invasive fungal infections in the following Loading dose of 300 mg (three 100 mg tablets) twice a day on the
tablet adult patients: i) Patient receiving remission-induction first day, then 300 mg (three 100 mg tablets) once a day
chemotherapy for acute myelogenous leukemia (AML) or thereafter.
myelodysplastic syndrome (MDS) expected to result in
prolonged neutropenia and who are at high risk of
developing invasive fungal infections. ii) Haematopoietic
stem cell transplant (HSCT) recipients who are
undergoing high-dose immunosuppressive therapy for
graft versus host disease and who are at high risk of
developing invasive fungal infections.
Potassium Chloride 0.15% w/v & Sodium A06AD10-921-L99-02-XXX B Prevention and treatment of potassium, sodium and None Dosage depends on the age, weight, clinical and biological (acid-
Chloride 0.9% w/v Injection chloride depletion base balance) conditions of the patient and concomitant therapy.
Maximum recommended dose of potassium is 2 to 3
mmol/kg/24hr
Potassium Chloride 1 g/10 ml Injection B05XA01-100-P30-01-XXX B For the correction of severe hypokalaemia and when None By slow IV infusion depending on the deficit or the daily
sufficient potassium cannot be taken by mouth maintenance requirements. 1 g diluted in 500 ml normal saline or
glucose and given slowly over 2 - 3 hours
Potassium Chloride 1 g/10 ml Mixture A12BA01-100-L21-01-XXX C Potassium depletion None 1 g once or twice daily until serum potassium is restored
Potassium Chloride 600 mg SR Tablet A12BA01-100-T50-01-XXX B For the treatment and specific prevention of None ADULT: 2 - 3 tablets daily. Severe deficiency: 9 - 12 tablets daily or
hypokalaemia according to the needs of the patient
April 2023 142


Potassium Citrate 3 g/10 ml and Citric Acid A12BA02-955-L21-01-XXX C For systemic or urinary alkalinization None ADULT: 10-20 ml 3 times daily, well diluted with water. CHILD up
Mixture to 1 year: 2.5 ml 3 times daily; 1 - 5 years: 5 ml 3 times daily; 6 -
12 years: 10 ml 3 times daily. To be taken well diluted with water,
after meals and at bedtime.
Potassium Dihydrogen Phosphate Injection B05XA06-170-P30-01-XXX A For treatment of hypophosphataemia None Up to 10mmol phosphate administered over 12 hours
Potassium Permanganate 1:10,000 Solution D08AX06-362-L99-01-XXX C+ Cleansing and deodorising suppurative eczematous None As soaks or wet dressing 1 - 3 times daily or as required
reactions and wounds
Potassium Permanganate 1:20,000 Solution D08AX06-362-L99-02-XXX C Cleansing and deodorising suppurative eczematous None As a bath once to twice daily or as required
reactions and wounds
Povidone Iodine 10% (equivalent to 1% iodine) D08AG02000L9902XX B Skin operation prior to surgery, in cleansing open To be applied undiluted in pre-operative skin disinfection and
Solution wounds, as an antiseptic for operative wounds infections general antisepsis.
Povidone Iodine 7.5% (equivalent to 0.75% D08AG02000L9901XX B As preoperative scrub for hands and skin Spread 5 ml over both hands and rub thoroughly for about 5
iodine) Scrub minutes. Rinse thoroughly. Repeat if desired. Pre-operative use
on patient: Apply scrub and rub thoroughly for about 5 minutes.
Rinse off using a sterile gauze saturated with water
Pralidoxime 25mg/ml Injection V03AB04-000-P30-02-XX B Antidote in the treatment of organophosphorus None Adult: Used in combination with atropine. Admin atropine via
insecticide poisoning and in the control of overdosage by IM/IV inj and repeat as needed until patient shows signs of
anticholinergic drugs used in the treatment of atropine toxicity. Maintain atropinisation for at least 48 hr. As
myasthenia gravis soon as the effects of atropine are observed, 1-2 g of pralidoxime
(chloride, iodide or mesilate) may be given via IM/IV inj. Repeat
dose after 1 hr, then every 8-12 hr, if necessary. In severe
poisoning, continuous infusion of 200-500 mg/hr may be given,
titrated according to response. Alternatively, pralidoxime chloride
may be given at an initial dose of 30 mg/kg via IV infusion over 20
minutes or IV inj over 5 minutes, followed by IV infusion at 8
mg/kg/hr. Max: 12 g/24 hr. Child: As mesilate: 20-60 mg/kg.
Renal impairment: Dose adjustment may be required.
Pramipexole Dihydrochloride 0.125 mg Tablet N04BC05-110-T10-01-XXX A* i) Treatment for signs and symptoms of advanced i) Dose escalation: 0.125 mg 3 times daily on week 1 then 0.25
idiopathic Parkinson's disease. It may be used as mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3.
monotherapy or in combination with levodopa ii) Increase by 0.75 mg at weekly intervals if needed up to maximum
Symptomatic treatment of idiopathic Restless Legs of 4.5 mg/day. Patient on levodopa: Reduce dose. Renal
Syndrome. impairment: In patient with creatinine clearance < 20ml/min, the
daily dose of pramipexole should be started at 0.125 mg daily
instead of 0.25mg and the maximum dose should not > 1.5 mg
daily ii) Dosing is according to Product Insert
Pramipexole Dihydrochloride 1 mg Tablet N04BC05-110-T10-02-XXX A* i) Treatment for signs and symptoms of advanced i) Dose escalation: 0.125 mg 3 times daily on week 1 then 0.25
idiopathic Parkinson's disease. It may be used as mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3.
monotherapy or in combination with levodopa ii) Increase by 0.75 mg at weekly intervals if needed up to maximum
Symptomatic treatment of idiopathic Restless Legs of 4.5 mg/day. Patient on levodopa: Reduce dose. Renal
Syndrome. impairment: In patient with creatinine clearance < 20ml/min, the
daily dose of pramipexole should be started at 0.125 mg daily
instead of 0.25mg and the maximum dose should not > 1.5 mg
daily ii) Dosing is according to Product Insert
April 2023 143


Pramipexole Dihydrochloride Extended Release N04BC05110T5001XX A Treatment for signs and symptoms of advanced Dose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week
0.375mg Tablet idiopathic Parkinson's disease. It may be used as 2, 1.5 mg/day on week 3. Increase by 0.75 mg at weekly intervals
monotherapy or in combination with levodopa if needed up to a max of 4.5 mg/day. Patient on l-dopa: reduce
dose. Renal Impairment: CrCl 30-50 mL/min Initially 0.375 mg
every other day. May be increased by 0.375 mg at weekly
intervals to max 2.25 mg/day
Pramipexole Dihydrochloride Extended Release N04BC05110T5003XX A Treatment for signs and symptoms of advanced Dose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week
1.5mg Tablet idiopathic Parkinson's disease. It may be used as 2, 1.5 mg/day on week 3. Increase by 0.75 mg at weekly intervals
monotherapy or in combination with levodopa if needed up to a max of 4.5 mg/day. Patient on l-dopa: reduce
dose. Renal Impairment: CrCl 30-50 mL/min Initially 0.375 mg
every other day. May be increased by 0.375 mg at weekly
intervals to max 2.25 mg/day
Prasugrel HCl 10 mg Tablet B01AC22110T1002XX A* Co-administered with aspirin, is indicated to reduce the Initiate treatment with a single 60mg oral loading dose. Continue
rate of thrombotic cardiovascular (CV) events (including at 10mg/5mg once daily with or without food. Patients should
stent thrombosis) in patients with acute coronary also take aspirin (75 mg - 325 mg) daily.
syndromes who are to be managed with percutaneous
coronary intervention (PCI) as follows: STEMI with or
without diabetes, UA and NSTEMI with diabetes, age
<75yrs old, weight >60kg, without history of TIA stroke
and clinically suspected clopidogrel resistance subset.
(Only to be used in Cardiology Centre as third line
treatment/ adjunctive therapy).
Pravastatin Sodium 20 mg Tablet C10AA03520T1001XX A/KK Hypercholesterolaemia and coronary heart disease 10 - 20 mg once daily. Maximum: 40 mg daily. In patients
intolerant or not responsive to other forms of therapy. concomitantly taking cyclosporine, with or without other
In health clinics, Pravastatin is restricted to HIV patients immunosuppressive drugs: Initial dose is 10mg/day and titration
on HAART. to higher doses should be performed with caution. Maximum
dose 20mg/day.
Prazosin HCl 1 mg Tablet C02CA01110T1001XX B Hypertension Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed
at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days:
further increased if necessary to maximum 20 mg daily
Pre/Post Natal Vitamin & Mineral Capsule A11AA03903C1001XX C+ Vitamin and mineral supplement for use during 1 capsule daily or based on individual requirements
pregnancy and lactation
Pre/Post Natal Vitamin & Mineral Tablet A11AA03903T1001XX C+ Vitamin and mineral supplement for use during 1 tablet daily or based on individual requirements
pregnancy and lactation
Prednisolone 2.5mg/5 ml Syrup H02AB06-000-L90-02-XX B i) Replacement therapy for primary and secondary None i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface
adrenocortical insufficiency ii) Adrenogenital syndrome daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2
iii) Other therapy mg/kg/day in divided doses every 6 - 8 hours or as a single daily
April 2023 144


Prednisolone 5mg Tablet H02AB06-000-T10-01-XX B i) Replacement therapy for primary and secondary None i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface
adrenocortical insufficiency ii) Adrenogenital syndrome daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2
iii) Other therapy mg/kg/day in divided doses every 6 - 8 hours or as a single daily
Prednisolone Acetate 1% ophthalmic S01BA04-122-D20-01-XXX A For steroid responsive inflammation of the palpebral and None 1 to 2 drops to be instilled into the conjunctival sac 2 to 4 times
suspension bulbar conjunctiva, cornea and anterior segment of the daily. During the initial 24 to 48 hours the dosage may be safely
globe. increased to 2 drops every hour. Care should be taken not to
discontinue therapy prematurely.
Pregabalin 150 mg Capsules N03AX16-000-C10-02-XXX A* i. Neuropathic pain ii. Fibromyalgia iii. Epilepsy Consultant/specialists for specific indications only, The dose range is 150 to 600 mg per day given in either two or
including Geriatricians three divided doses. Dosing is according to Product Insert
Pregabalin 50 mg capsule N03AX16-000-C10-03-XXX A* i. Neuropathic pain ii. Fibromyalgia iii. Epilepsy Consultant/specialists for specific indications only, The dose range is 150 to 600 mg per day given in either two or
Pregabalin 75mg Capsule N03AX16-000-C10-01-XXX A* i. Neuropathic pain ii. Fibromyalgia iii. Epilepsy Consultant/specialists for specific indications only, The dose range is 150 to 600 mg per day given in either two or
Primaquine 7.5mg base Tablet P01BA03-162-T10-01-XXX B i) Treatment of malaria ii) Prophylaxis together with a None 0.5mg/kg/day up to 30mg daily
schizonticide such as chloroquine
Probenecid 500 mg Tablet M04AB01000T1001XX A Hyperuricemia associated with gout and gouty arthritis 500 mg to 1000 mg twice daily
(for cases allergic to allopurinol or serum uric acid not
controlled by allopurinol alone)
Procaine Penicillin Fortified 4 MU Injection J01CE09702P4002XX B Treatment of infections due to Penicillin G-sensitive ADULT: 300,000 - 900,000 units (300 - 900 mg) IM daily. CHILD:
organisms Up to 1 year: 150 mg IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12
years: 600 mg IM daily
Procarbazine HCl 50 mg Capsule L01XB01110C1001XX A Lymphomas Adult: Monotherapy: Initially, 50 mg/day, increased by 50 mg
daily to 250-300 mg daily in divided doses. Continue doses until
max response is achieved or appearance of signs of toxicity.
Maintenance: 50-150 mg/day or 1-2 mg/kg daily until a
cumulative dose of at least 6 g. Combination Therapy: 100
mg/m2 on days 1-14 of each 4- or 6-wk cycle. Child: Initially, 50
mg/m2 daily, up to 100 mg/m2 adjust according to response.
Prochlorperazine Maleate 5mg Tablet N05AB04253T1002XX B i) Severe nausea and vomiting ii) Vertigo/labyrinthine Nausea and vomiting Adult: As maleate or mesilate: 20 mg,
disorders further doses are given if needed. Recommended buccal dose: As
maleate: 3-6 mg bid. Vertigo Adult: As maleate or mesilate: 15-30
mg daily, given in divided doses. May reduce gradually to 5-10 mg
daily. Recommended buccal dose: 3-6 mg bid. May be taken with
or without food.
Prochlorperazine Mesylate 12.5 mg/ml Injection N05AB04253P3001XX B i) Severe nausea and vomiting ii) Vertigo/labyrinthine Deep IM injection, 12.5 mg repeated if necessary after 6 hours
disorders and then followed by an oral dose. Not recommended in children
Procyclidine HCl 5 mg/ ml Injection N04AA04110P3001XX B i) All forms of Parkinson's disease (idiopathic paralysis i) Initial dose 2.5mg TDS, increasing by 2.5-5mg/day at intervals
agitants), post-encephalitis and arteriosclerosis ii) To of 2 or 3 days until the optimum clinical response is achieved.
control troublesome extrapyramidal symptoms induced Usual maintenance dose: 15-30mg/day. Max: 60mg/day ii) Initial
by neuroleptic drugs including pseudo-parkinsonism, dose 2.5mg TDS, increasing by 2.5mg daily until symptoms are
acute dystonic reactions and akathisia relieved. Usual maintenance dose: 10-30mg/day. IV Emergency: 5-
10 mg. IM Emergency: 5-10 mg as a single dose, may repeat after
20 mins if needed. Max: 20 mg/day.
April 2023 145


Progesterone 100 mg capsule G03DA04000-C10-01XX A* Oral: (i) Progesterone insufficiency (ii) Luteal - Oral route: (i) Daily dose of 200 to 300mg in two divided doses
insufficiency (iii)Menopause treatment associated with (ii)Daily dose of 200 to 300mg for 10 days per month, usually
estrogen therapy, Prevent risk of endometrial from 17th to the 26th day of the cycle. (iii) 200mg daily for 12 to
hyperplasia Vaginal: (iv) Progesterone substitution for 14 days in a month, the two last weeks of each cycle. Vaginal
ovarian proved women during complete deficiency (v) route: (iv) Taken with estrogen therapy: 100 mg given on the
Supplementation of the luteal phase during in vitro 13th and the 14th day of the cycle of transfer, then 200mg in
fertilization cycles (IVF) (vi)Supplementation of the luteal divided doses from the 15th to the 25th day of the cycle. From
phase during spontaneous or induced cycles 26th day and in the case of the onset of pregnancy, the dose is
(vii)Threatened abortion or prevention of repeated increased by 100mg per day each week, and rises to a maximum
abortions due to luteal insufficiency of 600mg per day divided into 3 intakes. This dosage will be
continued until the 60th day and until the 12th week of
pregnancy and no further. (v) 400 mg to 600mg per day, prior to
embryo transfer according to IVF protocol until the 12th week of
pregnancy (vi) 200mg - 300mg/day, from the 17th day of the
cycle for 10 days (vii)200 to 400mg daily in two divided doses
Progesterone 8% Vaginal Gel G03DA04-000-G30-01-XXX A* Progesterone supplementation of the luteal phase - 125g of 8% gel (90 mg progesterone) intravaginally daily from the
day of embryo transfer until confirmation of pregnancy in which
the therapy should be continued for a total treatment duration of
30 days
Prolase Tablet M09AB00000T1001XX B Oedema and inflammation in conjunction with other 2 tablet 4 times daily for the first day, then 1 tablet 4 times daily
physical or chemotherapeutic measures for at least 5 days.
Promethazine HCl 25 mg/ml Injection R06AD02-110-P30-01-XXX B i) Allergic conditions ii) Treatment and prevention of None i) Allergic Conditions Adult and adolescent dose: 25mg
vomiting including: - motion sickness - drug induced intramuscular or intravenous. May be repeated within 2 hours if
nausea - prevention and control of nausea and vomiting required. Children 2 years and older: intramuscularly-0.125mg/kg
associated with certain types of anaesthesia and surgery body weight every 4 to 6 hours OR 0,5mg/kg bodyweight at
bedtime as needed OR 6.25-12.5mg three times a day as needed
OR 25mg at bedtime as needed. ii. Treatment and prevention of
vomiting: - Motion Sickness Adult and adolescent dose: 25mg
twice a day as needed. Children: 0.5mg/kg every 12 hours as
needed OR 10 - 25mg twice a day as needed. - Anti Emetic
Therapy Adult and adolescent dose: 25mg initially and then 10 -
25mg every 4 - 6 hours as needed. Children: 0.25-0.5mg/kg every
4 to 6 hours as needed OR 10 - 25mg every 4 to 6 hours as
needed. Dosing is individualised and according to product
insert/protocol
Promethazine HCl 5mg/5ml Syrup R06AD02-110-L90-01-XXX B Allergic conditions None CHILD 2 - 5 years: 5 - 15 mg daily 5 - 10 years : 10 - 25 mg daily
Proparacaine HCI 0.5% Ophthalmic Drops S01HA04-110-D20-01-XXX B Topical anaesthesia in ophthalmic procedures None Deep anaesthesia:1 or 2 drops in the (eyes) every 5 to 10 minutes
for 3 to 5 doses. For minor surgical procedures: instill 1 to 2 drops
every 5 to 10 minutes for 1 to 3 doses. Tonometry and/or
tonography procedure: 1 to 2 drops in each eye before procedure.
Propiverine HCl 15 mg Tablet G04BD06110T1001XX A* Treatment of urinary incontinence, urgency and ADULT: 15 mg twice daily to 3 times daily, increase to 4 times
frequency in neurogenic detrusor overactivity (detrusor daily if required. Max dose: 60 mg daily. CHILD more than 5 years:
hyperreflexia) and in idiopathic detrusor overactivity 0.2 to 0.4 mg/kg per day in 2 divided doses
(overactive bladder)
April 2023 146


Propofol 10mg/ml (1%) Injection N01AX10000P9901XX A* Induction & maintenance of general anaesthesia. Adult: Induction: 20- 40 mg by injection or infusion every 10 sec.
Sedation of ventilated ICU patients Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr or
intermittent bolus inj of 20-50 mg. Child: >8 yr: Induction dose of
2.5 mg/kg. Maintenance dose: 9-15 mg/kg/hr by IV infusion or
intermittent bolus inj. Elderly: Including neurosurgical and
debilitated patients: Infuse at a rate of 20 mg every 10 sec.
Maintenance: 3-6 mg/kg/hr. Usual dose needed: 1-1.5 mg/kg.
Duration of use : Can be administered for a maximum period of 7
days. Sedation: 0.3 - 4 mg/kg/hour up to 3 days
Propofol 20mg/ml (2%) emulsion for injection N01AX10000P9902XX A* Induction & maintenance of general anaesthesia. Adult: IV Induction and maintenance of general anesth Induction:
of infusion Sedation of ventilated ICU patients 40 mg every 10 sec. Maintenance: 4-12 mg/kg/hr or intermittent
boluses of 20-50 mg. Sedation In diagnostic and surgical
procedures: Initial: 6-9 mg/kg/hr by infusion. Maintenance: 1.5-
4.5 mg/kg/hr. For ventilated patients: 0.3-4 mg/kg/hr. Monitor
lipid concentrations if duration of sedation >3 days.
Propranolol HCl 1 mg/ml Injection C07AA05110P3001XX A Arrhythmias and thyrotoxicosis crisis Slow IV injection in a dose of 1 mg over 1 minute, repeated if
necessary every 2 minutes until a maximum of 10 mg has been
given in conscious patients and 5 mg in patients under
anaesthesia. CHILD: 25 - 50 mcg/kg slow IV with appropriate
monitoring
Propranolol HCl 10 mg Tablet C07AA05110T1001XX B i) Hypertension ii) Angina pectoris iii) Myocardial infarct i) Initial: 40-80 mg twice daily Maintenance: 160-320 mg daily.
iv) Cardiac arrhythmias v) Migraine prophylaxis Max. 640 mg daily ii) Initial: 40 mg 2-3 times daily Maintenance:
vi)Hyperthyroidism vii) Hypertrophic obstructive 120-240 mg daily Max. 480mg daily iii) Initial (within 5-21 days of
cardiomyopathy MI): 40 mg 4 times daily for 2-3 days Maintenance: 80 mg twice
daily iv) 10-40 mg 3-4 times daily Max. 240 mg/day. v) Initial: 40
mg 2-3 times Maintenance: 80-160 mg daily Max. 240 mg/day. vi)
10-40 mg 3-4 times daily. Max. 240 mg/day. vii) 10-40 mg 3-4
times daily Dosing is individualised and according to product
insert / protocol.
Propranolol HCl 40 mg Tablet C07AA05110T1002XX B i) Hypertension ii) Angina pectoris iii) Myocardial infarct i) Initial: 40-80 mg twice daily Maintenance: 160-320 mg daily.
iv) Cardiac arrhythmias v) Migraine prophylaxis vi) Max. 640 mg daily ii) Initial: 40 mg 2-3 times daily Maintenance:
Hyperthyroidism vii) Hypertrophic obstructive 120-240 mg daily Max. 480mg daily iii) Initial (within 5-21 days of
cardiomyopathy viii) Portal hypertension MI): 40 mg 4 times daily for 2-3 days Maintenance: 80 mg twice
daily iv) 10 - 40 mg 3 - 4 times daily. Max. 240 mg/day. v) Initial:
40 mg 2-3 times. Maintenance: 80-160 mg daily. Max. 240
mg/day. vi) 10-40 mg 3-4 times daily. Max. 240 mg/day. vii) 10-40
mg 3-4 times daily viii) Initial: 40 mg twice daily Maintenance: 40-
80mg 3 times daily Max. 320mg daily Dosing is individualised and
Propylthiouracil 50 mg Tablet H03BA02000T1001XX B Hyperthyroidism ADULT Initially 300-450mg in 8 hourly intervals (can be given up
to 600-900mg/daily) until symptoms are controlled in 1-2
months. Maintenance 50-150mg daily for at least 12-18 months.
CHILDREN 6-10 years: 50-150mg. CHILDREN > 10 years: 150-
300mg daily. All doses are to be given in 3 divided doses daily.
Taken with food.
April 2023 147


Protamine Sulphate 10 mg/ml Injection V03AB14183P3001XX B Heparin overdose and following cardiac or arterial 5 ml slow IV injected over 10 minutes. If administered within 15
surgery or dialysis procedures when required to minutes of heparin dose, 1 mg will neutralise approximately 100
neutralize the effects of heparin administered during units of heparin. If longer time has elapsed, less protamine is
extracorporeal circulation required. Not more than 50 mg should be injected at any one
time. The dose is dependent on the amount and type of heparin
to be neutralised, its route of administration and the time
elapsed since it was last given and blood coagulation studies.
Protein Free Haemodialysate 10% Jelly D03AX00000G4001XX A Trophic lesions in patients with arterial occlusive disease Apply 3 - 5 times daily
and with chronic venous insufficiency, burn injuries,
impaired wound healing, decubitus ulcers and skin ulcer
caused by irradiation
Protein Free Haemodialysate 20% Eye Gel S01XA20-000-G30-01-XXX A Eyes disorders e.g. burns, scalds, ulcers, prevention and None Instill 1 drop 3 - 4 times daily
treatment of radiation dermatitis, traumatic and
ischaemic wound
Protein Free Haemodialysate 5% Ointment D03AX00000G5001XX A Trophic lesions in patients with arterial occlusive disease Apply 3 - 5 times daily
and with chronic venous insufficiency, burn injuries,
impaired wound healing, decubitus ulcers and skin ulcer
caused by irradiation
Protein Free Haemodialysate Dental Adhesive D03AX00000G6001XX A Painful and inflammatory affliction on the oral mucosa, Apply to lesions 3 - 5 times daily
Paste gums and lips, teething pain, denture pressure sores,
oral and maxillofacial surgery and dressing after scaling
Pyrantel Pamoate 125 mg Tablet P02CC01127T1001XX C Intestinal nematodes ADULT and CHILD : 2 years and older - single dose 10mg/kg body
weight once. Maximum 1 g
Pyrantel Pamoate 250 mg Tablet P02CC01127T1002XX C Intestinal nematodes ADULT and CHILD : 2 years and older - single dose 10mg/kg body
weight once. Maximum 1 g
Pyrazinamide 500 mg Tablet J04AK01000T1001XX B Tuberculosis Adult: 20-40mg/kg daily (max 1500mg) or 50mg/kg biweekly
(max 2000mg). Children: 20-30mg/kg daily or 30-40mg/kg thrice
weekly.
Pyridostigmine Bromide 60 mg Tablet N07AA02320T1001XX B Myasthenia gravis ADULT: 30 - 120 mg at suitable intervals throughout the day,
total daily dose 0.3 - 1.2 g. CHILD up to 6 years initially 30 mg, 6 -
12 years initially 60 mg, usual total daily dose 30 - 360 mg
Pyridoxine HCl 10mg Tablet A11HA02-110-T10-01-XXX C+ i)Pyridoxine-dependent convulsions in infant None i) INFANT 4 mg/kg daily for short periods ii) 100 - 400 mg daily in
ii)Sideroblastic anaemia iii)B6-deficient anaemia in adult divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv)
iv) Prophylaxis to peripheral neuritis in isoniazid therapy Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 -
v) Nausea and vomiting of pregnancy and irradiation 100 mg daily
sickness
Pyridoxine HCl Injection A11HA02-110-P30-01-XXX B i) Pyridoxine-dependent convulsions in infancy. ii) None i) INFANT 4 mg/kg daily for short periods. ii) 100 - 400 mg daily in
Sideroblastic anaemia. iii) B6-deficient anaemia in adult. divided doses. iii) ADULT 20 - 50 mg up to 3 times daily. iv)
iv) Prophylaxis to peripheral neuritis in isoniazid therapy. Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 -
v) Nausea and vomiting of pregnancy and irradiation 100 mg daily.
sickness
April 2023 148


Quetiapine Fumarate 100mg Immediate N05AH04-138-T10-02-XXX A* i) Schizophrenia ii) Short term treatment of acute manic Consultant/specialists for specific indications only, i) Initial titration schedule over 4 days: 25 mg twice daily on Day
Release Tablet episodes associated with bipolar I disorder, either including Geriatricians and Neurologists 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and
monotherapy or adjunct to lithium or divalproex iii) 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 -
Treatment of depressive episodes associated with 3 divided doses. Institute further dose adjustments, if indicated,
bipolar disorder at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii)
100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day
4). Further dosage adjustments up to 800 mg/day by Day 6
should be in increments of not more than 200 mg/day. Adjust
dose within the range of 200 - 800 mg/day depending on clinical
response and tolerability of the patient. Usual effective dose
range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1,
then 100 mg once daily on Day 2, then 200 mg once daily on Day
3, then 300 mg once daily on Day 4 (all doses given at bedtime);
patients requiring higher doses should receive 400 mg on Day 5,
increased to 600 mg on Day 8 (week 1)
Quetiapine Fumarate 200mg Extended Release N05AH04-138-T50-02-XXX A* i)Schizophrenia ii) Moderate to severe manic episodes in Consultant/specialists for specific indications only, i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2.
Tablet bipolar disorder iii) Major depressive episodes in bipolar including Geriatricians and Neurologists Maintenance dose: 400 to 800 mg once daily. Maximum dose:
disorder 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on
Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg.
May be titrated up to 600 mg daily. In elderly or hepatic
impairment:Start with 50mg/ day, may be increased in
increments of 50mg /day to an effective dose.
Quetiapine Fumarate 200mg Immediate N05AH04-138-T10-04-XXX A* i) Schizophrenia ii) Short term treatment of acute manic Consultant/specialists for specific indications only, i) Initial titration schedule over 4 days: 25 mg twice daily on Day
Release Tablet episodes associated with bipolar I disorder, either including Geriatricians and Neurologists 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and
monotherapy or adjunct to lithium or divalproex iii) 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 -
Treatment of depressive episodes associated with 3 divided doses. Institute further dose adjustments, if indicated,
bipolar disorder at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii)
100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day
4). Further dosage adjustments up to 800 mg/day by Day 6
should be in increments of not more than 200 mg/day. Adjust
dose within the range of 200 - 800 mg/day depending on clinical
response and tolerability of the patient. Usual effective dose
range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1,
then 100 mg once daily on Day 2, then 200 mg once daily on Day
3, then 300 mg once daily on Day 4 (all doses given at bedtime);
patients requiring higher doses should receive 400 mg on Day 5,
increased to 600 mg on Day 8 (week 1)
Quetiapine Fumarate 300mg Extended Release N05AH04-138-T50-03-XXX A* i) Schizophrenia ii) Moderate to severe manic episodes in Consultant/specialists for specific indications only, i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2.
Tablet bipolar disorder iii) Major depressive episodes in bipolar including Geriatricians and Neurologists Maintenance dose: 400-800 mg once daily. Maximum dose: 800
disorder mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3
and 300 mg on Day 4. Recommended daily dose is 300 mg. May
be titrated up to 600 mg daily
April 2023 149


Quetiapine Fumarate 400mg Extended Release N05AH04-138-T50-04-XXX A* i) Schizophrenia ii) Moderate to severe manic episodes in Consultant/specialists for specific indications only, i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2.
Tablet bipolar disorder iii) Major depressive episodes in bipolar including Geriatricians and Neurologists Maintenance dose: 400-800 mg once daily. Maximum dose: 800
disorder mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3
and 300 mg on Day 4. Recommended daily dose is 300 mg. May
be titrated up to 600 mg daily
Quetiapine Fumarate 50mg Extended Release N05AH04-138-T50-01-XXX A* i)Schizophrenia ii)Moderate to severe manic episodes in Consultant/specialists for specific indications only, i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2.
Tablet bipolar disorder iii)Major depressive episodes in bipolar including Geriatricians and Neurologists Maintenance dose: 400 to 800 mg once daily. Maximum dose:
disorder 800 mg daily. iii)50 mg on Day 1, 100 mg on Day 2, 200 mg on
Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg.
May be titrated up to 600 mg daily. In elderly or hepatic
impairment: Start with 50mg/ day, may be increased in
increments of 50mg /day to an effective dose.
Quinine Dihydrochloride 600 mg/2 ml Injection P01BC01110P3001XX B Severe and complicated malaria By slow intravenous infusion (over 4 hours). ADULT : 20 mg/kg
followed by 10 mg/kg every 8 hours. CHILD : 20 mg/kg followed
by 10 mg/kg every 12 hours, initial dose should be half in patients
who have received quinine, quinidine or mefloquine during the
previous 12 or 24 hours
Quinine Sulphate 300 mg Tablet P01BC01183T1001XX B Severe and complicated malaria 300 - 600 mg daily. Treatment : 1.2 - 2 g daily in divided doses.
CHILDS less than 1 year : 100 - 200 mg daily, 1 - 3 years : 200 -
300 mg daily, 4 - 6 years: up to 500 mg daily, more than 7 years :
up to 1 g daily. All above doses are given for 7 days in 2 - 3
divided doses
Rabies Vaccine Injection J07BG01000P4001XX B Pre-exposure and post-exposure vaccination against 1ml by IM. Dosing is according to product insert based on
rabies. patient’s needs (pre and post exposure).
Raloxifene HCl 60 mg Tablet G03XC01-110-T10-01-XXX A* i. Treatment and prevention of osteoporosis in - 1 tablet daily
postmenopausal women. ii. Risk reduction of invasive
breast cancer in postmenopausal women with
osteoporosis.
Raltegravir 400 mg tablet J05AX08500T1001XX A* Raltgeravir combination with other antiretroviral agents 400mg administered orally, twice daily with or without food, to
is indicated for the treatment of HIV-1 infection in be given combination with other antiretroviral agent.
patients who are contraindicated to boosted Protease
Inhibitor or who are intolerant to boosted Protease
Inhibitor.
Ramipril 2.5 mg Tablet C09AA05000T1001XX A i) Hypertension ii) Congestive heart failure iii) Reducing i) Initial: 2.5mg once daily Maintenance: 2.5-5mg once daily Max.
the risk of myocardial infarction, stroke, cardiovascular 10mg daily in 1-2 divided doses ii) Initial: 1.25mg once daily
death or revascularisation procedures in high- Maintenance: 10mg in 2 divided doses iii) Initial: 2.5mg twice
riskpatients iv) Prevention of progressive renal daily Maintenance: 5mg twice daily Max: 10mg daily iv) Initial:
impairment in patients with persistent proteinuria 1.25mg once daily Maintenance: 5mg once daily Dosing is
Ramipril 5 mg Tablet C09AA05000T1002XX A i) Hypertension ii) Congestive heart failure iii) Reducing i) Initial: 2.5mg once daily Maintenance: 2.5-5mg once daily Max.
the risk of myocardial infarction, stroke, cardiovascular 10mg daily in 1-2 divided doses ii) Initial: 1.25mg once daily
death or revascularisation procedures inhigh-riskpatients Maintenance: 10mg in 2 divided doses iii) Initial: 2.5mg twice
iv) Prevention of progressive renal impairment in daily Maintenance: 5mg twice daily Max: 10mg daily iv) Initial:
patients with persistent proteinuria 1.25mg once daily Maintenance: 5mg once daily Dosing is
April 2023 150


Ranibizumab 10mg/ml Intravitreal Injection S01LA04-000-P30-01-XXX A* i) Treatment of Neovascular (wet) Age-Related Macular Indication ii) and iii) approved to be used by retinal 0.5 mg (0.05ml) as a single intravitreal Injection.Interval between
Degeneration (ARMD). ii) Treatment of visual specialist only (PFUKKM 1/2015) 2 doses should not be shorter than 1 month, then monitor for
impairment due to diabetic macular edema (DME). iii) visual acuity monthly. Treatment is given monthly & continued
Treatment of visual impairment due to macular edema until max visual acuity is achieved, confirmed by stable visual
secondary to retinal vein occlusion (RVO). iv) Treatment acuity for 3 consecutive monthly assessments.
of visual impairment due to choroidal neovascularization
(CNV) secondary to pathologic myopia (PM).
Ranitidine 150 mg Tablet A02BA02110T1001XX B i) Benign gastric and duodenal ulcer ii) Reflux i) 150 mg twice daily (at morning and night) or 300 mg on night
oesophagitis iii) Non-ulcer dyspepsia iv) Zollinger-Ellison for 4-8 weeks. Maintenance: 150-300 mg on night ii) 150 mg
Syndrome twice daily or 300 mg on night for 8-12 weeks iii) 150 mg daily or
twice daily iv) 150 mg and may be increased as necessary to 6
g/day
Ranitidine 150 mg/10 ml Syrup A02BA02110L9001XX B Peptic ulcer disease CHILD 2-4 mg/kg 2 times daily. Maximum 300 mg daily
Ranitidine 25 mg/ml Injection A02BA02110P3001XX B i) Benign gastric/ duodenal ulceration, reflux i) ADULT: Slow IV injection of 50 mg diluted to 20 ml and given
oesophagitis, Zollinger Ellison Syndrome ii) Stress ulcer over at least 2 minutes. May be repeated every 6-8 hours or IV
prophylaxis in post-operative and high risk patients infusion at rate of 25 mg/hour for 2 hours, may be repeated at 6-
8 hours intervals or IM. CHILD: 1 mg/kg/dose 6-8 hourly. ii) Initial
slow IV injection of 50 mg, then continuous infusion of 125-250
mcg/kg/hour
Ranitidine 300 mg Tablet A02BA02110T1002XX B i) Benign gastric and duodenal ulcer ii) Reflux i) 150 mg twice daily (at morning and night) or 300 mg on night
oesophagitis iii) Non-ulcer dyspepsia iv) Zollinger-Ellison for 4-8 weeks. Maintenance: 150-300 mg on night ii) 150 mg
Syndrome twice daily or 300 mg on night for 8-12 weeks iii) 150 mg daily or
twice daily iv) 150 mg and may be increased as necessary to 6
g/day
Ravidasvir 200mg tablet J05AP00-110-T10-01-XXX A/KK To be used in combination with other medicinal In non-cirrhotic patients or compensated cirrhosis 200 mg once daily, to be taken orally with or without food.
products for the treatment of chronic hepatitis C virus patients who are treatment naïve to NS5A inhibitor Patients without cirrhosis: Ravidasvir plus sofosbuvir for 12
(HCV) infection in adults weeks. Patients with compensated cirrhosis: Ravidasvir plus
sofosbuvir for 24 weeks
Recombinant Factor IX (rFIX) 1000 IU injection B02BD09-000-P40-03-XXX A* Treatment and prophylaxis of bleeding in patients with - Number of factor IX units required = body weight (kg) x desired
haemophilia B (congenital factor IX deficiency) factor IX increase (% or units/dL) x reciprocal of observed
recovery (units/kg per units/dL). Average dose for secondary
prophylaxis for previously treated adult patients (PTP) was 40
units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
Dosing is individualised and according to product insert/protocol.
April 2023 151


Recombinant factor VIII 250 IU Injection B02BD02000P4001XX A* i)Control and prevention of bleeding episodes in adults The dosage and duration of treatment should be individualised
and children (0-16 years) with hemophilia A. ii)Surgical and taking into account the severity of factor VIII deficiency,
prophylaxis in adults and children with hemophilia A. location and extent of bleeding and patient's clinical condition.
iii)Routine prophylactic treatment to reduce the Dose can be calculated by using: i. Required dose (IU) = body
frequency of bleeding episodes and the risk of joint weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5
damage in children with no pre-existing joint damage. (IU/kg) or ii. Expected factor VIII rise (% of normal) = 2 x (dose
Not indicated fot the treatment of von willebrand's administered)/ bodyweight (kg) Dose administered should be
disease. titrated to patient's clinical response
Recombinant Factor VIII 500 IU Injection B02BD02000P4002XX A* i)Control and prevention of bleeding episodes in adults The dosage and duration of treatment should be individualised
and children (0-16 years) with hemophilia A. ii)Surgical and taking into account the severity of factor VIII deficiency,
prophylaxis in adults and children with hemophilia A. location and extent of bleeding and patient's clinical condition.
iii)Routine prophylactic treatment to reduce the Dose can be calculated by using: i. Required dose (IU) = body
frequency of bleeding episodes and the risk of joint weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5
damage in children with no pre-existing joint damage. (IU/kg) or ii. Expected factor VIII rise (% of normal) = 2 x (dose
Not indicated for the treatment of von willebrand's administered)/ bodyweight (kg) Dose administered should be
disease. titrated to patient's clinical response.
Remifentanil 5 mg Injection N01AH06110P4001XX A* i) As an analgesic agent for use during induction and/or For IV use only. ADULT: Induction:Bolus infusion: 1µg/kg over 30-
maintenance of general anaesthesia during surgical 60 seconds; Continuous infusion: 0.5-1µg/kg/min; Maintenance:
procedures including cardiac surgery. ii)Continuation of Continuous infusion: 0.025 to 2 µg/kg/min. CHILD (1-12 years of
analgesia into the immediate post-operative period age): Induction: Insufficient data; Neonates: IV infusion 0.4-1.0
under close supervision, during transition to longer mcg/kg/minute depending on the anaesthetic method and adjust
acting analgesia. iii)Provision of analgesia and sedation in according to patient response, supplemental IV inj of 1 mcg/kg
mechanically ventilated intensive care patients. dose may be given. 1-12 yr: initially 0.1-1 mcg/kg by IV inj over at
least 30 seconds (excluded if not needed), followed by IV infusion
0.05-1.3 mcg/kg/minute depending on the anaesthetic method
and adjust according to patient response, supplemental IV bolus
inj may be admin during infusion. 12-18 yr: 0.1-1 mcg/kg IV inj
over at least 30 seconds (excluded if not needed), followed by IV
infusion of 0.05-2 mcg/kg/minute depending on anaesthetic
method and adjust according to patient response, supplemental
IV bolus inj may be admin during infusion.
April 2023 152


Ribavirin 200mg Capsule J05AB04-000-C10-01-XXX A* For the treatment of chronic hepatitis C None ADULT (more than 18 years old): 50mg/kg/day Recommended:
Body weight: ≤ 75kg should receive 1000mg daily as two 200mg
capsules in the morning and three 200mg capsules in the evening
Body weight: >75kg should receive 1200mg as three 200mg
capsules in the morning and three 200mg capsules in the evening
Genotype 1,4: 48 weeks Genotype: 24 weeks duration should be
individualized in accordance with the baseline characteristics of
the disease.
Ribociclib 200mg tablet L01XE42-105-T32-01-XXX A* In combination with: - an aromatase inhibitor for the 600 mg daily for 21 consecutive days followed by 7 days off
treatment of postmenopausal women, with hormone treatment. Can be taken with or without food. For dose
receptor (HR)-positive, human epidermal growth factor modification, refer package insert.
receptor 2 (HER2)-negative advanced or metastatic
breast cancer, as initial endocrine-based therapy.
Riboflavine 3 mg Tablet A11HA04-000-T10-01-XXX C Treatment of riboflavine deficiency states - ADULT: Treatment dose: Up to 30 mg daily in divided doses.
Maintenance dose: 1 to 3 mg daily in divided doses CHILD: 3-10
mg/day in divided doses.
Rifampicin 100 mg/5 ml Syrup J04AB02000L9001XX A Tuberculosis and leprosy CHILD: 20 mg/kg body weight daily in 1 - 2 doses. Up to 1 year: 10
mg/kg body weight in a single daily dose
Rifampicin 150 mg Capsule J04AB02-000-C10-01-XXX B i) Tuberculosis ii) Leprosy iii) Prophylaxis for i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20
meningococcal meningitis iv)Staphylococcus biofilm mg/kg body weight daily in 1 - 2 doses. Directly observed therapy
related prosthetic joint infection or any biofilm sensitive (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600
to rifampicin in combination therapy with another mg ii) ADULT: 600 mg/day CHILD: 10mg/kg iii) ADULT: 600 mg
antibiotic twice daily for 2 days CHILD: 10mg/kg twice daily for 2 days
INFANT: 5mg/kg twice daily for 2 days iv) ADULT: 600mg OD
CHILD: 10-20mg/kg/day in 1-2 divided doses Dosing is
Rifampicin 150 mg, Isoniazid 75 mg, J04AM06000T1001XX B Treatment of both pulmonary and extrapulmonary ADULT: 30 - 37 kg: 2 tablets daily, 38 - 54 kg: 3 tablets daily, 55 -
Pyrazinamide 400 mg & Ethambutol HCl 275 tuberculosis, in the intensive treatment phase 70 kg: 4 tablets daily, more than 70 kg: 5 tablets daily
mg Tablet
Rifampicin 150mg + Isoniazid 75mg tablet J04AM02000T1001XX B For pulmonary tuberculosis in which organisms are 30-37kg: 2 tablets once daily, 38-54kg: 3 tablets once daily, 55-
susceptible in continuation phase treatment for 4 70kg: 4 tablets once daily, Above 70kg: 5 tabs once daily
months
Rifampicin 300 mg Capsule J04AB02-000-C10-02-XXX B i) Tuberculosis ii) Leprosy iii) Prophylaxis for - i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20
meningococcal meningitis iv)Staphylococcus biofilm mg/kg body weight daily in 1 - 2 doses. Directly observed therapy
related prosthetic joint infection or any biofilm sensitive (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600
to rifampicin in combination therapy with another mg ii) ADULT: 600 mg/day CHILD: 10mg/kg iii) ADULT: 600 mg
antibiotic twice daily for 2 days CHILD: 10mg/kg twice daily for 2 days
INFANT: 5mg/kg twice daily for 2 days iv) ADULT: 600mg OD
CHILD: 10-20mg/kg/day in 1-2 divided doses Dosing is
Rifampicin, Dapsone & Clofazimine J04AM02961T9901XX B For the treatment of leprosy and tuberculosis Rifampicin: 600 mg once monthly, Dapsone: 100 mg daily,
Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on
alternate days)
Ringers Solution (contained sodium chloride, B05XA30-905-P60-01-XXX B As a source of electrolytes and water for None According to the needs of the patient
potassium chloride and calcium chloride) hydration/replenishing of chloride
April 2023 153


Risperidone 1 mg Tablet N05AX08000T1001XX B i) Schizophrenia, including first episode psychosis, acute i) ADULT: Initial dose: 2 mg/day. Maintenance dose: 4 to 6 mg.
schizophrenic exacerbations, chronic schizophrenia and Max: 16mg/day CHILD: Not recommended ELDERLY: Initial dose:
other psychotic conditions ii) Short-term symptomatic 0.5 mg twice daily. Maintenance: 1 to 2 mg twice daily. ii) CHILD
treatment (up to 6 weeks) of persistent aggression in & ADOLESCENTS, 5-18 years ≥ 50 kg: Initial - 0.5 mg once daily
conduct disorder in children from the age of 5 years and Optimum dose: 1mg once daily < 50 kg: Initial - 0.25 mg once
adolescents with subaverage intellectual functioning or daily Optimum dose: 0.5mg once daily Dosing should be
mental retardation. individualized according to product insert.
Risperidone 1 mg/ml Oral Solution N05AX08000L5001XX A i) Schizophrenia, including first episode psychosis, acute i) ADULT: Initial dose: 2 mg/day. Maintenance dose: 4 to 6 mg.
schizophrenic exacerbations, chronic schizophrenia and Max: 16mg/day CHILD: Not recommended ELDERLY: Initial dose:
other psychotic conditions ii) Short-term symptomatic 0.5 mg twice daily. Maintenance: 1 to 2 mg twice daily. ii) CHILD
treatment (up to 6 weeks) of persistent aggression in & ADOLESCENTS, 5-18 years ≥ 50 kg: Initial - 0.5 mg once daily
conduct disorder in children from the age of 5 years and Optimum dose: 1mg once daily < 50 kg: Initial - 0.25 mg once
adolescents with subaverage intellectual functioning or daily Optimum dose: 0.5mg once daily Dosing should be
mental retardation. individualized according to product insert.
Risperidone 2 mg Tablet N05AX08000T1002XX B Schizophrenia ADULT: Initial dose: 2 mg/day. Maintenance dose: 4 to 6 mg.
Max: 16mg/day CHILD: Not recommended ELDERLY: Initial dose:
0.5 mg twice daily. Maintenance: 1 to 2 mg twice daily. Dosing
should be individualized according to product insert.
Risperidone 25 mg Injection (Long Acting) N05AX08000P3001XX A* Treatment of acute and chronic schizophrenic psychosis 25 mg IM every 2 weeks. Dose increments (if required) to 37.5
and other psychotic conditions, in which positive and mg or 50 mg can be considered after a minimum of 4 weeks on
negative symptoms are prominent. It also alleviates each dosage
affective symptoms associated with schizophrenia
Risperidone 37.5 mg Injection (Long Acting) N05AX08000P3002XX A* Treatment of acute and chronic schizophrenic psychosis 25 mg IM every 2 weeks. Dose increments (if required) to 37.5
Risperidone 50 mg Injection (Long Acting) N05AX08000P3003XX A* Treatment of acute and chronic schizophrenic psychosis 25 mg IM every 2 weeks. Dose increments (if required) to 37.5
Ritonavir 100 mg Capsule J05AE03000C1001XX A* Progressive or advanced HIV infection in combination Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells ADULT: (Single PI) initially 300 mg twice daily, increase by 100 mg
with other antiretroviral agents. or c) Viral load more than 10,000 copies/ml twice daily increments to 600 mg twice daily. (Dual PI) Initially
200mg BD, then increase by 100mg BD & reaching 400mg BD
within 2 wk.
Ritonavir 80 mg/ml Solution J05AE03000L9901XX A* Progressive or advanced HIV infection in combination Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells ADULT: 400 - 600 mg twice daily. CHILD: >1 month, initiate at dise
with other antiretroviral agents. or c) Viral load more than 10,000 copies/ml of 25mg/m2 twice daily, titrate dose upward every 2-3 days by
50mg/m2 twice daily (maximum dose 600mg twice daily)
April 2023 154


Rituximab 10mg/ml Injection L01XC02000P3001XX A* i) Treatment of patients with relapsed or chemo- i) 375 mg/m2 BSA administered as an IV infusion through a
resistant low grade or follicular B-cell Non-Hodgkin's dedicated line once weekly for 4 weeks ii) Combination with
lymphoma ii) Adjunctive therapy with combination CHOP (cyclophosphamide, doxorubicin, prednisone and
chemoagents for aggressive Non-Hodgkin Lymphoma iii) vincristine) as 375 mg/m2 BSA on day 1 of each chemotherapy
Severe active rheumatoid arthritis with inadequate cycle for 8 cycles after IV administration of the glucocorticoid
response or intolerance to other disease-modifying anti- component of CHOP. iii) 1000 mg IV infusion followed by a
rheumatic drugs (DMARDs) including one or more second 1000 mg IV infusion two weeks later iv) 375mg/m2 BSA
tumour necrosis factor (TNF) inhibitor therapies iv) once every 3 months until disease progression or for a maximum
Maintenance in relapsed/ refractory follicular lymphoma period of two years.
after response to induction therapy
Rituximab 1400mg/11.7ml solution for L01XC02-000-P30-04-XXX A* i) Treatment of patients with relapsed or chemo- i) As monotherapy, first cycle with rituximab (IV formulation)
subcutaneous injection resistant low grade or follicular B-cell Non-Hodgkin's 375mg/m2 administered as an intravenous infusion, followed by
lymphoma; ii) Adjunctive therapy with combination subsequent cycles with rituximab SC at a fixed dose of 1400mg
chemo-agents for aggressive Non-Hodgkin Lymphoma; per cycle, once weekly. In total: 4 weeks. ii) Combination with
iii) Maintenance in relapsed/ refractory follicular CHOP (cyclophosphamide, doxorubicin, prednisone and
lymphoma after response to induction therapy. vincristine): first dose with rituximab (IV formulation) 375 mg/m2
administered as an intravenous infusion followed by subsequent
cycles with rituximab SC injected at a fixed dose of 1400mg per
cycle. In total: for up to 8 cycles. Rituximab should be
administered on day 1 of each chemotherapy cycle after IV
administration of the glucocorticoid component of CHOP. iii)
1400mg SC once every 3 months until disease progression or for
a maximum period of two years. Note: • Premedication
consisting of an anti-pyretic, antihistamine (e.g. paracetamol and
diphenhydramine) and glucocorticoids, before each
administration of rituximab. • All patients must always receive
their first dose of rituximab by intravenous administration (using
intravenous formulation) at a dose of 375mg/m2 body surface
area. The subcutaneous formulation of 1400mg should only be
given at the second or subsequent cycles. • Patients who were
not able to receive the full rituximab intravenous infusion dose
should continue to receive subsequent cycles with rituximab IV
doses. • Subcutaneous formulation is not intended for
intravenous administration and should be given via subcutaneous
injection only. The 1400 mg strength is intended for
subcutaneous use in non-Hodgkin lymphoma (NHL) only.
Rivaroxaban 10 mg Tablet B01AX06000T1001XX A* Prevention of venous thromboembolism in patients 10 mg once daily. Initial dose should be taken 6 to 10 hour post-
undergoing elective hip or knee replacement surgery surgery provided that haemostasis has been established.
Duration of treatment: Major hip surgery 5 weeks. Major knee
surgery 2 weeks
April 2023 155


Rivaroxaban 15 mg Tablet B01AX06000T1002XX A* i) Prevention of stroke and systemic embolism in adult i) 20mg once daily or 15mg once daily (CrCl 15 – 49 ml/min) ii) &
patients with non-valvular atrial fibrillation with one or (iii) 15mg BD for 21 days, followed by 20mg OD
more risk factors, such as Congestive heart failure (CHF),
hypertension, age ≥ 75 yrs, diabetes mellitus, prior
stroke or transient ischaemic attack. ii)Treatment of
deep vein thrombosis (DVT), and prevention of recurrent
DVT and pulmonary embolism (PE) following an acute
DVT in adults. iii) Treatment of Pulmonary Embolism
(PE), and prevention of recurrent DVT and pulmonary
embolism (PE) following an acute PE in adults.
Rivaroxaban 20 mg Tablet B01AX06000T1003XX A* i)Prevention of stroke and systemic embolism in adult i) 20mg once daily or 15mg once daily (CrCl 15 – 49 ml/min) ii) &
patients with non-valvular atrial fibrillation with one or (iii) 15mg BD for 21 days, followed by 20mg OD
more risk factors, such as Congestive heart failure (CHF),
hypertension, age ≥ 75 yrs, diabetes mellitus, prior
stroke or transient ischaemic attack. ii)Treatment of
deep vein thrombosis (DVT), and prevention of recurrent
DVT and pulmonary embolism (PE) following an acute
DVT in adults. iii) Treatment of Pulmonary Embolism
(PE), and prevention of recurrent DVT and pulmonary
embolism (PE) following an acute PE in adults.
Rivastigmine 1.5 mg Capsule N06DA03123C1001XX A* Mild to moderately severe dementia associated with For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times
Alzheimer's or Parkinson's disease daily every 2 weeks to maximum of 6 mg 2 times daily. If
treatment is interrupted for several days, should be reinitiated at
the lowest daily dose
Rivastigmine 13.3mg/24hr Transdermal Patch N03DA03123M7003XX A* i) Mild to moderately severe dementia of the Alzheimer's Use as second line/alternative option if the first line Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once
type ii) Severe dementia of the Alzheimer's type iii) Mild medication with oral tablet failed or patients are not able daily after a minimum of 4 weeks and then 13.3mg/24hr if
to moderately severe dementia associated with to tolerate the oral medication. tolerated Dosing is individualised and according to product insert.
Parkinson's disease
Rivastigmine 2 mg/ml Oral Solution N06DA03123L9901XX A* Mild to moderately severe dementia associated with For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily. May be increased after a
Alzheimer's or Parkinson's disease minimum of 2 weeks of treatment to 3 mg 2 times daily.
Subsequently to 4.5 mg 2 times daily, up to maximum of 6 mg 2
times daily. If treatment is interrupted for several days, should be
reinitiated at the lowest daily dose
Rivastigmine 3 mg Capsule N06DA03123C1002XX A* Mild to moderately severe dementia associated with For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times
Rivastigmine 4.5 mg Capsule N06DA03123C1003XX A* Mild to moderately severe dementia associated with For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times
Rivastigmine 4.6mg/24hr Transdermal Patch N06DA03123M7001XX A* i) Mild to moderately severe dementia of the Alzheimer's Use as second line/alternative option if the first line Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once
to moderately severe dementia associated with to tolerate the oral medication tolerated Dosing is individualised and according to product insert.
Parkinson's disease
April 2023 156


Rivastigmine 6 mg Capsule N06DA03123C1004XX A* Mild to moderately severe dementia associated with For psychiatrists and neurologists only. Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times
Rivastigmine 9.5 mg/24hr Transdermal Patch N06DA03123M7002XX A* i) Mild to moderately severe dementia of the Alzheimer's Use as second line/alternative option if the first line Initial: 4.6mg/24hr once daily Maintenance: 9.5mg/24hr once
to moderately severe dementia associated with to tolerate the oral medication tolerated Dosing is individualised and according to product insert.
Parkinson's disease
Rocuronium Bromide 10mg/ml Injection M03AC09-320-P30-01-XXX A* As an adjunct to general anaesthesia to facilitate None Adult: Initial: 0.6mg/kg. Higher doses of 1 mg/kg may be used for
endotracheal intubation, to provide skeletal muscle intubation during rapid sequence induction of anaesthesia.
relaxation during surgery and to facilitate mechanical Maintenance: 0.15mg/kg (may reduce to 0.075-0.1 mg/kg if
ventilation in adults, children and infants from one inhalational anaesthesia is used) or by infusion at a rate of 0.3-
month of age. 0.6mg/kg/hr (0.3-0.4mg/kg/hr if inhalational anaesthesia is used).
Doses should be based on ideal body weight for obese patients
weighing >30% above the ideal body weight. Child: Infants and
children >1 mth: Initially: 0.6mg/kg. Maintenance: 0.15mg/kg or
by infusion at a rate of 0.3-0.6mg/kg/hr, maintenance doses may
be required more frequently than in adult patients.
Elderly/patients with hepatic and/or biliary tract disease and/or
renal impairment: Initially: 0.6mg/kg. Maintenance: 0.075-0.1
mg/kg or by infusion at a rate of 0.3-0.4mg/kg/hr.
Ropinirole HCI 2 mg Extended Release Tablet N04BC04110T5003XX A* Treatment of idiopathic Parkinson?s disease. It may be ADULT: Initially 2 mg once daily for the 1st week. May be
used as monotherapy or in combination with levodopa increased by 2 mg at ≥1 week intervals. Max: 24 mg/day.
Switching from ropinirole immediate-realease to prolonged-
release tablet; dose of ropinirole prolonged release tablet should
be based on the total daily dose of ropinirole immediate-release
tab the patient was taking. Tablets should be taken at a similar
time each day with or without food, must be swallowed whole
and must not be chewed, crushed or divided.
Ropinirole HCI 4 mg Extended Release Tablet N04BC04110T5004XX A* Treatment of idiopathic Parkinson?s disease. It may be ADULT: Initially 2 mg once daily for the 1st week. May be
used as monotherapy or in combination with levodopa increased by 2 mg at ≥1 week intervals. Max: 24 mg/day.
Switching from ropinirole immediate-realease to prolonged-
release tablet; dose of ropinirole prolonged release tablet should
be based on the total daily dose of ropinirole immediate-release
tab the patient was taking. Tablets should be taken at a similar
time each day with or without food, must be swallowed whole
and must not be chewed, crushed or divided.
Ropinirole HCl 0.25 mg Tablet N04BCO4-110-T10-01-XXX A* i) Treatment of idiopathic Parkinson's disease. It may be i) 0.25 mg 3 times daily gradually increasing till adequate
used as monotherapy or in combination with levodopa response obtained up to a maximum of 24 mg/day. Most patients
ii) Treatment of restless leg syndrome need 3-9 mg/day ii) Initial: 0.25mg ON for 2 days then increased if
tolerated to 0.5mg ON. Further dose increment of 0.5mg/week
can be made until optimal response is achieved
April 2023 157


Ropinirole HCl 1 mg Tablet N04BCO4-110-T10-02-XXX A* i) Treatment of idiopathic Parkinson's disease. It may be i) 0.25 mg 3 times daily gradually increasing till adequate
used as monotherapy or in combination with levodopa response obtained up to a maximum of 24 mg/day. Most patients
ii) Treatment of restless leg syndrome need 3-9 mg/day ii) Initial: 0.25mg ON for 2 days then increased if
tolerated to 0.5mg ON. Further dose increment of 0.5mg/week
can be made until optimal response is achieved
Ropivacaine HCl 2 mg/ml Injection N01BB09110P3001XX A* i) Surgical anaesthaesia including obstetrics ii) Acute pain Dose adjusted according to patient physical status and nature of
management procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution;
Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental
doses ( max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of
2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at
interval at of least 30 minutes. Labour pain 6-10 ml/hour of
2mg/ml solution
Ropivacaine HCl 7.5 mg/ml Injection N01BB09110P3002XX A* i) Surgical anaesthaesia including obstetrics ii) Acute pain Dose adjusted according to patient physical status and nature of
management procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution;
Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental
doses ( max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of
2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at
interval at of least 30 minutes. Labour pain 6-10 ml/hour of
2mg/ml solution
Rosuvastatin 10 mg Tablet C10AA07390T1002XX A/KK Dyslipidaemia not responsive to atorvastatin 40mg or Initially 5-10 mg once daily (5mg in patients with pre-disposing
equivalent doses of other statins factors to myopathy), increased if necessary at intervals of at
least 4 weeks to 20 mg once daily, increased after further 4
weeks to 40 mg daily ONLY in severe hypercholesterolemia with
high cardiovascular risk. Patient of Asian origin, patients on
concomitant ciclosporin/fibrate and patients with risk factors for
myopathy/rhabdomyolysis (including personal/family history of
muscular disorders/toxicity), the maximum dose should be 20 mg
daily
Rosuvastatin 20mg Tablet C10AA07390T1003XX A/KK Dyslipidaemia not responsive to atorvastatin 40 mg or Initially 5-10 mg once daily (5mg in patients with pre-disposing
equivalent doses of other statins factors to myopathy), increased if necessary at intervals of at
least 4 weeks to 20 mg once daily, increased after further 4
weeks to 40 mg daily ONLY in severe hypercholesterolemia with
high cardiovascular risk. Patient of Asian origin, patients on
concomitant ciclosporin/fibrate and patients with risk factors for
myopathy/rhabdomyolysis (including personal/family history of
muscular disorders/toxicity), the maximum dose should be 20 mg
daily
Ruxolitinib 15mg tablet L01XE18162T1002XX A* For the treatment of disease-related splenomegaly or None The recommended starting dose: i) Platelet count between
symptoms in adult patients with: i) primary 100,000/mm³ and 200,000/mm³: 15 mg twice daily for patients ii)
myelofibrosis (also known as chronic idiopathic Platelet count of >200,000/mm³: 20 mg twice daily for patients
myelofibrosis); or ii) post-polycythemia vera iii) Platelet counts between 50,000/mm³ and <100,000/mm³:
myelofibrosis; or iii) post-essential thrombocythemia Limited information to recommend a starting dose for patients.
myelofibrosis. The maximum recommended starting dose in these patients is 5
mg twice daily and the patients should be titrated cautiously.
April 2023 158


Ruxolitinib 20mg tablet L01XE18-162-T10-03-XXX A* For the treatment of disease-related splenomegaly or None The recommended starting dose: i) Platelet count between
myelofibrosis; or iii) post-essential thrombocythemia Limited information to recommend a starting dose for patients.
Ruxolitinib 5mg tablet L01XE18-162-T10-01-XXX A* For the treatment of disease-related splenomegaly or None The recommended starting dose: i) Platelet count between
myelofibrosis; or ii) post-essential thrombocythemia Limited information to recommend a starting dose for patients.
Sacubitril/ Valsartan 100 mg tablet C09DX04-000-T32-02-XXX A* Treatment of symptomatic chronic heart failure in adult i) NYHA class II-IV ii) Patients who are symptomatic The recommended starting dose of sacubitril/valsartan is one
patients with reduced ejection fraction. despite being on optimized treatment with an ACEi / ARB, tablet of 100 mg twice daily. The dose should be doubled at 2-4
a beta blocker, a diuretics and an mineralocorticoid weeks to the target dose of one tablet of 200 mg twice daily, as
receptor agonist (MRA). tolerated by the patient. For the following patients, initiate with
sacubitril/valsartan 50 mg twice daily. - Not currently on ACEI/
ARB - Switching from low dose of ACEI/ ARB - In patients with
systolic BP ≥100 to 110 mmHg. - In patients with moderate renal
impairment (eGFR 30-60 ml/min/1.73 m2) - In patients with
moderate hepatic impairment (Child-Pugh B classification) For
patients "Not currently on ACEI/ ARB" and "switching from low
dose of ACEI/ ARB", double the dose every 3-4 weeks to achieve
the target dose of 200 mg twice daily as tolerated by the patient.
Sacubitril/ Valsartan 50 mg tablet C09DX04-000-T32-01-XXX A* Treatment of symptomatic chronic heart failure in adult i) NYHA class II-IV ii) Patients who are symptomatic The recommended starting dose of sacubitril/valsartan is one
patients with reduced ejection fraction. despite being on optimized treatment with an ACEi / ARB, tablet of 100 mg twice daily. The dose should be doubled at 2-4
a beta blocker, a diuretics and an mineralocorticoid weeks to the target dose of one tablet of 200 mg twice daily, as
receptor agonist (MRA). tolerated by the patient. For the following patients, initiate with
April 2023 159


Sacubitril/Valsartan 200 mg tablet C09DX04-000-T32-03-XXX A* Treatment of symptomatic chronic heart failure in adult i) NYHA class II-IV ii) Patients who are symptomatic The recommended starting dose is one tablet of 100 mg twice
patients with reduced ejection fraction. despite being on optimized treatment with an ACEi / ARB, daily. The dose should be doubled at 2-4 weeks to the target
a beta blocker, a diuretics and an mineralocorticoid dose of one tablet of 200 mg twice daily, as tolerated by the
receptor agonist (MRA). patient. For the following patients, initiate with
Salbutamol 0.5% Inhalation Solution R03AC02-183-A30-01-XXX B Indicated for the relief of bronchospasm in patients with - 2.5 to 5mg (0.5ml – 1ml), repeat according to response and
reversible obstructive airway disease and acute tolerability. Dosing is individualised and according to product
bronchospasm. insert/protocol.
Salbutamol 0.5mg/ml Injection R03CC02-183-P30-01-XXX A i. Asthma and other conditions associated with None i. 500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If
reversible airways obstruction ii. For prevention of required, by IV infusion, initially 5 mcg/min adjusted according to
uncomplicated premature labour response and heart rate, usually in the range 3 - 20 mcg/min ii.
Infusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 -
45 mcg/min increased at intervals of 10 minutes until evidence of
patient response as shown by reduction of strength, frequency or
duration of contractions; maintain rate for 1 hour after
contractions have stopped, then gradually reduce by 50% every 6
hours
Salbutamol 100mcg/dose Inhalation R03AC02-183-A10-01-XXX B Asthma and other conditions associated with reversible None ADULT : 100 - 200 mcg up to 3 - 4 times daily. CHILD : 100 mcg
airways obstruction increased to 200 mcg if necessary
Salbutamol 200mcg/dose Inhaler R03AC02-183-A20-01-XXX B Asthma and other conditions associated with reversible None CHILD : 100 - 200 mcg. Maintenance : 100 - 200 mcg 2 - 4 times
airways obstruction daily. ADULT : 100 - 400 mcg. Maitenance : 100 - 400 mcg 2 - 4
times daily
Salbutamol 2mg Tablet R03CC02-183-T10-01-XXX B Asthma and other conditions associated with reversible None CHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily 6 - 12 years : 2 mg 3 -
airways obstruction 4 times daily. over 12 years and ADULT : 2 - 4 mg 3 - 4 times daily
Salbutamol 2mg/5ml Syrup R03CC02-183-L90-01-XXX B Asthma and other conditions associated with reversible None CHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12 years : 2 mg 3 -
airways obstruction 4 times daily
Salbutamol 5mg/5ml Injection R03CC02-183-P30-02-XXX A i. Asthma and other conditions associated with None i. 500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If
reversible airways obstruction ii. For prevention of required, by IV infusion, initially 5 mcg/min adjusted according to
uncomplicated premature labour response and heart rate, usually in the range 3 - 20 mcg/min ii.
Infusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 -
45 mcg/min increased at intervals of 10 minutes until evidence of
patient response as shown by reduction of strength, frequency or
duration of contractions; maintain rate for 1 hour after
contractions have stopped, then gradually reduce by 50% every 6
hours
April 2023 160


Salicylazosulphapyridine (Sulfasalazine) 500 mg A07EC01000T1001XX A/KK i) Treatment of inflammatory bowel disease of ulcerative i) ADULT, acute attack 1-2 g 4 times daily until remission occurs (if
Tablet colitis and Crohn's disease ii) Rheumatoid arthritis necessary corticosteroids may also be given), reducing to a
maintenance dose of 500 mg 4 times daily, CHILD over 2 years,
acute attack 40-60 mg/kg daily, maintenance dose 20-30 mg/kg
daily ii) ADULT, initially; 0.5-1 g/day, increase weekly to
maintenance dose of 2 g/day in 2 divided doses, maximun 3
g/day. CHILD over 6 years, juvenile rheumatoid arthritis: 30-50
mg/kg/day in 2 divided doses up to a maximum of 2 g/day
Salicylic Acid 2 - 10% Cream D01AE12000G1001XX C Seborrhoeic dermatitis, scalp psoriasis and Apply sparingly to the affected area 2-3 times daily
hyperkeratotic skin conditions
Salicylic Acid 2 - 10% Ointment D01AE12000G5001XX C Seborrhoeic dermatitis, scalp, psoriasis and Apply sparingly to the affected area 2-3 times daily
hyperkeratotic skin disorders
Salicylic Acid 2 % Lotion D01AE12000L6001XX B Seborrhoeic dermatitis, scalp, psoriasis and Apply sparingly to the affected area 2-3 times daily. Wash with
hyperkeratotic skin conditions cleanser 2 - 3 times per day
Salicylic Acid 20% Ointment D01AE12000G5002XX C Plantar warts Apply daily and protect surrounding skin (eg with soft paraffin or
specially designed plaster) ,may need to continue up to 3 months
Salicylic Acid, Starch, Zinc Oxide Paste D01AE12952G6001XX C Use as a protective or base Apply the paste liberally and carefully to the lesions twice daily
Salmeterol 25mcg and Fluticasone Propionate R03AK06-989-A21-02-XXX A* Regular treatment of reversible obstructive airway None ADULT and CHILD more than 12 years : 1 - 2 puff twice daily.
125mcg Inhalation diseases including asthma. CHILD over 4 years : 1 puff twice daily
Salmeterol 25mcg and Fluticasone Propionate R03AK06-989-A21-04-XXX A* Regular treatment of reversible obstructive airway Limited to paediatric population for the purpose of dose CHILD more than 12 years : 2 puff twice daily. CHILD over 4 years
50mcg Inhalation diseases including asthma in children, where use of tapering : 2 puff twice daily No data on use for children aged under 4 years.
lower dose of a combination (bronchodilator and inhaled
corticosteroids) is appropriate.
Salmeterol 50mcg & Fluticasone Propionate R03AK06-989-A21-01-XXX A*, A/KK Prescriber Category A*: i) Treatment of COPD patients None ADULT and CHILD more than 12 years : 1 puff twice daily.
250mcg Inhalation with a blood eosinophil count of 300 cells/microliter and
more ii) Treatment of COPD patients with blood
eosinophil count of 100 cells/microliter and more with
history of repeated exacerbation despite regular
treatment with long-acting bronchodilators. Prescriber
Category A/KK: - Regular treatment of reversible
obstructive airways diseases including asthma.
Salmeterol 50mcg and Fluticasone Propionate R03AK06-989-A21-06-XXX A*, A/KK Prescriber Category A*: i) Treatment of COPD patients None ADULT and CHILD more than 12 years : 1 puff twice daily
500mcg Inhalation with a blood eosinophil count of 300 cells/microliter and
more ii) Treatment of COPD patients with blood
eosinophil count of 100 cells/microliter and more with
history of repeated exacerbation despite regular
treatment with long-acting bronchodilators. Prescriber
Category A/KK: - Regular treatment of reversible
obstructive airways diseases including asthma.
April 2023 161


Saxagliptin 2.5 mg Tablet A10BH03000T1001XX A/KK FUKKM restriction: As add-on therapy for patient who Recommended starting dose and maintenance dose in patients
failed therapy and/or contraindicated/unable to tolerate with normal renal function and mild renal insufficiency (CrCl more
metformin and/or sulphonylurea. i) As add on therapy in than 50 ml/min) is 5 mg once daily. For patients with moderate to
type 2 diabetes patients inadequately controlled on severe renal insufficiency (CrCl less than or equal to 50 ml/min)
metformin monotherapy and high risk of hypoglycaemia, dose is 2.5 mg once daily
especially elderly patients with co-morbidities. ii) As add
on therapy in type 2 diabetes patients inadequately
controlled with a sulphonylure and
intolerant/contraindicated for metformin therapy iii) As
add on therapy in type 2 diabetes patients inadequately
controlled on metformin and sulphonylurea combination
therapy iv) In patients with renal failure where
metformin contraindicated Not to be used in patients
with HbA1c > 8% on single/combination OAD, as insulin
initiation is preferred.
Saxagliptin 2.5mg and Metformin HCl 1000mg A10BD10926T1001XX A Indicated as an adjunct to diet and exercise to improve As add-on therapy for patient who failed therapy and/or The recommended starting dose of in patients who need 5mg of
Extended-Release Tablet glycemic control in adults with type 2 diabetes mellitus contraindicated/unable to tolerate metformin and/or saxagliptin and who are not currently treated with metformin is
when treatment with both saxagliptin and metformin is sulphonylurea. 5mg saxagliptin/500 mg metformin extended-release once daily
appropriate. with gradual dose escalation to reduce the gastrointestinal side
effects due to metformin. In patients treated with metformin, the
dose of should provide metformin at the dose already being
taken, or the nearest therapeutically appropriate dose. Patients
who need 2.5mg saxagliptin in combination with metformin
extended-release may be treated with 2.5mg/1000mg. Patients
who need 2.5mg saxagliptin who are either metformin naive or
who require a dose of metformin higher than 1000mg should use
the individual components. Max daily recommended dose is
5mg/2000mg.
Saxagliptin 5 mg Tablet A10BH03000T1002XX A/KK i) As add on therapy in type 2 diabetes patients As add-on therapy for patient who failed therapy and/or 2.5-5mg once daily. Patients with CrCl < 50ml/min, and when
inadequately controlled on metformin monotherapy and contraindicated/unable to tolerate metformin and/or coadministered with strong CYP450 3A4/5 inhibitors: 2.5mg OD
high risk of hypoglycaemia, especially elderly patients sulphonylurea.
with co-morbidities. ii) As add on therapy in type 2
diabetes patients inadequately controlled with a
sulphonylure and intolerant/contraindicated for
metformin therapy iii) As add on therapy in type 2
diabetes patients inadequately controlled on metformin
and sulphonylurea combination therapy iv) In patients
with renal failure where metformin contraindicated Not
to be used in patients with HbA1c > 8% on
single/combination OAD, as insulin initiation is preferred.
April 2023 162


Saxagliptin 5mg and Metformin HCl 1000mg A10BD10926T1002XX A - Indicated as an adjunct to diet and exercise to improve As add-on therapy for patient who failed therapy and/or The recommended starting dose of in patients who need 5mg of
5mg/2000mg.
Saxagliptin 5mg and Metformin HCl 500 mg A10BD10926T1003XX A - Indicated as an adjunct to diet and exercise to improve As add-on therapy for patient who failed therapy and/or The recommended starting dose of in patients who need 5mg of
5mg/2000mg.
Secukinumab 150mg/ml injection L04AC10000P5001XXX A* i) Alone or in combination with methotrexate (MTX), is (i) & (ii): 2nd or 3rd line, after failure of conventional i) 150 mg by subcutaneous injection with initial dosing at Weeks
indicated for the treatment of active psoriatic arthritis DMARDs or TNF-inhibitors. 0, 1, 2 and 3, followed by monthly maintenance dosing starting at
(PsA) in adult patients when the response to previous Week 4. For patients who are anti-TNFα inadequate responders
disease-modifying anti-rheumatic drug (DMARD) therapy (IR) or patients with concomitant moderate to severe plaque
has been inadequate. ii) Indicated for the treatment of psoriasis; 300 mg by subcutaneous injection with initial dosing at
active ankylosing spondylitis (AS) in adults who have Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing
responded inadequately to conventional therapy. iii) starting at Week 4. Each 300 mg dose is given as two
Indicated for the treatment of moderate to severe subcutaneous injections of 150 mg. ii) 150 mg by subcutaneous
plaque psoriasis (PsO) in adult patients who are injection with initial dosing at Weeks 0, 1, 2 and 3, followed by
candidates for systemic therapy or phototherapy monthly maintenance dosing starting at Week 4. Based on clinical
response, the dose can be increased to 300 mg. iii) 300 mg by
subcutaneous injection with initial dosing at weeks 0, 1, 2 and 3,
followed by monthly maintenance dosing starting at week 4. Each
300 mg dose is given as two subcutaneous injections of 150 mg.
For some patients, a dosage of 150 mg may be acceptable.
Selegiline HCl 5 mg Tablet N04BD01110T1001XX A* Only for treatment of late stage Parkinsonism with on 5 mg twice daily at breakfast and lunch. Maximum 10 mg/day
and off phenomenon
April 2023 163


Selenium Sulphide 2.5% Shampoo D11AC03-180-L52-01-XXX A/KK Dandruff, seborrheic dermatitis of scalp None Apply onto wet hair, lather and leave on scalp for 3 minutes.
Rinse. Repeat treatment. Rinse thoroughly. Use twice weekly at
first, then as necessary as directed by the physician.
Sertraline HCI 50 mg Tablet N06AB06-110-T10-01-XXX B i) Major depression, obsessive-compulsive disorder i) Depression, obsessive-compulsive disorder: 50 mg/day, may
(OCD), panic disorder ii) Social anxiety disorder (social increase in steps of 50mg at weekly interval, max:200mg/day.
phobia) Panic disorder: Initially 25 mg/day. After 1 week, increase dose to
50 mg/day. All dose changes should be made at intervals of more
than 1 week, max: 200 mg/day ii) Therapy should be initiated at
25 mg/day. After one week, the dose should be increased to 50
mg once daily. Patients not responding to a 50 mg dose may
benefit from dose increases. Dose changes should be made at
intervals of at least one week, up to a maximum of 200 mg/day.
Sevelamer 800mg Tablet V03AE02121T1001XX A* Control of hyperphosphatemia in adult patients Sevelamer carbonate 800mg tablet should be used in Starting dose is one or two 800mg tablets three times per day
receiving haemodialysis and peritoneal dialysis. context of multiple therapeutic approach which include with meals. Adjust by one tablet per meal in two weeks interval
calcium supplement, 1, 25-hydroxy Vitamin D3 or one of as needed to obtain serum phosphorus target (1.13 to
its analogues to control the development of renal bone 1.78mmol/L).
disease.
Sevoflurane Liquid N01AB08000L5001XX A* To be used only for i) induction and ii) maintenance of i) Adult: Given via a calibrated vaporiser: Up to 5% v/v with
anaesthesia oxygen or a mixture of oxygen and nitrous oxide. Child: Given via
a calibrated vaporiser: Up to 7% v/v. ii) Adult: 0.5-3% v/v with or
without nitrous oxide. Child: 0.5-3% v/v with or without nitrous
oxide.
Sildenafil Citrate 20 mg Film-coated Tablet G04BE03-136-T10-04-XXX A* Treatment of adult patients with pulmonary arterial - ADULTS ≥ 18 years: The recommended dose is 20mg three times
hypertension classified as WHO functional class II and III, a day. Tablets should be taken approximately 6 to 8 hours apart
to improve exercise capacity. with or without food. ELDERLY (≥65 years): Dosage adjustments
are not required in elderly patients. Clinical efficacy as measured
by 6-minute walk distance could be less in elderly patients.
IMPAIRED RENAL FUNCTION: Initial dose adjustments are not
required in patients with renal impairment, including severe renal
impairment (creatinine clearance <30ml/min). A downward dose
adjustment to 20 mg twice daily should be considered after a
careful benefit-risk assessment only if therapy is not well-
tolerated. IMPAIRED HEPATIC FUNCTION: Initial dose
adjustments are not required in patients with hepatic impairment
(Child-Pugh class A and B). A downward dose adjustment to
20mg twice daily should be considered after a careful benefit-risk
assessment only if therapy is not well-tolerated.
Silver Nitrate 0.5% Lotion D08AL01221L6001XX B Use as antiseptic Apply undiluted to affected area for a limited period
Silver Sulfadiazine 1% Cream D06BA01199G1001XX B Prevention and treatment of infections in severe burns, Burns: Apply 3 mm thick layer twice daily with sterile applicator.
leg ulcers where infections may prevent healing and for Leg ulcer: apply at least 3 times a week
the prophylaxis of infections in skin grafting
Simvastatin 10 mg Tablet C10AA01000T1001XX B i) Hypercholesterolaemia ii) Prevention of cardiovascular i) & ii) 10 - 40 mg once daily. Maximum: 80 mg daily
disease
April 2023 164


disease
disease
Sitagliptin 100 mg Tablet A10BH01000T1003XX A* Management of diabetes in patients with renal failure Consultant/specialists for specific indications only, ADULT over 18 years, 100 mg once daily CrCl ≥ 30 to < 50ml/min:
where metformin/sulphonylurea is including Geriatricians As add-on therapy for patient who 50mg once daily CrCl < 30 ml/min: 25mg once daily
contraindicated/untolerated and elderly with multiple failed therapy and/or contraindicated/unable to tolerate
co-morbidities that always experience hypoglycemia metformin and/or sulphonylurea
with other antidiabetic. Not to be used in diabetic
patient whose HbA1c is more than 9%.
contraindicated/untolerated and elderly with multiple co failed therapy and/or contraindicated/unable to tolerate
morbidities that always experience hypoglycemia with metformin and/or sulphonylurea.
other antidiabetic. Not to be used in diabetic patient
whose HbA1c is more than 9%.
Sitagliptin 50 mg and Metformin HCl 1000 mg A10BD07926T1003XX A* i) Type 2 diabetes patients, especially the elderly, with Consultant/specialists for specific indications only, 50 mg/500 mg twice daily. The recommended maximum daily
Tablet multiple co-morbidities that always experience including Geriatricians As add-on therapy for patient who dose is 100 mg sitagliptin plus 2000 mg metformin
hypoglycaemia with other antidiabetics who are failed therapy and/or contraindicated/unable to tolerate
inadequately controlled on metformin or sitagliptin metformin and/or sulphonylurea.
alone or already being treated with the combination of
sitagliptin and metformin. ii) Newly diagnosed type 2
diabetes patients with high baseline HbA1c and multiple
co-morbidities who may experience hypoglycaemia with
other antidiabetics.
Sitagliptin 50 mg and Metformin HCl 500 mg A10BD07926T1001XX A* i)Type 2 diabetes patients, especially the elderly, with Consultant/specialists for specific indications only, 50 mg/500 mg twice daily. The recommended maximum daily
sitagliptin and metformin. ii)Newly diagnosed type 2
Sitagliptin 50 mg and Metformin HCl 850 mg A10BD07926T1002XX A* i) Type 2 diabetes patients, especially the elderly, with Consultant/specialists for specific indications only, 50 mg/500 mg twice daily. The recommended maximum daily
sitagliptin and metformin. ii) Newly diagnosed type 2
April 2023 165


contraindicated/untolerated and elderly with multiple co failed therapy and/or contraindicated/unable to tolerate
morbidities that always experience hypoglycemia with metformin and/or sulphonylurea.
other antidiabetic. Not to be used in diabetic patient
whose HbA1c is more than 9%.
Sodium Acid Phosphate (500mg Phosphorus) B05XA09-902-L50-01-XXX A For supplemental ionic phosphorus for correction of According to the needs of the patient
Effervescent Tablet hypophosphataemia
Sodium Alginate 1000 mg/10 ml & Potassium A02BX13-915-L80-01-XXX A* Treatment of symptoms of gastro-oesophageal reflux eg. Adult, elderly & children ≥12 year: 5-10 mL.
Bicarbonate 200 mg/10 ml Suspension acid regurgitation, heartburn, indigestion due to the
reflux of stomach contents not responding to
conventional antacids or as an addition to PPI when PPI
alone fails to control the symptoms
Sodium Bicarbonate 1 g/15 ml Mixture A02AH00131L2102XX B i) Relief of discomfort in mild urinary tract ii) i) 3 g in every 2 hours until urinary pH exceeds 7 ii) Maintenance
Alkalinisation of urine of alkaline urine 5-10 g daily
Sodium Bicarbonate 5% w/v Ear Drops S02DC00-131-D10-01-XXX C To soften the impacted ear wax None 2-3 drops 3-4 times daily
Sodium Bicarbonate 8.4% (1 mmol/ml) Injection B05XA02131P3002XX B i) For acceleration of excretion in drug intoxication According to the needs of the patient. In severe shock due to
(where excretion of the drug into the urine is cardiac arrest: 50 ml by IV
accelerated by elevated urine pH) ii) For metabolic
acidosis secondary to underlying diseases
Sodium Bicarbonate and Magnesium A02AH00912L2101XX C Heartburn, for rapid relief of dyspepsia ADULT 10-20 ml 3 times daily
Carbonate Compound Mixture
Sodium Bicarbonate Mixture (Paediatric) A02AH00131L2101XX C Heartburn for rapid relief of dyspepsia CHILD up to 1 year 5 ml; up to 1-5 years 10 ml in 4 to 6 divided
doses
Sodium Bicarbonate, Citric Acid, Sodium Citrate B05CB10955M4001XX B For relieving of discomfort in mild urinary tract infection, 4 - 8 g (1- 2 sachets) dissolved in a glass of cold water 4 times
and Tartaric Acid - 4 g per sachet symptomatic relief of dysuria to enchance the action to daily as prescribed
certain antibiotics especially some sulphonamides. In
gout as urinary alkalinizers to prevent cystallisation of
urates
Sodium Biphosphate 16%, Sodium Phosphate A06AG01162G2001XX A Bowel cleansing before colonic surgery, colonoscopy or ADULT 133 ml (1 bottle) administered rectally. CHILD more than 2
6% Rectal Solution radiological examination to ensure the bowel is free of years half the adult dose (66.6ml)
solid contents. It is not to be used for treatment of
constipation
Sodium Biphosphate 16%, Sodium Phosphate A06AG01162L9901XX A Bowel cleansing before colonic surgery, colonoscopy or 45 ml diluted with half a glass (120 mL) of water, followed by one
6% Solution radiological examination to ensure the bowel is free of full glass (240 mL) of water. Timing of doses is dependent on the
solid contents. It is not to be used for treatment of time of the procedure. For morning procedure, first dose should
constipation be taken at 7 a.m. and second at 7 p.m. on day before the
procedure. For afternoon procedure, first dose should be taken at
7 p.m. on day before and second dose at 7 a.m. on day of the
procedure. Solid food should not be taken during the bowel
preparation period. However clear fluids or water can be taken
liberally. CHILD under 12 years not recommended
Sodium Chloride 0.18% with Dextrose 10% B05XA03904P6001XX B For replenishing fluid and energy and for restoring or According to the needs of the patient
Injection maintaining the concentration of sodium and chloride
ions
April 2023 166


Sodium Chloride 0.18% with Dextrose 4.23% B05XA03904P6004XX B For replenishing fluid and energy and for restoring or According to the needs of the patient
ions
Sodium Chloride 0.45% Injection B05XA03100P6001XX B For replenishing fluid and for restoring / maintaining the 100 - 1000 ml by IV or according to the needs of the patient
concentration of sodium and chloride ions
ions
ions
Sodium Chloride 0.9% Eye Drops S01XA03-000-D20-01-XXX C Irrigation of conjunctival sac None 1 - 2 drops every 3 - 4 hours
Sodium Chloride 0.9% Injection B05XA03100P6002XX C+ For replenishing fluid and for restoring/maintaining the 100 - 1000 ml by IV or according to the needs of the patient
concentration of sodium and chloride ions
Sodium Chloride 0.9% with Dextrose 5% B05XA03904P6003XX C+ For replenishing fluid and energy and for restoring or According to the needs of the patient
ions
Sodium Chloride 20% Injection B05XA03100P9902XX B Addition of sodium electrolyte in parenteral nutrition According to the needs of the patient
bags especially in paediatrics or neonates with restricted
fluid allowance
Sodium Chloride 3% Injection B05XA03100P9901XX B Acute dilutional hyponatraemia According to the needs of the patient
Sodium Chromate (Chromium-51) Solution V09GX00143L9901XX A* Labelling of erythrocytes for the investigation of Usual dose range : 10 - 200 microcuries IV by IV injection
haemotological disorders
Sodium Citrate 0.3 M Solution B05CB02136L9901XX B Prophylaxis for aspiration pneumonitis (use as an oral Dose depending on clinical cases. Usually, 30 ml given 10- 60
solution) minutes before anaesthesia prior to elective cesarean surgery is
an effective antacid
Sodium Citrate 3.8% Solution B05CB02136H3001XX B Sterile solution for irrigation or washout of infected Dose depending on clinical cases
bladder
Sodium Citrate, Citric Acid Mixture 3 g/10 ml B05CB02136L2101XX B Citrates and citric acid solutions are used to correct the ADULT 10 - 20 ml. CHILD up to 1 year 2.5 ml tds; 1-5 year 5 ml
acidosis of certain renal tubular disorders to treat tds; 6-12 years 10 ml tds. To be taken well diluted with water
metabolic acidosis for long-term urine alkalinization for
prevention and treatment of uric acid and calcium
kidney stones and as nonparticulate neutralizing buffers
Sodium Cromoglycate 2% Eye Drops S01GX01-520-D20-01-XXX A/KK Prevention and treatment of allergic conjunctivitis None 1 or 2 drops 4 times daily
including seasonal and perennial allergic conjunctivitis
and vernal keratoconjunctivitis
Sodium Dichloroisocyanurate 5 g Tablet V07AV00000T1002XX C Low and medium level disinfectant 50 - 10,000 ppm av chlorine
Sodium Dichloroisocyanurate Tablet V07AV00-000-T10-01-XXX C Low and medium level disinfectant None 50 - 10,000 ppm av chlorine
Sodium Fusidate 2% Ointment D06AX01520G5001XX A Skin infections caused by staphylococci, streptococci, Apply to affected area 2 - 3 times daily
corynebacterium minutissumun and other sodium
fusidate-sensitive organisms
Sodium Fusidate 250 mg Tablet J01XC01520T1001XX A* Treatment of infections caused by susceptible organisms ADULT: 500 mg 3 times daily, skin and soft tissue infection: 250 -
especially Staphylococcal infections including Methicillin 500 mg twice daily
Resistant Staphylococcus aureus (MRSA)
April 2023 167


Sodium glycerophosphate for addition into B05XA14171P3001XX A Indicated in adult patients and infants as a supplement Adults: The recommended dosage is individual. The
infusion solution, 20ml vial in intravenous nutrition to meet the requirement of recommended daily dosage of phosphate during intravenous
phosphate. nutrition would normally be 10-20mmol. This can be met by
using 10-20ml of sodium glycerophosphate to the infusion
solution or to the admixture for which compatibility has been
proved. Infants: The recommended dosage is individual. The
recommended dose for infants and neonates is 1.0-1.5 mmol/kg
bodyweight/day.
Sodium Hypochlorite Solution V07AV00000L9903XX C Low-level disinfectant and antiseptic Antiseptic: less than 0.5%. Disinfectant: 5%
Sodium Iodide (Iodide-131) Injection V09FX03200P3001XX A* Used in the determination of various thyroid functions 5 - 50 millicuries
Sodium Iodide (Iodine-131) Capsule V09FX03200C1001XX A* Determination of various thyroid functions 5 - 10 milicuries (5 mCi for whole body scan)
Sodium Iodide (Iodine-131) Capsule V10XA01200C1001XX A* i) Thyrotoxicosis ii) Thyroid carcinoma i) 2 - 30 millicuries ii) 80 - 300 millicuries
(Therapeutic)
Sodium Iodide (Iodine-131) Solution V10XA01200L9901XX A* i) Thyrotoxicosis ii) Thyroid carcinoma i) 5-25 millicuries ii) 30-150 millicuries
Sodium Nitrite 30mg/ml Injection V03AB08-220-P30-01-XX B For cyanide poisoning None Adult: 300 mg sodium nitrite IV over 3 minutes followed after 5
minutes with 12.5g sodium thiosulphate IV administered over 10
minutes. CHILD: 4 - 10 mg/kg of sodium nitrite (max: 300 mg)
followed by 400 mg/kg of sodium thiosulfate, as a 25 or 50%
solution (max: 12.5 g). Methaemoglobin concentration should
not exceed 30-40%. If symptoms of cyanide toxicity recur, the
doses of nitrite and thiosulfate may be repeated after 30 min at
half the initial doses.
Sodium Nitroprusside 10 mg/ml Injection C02DD01520P3001XX A i) Hypertensive crisis ii) Controlled hypotension during i) By IV infusion, initially 0.5-1.5 mcg/kg/min, then adjusted
anaesthesia in order to reduce bleeding in surgical before increasement of 0.5 mcg/kg/min every 5 mins within
procedures range 0.5-8 mcg/kg/min (lower doses in patients already
receiving other antihypertensives); stop if marked response not
obtained with max dose in 10 minutes. Use only in infusion with
5 % Dextrose IV. ii) By IV infusion, max: 1.5 mcg/kg/min
Sodium Phosphate (Phosphorus-32) Injection V10XX01162P3001XX A* Polycythemia vera, chronic myeloid and chronic Initially 5 millicuries, follow if necessary by a dose of not more
lymphocytic leukaemia and palliative treatment of bone than 3 or 4 millicurie at intervals of not less than 2 months
metastases
April 2023 168


Sodium picosulfate, magnesium oxide & citric A06AB58-921-L50-01-XXX A/KK i) To clean the bowel prior to X-ray examination or ADULTS: a) Split-Dose Dosing Regimen (Preferred Method) • First
acid powder for oral solution endoscopy. ii) To clean the bowel prior to surgery when dose should be taken during the evening before the procedure
judged clinically necessary. (e.g. 5:00 to 9:00 PM) followed by five 250 ml drinks (upper line
on the dosing cup) of clear liquids before bed. Clear liquids
should be consumed within 5 hours. • Second dose to be taken
the next day approximately 5 hours before the procedure
followed by at least three 250ml drinks of clear liquids before the
procedure. Clear liquids should be consumed within 5 hours up
until 2 hour before the time of the procedure. b) Day-Before
Dosing Regimen (Alternative Method) (Alternative dosing
method for patients for whom the Split-Dosing is inappropriate).
• First dose to be taken in the afternoon or early evening (e.g.,
4:00 to 6:00 PM) before the procedure followed by five 250 ml
drinks (upper line on the dosing cup) of clear liquids before the
next dose. Clear liquids should be consumed within 5 hours. •
Second dose to be taken approximately 6 hours later in the late
evening (e.g., 10:00 PM to 12:00 AM), the night before the
procedure followed by three 250 ml drinks of clear liquids before
bed. Clear liquids should be consumed within 5 hours. CHILDREN:
The first dose reconstituted in water as directed, taken before 8
am on the day before the procedure. Second dose 6 to 8 hours
later. • 1 - 2 years: 1⁄4 sachet morning, 1⁄4 sachet afternoon • 2 -
4 years: 1⁄2 sachet morning, 1⁄2 sachet afternoon • 4 - 9 years: 1
sachet morning, 1⁄2 sachet afternoon • 9 and above: adult dose
Sodium Polystyrene Sulphonate Powder V03AE01520F2101XX A Treatment and prevention of hyperkalaemia associated ADULT : Oral : 15 g 1 - 4 times/day. Rectal : 30 g in 100 ml 2%
with anuria or severe oliguria, in dialysis patients or methylcellulose and 100 ml water as a daily retention enema.
those on prolonged peritoneal dialysis Retain for 9 hours followed by non-sodium cleansing enema.
CHILD : 1 g/kg in 1 - 4 doses in acute hyperkalemia. Maintenance :
0.5 g/kg/daily
Sodium Tetradecyl Sulphate 1 % Injection C05BB04183P3001XX A* Sclerotherapy of oesophageal varices, haemorrhoids and 0.5-2 mL into the submucosal layer at the base of the
varicose veins oesophageal varix or the haemorrhoid; several injections may be
given at different sites, max. total injected 10-15 mL of 1% per
treatment
Sodium Tetradecyl Sulphate 3 % Injection C05BB04183P3002XX A* Sclerotherapy of oesophageal varices, haemorrhoids and 0.5-2 mL into the submucosal layer at the base of the
varicose veins oesophageal varix or the haemorrhoid, several injections may be
given at different sites, max. total injected 10-15 mL of 1% per
treatment
Sodium Thiosulphate 10-20% Solution D01AE00181L9901XX C Fungicides. For the treatment of pityriasis versicolor Apply to all affected parts of the body and face with a brush after
a bath once daily or twice daily or 3 times daily
April 2023 169


Sodium Thiosulphate 500 mg/ml Injection V03AB06181P3001XX B For cyanide poisoning None ADULT: To be given after 300 mg of sodium nitrite has been
admin over 5-20 min: 12.5 g of sodium thiosulfate (50 ml of a
25% solution or 25 ml of a 50% solution) given over 10 min.
Methaemoglobin concentration should not exceed 30-40%. If
symptoms of cyanide toxicity recur, the doses of nitrite and
thiosulfate may be repeated after 30 min at half the initial doses.
CHILD: To be given after 4-10 mg/kg of sodium nitrite (max: 300
mg) has been admin: 400 mg/kg of sodium thiosulfate, as a 25 or
50% solution (max: 12.5 g). Methaemoglobin concentration
should not exceed 30-40%. If symptoms of cyanide toxicity recur,
the doses of nitrite and thiosulfate may be repeated after 30 min
at half the initial doses.
Sodium Valproate 200mg Tablet N03AG01520T1001XX B i. Epilepsy ii. Treatment and prevention of mania None i. Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses,
associated with bipolar disorders dose may be increased by 200 mg at 3-day intervals to max 2.5
g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day).
CHILD: - More than 20 kg. Initially 400 mg/day with spaced
increases until control is achieved (usually 20-30 mg/kg/day),
dose may be increased to 35 mg/kg/day. - Less than 20 kg 20
mg/kg/day, in severe cases the dose may be increased provided
plasma concentration can be monitored. ii. Treatment and
prevention of mania associated with bipolar disorders: ADULT:
The recommended initial dose is 1000mg/day. The dose should
be increased as rapidly as possible to achieve the lowest
therapeutic dose, which produces the desired clinical effects. The
recommended maintenance dosage for the treatment of bipolar
disorder is between 1000mg and 2000mg daily. In exceptional
cases, the dose may be increased to not more than 3000mg daily.
Sodium Valproate 200mg/5ml Syrup N03AG01-520-L90-01-XXX B i) Treatment of generalized or partial epilepsy. ii) None i. Epilepsy: ADULT: Initially 600 mg/day in 2 - 3 divided doses,
Treatment and prevention of mania associated with dose may be increased by 200 mg at 3-day intervals to max 2.5
bipolar disorder g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day).
CHILD: - More than 20 kg. Initially 400 mg/day with spaced
increases until control is achieved (usually 20-30 mg/kg/day),
dose may be increased to 35 mg/kg/day. - Less than 20 kg 20
mg/kg/day, in severe cases the dose may be increased provided
plasma concentration can be monitored. ii. Treatment and
prevention of mania associated with bipolar disorders: ADULT:
The recommended initial dose is 1000mg/day. The dose should
be increased as rapidly as possible to achieve the lowest
therapeutic dose, which produces the desired clinical effects. The
recommended maintenance dosage for the treatment of bipolar
disorder is between 1000mg and 2000mg daily. In exceptional
cases, the dose may be increased to not more than 3000mg daily.
April 2023 170


Sodium Valproate 400mg Injection N03AG01-520-P40-01-XX B Status epilepticus None ADULT and CHILD above 10 years: 10 to 15 mg/kg/day IV, may
increase 5 to 10 mg/kg/week to achieve optimal clinical response
(Maximum 60 mg/kg/day or less with a therapeutic range of 50 to
100 mcg/mL)
Sofosbuvir 400mg & velpatasvir 100mg film J05AP55-964-T32-01-XXX A*, A/KK For the treatment of chronic hepatitis C virus (HCV) PRESCRIBER CATEGORY A/KK: i. Non-cirrhotic patients One tablet, taken orally, once daily with or without food. Refer
coated tablet infection in adults who are treatment naïve to NS5A inhibitor, or package insert for the recommended treatment and duration for
PRESCRIBER CATEGORY A*: ii. With decompensated liver all HCV genotypes
cirrhosis who are treatment naïve to NS5A inhibitor, or iii.
For direct-acting antiviral (DAA) experienced patients who
failed to achieve sustained virological response (SVR) due
to virological failure (preferably based on resistant
associated substitution (RAS) report), or iv. Uninfected
recipients of liver and non-liver grafts of HCV-viremic
donors who are treatment naïve to NS5A inhibitor, or v.
HCV-infected recipients post-liver transplant who are
treatment naïve to NS5A inhibitor
Sofosbuvir 400mg tablet J05AP08-000-T32-01-XXX A/KK To be used in combination with other medicinal One 400 mg tablet, taken orally, once daily with food. Sofosbuvir
products for the treatment of chronic hepatitis C (CHC) should be used in combination with other medicinal products.
in adults. Monotherapy of sofosbuvir is not recommended.
Solifenacin Succinate 5 mg Tablet G04BD08000T1001XX A* Symptomatic treatment of urge incontinence and/or 5mg od. Dose can be increased to 10mg if necessary.
increased urinary frequency and urgency as may occur in
patients with overactive bladder syndrome.
Somatropin 10mg (30IU) Injection H01AC01-000-P50-02-XXX A* To be used in children for: i) Growth failure due to None Children: i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM. ii)
growth hormone deficiency (GHD) ii) Growth failure in 1.3-2mg/m2/day or 0.045-0.05 mg/kg/day SC. iii) 0.035
girls due to gonadal dysgenesis (Turner syndrome). iii) mg/kg/day or 1 mg/m2/day SC. Adult: i) Start treatment with a
Growth failure in short children born small gestational low dose of 0.1-0.3 mg/day. Titrate dosage gradually at monthly
age (SGA) To be used in adult for: i) Adult onset growth intervals based on patient's need and serum IGF-1. Maintenance
hormone deficiency (GHD) ii) Childhood onset growth dose: Vary from person to person, but seldom exceed 1.0 mg/day
hormone deficiency (GHD) (equal to 3 IU/day). ii)0.2-0.5mg/day with subsequent dose
adjustment on the basis of IGF-I concentration determination.
The dosing is individualized according to product insert / protocol.
Somatropin 5mg (15IU) Injection H01AC01-000-P50-01-XXX A* To be used in children for: i) Growth failure due to None Children: i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM. ii)
growth hormone deficiency (GHD) ii) Growth failure in 1.3-2mg/m2/day or 0.045-0.05 mg/kg/day SC. iii) 0.035
girls due to gonadal dysgenesis (Turner syndrome). iii) mg/kg/day or 1 mg/m2/day SC. Adult: i) Start treatment with a
Growth failure in short children born small gestational low dose of 0.1-0.3 mg/day. Titrate dosage gradually at monthly
age (SGA) To be used in adult for: i) Adult onset growth intervals based on patient's need and serum IGF-1. Maintenance
hormone deficiency (GHD) ii) Childhood onset growth dose: Vary from person to person, but seldom exceed 1.0 mg/day
hormone deficiency (GHD) (equal to 3 IU/day). ii)0.2-0.5mg/day with subsequent dose
adjustment on the basis of IGF-I concentration determination.
The dosing is individualized according to product insert / protocol.
April 2023 171


Somatropin 6mg solution for injection H01AC01-000-P30-04-XXX A* i) Growth failure due to inadequate endogenous growth For paediatric consultants/specialists use only This i) 0.025-0.035mg/kg/day ii) 0.045-0.05mg/kg/day iii) 0.035
hormone ii) Growth failure in girls due to gonadal medicine is for the following patients who will require the mg/kg/day
dysgenesis (Turner syndrome) iii) Growth failure in short specific features of the supplied device for treatment
children born small gestational age (SGA) optimization: 1. Young infants or toddlers who need very
precise dose administration (for example 0.19 mg, 0.27
mg and etc.) 2. Other older patients who are unable to
tolerate or who have poor medication compliance with
other growth hormone preparations
Somatropin 8mg (24IU) Injection H01AC01-000-P30-03-XXX A* i) Growth failure due to growth hormone insufficiency None i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4
ii)Growth failure in girls due to gonadal dysgenesis mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1
(Turner syndrome) iii)Growth failure in short children mg/m2/day SC
born small gestational age(SGA)
Sotalol HCl 80 mg Tablet C07AA07110T1001XX A* Ventricular tachyarrythmias Supraventricular and ventricular arrhythmias Adult: Initially, 80
mg/day as single or in 2 divided doses, increased gradually every
2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-
threatening ventricular arrhythmias Adult: Initially, 80 mg bid,
increased gradually every 3 days to 240-320 mg/day in divided
doses if needed. Maintenance: 160-320 mg/day in divided doses.
Max: 480-640 mg in divided doses.
Spironolactone 25 mg Tablet C03DA01000T1001XX B Oedema and ascites in cirrhosis of the liver, congestive ADULT: 100 - 200 mg daily in divided doses. Increase to 400 mg if
heart failure required. CHILD: initially 3 mg/kg daily in divided doses
Stavudine 30 mg, Lamivudine 150 mg & J05AR07964T1001XX A/KK Fixed dose triple therapy for treatment of HIV infection SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice
Nevirapine 200 mg Tablet in adults once patients have been stabilized on the daily
maintenance regimen of nevirapine 200 mg twice daily
and have demonstrated adequate tolerability to
nevirapine
Stavudine 40 mg, Lamivudine 150 mg & J05AR07964T1002XX A* Fixed dose triple therapy for treatment of HIV infection SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice
Nevirapine 200 mg Tablet in adults once patients have been stabilized on the daily
maintenance regimen of nevirapine 200 mg twice daily
and have demonstrated adequate tolerability to
nevirapine
Streptokinase 1,500,000 IU Injection B01AD01000P4001XX A* Acute myocardial infarction, acute pulmonary embolism Myocardial infarction: 1,500,000 units over 30 - 60 minutes.
Pulmonary embolism: 250,000 units by IV infusion over 30
minutes, then 100,000 units every hour for up to 12-72 hours
with monitoring of clotting factors
Streptomycin Sulphate 1 g Injection J01GA01-183-P40-01-XXX B i) Tuberculosis ii) Brucellosis iii) Bacterial endocarditis 15 mg/kg daily (Max: 1 g daily) Dosing is according to product
insert.
Strontium Ranelate 2 g Granules M05BX03000F1001XX A* Treatment of postmenopausal osteoporosis to reduce 2 g sachet once daily
risk of vertebral and hip fractures when biphosphonates
are contraindicated or not tolerated
Succindialdehyde 11% & V07AV00000L9907XX A High level disinfection for endoscopes, ultrasonicprobes, Immersion time is based on manufacturers recommendation
Dimethoxytetrahydrofuran 3% anaesthesia equipment etc
Sucralfate 1 g Tablet A02BX02000T1001XX A i) Benign gastric and duodenal ulceration ii) Stress ulcer i) 2 g twice daily or 1 g 4 times daily for 4-6 weeks or in resistant
prophylaxis cases up to 12 weeks (maximum 8 g daily) ii) 1 g 6 times daily
(maximum 8 g daily). CHILD not recommended
April 2023 172


Sugammadex 100 mg/ml Injection V03AB35000P3001XX A* Indicated for reversal of neuromuscular blockade 2 mg/kg sugammadex is recommended, if spontaneous recovery
induced by rocuronium and vecuronium in selective has occurred up to at least the reappearance of second twitch
patient group: obese, elderly, underlying cardiovascular tension of the train-of-four (T2). 4 mg/kg sugammadex is
disease. For pediatric population, sugammadex is recommended if recovery has reached at least 1- 2 post-tetanic
recommended for routine reversal counts (PTC). For immediate reversal following administration of
rocuronium a dose of 16 mg/kg sugammadex is recommended
Sulfadoxine 500 mg and Pyrimethamine 25 mg P01BD51981T1001XX B Treatment of Plasmodium falciparum malaria in patients Chloroquine resistant falciparum malaria acute attack Adult: Per
Tablet in whom chloroquine resistance is suspected and malaria tab contains pyrimethamine 25 mg and sulfadoxine 500 mg: 2-3
prophylaxis for travellers to areas where chloroquine- tabs as a single dose. Do not repeat for at least 7 days. Child:
resistant malaria is endemic Pyrimethamine 25mg + Sulfadoxine 500mg (Tablet): <2 yr (5-10
kg): 1/2 (half) tab as a single dose; 2-5 yr (>10-20 kg): 1 tab as a
single dose; 5-10 yr (< 20-30 kg): 1 1/2 (one and half) tab as a
single dose; 10-14 yr (> 30-45 kg): 2 tab as a single dose. Do not
repeat for at least 7 days. Renal impairment: Dose reduction may
be needed. Severe: contra-indicated. Hepatic impairment: Dose
reduction may be needed. Severe: contra-indicated.
Sulphamethoxazole 200 mg & Trimethoprim 40 J01EE01961L8001XX B Infections caused by susceptible pathogens Mild to moderate infections: more than 2months: 8 - 12mg
mg/5ml Suspension Trimethoprim/kg/day divided every 12hours. Serious Infections:
15-20mg Trimethoprim/kg/day divided every 6hours.
Sulphamethoxazole 400 mg & Trimethoprim 80 J01EE01961P3001XX A i) Severe or complicated infections when oral therapy is i) ADULT: 960 mg twice daily increased to 1.44 g twice daily in
mg Injection not feasible ii) Treatment and prophylaxis of severe infections. CHILD: 36 mg/kg daily in 2 divided doses
pneumocystis carinii pneumonia (PCP) in increased to 54 mg/kg/day in severe infections ii) Treatment:
immunocompromised patients ADULT & CHILD over 4 weeks: 120 mg/kg/day PO/IV infusion in 2 -
4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once
daily or 960 mg on alternate days (3 times a week) or 960 mg
twice daily on alternate days (3 times a week). CHILD 6 weeks - 5
months: 120 mg twice daily on 3 consecutive days or 7 days per
week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg
Sulphamethoxazole 400 mg & Trimethoprim 80 J01EE01961T1001XX B i) Severe or complicated infections due to susceptible i) ADULT: 1 - 3 tablets twice daily ii) Treatment: ADULT & CHILD
mg Tablet infection ii) Treatment and prophylaxis of pneumocystis over 4 weeks: 120 mg/kg/day in 2 - 4 divided doses for 14 days.
carinii pneumonia (PCP) in immunocompromised Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate
patients days (3 times a week) or 960 mg twice daily on alternate days (3
times a week). CHILD; 6 weeks - 5 months: 120 mg twice daily on
3 consecutive days or 7 days per week; 6 months - 5 years: 240
mg; 6 - 12 years: 480 mg
Sulphur 2% & Salicylic Acid 2% Cream D10AB02951G1001XX C Acne vulgaris and seborrhoeic dermatitis When used in scalp disorders, a small amount of cream should be
rubbed gently into the roots of the hair. When used in skin
disorders, the cream should be applied sparingly to the affected
area. Apply once daily or until noticeable improvement, then
once or twice a week
Sulpiride 200 mg Tablet N05AL01000T1001XX B Acute and chronic psychotic disorders 200-1000mg daily
Sumatriptan 100 mg Tablet N02CC01000T1002XX A/KK Treatment of acute migraine attacks 50 mg per attack and not more than 300 mg daily
Sumatriptan 50 mg Fast Disintegrating Tablet N02CC01000T5001XX A Treatment of acute migraine attacks 50 mg per attack and not more than 300 mg daily
Sumatriptan 50 mg Tablet N02CC01000T1001XX A/KK Treatment of acute migraine attacks 50 mg per attack and not more than 300 mg daily
April 2023 173


Sunitinib malate 12.5mg capsule L01XE04-253-C10-03-XXX A* Treatment of advanced renal cell carcinoma (RCC) i) KPS ≥70% ii) Clear cell histology iii) No brain metastases 50 mg orally once daily for 4 consecutive weeks, followed by a 2-
iv) Haemoglobin ≥9g/dl v) Creatinine ≤2x the ULN vi) week off period to comprise a complete cycle of 6 weeks.
Corrected calcium <12mg/dl vii) Platelet count of >100 x
103/uL viii) Neutrophil count>1500/mm3
Sunscreen SPF 30-50 Cream D02BA02-000-G10-01-XXX B Photodermatitis None Apply to exposed areas at least 15 minutes prior to solar
exposure; reapply after swimming, prolonged perspiration and
after 2 hours of continuous sun exposure.
Suxamethonium 50 mg/ml lnjection M03AB01-100-P30-01-XXX B As an adjunct to general anaesthesia to facilitate Intravenous: Muscle relaxant in general anaesthesia Adult: As
endotracheal intubation, to provide skeletal muscle chloride: single dose of 0.3-1.1 mg/kg injected; supplementary
relaxation during surgery and to facilitate mechanical doses of 50-100% of the initial dose may be given at 5-10 min
ventilation intervals. Max dose (repeated IV injection or continuous
infusion): 500 mg/hr Child: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1
mg/kg. Intramuscular: Muscle relaxant in general anaesthesia
Adult: As chloride: 3-4 mg/kg. Max total dose: 150 mg Child: As
chloride: <1 yr: Up to 4-5 mg/kg; ≥1 yr: Up to 4 mg/kg. Max dose:
150 mg.
Synthetic ACTH (Tetracosactrin Acetate) 250 H01AA02000P3001XX A Diagnostic test to differentiate primary adrenal from Diagnostic test for investigation of adrenocortical insufficiency
mcg/ml Injection secondary (pituitary) adrenocortical insufficiency Adult: As plain preparation: Measure plasma cortisol
concentration immediately before and exactly 30 min after IM/IV
inj of 250 mcg. Post-inj rise in plasma cortisol concentration ≥200
nmol/l (70 mcg/l) if normal adrenocortical function. As depot
preparation (if inconclusive results with plain preparation):
Measure plasma cortisol concentration before and exactly 30
min, 1, 2, 3, 4 and 5 hr after an IM inj of 1 mg tetracosactide
acetate depot. Adrenocortical function normal if the post-inj rise
in plasma cortisol concentration increases 2-fold in 1st hr, and
continues to rise steadily. Expected levels in 1st hr: 600-1,250
nmol/l, increasing slowly up to 1000-1800 nmol/l by 5th hr. Child:
IV 250 mcg/1.73 m2 BSA. Intramuscular
Tacrolimus 0.03% Ointment D11AH01000G5002XX A* For short-term and intermittent long-term therapy in the Adult ≥16 years: Apply 0.03% or 0.1% to the affected skin twice
treatment of patients with moderate to severe atopic daily and rub in gently and completely. Children ≥ 2 years: Apply
dermatitis in whom the use of alternative, conventional 0.03% ointment thinly to the affected skin bd and rub in gently
therapies are deemed inadvisable because of potential and completely. Treatment should be continued for 1 week after
risks, or in the treatment of patients who are not clearing of signs & symptoms of atopic dermatitis.
adequately responsive to or are intolerant of alternative,
conventional therapies
Tacrolimus 0.1% Ointment D11AH01000G5001XX A* For short-term and intermittent long-term therapy in the Adult ≥16 years: Apply 0.03% or 0.1% to the affected skin twice
treatment of patients with moderate to severe atopic daily and rub in gently and completely. Children ≥ 2 years: Apply
dermatitis in whom the use of alternative, conventional 0.03% ointment thinly to the affected skin bd and rub in gently
therapies are deemed inadvisable because of potential and completely. Treatment should be continued for 1 week after
risks, or in the treatment of patients who are not clearing of signs & symptoms of atopic dermatitis.
adequately responsive to or are intolerant of alternative,
conventional therapies
April 2023 174


Tacrolimus 0.5 mg Capsule L04AD02000C1003XX A* i) Primary immunosuppression in liver and kidney 0.1-0.2 mg/kg/day for liver transplantation and at 0.15-0.3
allograft recipients. ii) Liver and kidney allograft rejection mg/kg/day for kidney transplantation administered as 2 divided
resistant to conventional immunosuppressive agents. It doses.
is recommended to be used concomitantly with adrenal
corticosteroids. Because of the risk of anaphylaxis.
Injection should be reserved for patients unable to take
capsules only.
Tacrolimus 0.5mg Prolonged-Release Hard L04AD02000C2203XX A* i) Prophylaxis of transplant rejection in adult kidney or i) Prophylaxis of transplant rejection: a) Kidney Transplant:
Capsule liver allograft recipients. ii) Treatment of kidney or liver Tacrolimus PR therapy should commence at dose of 0.20-0.30
allograft rejection resistant to treatment with other mg/kg/day administered once daily in the morning.
immunosuppressive medicinal products in adult. Administration should commence within 24 hours after
completion of surgery. b) Liver Transplant Tacrolimus PR therapy
should commence at a dose of 0.10-0.20 mg/kg/day administered
once daily in the morning. Administration should commence
within 12-18 hours after completion of surgery. ii) Treatment of
allograft rejection: For conversion: a) From other
immunosuppressants to once daily Tacrolimus PR: Treatment
should begin with the initial oral dose recommended in kidney
and liver transplantation respectively for prophylaxis of
transplant rejection. b) From Tacrolimus to Tacrolimus PR:
Allograft transplant patients maintained on twice daily
Tacrolimus capsules dosing requiring conversion to once daily
Tacrolimus PR should be converted on a 1:1 (mg:mg) total daily
dose basis. Tacrolimus PR should be administered in the morning.
Tacrolimus 1 mg Capsule L04AD02000C1001XX A* i) Primary immunosuppression in liver and kidney 0.1-0.2 mg/kg/day for liver transplantation and at 0.15-0.3
capsules only.
April 2023 175


Tacrolimus 1mg Prolonged-Release Hard L04AD02000C2201XX A* i) Prophylaxis of transplant rejection in adult kidney or i) Prophylaxis of transplant rejection: a) Kidney Transplant:
Tacrolimus 5 mg Capsule L04AD02000C1002XX A* i) Primary immunosuppression in liver and kidney 0.1-0.2 mg/kg/day for liver transplantation and at 0.15-0.3
capsules only.
Tacrolimus 5mg Prolonged-Release Hard L04AD02000C2202XX A* i) Prophylaxis of transplant rejection in adult kidney or i) Prophylaxis of transplant rejection: a) Kidney Transplant:
April 2023 176


Tacrolimus 5mg/ml Injection L04AD02000P3001XX A* i) Primary immunosuppression in liver and kidney 0.01-0.05 mg/kg for liver transplant and 0.05-0.1 mg/kg for
allograft recipients. ii) Liver and kidney allograft rejection kidney transplant as 24-hours continuous infusion.
resistant to conventional immunosuppressive agents. It
capsules only.
Tafluprost 15mcg/ml & Timolol 5mg/ml S01ED51-990-D20-07-XXX A* Reduction of intraocular pressure (IOP) in adult patients • As third line of treatment in patients with POAG or OHT Instill 1 drop in the affected eye(s) once daily
Opthalmic Solution (Preservative Free) with primary open angle glaucoma (POAG) or ocular who require fixed-dose combination therapy. • To be
hypertension (OHT) who are insufficiently responsive to prescribed by Glaucoma consultants only
topical monotherapy with beta-blockers or
prostaglandin analogues and require a combination
therapy, and who would benefit from preservative free
eye drops
Tafluprost Ophthalmic Solution 0.0015% S01EE05-000-D20-01-XXX A* Indicated for the reduction of intraocular pressure in i. As monotherapy in patients who are better suited for Instill 1 drop in the affected eye(s) once daily
(Preservative-free) patients with primary open-angle glaucoma or ocular eye drops without preservative; ii. To be prescribed by
hypertension. Glaucoma consultants only
Tamoxifen Citrate 20 mg Tablet L02BA01136T1001XX A Breast cancer 20 mg in 1-2 divided doses. Max: 40 mg/day
Tamsulosin HCl 400 mcg Extended Release G04CA02110T5001XX A* Second line treatment of functional symptoms of benign Consultant/specialists for specific indications only, 400 mcg once daily
Tablet prostatic hyperplasia (BPH) in patients who do not including Geriatricians
tolerate first line drugs or when first line drugs are
inappropriate or contraindicated
Tar, Coal Tar and Oleyl Alcohol Liquid D05AA00952L5001XX A/KK Dandruff, seborrhoeic dermatitis and atopic dermatitis Massage into wet hair, rinse and repeat. Use once or twice weekly
April 2023 177


Technetium-99m Sterile Generator V09CA01000P3001XX A* Sodium pertechnetate is used for scintigraphy or nuclear Technetium-99m as pertechnetate is obtained by elution with a
scan particularly of the brain and thyroid to prepare sterile solution of Sodium Chloride 0.9%. The dosage depend on
various technetium-99m labelled injections for selective type of scan i) Thyroid scintigraphy: 18.5-80 MBq (0.5-2.2 mCi)
organ imaging Scintigraphy performed 20 minutes after intravenous injection ii)
Salivary gland scintigraphy: 40 MBq (1.1 mCi) Scintigraphy
performed immediately after intravenous injection and at regular
intervals up to 15 minutes iii) Meckel's diverticulum scintigraphy:
400 MBq (10.8 mCi) Scintigraphy performed immediately after
intravenous injection and at regular interval up to 30 minutes iv)
Brain scintigraphy: 370-800 MBq (10-22 mCi) Rapid sequential
images are taken immediately within the first minute after
intravenous administration, static images 1 to 4 hours later.
Thyroid and coriod plexus should be blocked to avoid non-
specific 99mTc uptake v) Cardiac and vascular scintigraphy: 740-
925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by
pretreating with a reducing agent. Dynamic images are taken in
the first minute after intravenous administration, followed by
regular images over 30 minutes vi) Gastrointestinal bleeding: 740-
925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by
pretreating with a reducing agent. Dynamic images are taken in
the first minutes after intravenous administration, followed by
regular images at appropriate intervals for up to 24 hours vii)
Lacrimal duct scintigraphy: 2-4 MBq each eye (50-100 mCi) Drops
are instilled into eye and dynamic images are taken over 2
minutes, followed by static images at appropriate intervals over
20 minutes
Tegafur 100 mg & uracil 224 mg Capsule L01BC53980C1001XX A* i) Non small cell lung cancer; ii) Tegafur Uracil plus folinic i) 300-600 mg daily in 2-3 divided doses; ii) Adjuvant setting -
acid (leucovorin) combination therapy is indicated for 300mg/m2/day , Day 1-28, rest 7 days; Leucovorin Calcium 75
the treatment of colorectal cancer in: a) Metastatic mg/day, Day 1-28, rest 7 days for 5 cycles; Concurrent setting -
stage; b) Adjuvant setting; c) Concurrent setting. 300mg/m2/day; Leucovorin Calcium 25 mg /day, D8- D36, for 4
weeks; Metastatic stage - 300mg/m2/day , Day 1-28, rest 7 days;
Leucovorin Calcium 75 mg/day, Day 1-28, rest 7 days for 5 cycles.
Telbivudine 600 mg Tablet J05AF11000T1001XX A* Treatment of chronic hepatitis B in patients with ADULT and CHILD over 16 years: 600 mg once daily. Renal Dose
evidence of viral replication and active liver inflammation Adjustment: 600mg every 48hours (30-49ml/min), 600 mg every
72hours. (<30ml/min; not requiring dialysis); 600mg every 96
days (ESRD)
Telmisartan 40 mg Tablet C09CA07000T1001XX A/KK Patients intolerant to ACE inhibitors in: i) Hypertension i) 40mg - 80mg once daily. Max: 160mg daily ii) 80mg once daily
ii) Reduction of the risk of myocardial infarction, stroke, Dosing is individualised and according to product insert /
or death from cardiovascular causes in patients 55 years protocol.
or older at high risk of developing major cardiovascular
events who are unable to take ACE inhibitors
Telmisartan 80 mg & Hydrochlorothiazide 12.5 C09DA07000T1001XX A/KK Hypertension in patients intolerant to ACE inhibitors Initial: Telmisartan/Hydrochlorothiazide 80mg/12.5mg once daily
mg Tablet Max: Telmisartan/Hydrochlorothiazide 160/25mg once daily
Dosing is individualised and according to product insert /
protocol.
April 2023 178


Telmisartan 80 mg Tablet C09CA07000T1002XX A/KK Patients intolerant to ACE inhibitors in: i) Hypertension i) 40mg - 80mg once daily. Max: 160mg daily ii) 80mg once daily
ii) Reduction of the risk of myocardial infarction, stroke, Dosing is individualised and according to product insert /
or death from cardiovascular causes in patients 55 years protocol.
or older at high risk of developing major cardiovascular
events who are unable to take ACE inhibitors
Temozolomide 100 mg Capsule L01AX03000C1003XX A* In patients with glioblastoma multiforme who fulfill all Concomitant phase : 75mg/m2 daily with radiotherapy for 42
the following criteria: i. Total /near total resection ii. days, followed by 6 cycle of adjuvant treatment. Adjuvant phase:
ECOG/WHO performance status 0-2 iii. Age less than 60 Additional 6 cycles of adjuvant phase. Cycle 1- 150mg/m2 once
years daily for 5 days followed by 23 days without treatment. Cycle 2-6
: 200mg/m2 once daily for 5 days per 28-day cycle
Temozolomide 20 mg Capsule L01AX03000C1001XX A* In patients with glioblastoma multiforme who fulfill all Concomitant phase : 75mg/m2 daily with radiotherapy for 42
the following criteria : i. total /near total resection ii. days, followed by 6 cycle of adjuvant treatment. Adjuvant phase:
ECOG/WHO performance status 0-2 iii. Age less than 60 Additional 6 cycles of adjuvant phase. Cycle 1- 150mg/m2 once
years daily for 5 days followed by 23 days without treatment. Cycle 2-6
: 200mg/m2 once daily for 5 days per 28-day cycle
Tenecteplase 10,000 unit (50 mg) Injection B01AD11000P4001XX A* Acute myocardial reinfarction where streptokinase is Less than 60 kg: 30 mg, 60 - 69 kg: 35 mg, 70 - 79 kg: 40 mg; 80 -
contraindicated due to previous streptokinase induced 90 kg: 45 mg, 90 kg or above: 50 mg. Administer single IV bolus
antibodies. [Indicated when antibodies was given more over 5-10 seconds
than 5 days and less than 12 months]
Tenofovir Disoproxil Fumarate 300 mg & J05AR03964T1001XX A/KK Treatment of HIV-1 infection in adults in combination 1 tablet once daily.
Emtricitabine 200 mg Tablet with other antiretroviral agents (such as non-nucleoside
reverse transcriptase inhibitors or protease inhibitors).
Tenofovir Disoproxil Fumarate 300 mg Tablet J05AF07138T1001XX A* i)Treatment of HIV-1 infected adults in combination with 300mg once daily. Renal Dose Adjustment: 300mg every 48hours
other antiretroviral agents. ii)Use as first line (30-49ml/min); 300mg every 72hours (10-29ml/min); 300mg
monotherapy for chronic hepatitis B or as a rescue every 7 days after dialysis (Hemodialysis)
therapy for patients with drug resistance hepatitis B
virus (according to resistant profile or treatment
guidelines).
Tenofovir Disoproxil Fumarate 300mg, J05AR06-964-T32-01-XXX A/KK Indicated for the treatment of HIV-1 infection in adults - One tablet once daily taken orally on an empty stomach. Dosing
Emtricitabine 200mg & Efavirenz 600mg at bedtime may improve the tolerability of nervous system
Tablets (Fixed-dose combination) symptoms
Terazosin HCl 1 mg Tablet G04CA03110T1001XX A/KK i) Treatment of Benign Prostatic Hyperplasia ii) i) Initial dose: 1 mg at bedtime. Maintenance dose: 5-10mg once
Hypertension daily ii) Initial dose: 1mg at bedtime. Maintenance dose: 1-5mg
once daily. Max: 20-40mg/day
Terazosin HCl 2 mg Tablet G04CA03110T1002XX A/KK i) Treatment of Benign Prostatic Hyperplasia i) Initial dose: 1 mg at bedtime. Maintenance dose: 5-10mg once
ii)Hypertension daily ii) Initial dose: 1mg at bedtime Maintenance dose: 1-5mg
Terazosin HCl 5 mg Tablet G04CA03110T1003XX A/KK i) Treatment of Benign Prostatic Hyperplasia i) Initial dose: 1 mg at bedtime. Maintenance dose: 5-10mg once
ii)Hypertension daily ii) Initial dose: 1mg at bedtime. Maintenance dose: 1-5mg
Terbinafine 1% gel D01AE15-110-G30-01-XXXX A/KK Skin infections caused by dermatophytes, mould and Second line treatment For adults and adolescents aged 12 years and over Apply topically
candida. once daily for 1 week to 2 weeks.
Terbinafine HCl 250 mg Tablet D01BA02110T1001XX A/KK Fungal infections especially onchomycosis caused by 250 mg once daily for 6 weeks for fingernails: 12 weeks for
dermatophytes toenails
April 2023 179


Terbutaline Sulphate 0.5mg/ml Injection R03CC03-183-P30-01-XXX B Bronchial asthma, chronic bronchitis, emphysema and None SC, IM or slow IV : 250-500 mcg up to 4 times daily. CHILD 2 - 15
other lung diseases where broncoconstriction is a years 10mcg/kg to a maximum of 300 mcg. Continuous IV
complicating factor infusion, as a solution containing 3 - 5 mcg/ml, 1.5 - 5
mcg/minute for 8 - 10 hours; reduce dose for children
Terbutaline Sulphate 10mg/ml Nebulizer R03AC03-183-A30-01-XXX B Asthma and other conditions associated with reversible None ADULT : 5 - 10 mg 2 -4 times daily, additional doses may be
Solution airways obstruction necessary in severe acute asthma. CHILD up to 3 years : 2 mg, 3 -
6 years : 3 mg, 6 - 8 years : 4 mg, over 8 years : 5 mg 2 - 4 times
daily
Teriflunomide 14 mg tablet L04AA31-000-T32-01-XXX A* Treatment of adult patients with relapsing remitting 14mg once daily.
multiple sclerosis (MS)
Terlipressin 1mg Injection H01BA04000P4001XX A* Acute oesophageal variceal bleeding 2 mg IV bolus over 1 minute. Maintenance: 1 - 2 mg IV bolus 4 - 6
hourly until bleeding is controlled, up to 24 - 36 hours. The
maximum daily dosage is 120-150 mcg/kg body weight.
Testosterone 250 mg/ml Injection G03BA03-000-P30-01-XXX A* i. In male: Testosterone replacement therapy for male By IM only. Hypogonadism 250 mg every 2-3 weeks. To maintain
hypogonadism, when testosterone deficiency has been an adequate androgenic effect 250 mg every 3-6 weeks. Potency
confirmed by clinical features and biochemical test. ii. In disorders 250 mg every 4 weeks. Male climateric disorders: 250
female: Additive therapy in cases of advanced breast mg every 3-4 weeks. Repeated 6-8 weeks courses at 2-3 months
cancer in postmenopausal women. interval
Tetanus Toxoid Injection J07AM01000P3001XX C+ Immunisation against tetanus infection. 0.5 mL by IM. Dosing is according to product insert.
Tetracycline HCl 250 mg Capsule J01AA07110C1001XX B Infections caused by susceptible pathogens "Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g
daily"
Tetracycline HCl 250 mg Tablet J01AA07110T1001XX B Infections caused by susceptible pathogens "Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g
daily"
Thalidomide 50 mg Capsule L04AX02000C1001XX A* Treatment of multiple myeloma. 50 mg to 200 mg daily
Thallous Chloride (Thallium-201) Injection V09GX01100P3001XX A* Used in myocardial perfusion scintigraphy, acute As IV infusion
myocardial infarction and post-surgical assessment of
coronary artery bypass graft patency, muscle perfusion
scintigraphy, visualisation of brain and thyroid tumours
and metastases
Theophylline 125mg Tablet R03DA04-000-T10-01-XXX B Reversible airways obstruction, acute severe asthma None ADULT: 125 mg 3 - 4 times daily after food, increased to 250 mg if
required. CHILD: 1 - 15 years : 5 mg/kg/dose (up to 600 mg/ day)
every 3 - 4 times daily
Theophylline 250mg Long Acting Tablet R03DA04-000-T50-01-XXX B Reversible airways obstruction and acute severe asthma None ADULT: 250 mg 2 times daily. CHILD under 12 years : Up to 10
mg/kg body weight 2 times daily
Theophylline 80mg/15ml Syrup R03DA04-000-L90-01-XXX B Reversible airways obstruction and acute severe asthma None ADULT : 125 mg 3 - 4 times daily after food, increased to 250 mg
if required. CHILD 1 - 15 years : 5 mg/kg/dose (up to 600 mg/day)
every 3 - 4 times per day
Thiamine HCl 100 mg/ml Injection A11DA01110P3001XX B i) For the prevention or treatment of Vitamin B1 i) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency:
deficiency syndromes including beri-beri and peripheral 200- 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by
neuritis associated with pellagra ii) Wernicke-Korsakoff 100 mg 2 times daily until patient can take oral dose
Syndrome
Thiamine Mononitrate 10 mg Tablet A11DA01-221-T10-02-XXX C Prevention and treatment of thiamine deficiency state - Mild chronic deficiency: 5mg to 30mg daily Severe deficiency: up
to 300mg daily
Thiamine Mononitrate 3 mg Tablet A11DA01-221-T10-01-XXX C Prevention and treatment of thiamine deficiency state - Mild chronic deficiency: 5mg to 30mg daily Severe deficiency: up
to 300mg daily
April 2023 180


Thioguanine 40 mg Tablet L01BB03000T1001XX A For acute leukaemia and chronic granulocytic leukaemia Refer to specific protocols. Usually 100 mg/m2 for 5 - 7 days
(acute myeloid leukaemia) or up to 2 weeks (chronic myeloid
leukaemia for accelerated/ advanced disease). CHILD: 40 - 60
g/m2 daily according to protocol
Thiopental Sodium 500 mg Injection N05CA19520P3001XX B i) General anaesthesia, induction ii) Anticonvulsant for None i) ADULT : For induction 200 - 400 mg. For repeat injection 3 - 5
cases resistant to conventional anticonvulsants in the ICU mg/kg over 10 - 15 seconds until desired depth of anaesthesia is
obtained. Not FDA approved for use in pediatric patients ii) 75 -
125 mg IV single dose; for local-anaesthetic induced convulsion:
125 - 250 mg IV over 10 minutes
Thymol Compound Gargle A01AD11985M2001XX C For sore throat and minor mouth inflammation To be gargled 3-4 times daily
Thyrotropin alfa 0.9mg/ml Injection H01AB01000P3002XX A* Thyrogen (thyrotropin alfa) is indicated for use as an A two-injection regimen is recommended for thyrotropin
adjunctive treatment for radioiodine ablation of thyroid administration. The two-injection regimen is thyrotropin 0.9 mg
tissue remnants in patients who have undergone a near- intramuscularly (IM), followed by a second 0.9 mg IM injection 24
total or total thyroidectomy for well-differentiated hours later. After reconstitution with 1.2 mL Sterile Water for
thyroid cancer and who do not have evidence of distant Injection, 1.0 mL solution (0.9 mg thyrotropin alfa) is
metastatic thyroid cancer. administered by intramuscular injection to the buttock. For
radioiodine imaging or treatment, radioiodine administration
should be given 24 hours following the final Thyrogen injection.
Diagnostic scanning should be performed 48 hours after
radioiodine administration, whereas post-therapy scanning may
be delayed additional days to allow background activity to
decline.
Tibolone 2.5 mg Tablet G03CX01-000-T10-01-XXX A* i. Treatment of complaints resulting from the natural or - 2.5mg daily
surgical menopause & in cases at high risk for breast
carcinomas where general hormone replacement
therapy is contraindicated ii. Prevention of osteoporosis
in postmenopausal women at high risk of future
fractures who are intolerant of, or contraindicated for,
other medicinal products approved for the prevention of
osteoporosis.
Ticagrelor 90 mg Tablet B01AC24-000-T10-01-XXX A* Co-administration with aspirin, for the prevention of Initially, 180mg as single dose followed by 90mg bd with
atherothrombotic events: a) Second line treatment for maintenance dose of ASA 75-150 mg daily.
patients readmitted to hospital with recurrent
atherothrombotic event failing treatment with
clopidogrel. b) STEMI patients going for invasive PCI c)
NSTEMI/UA patients with intermediate to high risk TIMI
score d) Other complicated ACS cases treated either
medically or invasively via PCI or CABG (risk of Stent
thrombosis, 3VD etc.)
Ticlopidine HCl 250 mg Tablet B01AC05110T1001XX A/KK i) Prevention of thrombotic stroke for patients who are 250 mg twice daily taken with food
sensitive /intolerant to Acetysalicylic Acid ii)
Maintenance of coronary bypass surgery or angioplasty
iii) Maintenance of patency of access in patients on
chronic haemodialysis
Timolol 0.5% Eye Drops S01ED01-253-D20-02-XX A Elevated intraocular pressure, chronic open angle None One drop in the affected eye(s) twice daily or as directed by
glaucoma physician
April 2023 181


Timolol 0.5% Ophthalmic Gel Forming Solution S01ED01-253-D20-02-XXX A Elevated intraocular pressure, chronic open angle None One drop in the affected eye(s) once a day
glaucoma
Tinidazole 500 mg Tablet P01AB02000T1001XX B i) Amoebiasis ii) Urogenital trichomoniasis and giardiasis i) ADULT : 2 g as a single dose for 2 - 3 days. CHILD 3 years and
older : 50 mg/kg daily for 3 days ii) ADULT : 2 g as a single dose
(repeated once if necessary). Sexual partners should be treated
concomitantly with the same dose. CHILD 6 years and older :
single dose of 1 gram
Tiotropium 2.5mcg and Olodaterol 2.5mcg per R03AL06-989-A10-01-XXX A/KK As a maintenance bronchodilator treatment to relieve Patients without inhaler coordination problem (Only 2 puffs once daily, at the same time of the day.
actuation, inhalation symptoms in adult patients with chronic obstructive applies to Primary Care settings)
pulmonary disease (COPD).
Tiotropium 2.5mcg/puff solution for inhalation R03BB04-320-A30-01-XXX A/KK i) Maintenance bronchodilator treatment to relieve For indication (i): The diagnosis of COPD should be 5 mcg (2 puff) once daily, at the same time of the day
symptoms of patients with chronic obstructive confirmed by spirometry.
pulmonary disease (COPD). ii) As add-on maintenance
bronchodilator treatment in adult patients (18 years and
older) with asthma who are currently treated with the
maintenance combination of inhaled corticosteroids
(≥800µg budesonide/day or equivalent) and long-acting
β2-agonist and who experienced one or more severe
exacerbations in the previous year.
Tirofiban HCl 0.25 mg/ml Injection B01AC17110P9901XX A* Unstable angina or non-ST segment elevation myocardial By IV infusion, 0.4 mcg/kg/min for 30 minutes, then 0.1
infarction with the following: elevated cardiac markers, mcg/kg/min for at least 48 hours, maximum 108 hours
refractory chest pain, ST-segment changes and
thrombolysis in myocardial infarction (TIMI) risk score 4
Tocilizumab 162mg/0.9ml solution for injection L04AC07000P3003XX A* Indicated for the treatment of moderate to severe active Adult patients: 162mg given once every week as a subcutaneous
in prefilled syringe (for subcutaneous injection) rheumatoid arthritis (RA) in adult patients: i) with injection.
inadequate respond or intolerance to conventional
disease- modifying antirheumatic drugs (DMARDS) ii)
who has failed antitumour necrosis factors (antiTNFs) iii)
where TNF is contraindicated (patients with history of
pulmonary tuberculosis [PTB]) It also can be used as
monotherapy or with combination with methotrexate
(MTX) and/ or other DMARDS.
Tocilizumab 20 mg/ml Injection L04AC07-000-P30-01-001 A* Indicated for the treatment of moderate to severe active Recommended dose for rheumatoid arthritis of tocilizumab for
rheumatoid arthritis (RA) in adult patients: i) with adult patients is 8mg/kg given once every 4 weeks as a single-drip
inadequate respond or intolerance to conventional IV infusion over 1 hour. It should be diluted to 100 ml by a
disease- modifying antirheumatic drugs (DMARDS) ii) healthcare professional with sterile 0.9% w/v sodium chloride
who has failed antitumour necrosis factors (antiTNFs) iii) solution over 1 hour. For patients whose body weight is more
where TNF is contraindicated (patients with history of than 100kg, doses exceeding 800mg per infusion are not
pulmonary tuberculosis [PTB]) It also can be used as recommended
monotherapy or with combination with methotrexate
(MTX) and/ or other DMARDS.
April 2023 182


Tofacitinib citrate 5mg film coated tablet L04AA29136T3201XX A* Indicated for the treatment of adult patients with One tablet twice daily
moderately to severely active rheumatoid arthritis who
have had an inadequate response or intolerance to
methotrexate. It may be used as monotherapy or in
combination with methotrexate or other non-biologic
disease-modifying anti-rheumatic drugs (DMARDs).
Tolterodine Tartrate ER 4 mg Capsule G04BD07-123-C20-02-XXX A* Treatment of overactive bladder with symptoms of - 4 mg once daily. May decrease to 2 mg once daily depending on
urinary, frequency or urge incontinence response and tolerability
Topiramate 100 mg Tablet N03AX11-000-T10-03-XXX A* As adjunctive therapy for adults and children (2 years ADULT: Usual daily dose: 200-400 mg/day. CHILD: Daily doses up
and above) with: i) partial onset seizures and generalized to 30mg/kg/day Dosing is according to product insert.
tonic-clonic seizures ii) seizures associated with Lennox
Gastaut syndrome.
Topiramate 25 mg Capsule Sprinkle N03AX11000C1002XX A* Add-on therapy for intractable partial epilepsy ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly
or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2
divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in
2 divided doses. Titrate at 25mg (or less, based on a range of 1-
3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly
intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
Gastaut syndrome.
Gastaut syndrome.
Trace Elements and Electrolytes (Adult) B05XA30905P3001XX A* Only to be used to cover daily loss of electrolyte and 10 ml added to 500-1000 ml solution, given by IV infusion
Solution trace elements for patient on parenteral nutrition
Trace Elements and Electrolytes (Paediatric) B05XA30905P3002XX A* Only to be used to cover daily loss of electrolyte and According to the needs of the patient. INFANT and CHILD
Solution trace elements for patient on parenteral nutrition weighing 15 kg or less: Basal requirements of the included trace
elements are covered by 1 ml/kg/day to a maximum dose of 15
ml. CHILD weighing 15 kg or more, a daily dose of 15 ml, should
meet basic trace element requirements. However, for patients
weighing more than 40 kg the adult preparation trace element
should be used
Tramadol HCl 50 mg/ml Injection N02AX02-110-P30-01-XXX A Moderate to severe acute or chronic pain (eg. Post- None ADULT: IV/IM/SC 50 - 100mg. (IV inj over 2-3 min or IV infusion).
operative pain, chronic cancer pain and analgesia/pain Initially 100 mg then 50 - 100 mg every 4 - 6 hours. . Max: 400 mg
relief for patients with impaired renal function) daily. CHILD (1 year and above): 1 - 2mg/kg/dose
Tramadol HCl 50mg Capsule N02AX02-110-C10-01-XXX A/KK Moderate to severe acute or chronic pain (eg. Post- ADULT: 50mg initially, can take another 50mg after 30 - 60 min if
operative pain, chronic cancer pain and analgesia/pain pain not relieved. Max 400 mg daily. CHILD: 1mg/kg/dose
relief for patients with impaired renal function) repeated every 6 hours (Max: 2mg/kg/dose and 100mg/dose)
Tramadol HCl 50mg Tablet N02AX02-110-T10-01-XXX A/KK Moderate to severe acute or chronic pain (e.g. Post- None ADULT: 50mg initially, can take another 50mg after 30 - 60 min if
operative pain, chronic cancer pain and analgesia/pain pain not relieved. Max 400 mg daily. CHILD: 1mg/kg/dose
relief for patients with impaired renal function) repeated every 6 hours (Max: 2mg/kg/dose and 100mg/dose
April 2023 183


Tranexamic Acid 100 mg/ml Injection B02AA02000P3001XX B Haemorrhage associated with excessive fibrinolysis ADULT: Slow IV 0.5-1 g (10 - 15 mg/kg) 3 times daily. Continuous
infusion at a rate of 25 - 50 mg/kg daily. CHILD: slow IV 10
mg/kg/day 2-3 times daily
Tranexamic Acid 250 mg Capsule B02AA02000C1001XX B Haemorrhage associated with excessive fibrinolysis ADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily. CHILD: 25
mg/kg/day 2-3 times daily. Menorrhagia (initiated when
menstruation has started), 1 g 3 times daily for up to 4 days;
maximum 4 g daily
Trastuzumab 440mg Injection L01XC03-000-P40-01-XXX A* i) Used only in adjuvant setting for patients with HER2 ii) To be prescribed by oncologists only i) Initial loading dose is 4 mg/kg administered as a 90 minutes IV
over-expressed breast cancer, that is HER2 3+ by infusion. Subsequent doses is 2 mg/kg administered as 30
immunohistochemistry and over-expressed by FISH minutes IV infusion weekly for 51 weeks ii) Initial loading dose of
(Fluorescence in situ hybridization) and high risk group ii) 8 mg/kg body weight, followed by 6 mg/kg body weight 3 weeks
Treatment of HER2-positive non-metastatic breast later and then 6 mg/kg repeated at 3-weekly intervals
cancer in combination with neoadjuvant chemotherapy administered as infusions over approximately 90 minutes. If the
followed by adjuvant trastuzumab, for locally advanced prior dose was well tolerated, the dose can be administered as a
(including inflammatory) breast cancer or tumours >2cm 30-minute infusion.
in diameter.
Trastuzumab 600mg/5ml Solution for Injection L01XC03-000-P30-01-XX A* Used only in adjuvant setting for patients with HER2 None The recommended fixed dose of trastuzumab 600mg is 600mg
(for subcutaneous) over-expressed breast cancer, that is HER2 3+ by irrespective of the patient's body weight. No loading dose is
immunohistochemistry and over-expressed by FISH required. This dose should be administered over 2-5 minutes
(Fluorescence in situ hybridization) and high risk group. every three weeks.
Travoprost 0.004% & Timolol 0.5% Eye Drops S01ED51-990-D20-03-XXX A* To decrease intraocular pressure (IOP) in patients with None 1 drop in the affected eye(s) once daily
open-angle glaucoma or ocular hypertension who are
insufficiently responsive to other topical anti glaucomas
Tretinoin 0.01% Gel D10AD01000G3001XX A/KK Acne vulgaris, recalcitrant cases of acne (comedonal Apply thinly to the affected area once daily or twice daily. Avoid
type) exposure to sunlight. Duration of treatment: 8-12 weeks is
required before any noticeable response
Tretinoin 0.05% Cream D10AD01-000-G10-01-XXX A/KK Acne vulgaris and recalcitrant cases of acne (comedonal None Apply once daily to the affected area, at bedtime, after cleansing
type) with soap and water.
Tretinoin 0.1% Cream D10AD01000G1002XX A Acne vulgaris and recalcitrant cases of acne (comedonal Apply thinly to the affected area once daily or twice daily. Avoid
type) exposure to sunlight. Duration of treatment: 8 - 12 weeks is
required before any noticeable response
Triamcinolone Acetonide 0.1% Oral Paste A01AC01-351-G31-01-XXX B As an adjunctive treatment and for the temporary relief - Apply thin film to affected areas 2 to 3 times daily
of symptoms associated with inflammatory or ulcerative
lesions of oral mucosa resulting from trauma.
Triamcinolone Acetonide 10 mg/ml Injection H02AB08-351-P30-01-XXX A Inflammation of joints, bursae and tendon sheaths - Smaller joints: 2.5 - 5 mg and larger joints: 5 - 15 mg. Treatment
should be limited to 1 mg/injection site to prevent cutaneous
atrophy
Triamcinolone Acetonide 40 mg/ml Injection H02AB08-351-P30-02-XXX A/KK Allergies, dermatoses, rheumatoid arthritis and - 40-80 mg deep into the gluteal muscle
inflammatory opthalmic diseases
Trifluoperazine HCI 5 mg Tablet N05AB06-110-T10-01-XXX B i) Schizophrenia, other psychotic disorder ii) Treatment ADULT: Initially 5 mg twice daily, increase by 5 mg after 1 week,
of behavioural disorders in adults and in children then at 3-day intervals. Maximum 40 mg/day. CHILD up to 12
years: Initially up to 5 mg daily in divided doses adjusted to
response, age and body weight. Elderly reduce initial dose by at
least half.
Trimetazidine 20 mg Tablet C01EB15110T1001XX B Prophylactic treatment of episodes of angina pectoris 20 mg 3 times daily
April 2023 184


Trimetazidine 35mg MR Tablet C01EB15110T5001XX B Prophylactic treatment of episodes of angina pectoris 35 mg twice daily in the morning and evening with meals
Trimethoprim 100 mg Tablet J01EA01000T1001XX B Treatment of urinary tract infections due to susceptible ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a
pathogens single dose. Acute infection: 200 mg twice daily. CHILD: 6-8
mg/kg/day in 2 divided doses. 6 - 12 years: 100 mg twice daily; 6
months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg
twice daily
Trimethoprim 300 mg Tablet J01EA01000T1002XX B Treatment of urinary tract infections due to susceptible ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a
pathogens single dose. Acute infection: 200 mg twice daily. CHILD: 6 - 12
years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily.
6 weeks - 5 months: 25mg twice daily
Trioxsalen 5 mg Tablet D05BA01000T1001XX A Vitiligo 5 - 10 mg daily, 2 - 4 hours before exposure to sunlight. To
increase pigmentation: 10 mg daily, 2 hours prior to UV irradiation
Triprolidine HCl 1.25mg and Pseudoephedrine R01BA52-110-L90-01-XXX B Decongestion of the upper respiratory tract in common None Adult and children over 12 years: 10ml 3 times a day (max 4 times
HCl 30mg/5ml Syrup cold, hay fever, allergic and vasomotor rhinitis and a day). CHILD: 6 - 12 years: 5 ml (6-8 hourly). 2 - 5 years: 2.5 ml (6-
sinusitis. Doses to be taken twice daily or three times 8 hourly).
daily
Triprolidine HCl 2.5mg and Pseudoephedrine R01BA52-988-T10-02-XXX B Decongestion of the upper respiratory tract in common None ADULT 2.5 mg every 4 - 6 hours; maximum dose 10 mg/day.
HCl 60mg Tablet cold, hay fever, allergic and vasomotor rhinitis and CHILD (syrup) 6 - 12 years : 1.25 mg every 4 - 6 hours; maximum
aerotitis dose 5 mg/day 4 - 6 years : 0.938 mg every 4 - 6 hours; maximum
dose 3.744 mg/day 2 - 4 years : 0.625 mg every 4 - 6 hours;
maximum dose 2.5 mg/day
Triptorelin 3.75 mg Injection L02AE04000P2001XX A i) Treatment of confirmed central precocious puberty 1 intramuscular injection every 4 weeks. The treatment must be
(preterm sexual development) in girls under 9 years, started in the first 5 days of the menstrual cycle. The duration of
boys under 10 years of age ii) Genital and extragenital treatment depends on the initial severity of the endometriosis
endometriosis (stage I to stage IV). Treatment should and the changes observed in the clinical features. In principle, the
not be administered for more than 6 months. It is not treatment should be administered for at least 4 months and for
recommended to start a second treatment course with at most 6 months. It is not recommended to start a second
triptorelin or another GnRH analogue. treatment course with triptorelin or another GnRH analogue.
Tropicamide 1% Eye Drops S01FA06-000-D20-02-XXX A/KK Topical use to produce cycloplegic refraction for None 1 - 2 drops several times a day
diagnostic purposes
Trospium Chloride 20mg coated tablet G04BD09-100-C10-01-XXX A* Symptomatic treatment for urge incontinence and/or Place in therapy: As first line treatment for overactive 1 tablet twice daily. Tablet should be swallowed whole with a
increased urinary frequency and urgency as may occur in bladder in patients with Parkinsonism, Alzheimer's or glass of water before meals on empty stomach. Severe renal
patients with overactive bladder (eg. Idiopathic or other cognitive disease impairment (CrCl between 10 & 30 mL/min/1.73 m2): 1 tab daily
neurologic detrusor overactivity) or every other day
Tuberculine PPD Injection V04CF01000P3001XX B For routine Mantoux (tuberculin sensitivity) test 10 units is injected intradermally
Typhoid Vaccine Capsule J07AP01000C1001XX B Active immunization against typhoid fever in adult and ADULT and CHILD 6 years of age or older, 1 capsule on days 1, 3
child 6 years of age or older and 5
Typhoid Vaccine Injection J07AP02000P3001XX B Active immunization against typhoid fever in adult and 0.5 ml single IM injection into the deltoid or vastus lateralis, may
child more than 2 years reimmunize with 0.5 ml IM every 3 years if needed.
Ulipristal Acetate 30mg Tablet G03AD02-122-T10-01-XXX A Emergency contraception within 120 hours (5 days) of - 30mg orally as soon as possible, but no later than 120 hours (5
unprotected sexual intercourse for sexual assault victim. days) after unprotected sexual intercourse or contraceptive
failure.
Umeclidinium 62.5mcg and Vilanterol 25mcg R03AL03-989-A20-01-XXX A* Indicated as a maintenance bronchodilator treatment to None One inhalation daily
inhalation relieve symptoms in adult patients with chronic
obstructive pulmonary disease (COPD).
April 2023 185


Urofollitropin (FSH) 150 IU Injection G03GA04-000-P30-02-XXX A* For stimulation of follicular growth in the treatment of To be individualised. Initial: 75 IU-150 IU daily for 7 days and then
infertility may be increased or decreased by 75 IU/day according to
follicular response. Max : 450 IU/day. In-vitro fertilisation: Initial:
150 IU daily from Cycle Day 2 or Day 3 until sufficient follicular
development is attained.
Urofollitropin (FSH) 75 IU Injection G03GA04-000-P30-01-XXX A* For stimulation of follicular growth in the treatment of - To be individualised. Initial: 75 IU-150 IU daily for 7 days and then
infertility may be increased or decreased by 75 IU/day according to
follicular response. Max : 450 IU/day. In-vitro fertilisation: Initial:
150 IU daily from Cycle Day 2 or Day 3 until sufficient follicular
development is attained
Urokinase 250,000 IU Injection B01AD04-000-P40-04-XXX A Treatment of thromboembolic disease such as ADULT: Acute pulmonary embolism: IV loading dose 4400 iu/kg
mycocardial infarction, peripheral artery occlusion, over 10 mins, maintenance 4400 iu/kg/hour for 12 hours.
pulmonary embolism, retinal artery thrombosis and Peripheral vascular occlusion: infuse 2500 iu/ml into clot at a rate
other ophthalmologic use of 4000 iu/min for 2 hours. This may be repeated up to 4 times.
Hyphaema: 5000 IU in 2 ml saline solution is injected and
withdrawn repeatedly over the iris. If residual clot remains, leave
0.3ml in the anterior chambers for 24-48 hours to facilitate futher
dissolution
Ursodeoxycholic Acid 250 mg Capsule A05AA02-000-C10-01-XXX A Cholestatic liver diseases (eg. primary biliary cholangitis, - 10-15 mg/kg daily in 2 to 3 divided doses Dosing is individualised
primary cholangitis etc.) based on body weight and according to product insert/protocol
Ustekinumab 90 mg/ml Injection L04AC05000P3002XX A* Treatment of moderate to severe plaque psoriasis in Body weight less than 100kg: Initial dose of 45 mg SC, followed
adults who failed to, or who have contraindication to, or by 45 mg 4 weeks later, then every 12 weeks thereafter. Body
are intolerant to conventional systemic therapies weight more than 100 kg: initial dose 90 mg SC, followed by 90
including ciclosporin, methotrexate and mg 4 weeks later, & then every 12 weeks thereafter.
photochemotherapy (PUVA).
Valganciclovir 450 mg Tablet J05AB14110T1001XX A* For the prevention of cytomegalovirus (CMV) disease in For adult patients who have received other than kidney
CMV-negative patients who have received a solid organ transplant, the recommended dose is 900 mg (two 450 mg
transplant from a CMV-positive donor tablets) once a day starting within 10 days of transplantation
until 100 days post-transplantation. For adult patients who have
received a kidney transplant, the recommended dose is 900 mg
(two 450 mg tablets) once a day starting within 10 days of
transplantation until 200 days post-transplantation.
Valproic Acid and Sodium Valproate (ER) N03AG01-520-T50-01-XX B i) In the treatment of generalized or partial epilepsy, None i) Adults: Dosage should start at 500mg daily increasing by 200mg
500mg Tablet particularly with the following patterns of at three-day intervals until control is achieved. This is generally
seizures:absence, myoclonic, tonic-clonic, atonic-mixed within the dosage range 1000mg to 2000mg per day. Children:
as well as, for partial epilepsy:simple or complex >20KG: 500mg/day (irrespective of weight) with spaced increases
seizures, secondary generalized seizures, specific until control is achieved. ii) Initial dose of 1000mg/day, to be
syndrome (West, Lennox-Gastatut). ii) Treatment and increase rapidly as possible to achieve lowest therapeutic dose,
prevention of mania associated with bipolar disorders. which produce desired clinical effects. Recommend initial dose is
1000mg & 2000mg daily. Max dose 3000mg daily.
Valsartan 160 mg and Hydrochlorothiazide 12.5 C09DA03935T1005XX A/KK Hypertension in patients intolerant to ACE inhibitors Initial: Valsartan/Hydrochlorothiazide 80/12.5mg once daily Max:
mg Tablet Valsartan/Hydrochlorothiazide 320/25mg once daily Dosing is
April 2023 186


Valsartan 160 mg Tablet C09CA03000T1002XX A/KK Patients intolerant to ACE inhibitors in: i) Heart failure ii) i) Initial: 40mg twice daily. Titrate up to highest tolerated dose.
Post myocardial infarction iii) Hypertension Max: 320mg daily in divided doses ii) Initial: 20mg twice daily
Titrate up to 160mg over next few weeks. Max: 160mg twice
daily iii) 80mg or 160mg once daily Max: 320mg daily Dosing is
individualised and according to package insert / protocol.
Valsartan 80 mg and Hydrochlorothiazide 12.5 C09DA03-935-T10-01-XXX A/KK Hypertension in patients intolerant to ACE inhibitors Initial: Valsartan/Hydrochlorothiazide 80/12.5mg once daily Max:
mg Tablet Valsartan/Hydrochlorothiazide 320/25mg once daily Dosing is
Valsartan 80 mg Tablet C09CA03-000-T10-01-XXX A/KK Patients intolerant to ACE inhibitors in: i) Heart failure ii) i) Initial: 40mg twice daily. Titrate up to highest tolerated dose.
Post myocardial infarction iii) Hypertension Max: 320mg daily in divided doses ii) Initial: 20mg twice daily
Titrate up to 160mg over next few weeks. Max: 160mg twice
daily iii) 80mg or 160mg once daily Max: 320mg daily Dosing is
individualised and according to package insert / protocol.
Vancomycin HCl 500mg Injection J01XA01-110-P40-01-XXX A* i. Treatment of infections due to susceptible gram- Slow IV infusion. ADULT: 15-20mg/kg q 8-12 hours, not to exceed
positive organisms which cannot be treated with other 2gm per dose. NEONATE up to 1 week, 15 mg/kg initially, then 10
agents (eg. MRSA and Enterococcus sp.) ii. Treatment of mg/kg every 12 hours. INFANT 1 - 4 weeks, 15 mg/kg initially then
severe staphylococcal infections in patients who cannot 10 mg/kg every 8 hours. CHILD over 1 month, 10 mg/kg every 6
receive or who have failed to respond to the penicillins hours
and cephalosporins.
Varenicline Tartrate 0.5 mg Tablet N07BA03123T1001XX A/KK Smoking cessation treatment 0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7,
then 1 mg twice daily; duration of treatment is 12 weeks
Varenicline Tartrate 1 mg Tablet N07BA03123T1002XX A/KK Smoking cessation treatment 0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7,
then 1 mg twice daily; duration of treatment is 12 weeks
Varicella Virus Vaccine Live Attenuated Injection J07BK01000P4001XX A* Immunisation against varicella virus infection. 0.5ml by SC. Dosing is according to product insert.
Vasopressin 20 units/ml Injection H01BA01000P3001XX A i) Pituitary diabetes insipidus ii) Oesophageal variceal i) 5 - 20 units SC or IM every 4 hours ii) 20 units in 100 - 200 ml
bleeding 5% dextrose saline over 15 minutes as infusion which may be
repeated after at intervals of 1 - 2 hours. Maximum: 4 doses
Vedolizumab 300mg powder for concentrate L04AA33-000-P41-01-XXX A* i) Indicated for the treatment of adult patients with None 300 mg administered by intravenous infusion at zero, two and six
for solution for infusion moderately to severely active ulcerative colitis who have weeks and then every eight weeks thereafter.
had an inadequate response with, lost response to, or
were intolerant to tumour necrosis factor-alpha (TNF-α)
antagonist. ii) Indicated for the treatment of adult
patients with moderately to severely active Crohn’s
disease who have had an inadequate response with, lost
response to, or were intolerant to tumour necrosis
factor-alpha (TNFα) antagonist.
Venlafaxine HCl 150 mg Extended Release N06AX16110C2002XX A* i) Depression ii) Generalized anxiety disorder iii) Social i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75
Capsule anxiety disorder (social phobia) iv) Panic disorder mg/day every 4 days to a maximum dose of 225 mg/day, (severe
depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7
days after which the dose should be increased to 75 mg once
daily. CHILD and ADOLESCENT under 18 years not recommended.
April 2023 187


Venlafaxine HCl 75 mg Extended Release N06AX16110C2001XX A* i) Depression ii) Generalized anxiety disorder iii) Social i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75
Capsule anxiety disorder (social phobia) iv) Panic disorder mg/day every 4 days to a maximum dose of 225 mg/day, (severe
depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7
days after which the dose should be increased to 75 mg once
daily. CHILD and ADOLESCENT under 18 years not recommended
Verapamil HCl 2.5 mg/ml Injection C08DA01110P3001XX A/KK Supraventricular tachycardia Initially 5-10mg given by slow IV over at least 2 minutes. The dose
can be repeated 10mg 30 minutes after the first dose if the initial
response is not adequate.
Verapamil HCl 40 mg Tablet C08DA01-110-T10-01-XXX B i) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) i) 120-480mg in 2-3 divided doses ii) 80mg – 120mg 3 times daily
Angina iii) Hypertension iii) Initial: 240 mg daily in 2-3 divided doses. Max: 480 mg daily
Vildagliptin 50 mg and Metformin HCl 1000 mg A10BD08926T1002XX A/KK FUKKM restriction: As add-on therapy for patient who 50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily
Tablet failed therapy and/or contraindicated/unable to tolerate dose is 100 mg vildagliptin plus 2000 mg metformin
metformin and/or sulphonylurea. - Treatment of type 2 hydrochloride.
diabetes mellitus patients who are unable to achieve
sufficient glycaemic control at their maximally tolerated
dose of oral metformin alone or who are already treated
with the combination of vildagliptin and metformin as
separate tablets.
Vildagliptin 50 mg and Metformin HCl 500 mg A10BD08926T1003XX A/KK FUKKM restriction: As add-on therapy for patient who 50/500mg or 50/850mg or 50/1000mg twice daily. Maximum
Tablet failed therapy and/or contraindicated/unable to tolerate daily dose is 100mg vildagliptin and 2000mg metformin.
metformin and/or sulphonylurea. - Treatment of type 2
separate tablets.
Vildagliptin 50 mg and Metformin HCl 850 mg A10BD08926T1001XX A/KK FUKKM restriction: As add-on therapy for patient who 50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily
Tablet failed therapy and/or contraindicated/unable to tolerate dose is 100 mg vildagliptin plus 2000 mg metformin
metformin and/or sulphonylurea. - Treatment of type 2 hydrochloride.
separate tablets.
April 2023 188


Vildagliptin 50mg Tablet A10BH02-000-T10-01-XXX A/KK FUKKM restriction: As add-on therapy for patient who None ADULT over 18 years: 50mg bd when combine with metformin,
failed therapy and/or contraindicated/unable to tolerate 50 mg od when combine with sulphonylurea
metformin and/or sulphonylurea. i) As second line
therapy in type 2 diabetes patients inadequately
controlled on maximal tolerated dose of metformin
monotherapy and high risk of hypoglycaemia; ii) As
second line therapy in type 2 diabetes patients
inadequately controlled on maximal tolerated dose of
sulphonylurea and intolerant/contraindicated for
metformin therapy; iii) As third line therapy in type 2
diabetes patients inadequately controlled with dual OAD
combination therapy with sulphonylurea and metformin;
iv) As a monotherapy in type 2 diabetes mellitus patients
inadequately controlled by diet and exercise alone and
for whom metformin is inappropriate due to
contraindications or intolerance; v) An adjunct to diet
and exercise to improve glycaemic control in patients
with type 2 diabetes mellitus: As a dual therapy in
combination with insulin in patients with insufficient
glycaemic control. Insulin dose and regimen should be
optimized before addition of vildagliptin.
Vinblastine Sulphate 10 mg Injection L01CA01183P3002XX A Hodgkin's disease, choriocarcinoma resistant to other Adult: Initially, 3.7 mg/m2, increase dose weekly based on WBC
chemotherapeutic agents, non-small cell lung cancer, counts in increments of about 1.8 mg/m2 until leukocyte count
Langerhans cell histiocytosis decreases to about 3000/mm3, or maximum weekly dose of 18.5
mg/m2 reached. Usual dose: 5.5-7.4 mg/m2 per week. Do not
administer next dose, even though 7 days have lapsed unless the
leukocyte count has returned to at least 4000/mm3. Child: Initial
2.5 mg/m2 of BSA, increased dose at weekly intervals in
increments of about 1.25 mg/m2 until leukocyte count decreases
to about 3000/ mm3, or maximum weekly dose of 12.5 mg/m2
reached. Do not increase dose once leukocyte count reaches
approximately 3000 cells/mm3, instead, a dose of 1 increment
smaller to be admin at wkly intervals for maintenance. Do not
administer next dose, even though 7 days have lapsed unless the
leukocyte count has returned to at least 4000/mm3.
Vincristine Sulphate 1 mg/ml Injection L01CA02183P3001XX A i) Solid tumours ii) Gestational trophoblastic disease iii) ADULT 1.4 mg/m2 injection CHILD 1 mg/m2 to 2 mg/m2 weekly
Lymphoma iv) Multiple myeloma v) Acute lymphoblastic (0.05 mg/kg for infants less than 10kg) Dosing is according to
leukemia product insert/protocol
April 2023 189


Vinorelbine 10mg/mL Injection L01CA04000P4002XX A* i) First line treatment in non-small cell lung cancer in i) Single agent: Adult 30mg/m2 IV administered over 6-10
combination with cisplatin/ifosfomide ii) Metastatic minutes once weekly Combination with cisplatin : 30mg/m2 IV
breast cancer administered over 6-10mintes once weekly combination with
cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine
administered at a dose of 25mg/m2 IV weekly in combination
with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 -
30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes,
administered weekly or vinolrebine maybe given as an 8mg/m2
IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion.
Vitamin A 50,000 IU Capsule A11CA01000C1001XX C Children with measles malnutrition and serious i) 0-5 months, 50,000 IU ii) 6-11 months, 100,000 IU iii) 1-5 years,
infections. Category C can use this drug for Orang Asli 200,000 IU. Frequency twice daily
and in Sabah
Vitamin B Complex Tablet A11EA00901T1001XX C+ Prophylaxis and treatment of vitamin B deficiency 1-2 tablets daily
Vitamin B1, B6, B12 Tablet A11DB00901T1001XX B For deficiency or raised requirement of Vitamin B1, B6, 1 tablets 3 times daily swallowed unchewed.
B12
Vitamin K1 1 mg/ml Injection B02BA01000P3001XX C+ Vitamin K deficiency in neonates Prophylaxis of vitamin K deficiency bleeding in neonates Child:
Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively,
2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-
7 days. Intravenous Vitamin K deficiency bleeding in neonates
Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if
necessary.
Vitamin K1 10 mg/ml Injection B02BA01000P3002XX B Haemorrhage associated with hypoprothrombinaemia 0.5 - 20 mg by very slow IV at a rate not exceeding 1 mg per
caused by overdose of anticoagulants minute
Voriconazole 200 mg Injection J02AC03000P3001XX A* i) Treatment of immunocompromised patients with Adult and Children 12 years and greater: Loading dose: 6 mg/kg
progressive, possibly life-threatening infections such as 12 hourly for first 24 hours. Maintenance: i) 4 mg/kg 12 hourly ii)
invasive aspergillosis, fluconazole-resistant serious 3 mg/kg 12 hourly. Dose may be increased to 4 mg/kg 12 hourly if
invasive candidiasis, serious fungal infections caused by response is inadequate. Children aged 2years to <12years with
Scedosporium species and Fusarium species normal hepatic and renal function: No loading dose needed;
ii)Prevention of breakthrough fungal infections in febrile 7mg/kg 12hourly
high-risk neutropenic patients
Voriconazole 200 mg Tablet J02AC03000T1002XX A* i) Treatment of immunocompromised patients with Adult and Children 12 years and greater and over 40 kg: Loading
progressive, possibly life-threatening infections such as dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300
invasive aspergillosis, fluconazole-resistant serious mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly
invasive candidiasis, candidiasis of the oesophagus, for first 24 hours. Maintenance: 100 - 150 mg 12 hourly. Children
serious fungal infections caused by Scedosporium aged 2years to <12years with normal hepatic and renal function:
species and Fusarium species ii) Prevention of No loading dose needed; 200mg 12hourly
breakthrough fungal infections in febrile high-risk
neutropenic patients
Voriconazole 50 mg Tablet J02AC03000T1001XX A* i) Treatment of immunocompromised patients with ADULT and CHILDREN 12 years and greater and over 40 kg:
progressive, possibly life-threatening infections such as Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance:
invasive aspergillosis, fluconazole-resistant serious 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12
invasive candidiasis, candidiasis of the oesophagus, hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly
serious fungal infections caused by Scedosporium
species and Fusarium species ii) Prevention of
breakthrough fungal infections in febrile high-risk
neutropenic patients
April 2023 190


Vortioxetine 10mg tablet N06AX26-330-T32-01-XXX A* Treatment of major depressive episodes in adults. Consultant/specialists for specific indications only, 10mg once daily in adults less than 65 years of age. Depending on
including Geriatricians and Neurologists the individual patient response, the dose may be increased to a
maximum of 20mg vortioxetine once daily or decreased to a
minimum of 5mg vortioxetine once daily. After the depressive
symptoms resolve, treatment for at least 6 months is
recommended for consolidation of the anti-depressive response.
Warfarin Sodium 1 mg Tablet B01AA03520T1001XX B Treatment and prophylaxis of thromboembolic disorders Initially 2 to 5mg per day. Maintenance dose 2-10mg daily
according to the INR Dosing is individualised based on patient’s
INR and according product insert/protocol/ guideline.
Water for Injection V07AB00000P3001XX C+ As a diluent and vehicle for the administration of According to the needs of the patient
medications
Zidovudine 1% Injection J05AF01000P3001XX A To reduce the rate of maternal-foetal transmission of i) Prophylaxis of maternal-foetal HIV transmission during labour
HIV in: i) HIV-positive pregnant women over 14 weeks of and delivery Adult: Loading dose: 2 mg/kg, followed by
gestation ii) Their newborn infants continuous infusion of 1 mg/kg/hr until umbilical cord is clamped.
If caesarean section is planned, start the IV infusion 4 hr before
the operation. Renal and Hepatic impairment: Dose reduction
may be needed. HIV infection (to be discuss: not in indication)
Adult: 1-2 mg/kg every 4 hr, given as 2-4 mg/ml infusion over 1
hr. Child: As continuous infusion: 20 mg/m2/hr. Alternatively, as
intermittent infusion: 120 mg/m2 every 6 hr. Renal impairment:
Haemodialysis or peritoneal dialysis: 1 mg/kg every 6-8 hr. ii)
Prophylaxis of HIV infection in neonates Child: Neonates: 1.5
mg/kg every 6 hr. Start treatment within 12 hr after birth and
continue for 1st 6 wk of life. Dose to be given via IV infusion over
30 minutes. Renal impairment: Dose adjustment may be needed.
Zidovudine 10 mg/ml Syrup J05AF01000L9001XX A* i) Management of patients with asymptomatic and i) HIV infection Adult: 600 mg daily in divided doses, in
symptomatic (early or advanced) HIV infections with CD4 combination with other antiretroviral agents. Child: 6 wk - 12 yr:
cell counts less than 500 cu. mm. ii) Neonatal prophylaxis 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in
combination with other anti-retrovirals. Renal and Hepatic
impairment: Dose reduction may be needed. ii) Prophylaxis of
HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for
1st 6 wk of life, starting within 12 hr after birth. Renal and
hepatic impairment: Dose adjustment may be needed.
April 2023 191


Zidovudine 100 mg Capsule J05AF01000C1001XX A/KK i) Management of patients with asymptomatic and i) HIV infection Adult: 600 mg daily in divided doses, in
symptomatic (early or advanced) HIV infections with CD4 combination with other antiretroviral agents. Child: 6 wk - 12 yr:
cell counts less than 500 cu. mm ii) Neonatal prophylaxis 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in
combination with other anti-retrovirals. Renal and Hepatic
impairment: Dose reduction may be needed. ii) Prophylaxis of
HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for
1st 6 wk of life, starting within 12 hr after birth. Renal and
hepatic impairment: Dose adjustment may be needed.
Zidovudine 300 mg & Lamivudine 150 mg J05AR01964T1001XX A/KK HIV infection in combination with at least one other ADULT and CHILD over 12 years: 1 tablet twice daily
Tablet antiretroviral drug
Zidovudine 300 mg Tablet J05AF01000T1001XX A* i) Management of patients with asymptomatic and HIV infection Adult: 600 mg daily in divided doses, in combination
symptomatic (early or advanced) HIV infections with CD4 with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2
cell counts < 500 cu. mm ii) HIV positive pregnant every 8 hr. Max: 200 mg every 8 hr. May be used in combination
mothers with other anti-retrovirals. ii)Prophylaxis of maternal-foetal HIV
transmission Adult: 100 mg 5 times daily or 200 mg tid or 300 mg
bid. Start treatment after 14th wk of gestation until the start of
labour. Haemodialysis or peritoneal dialysis (CrCl <10 ml/min: 100
mg every 6-8 hr.
Zinc Oxide Cream D02AB00000G1001XX C+ Skin protective in various skin conditions such as nappy Apply 3 times daily or as required
rash, eczema and problem skin
Zinc Oxide Ointment D02AB00240G5001XX C Skin protective in various skin conditions such as nappy Apply 3 times daily or as required
rash and eczema
Zinc oxide, benzyl benzoate and balsam peru C05AX04931S1001XX C For relief of pruritus, burning and soreness in patients Insert 1 suppository night and morning after bowel movements;
suppository with haemorrhoids and perianal conditions do not use for longer than 7 days OR please refer to the product
insert.
Zoledronic Acid 4 mg Injection M05BA08000P3001XX A* i) Treatment of hypercalcaemia of malignancy ii) i) 4mg single dose ii) 4mg every 3-4 weeks iii) 4mg reconstituted
Prevention of skeletal related events (SREs) in patients and should be given as a 15- minute IV infusion every 12 weeks
with multiple myeloma involving multiple bone lesions (as advised in MaHTAS 2018 Report)
iii) Prevention of skeletal related events (SREs) for
metastatic cancers of solid tumours
Zolpidem Tartrate 10 mg Tablet N05CF02123T1001XX A For treatment of insomnia ADULT: 10mg daily at bedtime ELDERLY OR DEBILITATED
SUBJECTS: 5mg daily at bed time Max. dose: 10mg daily
Zonisamide 100mg tablet N03AX15-000-T10-01-XXX A* As adjunctive therapy in the treatment of partial seizures As adjunctive therapy in the treatment of partial seizures For adults, usually 100 to 200mg of zonisomide is to be
in adults with epilepsy. in adults with epilepsy when 1st line and 2nd line therapy administered orally 1 to 3 times a day initially. The dose is
failed. gradually increased at every one to two weeks up to 200-400mg
daily, in 1 to 3 divided dose. The maximum daily dose should not
exceed 600mg per day.
Zuclopenthixol 20 mg/ml Drops N05AF05000D5001XX A* i) Acute schizophrenia and other acute psychoses, i) & iii) 10-50mg daily Max. dose: 100-150mg daily in 2-3 divided
including agitation ii) Chronic schizophrenia and other doses ii) 20-40mg daily
chronic psychoses iii) Mania
Zuclopenthixol Acetate 50 mg/ml Injection N05AF05122P3001XX A* Initial treatment of acute psychoses, including mania, 50-150mg IM repeated if necessary, preferably within a time
and exacerbations of chronic psychoses in patients not interval of 2-3 days. Additional injection may be needed 24-48
responding to available standard drugs hours following the first injection
April 2023 192


Zuclopenthixol Decanoate 200 mg/ml Injection N05AF05135P2001XX B Maintenance treatment of schizophrenia and other By deep IM injection test dose 100 mg followed after 7 - 28 days
psychoses, especially with symptoms such as by 100 - 200 mg or more followed by 200 - 400 mg at intervals of
hallucinations, delusions and thought disturbances along 2 - 4 weeks adjusted according to response. Maximum 600 mg
with agitation, restlessness, hostility and aggressiveness weekly. Child not recommended
in patients not responding to available standard drugs
April 2023 193

Blue Book 2023

Uploaded by

Copyright:

Available Formats

Blue Book 2023

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Blue Book 2023

Uploaded by

Copyright:

Available Formats

FORMULARI UBAT KEMENTERIAN KESIHATAN MALAYSIA BILANGAN 1/2023

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage

Generic Name MDC Category Indications Prescribing Restrictions Dosage